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In this thesis, analytical approaches for the design and evaluation of cluster randomised trials 
are presented and reviewed. In particular, statistical power/ sample size issues relating to the 
design of cluster randomised trials for which only a limited number of clusters are available 
are assessed using a series of simulation studies. The use of computer simulation methods 
made it possible to investigate how well cluster randomised trials with limited numbers of 
clusters available can be optimised both in terms of statistical power and also the accuracy of 
parameter estimates. The study design conditions performing best in the simulation studies 
were then applied to a community intervention study involving informal healthcare 
providers: the 'Triage Plus integrated tuberculosis (TB) and human immuno-deficiency virus 
(HIV) community intervention project in Lilongwe rural, Malawi'.   
Aims and objectives  
The general aims of this dissertation were to: 
1. investigate if it is possible to improve the analytical approach to the evaluation of 
cluster-randomised trials where the complexity of the intervention demands a small 
number of clusters and in which the primary outcome measure is a count of events 
occurring in a specified time interval; 
2. investigate the effectiveness of engaging informal healthcare providers in integrated 
TB and HIV community intervention in treatment initiation rates and testing access 
rates, a cluster randomised trial was conducted in Malawi for which only a limited 
number of clusters were available to the researchers.  
The specific objectives were: 
1. to review cluster randomised trials and the statistical methods used in the assessment 
of the effectiveness of the intervention in this type of trial when the primary outcome 
measure is a count of events occurring in a specified time interval;  
2. to assess the statistical efficiencies of different design conditions in terms of statistical 
power and the accuracy of parameter estimates when determining the effectiveness of 
complex interventions with a limited number of clusters in this situation; 
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3. to identify the circumstances under which each of the statistical methods would be 
most robust in detecting significant intervention effects or providing accurate 
estimates of intervention effects; 
4. to apply these statistical approaches to the data collected in the cluster randomised 
clinical trial of community based interventions for TB and HIV (the 'Triage Plus' 
study); 
5. to assess the effect of involving non-paid informal healthcare providers in integrated 
TB and HIV community interventions aimed at improving testing and treatment 
initiation rates for these two diseases. 
Methods  
Two research approaches were used in this dissertation: 
1. Simulation studies were used to investigate statistical efficiencies in terms of statistical 
power and accuracy in parameter estimation under different study design conditions 
for cluster randomised trials in which the primary outcome measure is a count of the 
number of events occurring during a specified period of time. 
2. These statistical approaches were then applied to obtain robust estimates of the effect 
of the test intervention using the data collected during the “Triage Plus” study. The 
Triage Plus intervention, implemented in rural areas of Lilongwe, involved informal 
healthcare providers in an integrated TB and HIV community intervention. This 
intervention specifically involved empowering the informal healthcare providers in 
disease recognition, sputum specimen collection, referral of presumptive TB cases, and 
conducting community TB and HIV awareness meetings.  
Results  
The simulation studies showed that statistical efficiency and power both varied considerably 
under the different design conditions investigated. Non-coverage rates within the nominal 
value of 5% and negligible biases in the estimated fixed effects parameters (regression 
coefficients) were observed for all scenarios investigated including the (minimal) 3 cluster per 
arm design. However, it was discovered that, in order to achieve adequate power in low 
incidence disease conditions such as TB treatment initiation rates, more repeated 
measurement times were required to achieve adequate power of 80% with a true effect size of 
20% or lower (for example, 12 measurement times were needed to achieve adequate power in 
this situation in a 3 cluster per arm design when the ICC was 0.00154).  With an ICC of 0.081 
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at least 9 clusters were needed to achieve adequate statistical power of ≥80% with an effect 
size of 20% with 6 and 12 measurement time points respectively for high and low incidence 
disease conditions. For an effect size of 40%, at least 3 clusters per arm were needed to achieve 
adequate power with 4 repeated measurement times in low incidence diseases and 3 
measurement times for high incidence diseases. For ICCs of 0.321 and above, no adequate 
statistical power was achieved with an effect size of ≤40% in both high and low disease 
incidence conditions.   
In the analysis of the TB services access data from the Triage plus study, the intervention 
significantly increased the number of presumptive TB cases accessing testing sites by 15.2% 
(p=0.003) in the first 12 months of the intervention; however, this was followed by a 
statistically non-significant reduction of 18.3% (p=0.224) when the intervention was rolled-out 
into the control clusters. Overall, the intervention was associated with a non-significant 
increase in TB treatment initiation rates of 18% (p=0.112).  
In the analysis of HIV services access rates, antiretroviral therapy (ART) initiation rates 
increased significantly by 34.7% (p=0.048) in the intervention clusters in the first 12 months of 
intervention, and the ART initiation rates were similar after rolling-out the intervention to the 
control clusters. Overall, the intervention was associated with a 61% increase in HIV testing 
uptake rates (p<0.001).  
Conclusion:  
To achieve adequate statistical power and improved precision in parameter estimation in 
cluster randomised trials with a count outcome measure, with the ICC of 0.00154 the 
simulation results suggested that a minimum of 3 clusters per arm is required with at least 12 
measurement times for the estimation of an effect size of 20% (or higher) in low incidence 
disease situations. However, for high incidence outcomes, a minimum of 3 clusters per arm 
with 3 or more measurement times may be adequate to achieve a statistical power of at least 
80%.  For an ICC of 0.081, at least 3 clusters per arm were needed to achieve adequate power 
if the effect size was 40% after 4 repeated measurement times in low incidence diseases and 3 
measurement times for high incidence diseases. With ICCs of 0.321 and above, no adequate 
statistical power was achieved with an effect size of ≤40% in both high and low disease 
incidence conditions. 
For the TB and HIV interventions in the “Triage Plus” study, engaging informal health care 
providers was clearly effective in improving TB and HIV testing uptake as well as ART 
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initiation. This reinforces the need for community participation in integrated TB and HIV 
interventions to combat the two diseases. However, for these providers to be effective in 
promoting TB treatment initiation, the number of sites offering TB testing and treatment 
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GENERAL INTRODUCTION AND CONTEXT 
1.1 Overview of the Triage Plus study and its objectives 
 
1.1.1 Introduction 
Tuberculosis (TB) and human immuno-deficiency virus (HIV) remain the major determinants 
of morbidity and mortality in Sub-Saharan Africa. The region includes most of the countries 
with the highest burden of the tuberculosis epidemic (WHO, 2009). The TB epidemic in Sub-
Saharan Africa has worsened because of its interaction with HIV and AIDS (Corbett et al. 2002; 
Corbett et al., 2003; WHO, 2009). Of the 9.27 million TB cases in 2007 globally, 15% (1.37 
million) cases were HIV-related tuberculosis, of which 79% were from the African region 
(WHO, 2009).  Because of this interaction, these two diseases form a vicious cycle: TB is the 
main cause of morbidity and mortality in people with HIV; a quarter of HIV-related deaths 
are due to TB, and HIV enhances the progression of latent tuberculosis infection to active 
disease thereby driving the TB epidemic (WHO, 2009; Naidoo and Taylor, 2007;Mukadi, 
Maher and Harries, 2001). 
 
Although interventions to address the two disease conditions exist, patient and health system 
barriers affect service utilisation. Barriers such as cost, distance, delays and repeated visits to 
multiple health facilities increase patient drop-out rates in the course of care seeking especially 
in Sub Saharan Africa (Lawn et al., 1998; Squire et al., 2005; Xu et al., 2007; Storla et al. 2008). 
This is particularly so among the poor who face challenges in getting a definitive diagnosis, 
starting on treatment and adhering to treatment regimens. To address these access challenges, 
the Triage plus study - a cluster randomised intervention study involving informal health care 
providers - was implemented in rural Malawi. Primarily, the intervention aimed at evaluating 
the effectiveness of engaging informal health care providers in TB and HIV testing and 
treatment services.  
 
1.1.2 Access to TB and HIV services 
Globally, the tuberculosis (TB) burden remains high, but its incidence rates are slowly 
declining (Lönnroth et al., 2010). TB treatment success rates are high internationally; at least 
85% for new smear positive TB treated in National TB Programmes was reached in the 2007 
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cohort. TB treatment success rates surpassed the 85% target in the WHO eastern 
Mediterranean region (88%), the south eastern Asian region (88%), and the western Pacific 
region (92%) (WHO, 2009). However, treatment success rates in the African Region remain 
below the 85% target, and case detection rates of smear-positive TB remain below the 2005 
target of 70% in many countries (WHO, 2009).   
 
Achieving high treatment success rates and timely case detection for smear positive TB cases 
have long been considered key factors for controlling TB because they cut transmission rates 
and avert TB related deaths. However, achieving high TB case detection rates is the greatest 
challenge to controlling TB in many countries. In Malawi, despite the increase in TB case 
notifications reported at the National TB Programme from 19,496 in 1994 to 28,234 in 2003, 
WHO estimated that the country was only notifying 41% of the TB cases (Nyirenda, 2006; 
WHO, 2007a).  Thus, improving TB case detection and timely initiation of TB treatment, 
especially for smear-positive TB cases, is the focus of most TB intervention initiatives because 
it is the most effective way to reduce TB transmission in the general community.  
 
Although swift and accurate TB case detection is essential, the most commonly used approach 
for case detection is based on screening patients with a chronic cough at health facilities, a 
method which is less efficient in detecting a large proportion of smear positive TB cases (Ayles 
et al., 2009; Hoa et al., 2010), than the active case finding strategies that screen all at risk 
populations (WHO, 2011). The difficulty is to ensure sustainability of such active case finding 
strategies. Debate continues on the effectiveness of the active case finding strategies 
considering the cost and logistics involved in implementing such interventions in low-income 
countries (Golub et al., 2005; Uplekar and Raviglione, 2007).   
 
In regards to access to Human Immuno-deficiency Virus (HIV) services, uptake rates for HIV 
testing and the number of patients put on Anti-Retroviral Therapy (ART) treatment remains 
low in Sub-Saharan Africa and in developing countries.  Of the 7.1 million in need of ART 
treatment in 2006, only 28% were on  ART treatment in Sub-Saharan Africa, 19% in Asia and 
only 14% in low and middle income countries of Eastern Europe and Central Asia (Giuliano 




The recently completed 'Demographic and Health Surveys in the Sub Saharan Africa' revealed 
that the percentages of men and women who know their sero-status ranged from 14% to 51% 
in men and 15% to 72% in women (see National Population Commission (Nigeria) and ICF 
Macro, 2009; National Statistical Office [Malawi] and ICF Macro, 2011; Central Statistical 
Agency [Ethiopia] and ICF International, 2012).This suggests that many of those who are 
infected do not know their HIV status, and, therefore, are at risk of spreading the infection or 
being re-infected with ART resistant strains. If such populations are not reached with 
preventive interventions such as HIV testing services they may end up spreading the infection 
or being re-infected with resistant strains.  Thus, to combat the HIV pandemic, there has been 
an increased emphasis on prevention of new HIV infections through early HIV detection by 
promoting voluntary HIV testing. 
 
Given that early ART treatment has the potential of reducing the risk of HIV transmission to 
an uninfected partner (Cohen and Gay, 2010; Anglemyer  et al., 2011; Cohen et at, 2011), 
reaching all eligible patients with ART services,  coupled with improved HIV testing  uptake, 
is likely to reduce HIV transmission. With the HIV burden in Sub-Saharan Africa worsening 
the tuberculosis epidemic: HIV enhances the progression of latent tuberculosis infection to 
active disease and therefore drives the TB epidemic(Corbett et al. 2002; Corbett et al., 2003; 
WHO, 2009), interventions targeting both TB and HIV are essential to reduce TB and HIV 
transmission. 
 
1.1.3 The relationship between poverty and TB or HIV/AIDS 
Recognition of the relationship between poverty and timely access to diagnostic and treatment 
services from health facilities is well documented (Squire et al., 2005; Storla et al., 2008). In 
particular, the poor are most likely to contract TB, progress to disease, and have poor 
treatment outcomes but have the most difficulty accessing formal public health services. This 
creates the potential problem of continued TB transmission, which, in turn, maintains the risk 
of TB transmission among the general population (Squire et al., 2005;Lönnroth et al., 2009).  
 
The difficulty of timely intervention amongst the poor is a result of the skewed distribution 
of health facilities: most are located in urban areas; so many rural poor are unable to easily 
gain access to health services. Additionally, the poor may not be able to afford the costs related 
to medical care such as transport, medication and other medical-related costs (Kemp et al., 
2007; Barter et al., 2012). These costs result in those in the lowest socio-economic groups 
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delaying seeking health care from formal sources. These individuals, in turn, resort to 
informal health care sources, such as traditional healers and store-keepers. Detrimental 
behaviour patterns, such as delaying health care or seeking alternatives, are compounded by 
health system barriers, including the incorrect diagnosis of TB and HIV and, errors in referring 
TB and HIV symptomatic patients to the appropriate departments within the facility, both of 
which results in extending the time before a correct diagnosis is made (Storla et al., 2008). 
These factors contribute to long care-seeking pathways and high direct and indirect costs; 
further depleting a household's already strained financial status (Kemp et al., 2007).  
 
TB and HIV/AIDS are chronic conditions leading to prolonged care and support and which 
create a vicious cycle of poverty within affected households.  Poor households with TB or 
HIV/AIDS affected members may be caught in a damaging cycle of poverty and ill-health. By 
strengthening health systems (especially at the community level) and improving the 
awareness of TB, and general health among communities, early TB diagnosis and treatment 
of the most infectious forms, can occur (WHO, 2011).   
 
1.1.4 The need for community participation in integrated TB and HIV interventions 
Given the structural barriers (e.g. transportation costs) faced by the poor and the vulnerable 
in accessing TB and HIV/AIDS services, and the need to prevent TB and HIV in order to 
reduce transmission, community-based strategies involving informal healthcare providers 
such as store-keepers are essential for ensuring access to health services (WHO, 2011; 
Simwaka et al., 2012). WHO (1989, page 6) described informal healthcare providers as 
'members of the communities where they work, selected by the communities, answerable to the 
communities for their activities, supported by the health system but not necessarily a part of its 
organization, and have shorter training than professional workers'. Informal healthcare providers 
have been used in community interventions to improve access to services for various diseases 
and conditions including treatment of uncomplicated malaria in Kenya and nutrition 
education intervention that has resulted in improved case detection for diarrhoea, respiratory 
infections and malnutrition in Nepal (Curtale et al., 1995;Datiko and Lindtjørn, 2009; Marsh 
et al., 1999 & 2004; Simwaka et al., 2012). 
 
In Ethiopia, extension health workers have been used in TB identification: collecting sputum 
and storing and transporting it to the nearest microscopic centres for TB diagnosis (Datiko 
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and Lindtjorn, 2009). This resulted in improved case detection: 122.2% in intervention areas 
compared to 69.4% in control areas, with women showing the highest rise in case detection 
(Datiko and Lindtjorn, 2009).  In China, village doctors increased TB case detection from 36.2 
to 49.9/100,000 following a similar community intervention (Xiong et al., 2007). In Malawi, 
storekeepers engaged in the referral of presumptive TB cases to the nearest health facility, 
significantly increased the smear positive TB case notification from 0.6 per 1000 people in the 
control areas to 1.2 per 1000 in the intervention areas (Simwaka et al., 2012). 
 
Informal health care providers play a critical role in reaching out to individuals who might 
otherwise not access TB and HIV services due to factors such as inadequate knowledge of TB 
and HIV (Storla et al., 2008). The use of community structures, such as informal health care 
providers, in promoting health information at the community level does not only promote the 
dissemination of culturally appropriate health information, it also reduces the stigma 
associated with TB and HIV (Norris et al., 2006; Corkery et al., 2007; Farid et al., 2007; Mock 
et al., 2007; O’Donnell et al., 2012). 
 
By equipping these informal health care providers with the necessary skills to conduct 
community interventions and improve access to TB and HIV services, diagnostic and 
treatment delays that would lead to unnecessary deaths or transmission, can be reduced 
(Storla et al., 2008). Working with informal healthcare providers, in improving disease 
recognition, health communication, treatment, and referral at the first point of access in the 
community, is in line with WHO recommendations (WHO, 2011). 
 
However, engaging informal health care providers in vertical programs may lead to a 
duplication of efforts as the same informal healthcare providers are usually engaged to 
provide information on a range of diseases. In contrast, the engagement of informal health 
care providers to assist with multiple conditions such as TB and HIV in an integrated manner 
is likely to be more efficient. Studies of the clinic based integration of TB and HIV in service 
provision for co-infected individuals have shown promising results in improving TB and HIV 
health outcomes (Hermans et al., 2012).    
 
Although evidence exists concerning the effectiveness of clinic based integration of TB and 
HIV services and paid community care providers (Hermans et al., 2012; Uwimana et al., 2012), 
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there is limited evidence that the involvement of non-paid informal health care providers in 
the provision of integrated TB and HIV services at the community level might lead to an 
improvement in access to TB and HIV services.  A randomised, controlled health system 
intervention trial involving informal health care providers called 'Triage plus' was therefore 
set up to investigate their impact on access to TB and HIV services in rural Lilongwe, Malawi. 
Primarily, the intervention aimed to investigate whether the engagement of informal health 
care providers in integrated TB and HIV community interventions would be effective in 
improving services access rates for the two diseases, thereby guiding evidence based policy 
formulation on using informal providers in TB and HIV interventions at the community level. 
Specifically, the Triage Plus study aimed to determine the overall effect on a) TB and Anti-
Retroviral Therapy (ART) treatment initiation and b) testing uptake of TB and HIV services.  
 
1.1.5 The Triage Plus study and the previous studies implemented by the REACH Trust 
This study continues the work of previous studies conducted by the Research for Equity and 
Community Health (REACH) Trust which focused on health issues for the poor and the 
vulnerable in Malawi (e.g. Simwaka et al., 2012). Previous research by the REACH Trust was 
conducted primarily in semi-urban areas where the effectiveness and acceptability of 
engaging community based structures in single disease conditions was assessed (e.g. 
Simwaka et al., 2012).  
Due to the interaction between  TB and HIV (Corbett et al. 2002; Corbett et al., 2003; WHO, 
2009), this  current study assessed the effectiveness of community engagement, utilising a 
variety of informal health care providers, to improve access to both TB and HIV services 
among the poor. A detailed description of the project is provided in Chapter 2.  
1.2 Statistical power in cluster randomised studies 
Although previous research by the REACH Trust focused on semi-urban areas, this study 
extends these efforts into the rural community where different challenges exist. The level of 
infection of Mycobacterium tuberculosis (MTB)is generally lower in rural than in urban settings, 
where new cases of TB are less common (see Ayles et al., 2009). To obtain an adequate number 
of TB cases, large cluster sizes are required for randomisation to different study arms, thereby 
creating the problem of fewer clusters available for randomisation. Because of the need to 
obtain adequate sample sizes for the primary outcome measures, especially TB treatment 
initiation rates, the Triage Plus study used 3 clusters per arm, which was achieved by 
subdividing the Lilongwe rural area into six large clusters.  
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The use of a small number of clusters for this study had its own statistical implications. First, 
there would be statistical challenges in achieving statistical power and obtaining robust 
estimates when assessing effectiveness of the intervention. These challenges stem from the 
need for conducting statistical analysis using clusters as units of analysis, which reduces the 
number of degrees of freedom for adequate statistical power (Murray, Hannan and Baker, 
1996; Donner and Klar, 2000).  Second, the randomisation process of clusters to different study 
arms may not be efficient in ensuring the even distribution of confounding factors between 
study arms (Murray, 1998a).  To achieve adequate power and robust estimates in cluster 
randomised studies, previous simulation studies have recommended a minimum of 30 
clusters per arm (Maas and Hox, 2005; Moineddin et al., 2007). 
With only 3 clusters per arm in the Triage Plus intervention, it is likely that the statistical 
power to detect significant intervention effects is reduced because there is a limited number 
of degrees of freedom for the between-cluster residual errors (Cornifield 1978; Koespell et al., 
1991; Feldman, McKinlay and Niknian, 1996; Murray, 1998a, Donner and Klar, 2000).  
 
To improve statistical power in studies with a limited number of clusters, the use of external 
intracluster correlation coefficients and the subdivision of the clusters into small sub-clusters 
have been proposed (Feldman, McKinlay and Niknian, 1996; Murray, Hannan and Baker 
1996).  Hayes and Moulton (2009) caution against using external intracluster correlations of 
outcome measures from a different setting.  Although use of sub-clusters improves power and 
type I error rates, Feng et al (2001) recommended the use of the original analysis clusters for 
valid estimates. To achieve robust estimates and adequate statistical power in the Triage plus 
study, alternative statistical approaches were needed. 
1.3 Estimation of prevalence and incidence rate ratios in cluster randomised trials 
As a measure of intervention effectiveness in cross-sectional studies, prevalence ratios or 
incidence rate ratios have been preferred to odds ratios. In cross-sectional studies with a 
common outcome, odds ratios tend to overestimate the impact of an intervention (Lee and 
Chia, 1993;  Skov et al. 1998; McNutt et al., 2003). Estimation of prevalence ratios in cross-
sectional studies or incidence rate ratios in longitudinal studies arise from different statistical 
models. Most notably, approaches based on Cox regression (Breslow, 1974; Lee and Chia, 
1993), Poisson regression (McNutt et al., 2003; Petersen and Deddens, 2008), log-binomial 
regression (Zocchetti, 1995; Skov et al., 1998), and the COPY method when convergence of 
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log-binomial models fail (Deddens et al., 2003). These models are based on the generalised 
linear model (GLM) theory- a class of fixed effects models (McCullagh and Nelder, 1989). The 
GLM framework involves specification of a link function 𝑔(. )  that relates the expected 
response to the linear predictor 𝜂𝑖 =  𝑥𝑖𝛽 (where 𝑖 represents the individual observations, 𝑥𝑖 
is a vector of explanatory variables with fixed effects 𝛽 ), and variance structure for the 
response variable that is assumed to follow a distribution from the exponential family 
(McCullagh and Nelder, 1989). A brief description of the GLM is provided in section 3.7 in 
Chapter 3. 
 
The statistical approaches based on the generalised linear model theory are typically applied 
to data derived from clinical trials or cohort studies whose observations are independent. 
However, in cluster randomised trials, where clusters of individuals or communities (such as 
villages, schools) are assigned randomly to different intervention arms, the study 
observations or responses are usually correlated, so standard models can no longer be used 
to analyse such data (Breslow and Clayton, 1993, Murray et al., 1998a, Hayes and Moulton, 
2009). Therefore, the analysis of data from cluster randomised trials needs to take into account 
the non-independence of the observations within the clusters, usually referred to as 
intracluster correlation (ICC).To account for the inherent dependency or correlation of data 
derived from community randomised interventions, a generalised linear mixed model 
(GLMM)framework, an extension of the generalised linear model theory, is usually used 
(Breslow and Clayton, 1993).  
 
The GLMM framework involves incorporation of random effects in the linear predictor of the 
fixed effects model. This framework has several advantages, including easy incorporation of 
both cluster-level and individual-level covariates, possibilities of exploring variance structure, 
extension to various outcome types, and flexibility in addressing heterogeneity and over-
dispersion (Breslow and Clayton, 1993; Omar et al., 2000).  However, because of the 
intractability of the marginal likelihood of the response variable that is obtained by integrating 
out the random effects in GLMM framework, approximation methods are used (Breslow and 
Clayton, 1993). Approaches based on numerical integration (Rabe-Hesketh, Skrondal and 
Pickles, 2005) or penalised quasi-likelihood estimation (Breslow and Clayton, 1993) have been 
proposed to estimate the marginal likelihood. More recently, Bayesian estimation using 
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Markov chain Monte Carlo methods have been considered (Zhao et al., 2006). A detailed 
description of the GLMM framework and modelling approaches are presented in Chapter 4. 
1.4 Aim of the study 
There have been many studies like the Triage Plus intervention employing a limited number 
of clusters, a factor which is likely to have had profound consequences on both the statistical 
power and the statistical precision of the parameter estimates. Most empirical research has 
investigated power and parameter estimation issues in cluster randomised designs with at 
least 30 clusters per arm for valid estimates (e.g. Moineddin et al., 2007). The main aim of the 
present study was to investigate if it is possible to improve the analytical approach to the 
evaluation of cluster-randomised trials where the complexity of the intervention demands a 
small number of clusters and to investigate the effectiveness of engaging informal healthcare 
providers in integrated TB and HIV community intervention in treatment initiation rates and 
testing access rates.  
 
The specific objectives of the study are:  
1. To review cluster randomised trials and the statistical methods for assessing 
effectiveness of the intervention in cluster randomised trials.  
 
2. To assess the statistical efficiencies of different design conditions in terms of statistical 
power and accuracy in parameter estimates when determining the effectiveness of 
complex interventions with a limited number of clusters, and to identify the 
circumstances under which each of the statistical methods would be more robust in 
detecting significant intervention effects or providing accurate estimates of 
intervention effects.   
 
3. To apply these statistical approaches to the actual data from the current community 
based intervention on TB and HIV called 'Triage Plus'.  
 
4. To assess the effect of involving non-paid informal healthcare providers in integrated 
TB and HIV community interventions in improving testing and treatment initiation 
rates.   
10 
 
1.5 Structure of the thesis 
This dissertation is organised into seven chapters including this introductory Chapter. 
Chapter 2 describes the Triage Plus intervention study involving informal healthcare 
providers. Chapter 3 presents an overview of cluster randomised trials while highlighting the 
challenges and implications of a limited number of clusters. It also presents measures of effect, 
and statistical approaches applied in estimating intervention effectiveness. Chapter 4 presents 
statistical models in the context of a generalised linear mixed model framework in the 
estimation of prevalence ratios or incidence rate ratios under a correlated data structure. It 
also provides modelling approaches for prevalence ratios or incidence rate ratios in the 
context of generalised linear mixed models using the likelihood and Bayesian approaches for 
intervention effect estimation and model selection. Chapter 5 presents an evaluation of the 
statistical models using a series of simulation studies under different design conditions in 
order to guide the choice of statistical approaches to be pursued, while Chapter 6 presents the 
statistical analysis of the Triage Plus study. It also presents the results of the various statistical 
models, taking into account the phased design of the Triage Plus cluster randomised 
intervention study. Lastly, Chapter 7 offers a general discussion and draws conclusions. This 
final chapter ends by assessing the policy implications of this study’s findings on current 





THE TRIAGE PLUS STUDY 
2.1 Introduction 
This Chapter provides an overview of the study design for the Triage Plus study, a TB and 
HIV community-based intervention implemented in rural Malawi. The intervention was 
participatory, involving informal healthcare providers delivering elements of the intervention 
in rural communities with technical support from health surveillance assistants (front line 
public health workers). This Chapter first extends the discussion of TB and HIV services access 
issues presented in Chapter 1 and the need for timely treatment initiation for the two diseases. 
The Chapter then explains the need for an integrated approach to TB and HIV in community 
interventions. A description of the study design and intervention package as well as the 
outcome measures and data collection methods used during the implementation of the Triage 
Plus study is given. Study design limitations, in terms of the number of clusters used for 
randomisation and the possible statistical implications, are provided. This Chapter concludes 
with the suggestion that there is a need for further evaluation of the statistical implications of 
limited cluster numbers as in the Triage Plus study design.   
2.2TB and HIV Case detection, treatment and the need for community interventions 
2.2.1 Tuberculosis case detection and treatment 
Despite global adoption of the STOP-TB strategy to improve case detection rates and reduce 
TB incidence, tuberculosis case detection rates are far from reaching the global target of at 
least 70%. Moreover, the halving of TB prevalence and death rates by 2015 are less likely to be 
met in the Africa region (WHO, 2009). 
 
Tuberculosis management and access to timely TB services is complicated by both system and 
patient barriers.  Barriers characterised by delays and repeated visits to multiple care 
providers increases patient drop-out rates in the course of care seeking especially in Sub 
Saharan Africa (Lawn et al., 1998; Squire et al., 2005; Xu et al., 2007; Storla et al. 2008). Timely 
case detection and treatment initiation is further compounded by health system barriers, such 
as incorrect management of patients with negative smears or with no haemoptysis, and health 
workers failing to identify all TB patients in outpatient clinics, thereby contributing to long 




Improved TB case detection and timely diagnosis and treatment are essential for effective 
tuberculosis control in order to reduce the period of infectivity in the community (Golub et 
al., 2005).  Delayed or incorrect diagnosis and treatment of tuberculosis results in severe 
disease and more complications that lead to increased mortality (Glynn et al., 1998). However, 
despite the popularity of active case finding which has remained an integral part of 
tuberculosis control in high risk settings, its effectiveness still remain uncertain (Golub et al., 
2005). It is discouraged because of the associated high costs and weaknesses in treatment 
programmes (Golub et al., 2005; Uplekar and Raviglione, 2007). Given that recent TB 
prevalence surveys have shown that a large proportion of smear positive TB cases do not 
report any TB symptoms early in the disease course (Ayles et al., 2009;Hoa et al., 2010), active 
case finding strategies need to be reconsidered (especially in high prevalent settings for TB 
and HIV).   
 
Active case finding studies recently conducted in Harare, Zimbabwe, demonstrated that the 
use of community based case finding approaches in high TB and HIV prevalence settings 
could improve TB case detection rates (Corbett et al., 2010). In Uganda, using a model based 
analysis of the effectiveness of active case finding strategies in tuberculosis control found an 
additional 1,594 TB cases over one year, and 675 deaths were averted over a 5 year period 
(Mupere et al., 2013).  Nevertheless, the costs and logistics of implementing such strategies in 
resource-limited settings are unlikely to be sustainable. These approaches are more suited for 
select risk groups such as prisoners. New, innovative approaches for improving TB case 
detection in the general population are thus required, with active case finding strategies being 
adopted as complementary approaches.  
 
Given that community management of undiagnosed tuberculosis remains a challenge (Wood 
et al., 2007;Sekandi et al., 2009), and that most new tuberculosis infections occur outside 
households in high incidence settings (Verver et al., 2004), adopting interventions that involve 
community participation is necessary for reducing tuberculosis transmission (O'Donnell et al., 
2012).  Such interventions may range from those that improve a community's knowledge and 
awareness of TB, informing them what to do when they have symptomatic TB, to 
interventions which ensure improved access to TB case detection and effective treatment by 




2.2.2 HIV and AIDS diagnosis and the need for timely ART treatment initiation 
Although HIV infection is incurable, recent advances in medical technology, such as the 
introduction of Highly Active Anti-Retroviral Therapy (HAART) in 1996 have generally 
improved the quality of life (Cohen et al., 1998; Brechtl et al., 2001) and survival rates of HIV 
infected individuals (Hogg et al., 1998; Palella et al. 1998). In particular, standardised clinical 
practice and improved availability of HIV medication have contributed to a decline in HIV 
related mortality rates in most affected countries (Malawi National AIDS Commission, 2007 
& 2010, Ray et al., 2010).  
 
Because of the reduced viral load in genital secretions following ART treatment (Vernazza et 
al., 2000; Graham et al., 2007), ART reduces HIV transmission rates (Cohen et al., 2011). HIV 
transmission probabilities are increased when  ART initiation is delayed(Cohen et al., 2011); 
therefore, the early diagnosis of HIV infection followed by the timely initiation of 
antiretroviral treatment would most likely reduce transmission rates, the progression of HIV 
to AIDS and early mortality (Castilla et al., 2002, Cohen et al., 2011). Castilla and colleagues 
found that a late diagnosis of HIV was associated with the early onset of AIDS because those 
with a late diagnosis cannot benefit from antiretroviral therapy.  
 
Effective HAART for HIV-infected persons has been inaccessible in most developing 
countries. Recently, free antiretroviral treatment has been scaled up following the "3 by 5" 
initiatives to ensure universal access to HIV services (Kim and Ammann, 2004).The increased 
availability of effective antiretroviral treatment has led to new insights into HIV prevention 
strategies, such as voluntary HIV counselling and testing. Instead of promoting only HIV 
infection prevention (through abstinence, being faithful among partners or the consistent use 
of condoms), focus is now given to the early detection of HIV by promoting HIV counselling 
and testing (Campbell et al., 1997; Creek et al., 2007; Preidis et al., 2013).  
 
With the availability of effective HAART, early HIV detection is beneficial as it not only 
ensures the timely initiation of ART treatment but also allows HIV infected persons to access 
treatment, care and support.  Hence, most countries affected by the epidemic have changed 
their national HIV policies from risk-based HIV testing to routine testing (Creek et al., 2007; 
Preidis et al., 2013). Thus, the comprehensive approach to HIV testing has not only been 
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promoted to prevent the spread of HIV but also as an essential component for one’s entry into 
the antiretroviral treatment programme. Furthermore, as described below, the STOP-TB 
strategy has been unable to sufficiently contain TB incidence in the face of rising HIV 
prevalence.  Improving early HIV detection and timely ART initiation by involving 
community structures such as informal healthcare providers will, in turn, help contain TB 
incidence (De Cock and Chaisson, 1999).   
2.2.3 The need for an integrated approach to TB and HIV/AIDS 
In Sub-Saharan Africa the TB epidemic has worsened because of its interaction with HIV and 
AIDS (Corbett et al. 2002; Corbett et al., 2003; WHO, 2009). This interaction of TB and HIV has 
created a need to confront the dual pandemic with an integrated approach using models that 
range from offering TB and HIV services at the same facility to a complete TB/HIV package 
that is delivered by one health care team (Harries et al., 2002, WHO, 2004; Legido-Quigley, 
2013).  According to the interim policy on collaborative TB and HIV activities (WHO, 2004), 
TB and HIV services can be integrated in two ways. First, tuberculosis services may be 
integrated into HIV health-care settings in order to reduce the TB burden among HIV. Second, 
HIV services may be integrated into tuberculosis control programmes with a view to reducing 
the HIV burden in patients with TB.  
 
The integration of TB and HIV services in TB or HIV clinics is meant to improve diagnosis 
and treatment outcomes among co-infected patients as well as overcome challenges such as 
losing patients when they are referred between TB and HIV services, increased patient travel 
costs due to multiple visits and increased time spent in clinics (Kerschberger et al., 2012; 
Legido-Quigley, 2013; Hermans et al., 2012).  This integration not only offers benefits for 
patients, health providers and the health system, but also benefits from shared resources, as 
the complete integration of TB and HIV services uses the same health system resources, 
including the drug procurement supply chain and human resources (Maher, 2010). 
 
2.2.4 The need for community participation in integrated TB and HIV interventions 
Studies conducted to assess the effectiveness of the clinic based integration of TB and HIV in 
service provision for co-infected individuals have shown integration to be effective in 
improving TB and HIV health outcomes and reducing the delay in treatment initiation 
(Hermans et al., 2012; Kerschberger et al., 2012). However, although the integration of TB and 
HIV services in resource-constrained settings is feasible, some implementation challenges still 
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exist such as inadequate laboratory infrastructure and skilled staff with required expertise 
and experience to manage TB and HIV co-infected patients(Howard and El-Sadr, 2010). 
 
Furthermore, given the structural barriers faced by the poor and the vulnerable in accessing 
TB and HIV services in health facilities, the use of community based strategies involving 
informal healthcare providers would ensure equitable access to the health services. As 
described in Chapter 1 section 1.1.4, the use of informal healthcare providers in community 
interventions is well documented (Datiko and Lindtjørn, 2009; Marsh et al., 1999; Simwaka et 
al., 2012). However, there is little research involving informal healthcare providers in the 
provision of integrated TB and HIV services at the community level. To address this research 
gap, a cluster randomised intervention study involving informal health care providers called 
‘Triage Plus’ was implemented in rural Malawi.  
2.3 The Triage Plus Study design 
The overall design of the study is illustrated in a flow diagram shown in Figure 1 (Campbell, 
Elbourne, and Altman, 2004).  A detailed description of the study design follows. 
2.3.1 The study areas 
As indicated in Chapter 1 section 1.1.5, earlier research by the REACH Trust focused on health 
issues for the poor and the vulnerable in semi-urban areas (see Simwaka et al., 2012). This 
study continued these efforts in rural areas where different challenges exist. Thus, the Triage 
Plus study was implemented in rural areas of Lilongwe District.  
 
Lilongwe is the capital city of Malawi.  It is in the centre of Lilongwe District, an administrative 
demarcation.  The city is therefore surrounded by a large rural district. Lilongwe rural is 
served by 18 traditional authorities with a total population of 1,230,834 (NSO, 2010).There are 
4 mission hospitals, 2 community hospitals, 32 health centres, and 68 health posts in Lilongwe 
rural. In addition, the district is served by a referral hospital and private clinics located in the 
urban areas. All the mission and community hospitals located in the rural areas offer TB and 
HIV services (e.g. TB and ART treatment initiations). All health centres offer HIV testing while 
TB testing is done in 16 health facilities in the rural areas. 
In general, rural areas of Lilongwe are dominated by the Chewa tribe that accounts for 99% 
of the total rural population (NSO, 2010) and the areas are generally poor. According to 
poverty mapping analysis carried out by Benson and Colleagues of the International Food 
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Policy Research Institute (IFPRI), Washington, DC, USA and the National Statistical Office 
(NSO), Malawi, respectively in 1998, 64.3% of the Malawian population live in poor 
households of which 76.6% are situated in rural Lilongwe (Benson et al., 2002).  
 
2.3.2 Study design 
As the intervention was meant to alter general health seeking behaviour in the intervention 
areas, an individually randomised clinical trial was considered inappropriate, and a cluster 
randomisation approach was, therefore, adopted in this study. In cluster randomised trials, 
distinct and identifiable groups, such as communities or schools, are randomly assigned to 
study conditions, and data for impact evaluation is collected from the members of those 
groups (Murray et al., 1998a; Hayes and Moulton, 2009). However, because the effects of the 
intervention were likely to persist for some time, stepped wedged (De Allegri et al., 2008) and 
crossover designs (Sjögren et al., 2005) were considered to be inappropriate. A parallel cluster 
randomised trial design was therefore used. Such parallel designs have previously been used 
in cluster randomised trials in the evaluation of different health intervention strategies (see 
Corbett et al., 2010).  
 
Unlike parallel designs, crossover designs allow each cluster to receive both the intervention 
and control treatment at equal time intervals (Palmer et al., 1985; Chavasse et al., 1999; Sjogren 
et al., 2005). The within-cluster evaluation design allows a more precise intervention 
evaluation and requires fewer clusters than parallel designs (Hussey and Hughes, 2007).  
 
In the stepped wedge design, a type of crossover design, different clusters switch 
interventions at different times, and the crossover is in one direction from control to 
intervention (Hussey and Hughes, 2007; Brown and Lilford, 2006, The Gambia Hepatitis 
Study Group, 1987; De Allegri et al., 2008).  This design approach not only removes the ethical 
concern of withholding the intervention from some communities (Hussey and Hughes, 2007), 
but it is also more efficient as clusters act as their own control.   
 
In the Triage Plus study,  the areas that acted as control areas in the first 12 months of the 
intervention later received the intervention while the Early intervention areas continued 
receiving the intervention (see section 2.3.3). Although, this was similar to the stepped 
17 
 
wedged design, a formal stepped wedged design randomisation was not implemented 
because of the limited number of clusters.  
 
Cluster randomization has practical advantages: all subjects in the cluster are treated in the 
same way thereby reducing costs and ethical concerns (Donner et al., 1990). However, cluster 
randomisation may not permit the direct determination of the extent to which individual 
subjects were exposed to the intervention.  
 
2.3.3 The phased intervention design 
2.3.3.1 Number of clusters for randomisation 
The Triage Plus study was implemented in rural areas of Lilongwe where the level of infection 
with mycobacterium tuberculosis is generally low compared to the urban areas.  For instance, in 
a TB prevalence survey conducted by Ayles et al (2009), two areas (one urban and the other 
rural) in Zambia showed that the adjusted TB prevalence in urban areas was approximately 
two times higher than that of rural areas (650/100,000 (95% CI 360–940) in the rural areas vs 
1200/100,000 (95% CI 750–1640 in urban areas).  However, it is acknowledged that in other 
settings different patterns exist. A TB prevalence study conducted in India found higher TB 
prevalence in rural areas than in urban areas (Rao et al., 2012).  To obtain an adequate number 
of TB cases for the primary outcome measures, such as TB treatment initiation rates, large 
cluster sizes were used for randomisation to different study arms.  In total, 6 clusters were 
formed by subdividing the Lilongwe rural communities. The cluster boundaries were based 
on existing boundaries drawn by traditional authorities. Approximately three traditional 
authorities were grouped to form a cluster. This not only permitted obtaining adequate 
numbers of TB and HIV cases but also minimised the risk of potential contamination of the 
intervention between intervention arms due to reduced interactions of people between 
clusters due to the large size of the clusters. When small clusters with no corresponding buffer 
zones are used, there is a high likelihood of people between clusters interacting thereby 
affecting the effectiveness of the intervention (Hayes et al., 2000; Torgerson, 2001; Borm et al., 




Strengthening of data recording in patient registers for ART, 
HIV testing, TB treatment and diagnosis by training health 
workers.  








Excluded  (n= 0 clusters  ) 
 Not meeting inclusion criteria (n=0 clusters) 
Declined to participate (n=0 clusters) 
Other reasons (n= 0 clusters) 
 
Analysed using optimal study designs from the 
simulations (n= 3 ) 
Training of IHPs and implementation of 
intervention (n= 3 clusters ) 
Allocated to Early arm (n= 3 clusters ) 
 Received allocated intervention (n=3 clusters) 
 Did not receive allocated intervention (n= 0 clusters) 
 Total population=602,143; mean=200,714 
 No of sites (TB testing=7, HIV testing=20,TB treatment 
initiation=2, ART initiation=3) 
No intervention (n= 3 clusters ) 
Allocated to Delayed arm (n=3 clusters  ) 
 No intervention (n= 3 clusters ) 
 Did not receive allocated intervention(n= 0 clusters) 
 Total population=628,691; mean=209,564 
 No of sites (TB testing=9, HIV testing=18,TB treatment 
initiation=4, ART initiation=6) 
 
Analysed using optimal study designs from the 




Randomized (n= 6 clusters ) 
Enrolment Assessed clusters for eligibility (N= 6 Clusters) 
 
Implementation of intervention and supervision (n= 
3 clusters ) 
Training of IHPs and implementation of 
intervention (n= 3 clusters ) 
 Blinded allocation of patient data to study 
clusters (n= 3 clusters )  




 Blinded allocation of patient data to study clusters 
(n= 3 clusters )  
 Simulations using baseline data parameters 
  
Figure 1: Flow diagram 
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2.3.3.2 Matching of clusters 
Although randomising clusters to the interventions arms without stratification or matching 
improves statistical power, this approach is actually ideal when there are many clusters 
available for randomisation (Klar and Donner, 1997). However, with the 6 clusters available 
for randomisation in the Triage Plus study, obtaining balanced distribution of potential risk 
factors between intervention arms was difficult.  Thus, before the 6 clusters were randomised 
to different intervention arms (an Early arm and a Delayed arm) as described below in section 
2.3.3.3 and 2.3.3.5, the 6 clusters were pair-matched according to population sizes and whether 
or not the clusters bordered urban areas. The pair-matching was done when all the available 
clusters (i.e. the 6 clusters) had been enrolled in the study. Similar clusters based on 
population sizes and proximity to urban areas were pair-matched. One of the pair-matched 
pairs was then randomly assigned to the intervention arm as described in 2.3.3.3.This was 
done to minimise the imbalance between the two intervention arms as well as to control for 
the effects of urbanisation (Mc Clatchey et al., 1992; Hayes et al., 2000).   
2.3.3.3 The randomisation process 
A randomisation process of the pair-matched clusters was carried out in Microsoft Excel, 
which involved grouping the clusters into two. One cluster pair was allocated to group 1 and 
the other to group 2. Using a built in random number generator in each cluster pair, the pair 
with the lower randomised number was assigned to arm A and the other to arm B.  To ensure 
that the final randomisation process was participatory by all the key stakeholders, then, two 
pieces of paper were labelled either arm A or arm B and placed in an opaque envelope of 
equal size and appearance and then sealed. One of the key stakeholders not involved in the 
randomisation process was asked to pick one envelope after the two envelopes were swapped 
several times. This randomisation process was discussed in detail at district and national level 
and the decision taken to not involve the communities in terms of where the intervention 
would be implemented because all communities eventually received the intervention during 
the full study period. Randomisation involving communities is most attractive in situations 
where the intervention may not be scaled out to the control communities (Ayles et al, 2013). 
Before selection began, it was agreed that the envelope selected would be the Early 
intervention arm and the other would be the Delayed intervention arm. Figure 2 shows the 
distribution of clusters between the intervention arms. 
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2.3.3.4 Blinding of the intervention 
Because of the nature of the intervention implemented at community level, it was not possible 
to conceal either the allocation of the intervention from the communities or from the research 
team involved in the study. However, patient allocation to specific clusters was blindly done 
by an independent person who had no knowledge of the intervention.  
2.3.3.5 The Triage Plus study implementation phases 
In the Early intervention clusters, the schedule of the project implementation was decided 
randomly and each selected cluster received the full intervention before moving to the 
subsequent clusters. All 3 clusters in the Early intervention arm received the full intervention 
package within 3 months. The intervention package was implemented in the Early 
intervention clusters for a period of 12 months. During this time, the Delayed intervention 
arm continued receiving standard care. In both Early and Delayed arms, data collection 
continued throughout the 12 months called ‘Phase I’.  
 
Due to time constraints (inadequate time to conduct data entry, cleaning, analysis and final 
write up of the thesis), the Delayed intervention arm received a full intervention package for 
only the 11 months immediately following the initial 12 months of Phase I. The Early arm 
clusters continued to receive the intervention during this time. In both arms, data collection 
continued in the 11 month period called ‘Phase II’.   
 
Before cluster randomisation was done, baseline data for the study outcome measures and 
contextual factors (see section 2.6) was collected over the 12 month period before the initiation 
of the intervention in all clusters (called ‘Baseline period’).   Figure 3 summarises the phased, 
pair-matched, parallel cluster design used in the Triage Plus study. 
 
In the Triage Plus study, an approximately equal target population was allocated to each of 
the two intervention arms. There was a total population of 602,143 (49%) in the Early 
intervention clusters and 628,691 (51%) in the Delayed intervention clusters based on the 2008 
National population and housing census (National Statistical Office, 2010). Mean cluster 
population sizes were 200,714 (ranged from 166,702 to 243, 826) in the Early arm and209,564 
(ranged from 167,074 to 232,433) in the Delayed arm (see Appendix 8.3 for cluster level 
populations).  Overall, poverty levels between the two intervention arms (Early and Delayed) 
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were similar (see Table 1). Cluster characteristics are compared in section 6.4 of the statistical 
analysis (Chapter 6). 
 
Table 1: Poverty incidence in Lilongwe rural areas 

























Chadza 19,173 80.6 52.7 Kalolo 23,457 96.1 39.7 
Kabudula 17,435 80.3 50.0 Chiseka 40,371 66.3 39.8 
Mazengera 18,358 82.8 56.6 Chimutu 15,403 87.9 64.8 
Chitekwere 6,632 75.0 42.0 Chitukula  4,824 83.9 54.7 
Khongoni 15,954 75.9 45.1 Mtema  7,648 82.9 53.4 
Kalumbu  11,321 89.0 66.9 Malili  14,895 74.2 44.0 
Tsabango  4,885 87.1 63.3     
Kalumba  4,289 76.7 50.1     
Njewa  4,891 75.3 47.1     
*Early arm = clusters that received the intervention early;  
**Delayed arm = clusters that received the intervention in the second half (next 11 months) of the study 
period.  




Figure 2: Map of Lilongwe showing the distribution of the Triage Plus study clusters between 
intervention arms.    
The pink background represents clusters in the Early intervention arm and the green background 
represents clusters in the Delayed intervention arm. Each cluster is formed by grouping 2 to 3 
traditional authorities which have purple boundary lines. The names of the traditional authorities are 

































Intervention arm Baseline Intervention 
 
Baseline period Phase I Phase II 
 
1 - 12 months 13 - 24 months 25 - 35 months 
Early  Baseline data Intervention 
 
Delayed  Baseline data No intervention  Intervention 
Figure 3: Triage Plus study design.  
The figure shows the phased, pair-matched, parallel cluster design which was used to randomise study 
clusters to Early and Delayed arms. The blue colour represents the baseline period and the dark purple 
represents when the intervention package was implemented in the respective arms and the light purple 
under the Delayed intervention arm represents study period when no intervention was implemented 
in the Delayed arm. 
 
2.4 Study intervention 
2.4.1 The Intervention package 
Informal healthcare providers are known to be the first point of call along the health-seeking 
pathway for the most poor and vulnerable (e.g., see Simwaka et al., 2012).The Triage Plus 
study, therefore, aimed to assess the potential of involving a variety of informal health care 
providers such as storekeepers, traditional healers and village health committees in assisting 
in the diagnostic and treatment process for TB and HIV at the community level.  
Thus, the intervention package entailed: 
a) Training informal health care providers to effectively implement the components of 
the intervention. 
 
Informal health care providers were equipped with skills to implement TB and HIV 
interventions. They were trained to implement the following intervention components: 
recognising disease patterns for TB and HIV, assisting in TB sputum specimen collection, 
appropriately referring TB and HIV suspects to the public health system and conducting TB 
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and HIV community awareness meetings. Intervention materials were developed that were 
used in all community meetings to ensure accurate information was given, and guidelines 
were developed to assist informal healthcare providers with implementing specific tasks. 
Health surveillance assistants provided technical support to the informal healthcare 
providers during project implementation and linked them to the formal public health 
service.  
 
At community sensitisation meetings, the health messages included information on the signs 
and symptoms of TB, HIV and AIDS and that treatment is provided free in public health 
facilities. Thus, the primary focus of the intervention was to alter the health seeking 
behavioural patterns and service demand thereby influencing the community’s access to TB 
and HIV services.  
 
Community members with TB and HIV related symptoms were advised to seek medical care 
in public health facilities. However for those who could not afford to do so, especially for 
TB, sputum smears were collected in the community by the informal healthcare providers 
and sent to the nearest public health facility for microscopy testing. Results were fed back to 
the informal health care providers by local health surveillance assistants. 
 
b) Training front line public health personnel to effectively support informal health care 
providers in the project activities, and engaging local public health services and 
community leaders to support the intervention.  
 
To ensure the informal health care providers received the necessary support to implement 
the intervention, health surveillance assistants were also trained, and they acted as a link 
between the informal health care providers and the public health facilities and provided 
supplies for sputum collection. They also provided supportive supervision to the informal 
healthcare providers. In addition, all local leaders in the intervention areas were sensitised 
to the TB and HIV issues covered during the training of informal providers. This 
sensitisation of local leaders enabled the informal healthcare providers to be accepted in the 




2.4.2 Inclusion and exclusion criteria for the informal health care providers 
The informal healthcare providers were engaged if they were a likely access point for poor 
and vulnerable people in the community with TB and/or HIV and if they had a physical 
location within the study area for at least a year. These informal providers were identified 
among the existing community structures already functional in the community, such as 
community based organisations and village health committees. The selection process was 
participatory. They were excluded if they were already formally trained in clinical 
disciplines or public health, or funded through civil services.   
 
The informal health care providers engaged included store-keepers, patient support groups 
(including youth groups), home based care groups, faith-based organisations or volunteers 
from local non-governmental organisations (NGOs) or community based organisations 
(CBOs) based in the area, village health committees, or herbalists. 
 
To ensure even distribution of informal health care providers engaged in the Triage Plus 
study, the number of informal providers engaged was proportionate to the cluster 
population size. 
 
2.4.3 Conceptual basis of the intervention Framework 
Using intervention mapping (Bartholomew et al., 2006; 2011) and the Medical Research 
Council (MRC)  framework for the evaluation of complex interventions (Campbell et al., 
(2000), the TB and HIV community intervention was developed involving informal health care 
providers to improving access to services for the two diseases in the community. These 
frameworks were used in planning and developing the intervention. Using these frameworks 
in systematically developing the intervention improved the chances of the intervention being 
effective in achieving the study outcomes (Campbell et al., 2000; Bartholomew et al., 2006; 
2011). 
 
In conceptualising the Triage Plus intervention, results from previous studies on the use of 
informal health care providers in the delivery of health interventions (e.g. Marsh et al., 1999 
& 2004; Simwaka, et al., 2012) were used. To develop the actual intervention package, results 
from situational analysis, qualitative baseline studies and mapping studies, and input from 




This initial work provided data that was used in formulating the intervention (see Simwaka 
et al., 2012). This included data on community and health system barriers, TB and HIV 
knowledge and attitudes, existing TB and HIV burden, the optimum strategies for delivering 
TB and HIV health messages, the indicative capacity of different informal health care 
providers in the targeted areas and a matrix of specific activities that can be implemented by 
different types of informal health care providers.  
 
In particular, the baseline qualitative studies helped to define potential barriers to health 
seeking behaviours and the review of previously used training materials informed the exact 
content of training materials used in the study. The situational analysis coupled with data 
abstraction from patient registers and existing records formed the basis for calculating sample 
sizes for the main study outcome measures which were strategically chosen for feasibility 
purposes (Mannheim, 1999).  Sample sizes for the primary outcome measures of the Triage 
Plus study are given in section 2.5.  
 
The conceptual framework of the Triage Plus intervention was guided by a number of 
theoretical frameworks.  
 
First, the health belief model (Rosenstock, Strecher and Becker, 1988) and behavioural model 
of services utilisation (Phillips et al., 1998) were used for identifying and addressing barriers 
related to the health system and to individuals in accessing TB and HIV services. This 
theoretical framework primarily focused on health services access among the poor within the 
context of existing factors in the study communities.  
 
Second, attribution theory (Weiner, 1986) was examined for increasing the community’s 
understanding of the causality and control of TB and HIV/AIDS conditions. Social cognitive 
and learning theories (Rosenstock, Strecher and Becker, 1988;Bandura, 1971 & 1986) were 
examined in terms of using informal health care providers to conduct community awareness 
campaigns to improve a community’s knowledge of TB and HIV health risks, and the 
resulting benefits of the adoption of preventive behaviour and seeking a diagnosis or 
medication for the disease, in order to build a sense of self-efficacy among the community 




Third, the conceptual basis of the Triage Plus intervention model, derived from the social 
learning theory, entailed modifying the general health seeking behaviour among community 
members. This was first done by engaging community leaders through sensitisation meetings 
at the onset of the project to ensure their better understanding of the disease conditions 
targeted by the project. This was followed by the engagement of informal health care 
providers to implement TB and HIV awareness interventions to reach the general community 
and promote the adoption of positive health seeking behaviours, such as seeking a diagnosis 
for TB symptoms or an HIV test to know their HIV status, which would, in turn, lead to 
accessing TB and ART treatment. As the intervention progresses, the more individuals who 
have adopted good health care behaviours, the more community members in turn access the 
health services.  
 
The intervention was designed and implemented while recognising the sensitivities of 
involving informal health care providers in delivering TB and HIV activities at the community 
level. The initial work at different levels of project conceptualisation, design and execution 
helped in the implementation of the whole study. Figure 4 summarises the conceptualisation, 





Figure 4: The Triage Plus study implementation framework. 
The framework is showing the steps involved in designing and developing the intervention. Note that the order given does not necessarily reflect the order of 
the activities but shows the various steps involved in the development of the intervention. 
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IMPLEMENTATION 
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providers for TB and other diseases. Review on TB and HIV integration 
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capacity analysis to implement TB and HIV 
interventions. 
Stage 7: Matrix of activities formulated to be 
implemented by different informal health care 
providers 
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2.5 The Triage Plus study outcome measures and sample size 
Because of the complex nature of the Triage Plus intervention, many outcome measures were 
established (Table 2). The outcomes included changes in the number of people starting 
treatment for TB and ART, changes in TB and HIV case detection and changes in uptake rates 
of diagnostic tests.  Because there were two diseases/conditions investigated in this study, 
two primary outcome measures were used, one for each of the two diseases (TB and HIV); the 
analyses of the two outcome measures were carried out independently. In statistical analyses 
involving multiple comparisons when there are two or more primary outcome measures, 
Bonferroni-type adjustments are usually made to ensure that the overall type I error rate is 
held at the conventional 5% level by setting the alpha level for statistical significance for each 
individual comparison at a lower level (often as low as 1%). 
 
Table 2: Intervention effectiveness outcome measures used in Triage Plus trial 
Primary outcomes* 
TB treatment initiation rates  
ART treatment initiation rates  
Secondary outcomes* 
Smear positive TB treatment initiation rates  
TB testing uptake rates  
 HIV testing uptake rates  
* Treatment initiation and testing uptake rates were based on incidence rate ratios 
 
This analysis of multiple intervention outcomes is not only necessary to assess the 
effectiveness of the various intervention efforts but also to ensure that changes in the 
treatment initiation rates especially for TB should be preceded by changes in testing uptake 
rates. For instance, community awareness meetings run by informal health care providers 
increase  appropriate  knowledge on TB and HIV transmission, diagnosis and treatment, 
which results in changes in health seeking behaviours which increases the number of people 
accessing testing services and subsequently receiving treatment. Thus, treatment initiation 
rate changes are a consequence of changes in health seeking behaviour, testing services uptake 
and case detection rates. Some of these outcome measures are more likely to be sensitive in 
showing the effectiveness of the intervention than others, especially in TB treatment 
initiations, because TB treatment initiations are not as common as ART initiations. Thus, the 
use of multiple outcome measures in assessing the effect of the intervention allows the 
isolation of distinct intervention effects on the various outcomes measures.  
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The primary objective of the Triage Plus study was to measure the impact of engaging non-
paid informal health care providers in integrated TB and HIV community interventions on TB 
and HIV treatment initiation rates.  Although baseline summary data on TB and HIV were 
collected from the study areas during the study design stage to help in sample size 
determination, data on the clustering effects were not known. In addition, the study had a 
limited number of clusters available for randomisation that could potentially limit the 
statistical power. In this case sample size calculation to achieve adequate statistical power and 
the accuracy in parameter estimates was based on simulation studies that were conducted 
using a repeated measurement design (see Chapter 5). Because there was one primary 
outcome measure for each of the two diseases (TB treatment initiation and ART treatment 
initiations), the simulation studies investigated the adequacy of statistical power for both low 
incidence events (e.g. TB treatment initiations) and high incidence events (e.g. ART treatment 
initiations). Thus, baseline treatment initiation rates were used in the simulation process. We 
powered our study to be able to detect a 20% increase in the treatment initiation and testing 
uptake rates (see Chapter 5 for the details and the results of the simulations).   
 
The purpose of the simulations was to identify the study design conditions that would 
provide adequate statistical power and accuracy of parameter estimates for both the TB and 
HIV outcomes that would then be used in the final analysis of the Triage Plus study. Ideally 
the simulation studies should have been completed before the intervention was implemented 
but for logistical reasons the simulation studies had to be conducted concurrently with the 
implementation of the intervention (the study design 1  was later refined just before the 
intervention started).  Failure to specify the statistical analysis plan or appropriate design 
conditions such as the number of clusters available (Chapter 5) risks creating a situation in 
which only statistically significant findings can be reported. Our study was less likely to be 
affected by these challenges because the parameters used in the simulations were based on 
the baseline data and not the actual study data.  
 
 
                                                          
1The study design to include more clusters than the original two clusters was refined as part of my PhD 
thesis so as to be consistent with the standard practices in cluster randomised trials, though the number 
of clusters finally defined were still limited due to cost challenges as well as fear of contamination if 
very small clusters were to be defined within the study area.  
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The original individual level sample size determination was based on the data obtained 
through the situation analysis carried out at the design stage (see fourth paragraph in section 
2.4.3). Thus, sample size determination was targeted at determining the minimum number of 
TB and HIV cases that would be needed to start treatment after the intervention in order to 
detect a minimum pre-determined intervention effect size.  
 
To estimate the sample size for the TB primary outcome (i.e. TB treatment initiation rates), the 
number of smear positive TB cases starting treatment was used as the basis for sample size 
calculation. A minimum of a 20% increase in number of smear positive TB cases starting 
treatment from the baseline level of 50% was assumed (the WHO estimated that Malawi was 
detecting less than 50% of smear-positive TB cases nation-wide (WHO, 2009)). Thus, an 
increase in this proportion to the international case detection target of 70% in the intervention 
group was considered to be clinically significant.  
 
Using the secondary data collected as part of the situation analysis, the catchment population 
of the Lilongwe District rural health centres was estimated to be approximately 1.1 million 
and the total number of TB cases registered in these rural health centres for which data was 
available was 936, of which 329 were smear positives. By assuming that the actual TB cases 
were not rising in the community year on year, the expected number of smear positive TB 
cases registering for treatment in each study group over a one year period was thus estimated 
to be 165 (329/2). This constituted 50% of all smear positive TB cases, so the actual number of 
smear positive TB cases occurring in each study group was projected to be 330 (165/0.50).  
This provided 87.5% power to detect an increase in the number of smear positive TB cases 
registering for treatment from 165 (50%) in the control arm to 231 (70%) in the intervention 
arm. Given that 35% (329/936) of the TB cases were smear positive, then a minimum of 462 
TB cases (all forms of TB) were expected to start TB treatment at the end of the intervention in 
the intervention arm. 
 
For HIV infected patients starting treatment, an increase from the baseline level of 15% up to 
18% (i.e. a 20% proportional increase) in the intervention arm would be considered clinically 
significant. Malawi’s 5 year ART Scale-Up plan indicated that (approx.) 85,000 new patients 
become eligible for ART each year across the country, in which case 8,500 new patients would 
32 
become eligible for ART in the rural areas of Lilongwe2.  Data from ART programme in 
Lilongwe rural indicated that 1,300 people were already on ART treatment, a treatment 
initiation rate of 15% (1300/8500), and that the number of new patients eligible for ART was 
8,500 (4,250 for each of the two study groups). A 20% increase in ART treatment initiations 
from the baseline 15% in the intervention arm was again considered clinically significant, so 
the available sample size provided 86.9% statistical power to such an increase in the 
proportion of eligible patients starting ART (in absolute terms, from 15% in the control arm to 
18% in the intervention arm). 
In the calculation of the sample sizes for the primary outcome measures, the design effect was 
not used because an estimate of the intracluster correlation was not known at the design stage. 
In the absence of data from other studies sufficiently similar to Triage Plus study from which 
to obtain estimates of the likely ICC value for inclusion in the sample size calculations, the 
baseline data from Triage Plus were used; these provided ICC estimates for the four different 
outcome measures in this study.  The estimated ICC values for TB testing, ART initiation, TB 
treatment initiation and HIV testing rates were 0.00154, 0.0316, 0.046 and 0.081 respectively.  
For the simulation studies presented in Chapter 5, the smallest (0.00154) and largest (0.081) of 
these four ICC values were used, along with two much larger ICC values (0.321 and 0.699) 
taken from other similar studies, in order to test a very wide, but also realistic, range of ICC 
values in the simulations. The ICC of 0.321 was based on a cluster randomised trial to assess 
the effect of an education intervention on TB case detection and primary care of respiratory 
diseases in South Africa by Fairall et al, 2005 but cited and reanalysed by Clark and Bachmann, 
2009.  The ICC of 0.699 was based on the high ICCs implemented by Stryhn et al 2006 when 
they compared different approaches for determining ICCs in terms of their robustness (see 
also section 5.3.2 below).  
2.6 Data collection for impact evaluation 
2.6.1 HIV and TB treatment initiation and testing data 
As part of the evaluation of the intervention, new TB and HIV cases (individuals aged 12 years 
and above) reporting to health facilities in the study district from January 2009 to the 31st 
March 2012 were included in the analysis3. Routine TB and ART patient treatment registers 
                                                          
2The 1.1 million people living in Lilongwe rural accounted for the 10% of the total population in 
Malawi. 
3Children aged below 12 years were excluded because they rarely cough up sputum and confirmation 
by smear examination is impossible. For HIV, the study sought to exclude those who obtained HIV 
through vertical transmission.   
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were the primary sources of data used for measuring the primary outcome measures. Data 
for the TB and ART treatment initiations were collected from patient registers in all the health 
facilities by photographing register pages and directly entered into excel database. To ensure 
all cases were entered in the database, data entry verification was done by comparing number 
of cases in the database and those in the patient registers for each of the health facilities. The 
TB treatment register collected data on patient addresses, testing and treatment initiation 
dates, patient demographics, whether the patient had pulmonary or extra pulmonary TB, 
patient category (new, relapse, return after default, or others), sputum smear microscopy 
results and treatment outcome (cured, treatment completed, failure, died, and transferred out) 
(see Appendix 8.2.1). Similar critical variables were collected in ART patient treatment 
registers (see Appendix 8.2.2).  In addition to the treatment initiation data, testing data for TB 
and HIV were abstracted from registers in TB and HIV testing sites using similar approaches 
described for TB and ART treatment initiation data collection (see Appendices 8.2.3 and 8.2.4 
for data collection forms for TB and HIV testing data).  
Data for TB and ART treatment initiations and TB diagnoses were extracted from patient 
registers from all health facilities in the district. Patients were allocated to the different clusters 
based on their residential address. The rationale for this was the expectation that people 
within clusters might be influenced by the intervention to seek care, but may choose to visit a 
health facility outside their cluster catchment area for a variety of reasons.  However, because 
the HIV testing data were anonymised, data collection was confined to the rural areas and the 
HIV testing data were allocated to clusters based on the location of the HIV testing site, rather 
than by residential address of the person tested. This approach might have led to under-
reporting or over-reporting of cases in a given cluster in a number of ways. First, individuals 
in a given cluster might have gone to a different HIV testing site outside the cluster thereby 
under-reporting such cases from their cluster of residence and over-reporting in the clusters 
where the HIV testing was sought. Second, individuals seeking HIV testing in health facilities 
located in the urban area might have led to underreporting of cases in the study clusters.     
 
These data sources were chosen for several reasons: a) because the intervention was pragmatic 
and would be used to measure programme success rates, which is usually done using the 
routine data sources, b) because of the consistency of data collection methods, treatment 
initiation guidelines and testing methods across all health facilities whether public or not as 
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per policy guidelines, c) due to the extended period required for TB and HIV/AIDS treatment 
, these records are the only reliable source of data for tracking patients’ treatment progress.    
HIV and TB treatment initiation and testing data were collected at baseline (a full one year) 
and during the course of the intervention in both intervention arms.  To strengthen correct 
and complete documentation of data in patient registers in health facilities, all health workers 
involved in documenting patient data in the patient registers (i.e. completing patient registers) 
were trained and further supported by regular supervisory visits. 
 
2.6.2 Contextual factors (Health system and population characteristics data) 
Community contextual factors that are likely to affect the intervention, such as health system 
data (distribution of TB treatment sites, microscopy sites, ART sites, and HIV testing sites by 
cluster and population characteristics (age and gender distribution), were documented at 
baseline. The number of health facilities offering TB and HIV services (i.e. treatment initiations 
and testing services) in each cluster was based on the number of the health facilities physically 
located in the respective clusters. The demographic characteristics (age and gender) of the 
patients for each of the conditions studied were based on the data routinely collected from 
patient registers. Cluster specific populations were based on the 2008 Population and Housing 
census conducted by the National Statistics Office (NSO, 2010).  These cluster population data 
were used in the calculations of incidence rate ratios for the outcome measures for the Triage 
Plus study.   
2.7 Study limitations 
Because of the low level of TB infection in rural areas, the Triage Plus intervention used very 
large clusters. This in turn, created challenges in having adequate number of clusters for the 
two intervention arms (see section 2.3.3.1). The use of a limited number of clusters in the 
Triage Plus study posed some statistical challenges in achieving statistical power and 
obtaining robust estimates when assessing its effectiveness (Murray, Hannan and Baker, 1996; 
Donner and Klar, 2000). With this limited number of clusters, the Triage Plus study is at risk 
of being underpowered and, therefore, failing to detect significant effects.  
To address these foreseeable challenges, alternative approaches in the analysis of the Triage 
Plus study have been pursued in this dissertation. In particular, the use of a repeated 
measurements design to increase the number of degrees of freedom for statistical power and 
robust parameter estimation.  Although previous research has tried to assess this, most studies 
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used at least 5 clusters per arm and no specific guidelines on the number of repeated 
measurements required (e.g. Murray et al., 1998b). In this thesis we investigate the utility of 
taking repeated measurements in cluster randomised trials involving 3 clusters per arm in 
improving statistical power and the robust estimation of parameters (Chapter 5).  
2.8 Conclusion 
This Chapter has provided an overview of the need for engaging informal healthcare 
providers in community interventions to improve access to TB and HIV services. In addition, 
theoretic frameworks that guided the development of the Triage Plus have been briefly 
summarised. The frameworks helped to plan and develop the intervention in a manner that 
would be effective in achieving the intended objectives.  The methodological implementation 
for the Triage Plus study in terms of study design, the development of intervention package, 
randomisation procedures, and data collection methods and type of data collected, was also 
presented. The randomisation of the pair-matched clusters was to ensure comparability 
between intervention arms.  
Furthermore, possible challenges that the Triage Plus study is likely to face in terms of 
achieving adequate statistical power because of the limited number of clusters used for 
randomisation were also presented. The chapter finally suggests the need for further research 
for addressing the foreseeable challenge in statistical power, which forms part of the core 




CLUSTER RANDOMISED TRIALS 
3.1 Introduction 
Chapter 2 presented an overview of the Triage Plus study, which involved informal health 
care providers implementing integrated TB and HIV interventions at the community level. 
The study aimed to assess whether or not engaging these informal healthcare providers would 
improve access to TB and HIV services in Lilongwe rural areas. To allow a better evaluation 
of the intervention, a cluster randomised intervention design was used to allocate three 
clusters to each of the 2 intervention arms (Early and Delayed arms). Although the use of 
cluster randomised trial designs ensure the even spread of known and unknown confounding 
variables between intervention arms, cluster randomised trials have their own inherent 
challenges, such as they are limited by the number of clusters available for randomisation and 
by correlations in the data derived from such cluster randomised designs (Cornfield et al., 
1978; Murray, 1998a; Hayes et al., 2000). 
This Chapter reviews the most commonly used cluster randomised designs for community 
interventions; statistical methods for assessing intervention effectiveness, as well as the 
challenges encountered when cluster randomised intervention designs are used (presented in 
section 3.2). Section 3.3 also discusses some approaches that have been used to address these 
challenges, and section 3.4 discusses the implications of having a limited number of clusters 
in the Triage Plus study in terms of intervention effect estimation. 
 
Given the challenges in mitigating the limited number of clusters in cluster randomised 
designs for each of the alternative approaches, the possibility of adopting a repeated 
measurement design for evaluating cluster randomised designs with a limited number of 
clusters is discussed in section 3.5. The repeated measurement design’s longitudinal nature is 
normally used in investigating changes occurring within the subject or cluster over time, and 
then inferences are made from the results about the general population (Yee and Niemeier, 
1996). Repeated measurement designs may be used to avert the statistical challenges that arise 
due to a limited number of clusters.  This Chapter further reviews the effect measures and 
estimation approaches used in intervention effect evaluation in section 3.6.  Section 3.7 briefly 
presents alternative approaches for analysing hierarchically structured data and discussing 
the challenges inherent in them; section 3.8 concludes the Chapter.  
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3.2 Cluster randomisation trials and their challenges 
3.2.1 Cluster randomisation designs 
Cluster randomised trials are increasingly used in the evaluation of community interventions 
to ensure the generalisation of the intervention’s effectiveness (Campbell et al., 2000; Atienza 
and King 2002).  These cluster randomized trials, also called group randomised interventions 
or community randomised interventions, are comparative studies in which intact clusters of 
individuals are assigned to intervention or control groups. This cluster randomization has 
practical advantages in that all subjects in the cluster are treated in the same way, thereby 
reducing both costs and ethical concerns as pointed out by Donner et al. (1990). This 
randomisation design is usually employed largely because the nature of the intervention 
prevents its implementation at the individual level or for fear of treatment contamination 
between intervention and control groups, which results in a reduction of the effectiveness of 
the intervention (Hayes et al., 2000; Torgerson, 2001; Borm et al., 2005).  
 
Cluster randomised studies have primarily employed either parallel, crossover or stepped 
wedged designs in allocating clusters to intervention groups. In parallel designs, clusters are 
randomized to either an intervention or control arm at the same time point. This approach has 
been used in the evaluation of interventions in cancer research (Allen et al., 2001), antismoking 
interventions (Cummings et al., 1998; Aveyard et al., 2001), HIV and sexually transmitted 
infections (Grosskurth et al., 1995; Rotheram-Borus et al., 2001), and tuberculosis interventions 
(Corbett et al., 2010). In the analysis of parallel cluster randomised trials, Murray (1998a), 
Donner and Klar (2000), Murray et al. (2004,  2008), and Varnell et al. (2004)  have provided a 
review of analytic methods appropriate for such parallel group randomised trials. 
 
In a crossover design, each cluster both receives the intervention and in turn a control in equal 
time intervals (Palmer et al., 1985; Chavasse et al., 1999; Sjogren et al., 2005). In such within-
cluster evaluation designs, a more precise treatment evaluation is allowed and fewer clusters 
are required than in parallel designs (Hussey and Hughes, 2007). However, the time taken to 
complete the evaluation may be twice as long, and knowledge of how the intervention works 
is critical. If the time intervals between switching treatments are short then: a) the intervention 
may not have adequate time to take effect, b) inadequate measurements or outcomes for 
accurate estimates of the impact are possible, or c) there may be a carry-over effect that persists 
from the beginning of the first treatment (Hussey and Hughes, 2007). Thus, crossover cluster 
randomised trials are attractive in treatments with short term response (Pocock, 1997). 
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The stepped wedge design, also known as the dynamic wait-listed, delayed intervention, or 
phased intervention, is a type of crossover design in which different clusters switch treatments 
at different times and the crossover is in one direction from control to intervention (Hussey 
and Hughes, 2007; Brown and Lilford, 2006, The Gambia Hepatitis Study Group, 1987; De 
Allegri et al., 2008).  In a stepped wedge design, the baseline data collection or measurement 
corresponds to the first time point where none of the clusters receive the intervention. Clusters 
are then randomised to intervention at subsequent time points and the response to the 
intervention measured until all sets of clusters have received the intervention (see The Gambia 
Hepatitis Study Group, 1987). 
 
This design approach not only removes the ethical concern of withholding the intervention 
from some communities (Hussey and Hughes, 2007), but it also improves the efficiency of the 
intervention in that clusters act as their own control, thus fewer clusters receive the 
intervention. In addition, the phased assignment of clusters to the intervention leads to a high 
level of project implementation because it reduces the likeliness of intervention activities 
being thinly spread over a large geographical area due to limited human or financial resources 
(Brown et al., 2006). However, the approach extends the time required for the evaluation of 
the intervention. Furthermore, the one direction in which clusters switch treatments makes it 
hard to use within cluster comparisons normally employed in standard crossover designs 
(Hussey and Hughes, 2007).  In this design, the overall effect of the intervention is made 
by comparing between the data points in the intervention and control sections of the 
wedge (Hussey and Hughes, 2007). 
 
3.2.2 Challenges of cluster randomised trials 
The use of cluster randomised trials for evaluating community interventions has received 
considerable attention in recent years. Just as scientific evidence from individually 
randomised clinical trials is considered to be the gold standard, for interventions at the group 
level, the community randomised trial design, where distinct groups of individuals are 
randomised to intervention or control arms is considered to be the gold standard.  Although 
there is an increase in the use of community randomised trials for interventions that are better 
implemented at the group level, the adoption of this type of trial has in turn created 
methodological challenges in the design and evaluation of cluster randomised interventions 
(Murray, 1998; Campbell et al., 2000; Murray et al., 2004). These challenges are primarily the 
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limited number of clusters available for randomisation; and the reduced statistical power due 
to the presence of intracluster correlations (Hayes et al., 2000; Murray, 1998a).  
3.2.2.1 Number of clusters available for randomisation 
The first challenge in cluster randomised interventions is that the number of clusters available 
for randomisation is often limited as the intervention is delivered at the group level (Hayes et 
al., 2000). Ideally to achieve statistical power a large number of clusters are needed. However, 
often a small number of clusters with a large number of participants is randomised to each 
intervention arm (in the Triage Plus study, only 3 clusters were randomised to each 
intervention arm). As pointed out in Chapter 1 section 1.2 and Chapter 2 section 2.3.3.1, large 
numbers of clusters are commonly used for randomisation to different intervention arms to 
ensure adequate statistical power. However, to obtain adequate numbers of events for the 
primary outcome measures (in our case TB and ART treatment initiations), large number of 
people within the clusters are needed.  
 
However, if there is a small number of clusters randomised to each intervention arm, it results 
in a number of challenges: there would be a limited number of degrees of freedom for 
estimating between-cluster variance for cluster-level estimates, which limits the necessary 
power for a valid test for the effect of the intervention (Cornfield 1978; Koepsell et al., 1991; 
Murray, Hannan and Baker 1996; Murray, 1998; Donner and Klar, 2000).  Therefore, sample 
size calculation in cluster randomised trials should primarily be based on the number of 
clusters per condition and not only on the number of individuals (Murray, 1998a; Feldman, 
McKinlay and Niknian, 1996). Variations between cluster-level outcomes are more important 
than the within cluster variations when assessing intervention effect (Feldman, McKinlay and 
Niknian, 1996; Maas and Hox, 2005; Moineddin, Matheson and Glazier, 2007; Hayes and 
Moulton, 2009). However, the use of large cluster sizes in community interventions reduces 
variability in variance between clusters (Hayes and Moulton, 2009). Thus, the statistical power 
in a study and the precision of parameter estimates of intervention effects largely depend on 
the observed variability between clusters of the effect measure.  
 
However, despite the need for more clusters for improved power in intervention effect testing, 
underpowered community randomised intervention studies with inadequate groups still 
exist (Donner et al., 1990; Simpson, Klar, and Donner, 1995; Varnell et al., 2004; Murray et al., 
2008; Pals, Wiegand and Murray, 2011).  A review by Pals, Wiegand and Murray (2011) of the 
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HIV/AIDS community intervention trials published between 2005 and 2009 showed that 
about half of the trials used five or fewer groups per condition. Similarly, Varnell et al (2004), 
found that in a review of group randomised trials published in the American Journal of Public 
Health and Preventive Medicine from 1998 through 2002, 15 (25%) of the trials assigned five 
groups or less to each treatment, and 3 (5%) had one group per treatment arm. Simpson et al 
(1995) in a review of the same American Journal of Public Health and Preventive Medicine 
about a decade before in articles published from 1990 through 1993 observed similar trends. 
In their review they found that eight of the trials had 8 or fewer clusters per intervention group 
and two had one cluster per intervention group. A review by Donner et al. (1990) for trials 
published from 1979 through 1989 in various journals found similar results.  
 
With a limited number of clusters, another challenge is that the standard errors, p-values and 
confidence intervals of intervention effects are underestimated, though point estimation of 
intervention effects are unbiased (Feng et al., 2001; Maas and Hox, 2005; Moineddin, Matheson 
and Glazier, 2007).   
 
Furthermore, with a small number of clusters, it is difficult to achieve the even distribution of 
potential confounders between intervention arms, which compromises the internal validity of 
the trial (Murray, 1998a; Donner and Klar, 2000; Varnell et al., 2001). Statistical adjustments of 
the confounding variables may reduce the imbalance of the measured variables. However, 
this adjustment may not remove imbalances in unmeasured confounding variables as pointed 
out by Kramer et al. (2009). This reduces the likelihood of making causal inferences on the 
effect of the intervention when comparing the study conditions (Murray, 1998a).   
 
3.2.2.2 Reduced statistical power due to within cluster correlation of outcomes 
 
Use of clusters or communities as units of randomisation in cluster randomised studies leads 
to the correlation of outcome measures within the clusters because of the similarity of values 
for the outcome measures taken from members of the same cluster (Hayes and Moulton, 
2009).In cluster randomised interventions, the between and within group variability in the 
response outcomes is usually larger than that for individually randomised trials due to the 
correlation of outcomes within clusters (Kish, 1965; Mickey et al., 1991).    
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This extra variation is in part due to differences in characteristics between groups and in part 
by the mutual interaction of individuals within the same group as pointed out by Feng et al. 
(2001). Furthermore, people living within the same cluster tend to be more similar than do 
individuals across different clusters because they share the same environment and interact 
with each other (Kim et al., 2006). 
 
For example, in a community intervention aimed at reducing waterborne diseases, 
individuals in the same community are more likely to use the same water source, a different 
source than people in other communities use. If the community’s water source is 
contaminated with waterborne infections, then individuals using that water source would be 
more likely to develop the disease than the other individuals in different communities who 
do not use the contaminated source.  
 
The within cluster correlation of outcomes is usually assessed by the intracluster correlation 
coefficient (ICC) that measures magnitude of correlation among cluster members (i.e. the 
proportion of the true total variation in the outcome that is attributed to differences between 
the clusters).Specifically, the ICC measures the correlation between outcome measures for two 
randomly drawn individuals from the same cluster. The ICC, denoted as 𝜌, can be expressed 
in terms of the variance components as 𝜌 = 𝜎𝑏
2/(𝜎𝑏
2 + 𝜎𝑤
2 ), where 𝜎𝑏
2 is the between-cluster 
component of the variance and 𝜎𝑤
2  is the within-cluster component of the variance with 
subscripts 𝑏𝑏  and 𝑏𝑤  representing between and within variation respectively (Parker, 
Evangelou and Eaton, 2005; Kim et al., 2006).  
 
In cluster randomised trial designs, the within-cluster variance 𝜎𝑤
2  is usually larger than the 
variance between clusters𝜎𝑏
2, and therefore, ICCs obtained in cluster randomised trials are 
usually small. For example, in the thrombosis prevention trial conducted by the Medical 
Research Council, an intervention targeting directly at the patient, the two components of 
variance were 𝜎𝑤
2 = 1.28and 𝜎𝑏
2 = 0.0046, and therefore, the intracluster correlation coefficient 
was 0.0036 (Meade et al., 1992).   When the intervention is directly aimed at individual 
members of each cluster, then the variability of the outcome measurement is greater than the 
between cluster variability.  However, when the interventions aim to target, say, the doctor in 
order to change the doctors’ behaviour in the management of patients, then the ICC is likely 
to be higher because the estimated ICCs include the variation in the doctors' responses. For 
instance, the intracluster correlation was estimated to be 0.0190 in a trial of guidelines to 
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improve the appropriateness of general practitioners' referrals for x ray examinations 
(Oakeshott, Kerry, and Williams, 1994). 
 
The within-cluster correlation affects the required sample size of the study, which in turn, 
affects the statistical power and the precision of the estimates of the effect of the intervention 
(Smeeth and Siu-Woon Ng, 2002). The extent to which these within-cluster correlations affect 
the sample size required for a study is known as the design effect (DEFF) or variance inflation 
factor.  The design effect, defined as the ratio of the total number of individuals required using 
cluster randomisation to the number required using individual randomisation, is better 
presented in terms of the ICC and the number of individuals in each cluster (Kerry and Bland, 
1998). Thus, the design effect depends on both the size of each cluster (m) and the intracluster 
correlation coefficient (ρ) and is given by    
 
𝑏𝑏𝑏𝑏𝐷𝐸𝐹𝐹 = 1 + (𝑚 − 1)𝜌                       (3.1) 
 
However, in the case where population sizes vary across clusters, cluster population m can be 
replaced by an ‘adjusted’ mean cluster size (Kim et al., 2006) defined as 
 






         (3.2) 
where m denotes the cluster sizes, M is the total population across all clusters, j = 1,…, N 
indexes clusters.  
 
In this formulation of the design effect in (3.1), when m=1 the design effect would be 1 
denoting an individually randomised trial. Similarly, if the intracluster correlation coefficient 
𝜌 = 0, indicating the absence of the within-cluster correlations, then the design effect would 
be 1. Using the ICC of 0.019 from the x ray guidelines study (Oakeshott, Kerry, and Williams, 
1994) and m=60 referrals per practice, then the design effect, DEFF =1+(60−1)×0.019=2.121. 
Thus, to achieve the required statistical power and precision of the estimates of the effect of 
the intervention, the cluster randomised trial design would require just over twice as many 
individuals as an intervention study where individuals were randomised to the intervention 
arms (Kerry and Bland, 1998; Smeeth and Siu-Woon Ng, 2002).  
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The design effect, therefore, quantifies the extent to which the increase in variance resulting 
from the use of cluster sampling in a cluster randomised intervention design departs from the 
variance obtained under simple random sampling (Hayes and Moulton, 2009) as: 
 
𝐷𝑒𝑠𝑖𝑔𝑛 𝑒𝑓𝑓𝑒𝑐𝑡 =  
𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑓𝑜𝑟 𝑐𝑙𝑢𝑠𝑡𝑒𝑟 𝑠𝑎𝑚𝑝𝑙𝑖𝑛𝑔
𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 𝑓𝑜𝑟 𝑠𝑖𝑚𝑝𝑙𝑒 𝑟𝑎𝑛𝑑𝑜𝑚 𝑠𝑎𝑚𝑝𝑙𝑖𝑛𝑔
 
 
Therefore, the larger the ICC due to increased variation between clusters, the bigger the design 
effect and the more individuals that need to be recruited to get the same power as that of an 
individually randomised study (Kerry and Bland, 1998). Thus, the statistical power in cluster 
randomised studies is not only affected by the number of clusters available for randomisation, 
but also increases with decreasing ICC (Heo and Leon, 2005). In the simulation studies 
performed to assess the performance of a mixed effects logistic regression model for binary 
outcomes under unequal cluster sizes, the statistical power decreased from 88.1% to 10.4% 
when the ICC were 0.0 and 0.3 respectively with the number of clusters set at 20. It was also 
observed that statistical power was comparable for both equal and unequal cluster sizes (Heo 
and Leon, 2005) though You et al (2011) observed reduced statistical power with unequal 
cluster sizes and that increasing the number of clusters compensated for the power loss due 
to variation in cluster sizes. 
 
The presence of within-cluster variation (whatever its magnitude) makes the intracluster 
correlation coefficient 𝜌 > 0, and in turn, the design effect > 1, which then affects the sample 
size needed in the cluster randomised trial design. However, the main challenge in 
determining sample sizes for cluster randomised trials is having an estimate of the intracluster 
correlation. 
 
Given that in cluster randomised trials, a small number of clusters are commonly used with a 
relatively large number of individuals within each cluster, presence of even a small ICC can 
lead to a substantial design effect (Murray, 1998a).   For example, Kim et al (2006), 
demonstrated that even a small ICC of 0.01 resulted in the increase of the number of 
individuals from 675 in an individually randomised study design to 1000 individuals in a 
cluster randomised design when the average cluster size approached 50.  
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The presence of positive correlations within or between clusters in cluster randomised studies 
limits statistical power to detect intervention effect (Murray, Hannan and Baker, 1996). Cluster 
randomised trials are therefore attractive in settings in which individual randomization is 
difficult or impossible (Isaakidis and Ioannidis, 2003). 
 
Although the size of the ICC in community randomised interventions is usually very small 
(Gulliford, Ukoumunne, and Chinn, 1999), ignoring extra variation due to intra-cluster 
correlation results in under estimating the variance of the intervention effect, which, in turn, 
leads to an inflation of type I error rates, or the likelihood of rejecting a true null hypothesis 
(Feng et al., 2001, Murray et al., 2008). With the ICC in cluster randomised interventions often 
being small and the clusters often being fairly large, significance tests to determine whether 
the ICC differs from 0 usually have low power. Therefore, assuming that there is no clustering 
effect if the test is not significant would produce misleading results and is discouraged 
(Donner and Klar, 1996). Thus, standard analytical methods usually yield inflated type 1 error 
rates, thereby leading to false associations and misleading interpretations (Cornfield, 1978; 
Feng et al., 2001; Murray, 2008).  
3.3 Approaches to address the limited number of clusters 
To counteract the inherent challenges resulting from cluster randomised trials, in particular, 
the extra variation and reduced degrees of freedom that stem from the limited number of 
clusters available for randomisation, several approaches have been suggested (Hannan et al., 
1994; Feldman, McKinlay and Niknian, 1996; Murray, Hannan and Baker 1996; Varnell et al., 
2001).  
First, to control for the extra variation resulting from the intracluster correlation, the use of 
post hoc correction with a valid external estimate of the intracluster correlation coefficient has 
been proposed (Varnell et al., 2001; Hannan et al., 1994). However, because the ICC measures 
the proportion of total variation that can be attributed to being between-cluster, Hayes and 
Moulton (2009) caution using the ICC when similar outcome measures are obtained from 
different settings. Obtaining ICC estimates in the same target population for the same 
measures is usually not possible because no similar studies with the same measures might 
have been conducted in the target areas.   
 
A second proposal is to subdivide the original clusters into small sub-clusters and conduct an 
analysis at the sub-cluster level, to estimate the intervention effect (Feldman, McKinlay and 
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Niknian, 1996; Murray, Hannan and Baker, 1996; Varnell et al. 2001). Clusters are usually 
subdivided to increase the number of clusters within each intervention arm so that group level 
variation is captured and additional degrees of freedom for hypothesis testing are achieved 
(Feldman et al. 1996; Murray, Hannan and Baker, 1996; Varnell et 2001). 
 
In a simulation study by Murray, Hannan and Baker (1996) designed to test the validity of 
this approach, they showed that sub-cluster level analysis, in the case of two or more clusters 
per intervention arm, yielded type 1 error rates with small ICCs and captured most of the 
group level variance. However, using this approach one risks overstating the statistical 
significance of the effectiveness of the intervention; therefore, to ensure nominal type I and 
type II error rates, they recommended using the degrees of freedom based on the unit of 
randomisation when assessing the effectiveness of the intervention.  
 
Varnell et al., (2001) conducted simulation studies meant to test the validity of this approach 
for evaluating situations with one cluster per intervention arm. They achieved a nominal type 
I error rate when the ICC was close to zero or when there were fewer sub-clusters per cluster. 
Cluster-level variance was captured by the sub-clusters.  A similar study was conducted by 
Feldman, McKinlay and Niknian (1996) and was aimed at increasing the residual degrees of 
freedom: when two experimental units were applied (using the Pawtucket Heart Health 
Program with large social units which used one-group-per-condition randomisation design 
with one community in the intervention condition and one community in the control 
condition) the results showed that by dividing the experimental units into sub-communities 
per intervention arm, the statistical power improved when the number of sub-communities 
as well as the number of measurement time points increased.  
 
In studies that randomise  one cluster to each study arm, one could not determine the extent 
to which the overall cluster variation is captured by the sub-cluster variations - the cluster 
variation cannot be estimated because the degrees of freedom to estimate the intervention is 
zero (Varnell et al., 2001; Feng et al., 2001). 
3.4 Implications of the limited number of clusters in the Triage Plus study 
With only 3 clusters in the Triage Plus study, the statistical power to detect significant 
intervention effects is likely to be reduced due to the limited number of degrees of freedom 
for the between cluster residual error (Cornfield 1978; Koepsell et al., 1991; Feldman, 
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McKinlay and Niknian, 1996; Murray1998, Donner and Klar, 2000). Furthermore, any slight 
random variation may limit the power of the analysis to detect an intervention effect.  
 
However, it is worth noting that in certain situations, the availability of a sufficient number of 
clusters for randomization might not be practical and making major modifications to the 
intervention to suit its evaluation may not be recommended (Hayes et al., 2000). Having more 
clusters in such studies not only increases the marginal cost, which may be prohibitive, but 
also increases logistical challenges in its implementation.  
 
These challenges necessitate the use of methodological approaches that will address both 
design and analytic issues for the valid interpretation of community intervention trials. In 
particular, statistical methods and design conditions that will optimize statistical power and 
the accuracy of the estimated intervention effect are required. A number of simulation studies 
have compared the various design conditions that allowed the number of clusters per arm, 
number of subjects per cluster, intervention effect size and the intra-cluster correlation to vary 
(Austin, 2007; Moineddin, Matheson and Glazier, 2007; Maas and Hox, 2005; Bennett et al., 
2002). Most of these studies showed improved statistical power and parameter estimates 
when the number of clusters increased to at least 30 clusters in total. 
 
Considering the cost involved in cluster randomised interventions, the benefit of adopting an 
effective intervention of public health importance is crucial. It is imperative to assess the 
relative performance of different design approaches, such as the use of repeated 
measurements within the same cluster over time coupled with the use of statistical modelling 
approaches in estimating intervention effects when the design demands a small number of 
clusters. 
 
Thus, the use of correct and efficient design and evaluation procedures in interventions with 
a limited number of clusters is paramount (Feng et al., 2001). Identifying an appropriate 
statistical model that addresses the correlation inherent in cluster randomised interventions 
and the need for adequate degrees of freedom for adequate statistical power would provide 
robust estimates of intervention effectiveness.  
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3.5 The repeated cross-sectional design for impact evaluation 
Because the commonly used likelihood based approaches in evaluating intervention 
effectiveness require adequate degrees of freedom (i.e. adequate number of clusters) for 
proper analysis, utility of repeat observations within the same cluster in cluster randomised 
designs with limited clusters is assessed. Thus, in evaluating the Triage Plus study, the 
longitudinal nature of the study is used, as it provided cross-sectional data to assess the ability 
of multiple data collection points to provide adequate statistical efficiency in terms of the 
power and precision of parameter estimates. The repeated measurements design may not only 
induce cluster-level autocorrelation but also increase the degrees of freedom, resulting in 
some gain in statistical power to detect intervention effects (Donner and Klar, 2000; Hayes 
and Moulton, 2009). Murray et al. (1998b) observed that if the model is correctly specified, the 
repeated measurements in each clusters would increase the degrees of freedom for assessing 
the effectiveness of the intervention, especially in a random intercept model. Although power 
would increase in a random coefficients model because of the repeated measurements, the 
number of degrees of freedom would remain the same (Murray et al., 1998b).   
 
An investigation of the utility of repeated measurement design within the same clusters has 
been used in a wide range of statistical scenarios to assess the efficiency of their statistical 
power and their precision in parameter estimates (Feldman and McKinlay, 1994; Feldman, 
McKinlay, and Niknian, 1996; Murray et al., 1998b; Heo and Leon, 2009; Heo, Xue, and Kim, 
2013). Feldman, McKinlay and Niknian (1996) used simulation methods to investigate if 
increasing the number of repeated measurements within a cluster would improve the 
statistical power and the precision estimates of parameters in a study design involving two 
experimental units consisting of sub-clusters. Statistical power was shown to have improved 
with an increase in the number of measurement times.   
 
Murray et al. (1998b) used repeated measurement to assess the behaviour of type I error rates 
under different design conditions. Using 5 clusters per arm and 5 repeated measurement 
times, random intercepts and random coefficients models achieved nominal type I error rates, 
with the random coefficients model performing well under different data generation 
assumptions (random intercepts or random coefficients data structure). They further showed 
that at 10 groups or less the empirical sandwich method to estimate standard errors for fixed 
effects performed poorly, but at groups 20 or above, the sandwich estimator performed better.  
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In assessing the effect of study duration, frequency of observation and sample size on 
statistical power using published data, Raudenbush and Xiao-Feng (2001) demonstrated that 
statistical power increased with an increase in the frequency of observations and study 
duration. They also noted that having more participants included in the study was more 
efficient than increasing the frequency of observation for boosting statistical power.  However, 
most of these simulation studies tended to use at least 5 clusters per arm. 
Adopting a repeated measurement design such as multiple cross sectional data collection over 
the period of the intervention, a small number of clusters (as in the Triage Plus) would achieve 
a similar level of statistical power compared to a pre-post cross-sectional design with more 
clusters (Hedeker and Gibbons, 2006). In multiple cross sectional designs within the same 
clusters, the sampled individuals at each time point are usually independent (especially in 
large sized clusters) unlike in cohort designs where the same individuals within the clusters 
are measured (Feldman and McKinlay, 1994). Therefore, in repeated measurements using a 
cross sectional design, the outcome measures taken repeatedly in the same cluster are not 
perfectly correlated since ICCs in community interventions are usually small (Gulliford, 
Ukoumunne, and Chinn, 1999).  
With these two factors (independence of samples and non-perfect correlations in outcome 
measures), the repeated cross sectional design in the same clusters provides more 
independent data than in pre-post cross- sectional designs (Hedeker and Gibbons, 2006). At 
each cross section data collection point, a given number of participants would be included in 
the study. The likelihood of the same participants being included in the subsequent cross 
sectional studies would be minimal especially in studies involving large clusters with large 
populations (Hedeker and Gibbons, 2006).  Thus, studies employing cross sectional designs 
with more data collection time points would therefore yield more individual data for 
improved statistical power than when just one cross section data collection is conducted in 
each cluster.   
Furthermore, because in repeated cross sectional designs, the sampled individuals remain 
independent and representative at each time of data collection, the method is less affected by 
both secular trends and the Hawthorne effect (i.e. where the subject's behaviour may be 
affected by the repeated measurement e.g. in a cohort design) as pointed out by Feldman and 
McKinlay (1994).  However, in the health facility based data collection of the Triage Plus 
study, the observed number of individuals accessing health services from each cluster at each 
time point would be correlated. The number of events (e.g. TB cases starting treatment) would 
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not only change with time due to either more cases being detected earlier or the number of 
cases detected increasing with increased exposure to the intervention, but also the interaction 
of these individuals accessing health services with other community members. This, therefore, 
necessitates the use of modelling approaches that takes into account the correlations of the 
outcome measures.    
The number of degrees of freedom required to detect significant effects for a given power 
which is achieved through a repeated measurement design, is given by (Feldman, McKinlay 
and Niknian, 1996) 
 
Degrees of freedom = 𝐼(𝑁 − 1)(𝑇 − 1) 
 
where  
I refers to the number of treatment arms,  
N is the number of clusters per arm, and  
T is the number of repeated measurements (i.e. cross sectional data collection) within each 
cluster.  
 
Given that the Triage Plus study has 2 intervention arms, 3 clusters per arm, and the 
intervention was implemented for 12 months before roll out to the Delayed arm; the number 
of degrees of freedom increases from 4 for a pre-post design to 44 for 12 repeated 
measurements. Details for model formulation for the cross sectional design or repeated 
measurements approach are given in Chapter 4 and Chapter 5.  
3.6 Measures of effect: Odds ratios, prevalence ratios and incidence rate ratios 
 
3.6.1 Appropriate measures for the effectiveness of the intervention 
There has been intensive debate regarding the appropriateness of the prevalence odds ratio 
(OR) and the prevalence ratio (PR) as measures of effect in cross sectional studies, following 
a letter by Lee and Chia (1993) proposing the use of Cox regression models for a binary 
outcome in a cross-sectional study in order to estimate prevalence rate ratios. The prevalence 
ratio (PR) in cross-sectional studies is similar to the incidence rate ratio (IRR) in longitudinal 
cohort studies.  They noted that prevalence odds ratios lacked intelligibility, unlike prevalence 
ratios, which are easy to interpret and communicate.  Stromberg (1994) argued that under 
certain stationarity assumptions on the study population and given that the mean duration of 
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the disease among exposed and non-exposed subjects is known, a prevalence odds ratio can 
be converted into an incidence rate ratio (IRR).  
 
However, Axelson et al. (1994) noted that such stationarity assumptions may not always work 
and concluded that prevalence ratios may be more interpretable and intelligible measures of 
effect than prevalence odds ratios. Osborn and Cattaruzza (1995), while agreeing that in some 
cases prevalence odds ratios may be incomprehensible compared to prevalence ratios, argued 
that the effect measure to be used in the study depends on the problem at hand.   However, 
McNutt et al. (2003) and Thompson et al. (2004) as cited in Laupacis et al. (1988) noted that in 
public health, one is interested in estimating prevalence ratios or risk ratios and not prevalence 
odds ratios.  
 
Not only do prevalence odds ratios overestimate prevalence ratios, especially when a disease 
outcome is common (say more than 10%), but also controlling for confounding in prevalence 
odds ratio results in an estimate that is even further away from the prevalence ratio than the 
unadjusted prevalence odds ratio (Axelson et al., 1994).  However, if the disease is rare, the 
difference between the prevalence odds ratio and prevalence ratio is numerically negligible 
(Axelson et al., 1994, Skov et al. 1998). Therefore, when testing rare diseases, the prevalence 
ratio can be estimated by using logistic regression. However, it worth noting that in cross-
sectional studies, high prevalence diseases are usually targeted, and the estimation of the 
prevalence ratio using logistic regression would be a poor approximation (Skov et al., 1998).  
 
Historically, in cohort studies the Mantel-Haenszel procedure (Mantel and Haenszel, 1959) 
was used to estimate adjusted risk ratios if the covariates were all categorical but the 
procedure failed to work when some of the covariates were continuous (Deddens and 
Petersen 2008). Zhang and Yu (1998) proposed a formula to derive relative risks from adjusted 
odds ratios obtained through logistic regression as: 
 
RR =  
OR
(1 − P0) + (P0xOR)
 
 
where P0 indicates the incidence of the outcome in the non-exposed group, and (1- P0) in the 
exposed group; OR is the odds ratio, and RR is the risk ratio.   
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However, McNutt et al. (2003) noted that this conversion of odds ratios to relative risks would 
result in biased estimates if confounding is present.  
These discussions led to investigators recommending alternative statistical models for directly 
estimating prevalence ratios and confidence intervals from cross-sectional or longitudinal 
studies (Wacholder 1986; Breslow 1974; Lee, 1994; Skov et al. 1998; McNutt et al., 2003; 
Deddens et al. 2003; Lumley et al., 2006; Savu et al., 2010). Although the use of prevalence 
ratios in cross-sectional studies is widely recommended, the only drawback is its lack of a 
practical model from which to conduct statistical analysis. Statistical methods that can directly 
estimate and test prevalence ratios, while adjusting for several confounders, are needed. In 
this section, we, therefore, review the different statistical methods for estimating intervention 
effectiveness using prevalence ratios as measures of intervention effect.  
3.6.2 Estimation of prevalence ratios and incidence rate ratios 
Estimations of prevalence ratios (PR) in cross sectional studies or incidence rate ratios (IRR) 
in longitudinal cohort studies arise from different statistical approaches in varying forms. 
Most notably, approaches based on Cox regression (Breslow, 1974; Lee, 1994), Poisson 
regression (McNutt et al., 2003; Petersen and Deddens, 2008), log-binomial regression 
(Wacholder, 1986; Zocchetti, 1995; Skov et al., 1998), and the COPY method (Deddens et al., 
2003) have been used to estimate prevalence ratios. These models fall under the generalised 
linear models framework, a class of fixed effects models which provides a unified procedure 
for fitting models based on a likelihood framework (Nelder and Wedderburn, 1972; 
McCullagh and Nelder, 1989).  These models accommodate non-normal response variables 
such as count or binomial data. The formulation of generalised linear models involves the 
specification of a linear predictor, link function and variance structure for the response 
outcome 𝑦𝑖 for the individuals (McCullagh and Nelder, 1989). 
 
The linear predictor in the GLM framework is given by: 
 
𝜂𝑖 =  𝑥𝑖𝛽                            (3.3) 
 
where 𝑖 = 1, … , 𝑛 indexes the individual observations, 𝑥𝑖 is a vector of explanatory variables, 
𝛽 is a vector of corresponding regression coefficients.  
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The link function 𝑔(. ) relates the mean value 𝜇𝑖 of response variable 𝑦𝑖 [ie 𝜇𝑖 = 𝐸(𝑦𝑖)] to the 
linear predictor 𝜂𝑖 
 
𝑔(𝜇𝑖) =   𝜂𝑖                        (3.4) 
 
This is then concluded by specifying the variance structure of the mean 𝜇𝑖, which depends on 
the distribution of the response variable 𝑦𝑖. The link function and variance of 𝜇𝑖 is assumed to 
be within the exponential family (McCullagh and Nelder, 1989).  
 
Below are the various statistical approaches for estimating prevalence ratios (or risk ratios) 
assuming no clustering of individuals. These are given with the aim of identifying models to 
be pursued in Chapter 4 in the context of a generalised linear mixed model framework, in 
which clustering will be taken into account.    
3.6.2.1 Cox regression model 
The Cox proportional hazards regression model was designed for estimating conditional 
hazard ratios and survival rates in subjects with different risk periods and has been adapted 





Given ℎ0(𝑡)  is the baseline hazard at time 𝑡,  then the individual hazard ℎ𝑖(𝑡)  at time 𝑡  is 
defined as 
ℎ𝑖(𝑡) = ℎ0(𝑡)𝑒
𝑥𝑖𝛽               (3.5) 
 
or, equivalently,  
𝑙𝑜𝑔ℎ𝑖(𝑡) = 𝑙𝑜𝑔ℎ0(𝑡) +  𝑥𝑖𝛽               (3.6) 
 
in a log scale, with subscript  𝑖  =1,...,n indexing individual observations, 𝑥𝑖  is a vector of 
explanatory variables and 𝛽 is a vector of corresponding regression coefficients.  
 
By assuming a constant risk period for all individuals, the Cox regression model estimates a 
cumulative incidence ratio (Breslow, 1974), which can then be adapted to estimate the 
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prevalence ratio in cross-sectional studies (Lee 1994). Skov et al. (1998) and Barros and 
Hirakata (2003) showed that point estimates derived from the Cox model were close to the 
true parameters with negligible bias. However, the standard errors were too large when the 
disease is a common one, due to the underlying distribution of the outcome following a 
Poisson distribution (Skov et al., 1998; Barros and Hirakata, 2003). But in cross sectional 
studies, prevalence data follows a binomial distribution; therefore, the variance of the 
coefficients derived from the Cox model are overestimated, which results in wider confidence 
intervals for the estimated parameters (Barros and Hirakata, 2003).  
 
With a constant risk period and by handling ties properly, Breslow (1974) showed that the 
partial likelihood estimates and the estimated standard errors of the non-intercept parameters 
from the Cox proportional hazards regression model are similar to those from a Poisson 
regression model. Barros and Hirakata (2003) pointed out that the Poisson model has 
advantages over the Cox proportional hazards regression model in that the Cox model does 
not have an intercept and therefore cannot estimate probabilities. The Poisson regression 
model, in this instance, is preferred.  
3.6.2.2 Poisson regression model 
The Poisson regression model was developed for studies of rare conditions where subjects 
may be followed up for different time periods. However, if the exposure time for all subjects 
is the same, then the exponentiated coefficients in the log link function in the Poisson 
regression model are interpreted as incidence rate ratios (Rabe-Hesketh and Skrondal, 2012, 
McNutt et al., 2003).  
 
Poisson models yield less precise estimates, especially when the outcome is common, since 
Poisson errors overestimate binomial errors (McNutt et al. 2003). The overestimation of 
binomial errors occurs because the variance for the binomial distribution reaches its 
maximum when the prevalence is 0.5, unlike that of the Poisson distribution which increases 
progressively (Coutinho et al. 2008).  In correcting for the error misspecification in Poisson 
models, Zou (2004) proposed using a sandwich estimator to obtain the corrected variance, 
which improves variance estimation considerably. Barros and Hirakata (2003) also assessed 
Poisson regression with scale parameter adjustments with deviance and chi-square (i.e. the 
estimated Poisson variance is multiplied by an estimate of the overdispersion obtained by 
dividing the deviance or the chi-square of the estimated model by their respective residual 
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degrees of freedom). They concluded that the Cox and Poisson regression models with robust 
variance estimation performed well. However, the Cox and Poisson regression methods may 
give rise to predicted probabilities above unity (Deddens and Petersen, 2004; Petersen and 
Deddens, 2008), especially when the estimates are on the boundaries of the parameter space.   
 
The Poisson model 
Given that a Poisson distribution is assumed for the response variable 𝑦𝑖  (i= 1,...,n), 
representing the number of events detected during an interval of time e.g. per month, and the 
average number of events are denoted by parameter  𝜇 , then the likelihood of response 
outcome 𝑦𝑖 given parameter 𝜇 (Kuhn et al. 1994) is given by 
 
𝑝(𝑦 = 𝜇) =
𝑒−µµ𝑦
𝑦!
, 𝑦 = 0, 1, … , ;  µ > 0                  (3.7) 
and 
𝐸(𝑦𝑖) = 𝑣𝑎𝑟(𝑦𝑖) = 𝜇. 
 
Since in the Poisson model relative risk or prevalence ratio estimates are often desired instead 
of the mean, the expectation of the response outcome should be modelled as a function of the 
relative risk λ given the independent variables  𝑥𝑖  and corresponding regression parameters 
𝛽𝑖. Given vector  𝑌 is the number of events from a population size of𝑁 thenin vector notation 
 
E(Y) = N λ(X, β)    (3.8)     
 
To obtain the estimates of the β parameters, the function λ is modelled as an exponential 
function of independent covariates, 
  
𝜆(𝑋, 𝛽)  =  𝑒𝑥𝑝(𝑋 𝛽)  =  exp(𝑥𝑖𝛽) 
or, equivalently,  
 
log(µ) = 𝑥𝑖𝛽 , 𝑖 = 1, 2 . . 𝑛.           (3.9) 
 
where 𝜇 is the mean number of events recorded in 𝑛 subjects. To obtain the rates of incidence 
of an event, the Poisson regression model (3.9) is then given by 
 
55 
log(µ) = log(𝑁) + 𝛽0 + 𝛽1𝑥1𝑖 + … …                  (3.10) 
 
log (N) is used as an offset with a constant coefficient of 1 for each observation, with  𝑥𝑖 and 𝛽  
as defined above. Given that the 𝑥1 is a variable denoting the individual’s exposure to the 
intervention, then using this approach, 𝛽1 denotes the intervention effect on the log relative 
risk scale for follow up studies or logged prevalence ratios in cross sectional studies for the 
early compared to the delayed groups while adjusting for all other covariates in the model. 
The significance of the intervention effect is then assessed by testing the hypothesis 𝐻𝑜: 𝛽1 =
0 
3.6.2.3 Log-binomial models 
Given that estimates derived from Cox/Poisson regression models are less precise, Wacholder 
(1986) and Zocchetti (1995) proposed to model the prevalence ratio with a logarithmic link 
function in the context of binomial variability, and Skov et al. (1998) called this a log-binomial 
model which estimates prevalence ratios directly (Wacholder, 1986; Zocchetti et al. 1995; Skov 
et al., 1998; Barros and Hirakata, 2003; Lumley et al., 2006; Petersen and Deddens, 2008).  
 
If 𝑛 represents independent observations assumed to come from a binomial distribution with 
response variable  𝑦𝑖  taking values 1/0 denoting the presence/ absence of the event in a 
subject, then the conditional probability of response variable 𝑦𝑖: p(𝑦𝑖= 1|𝑥𝑖) given 𝑥𝑖vector of 
covariates for each subject under the log-binomial regression model is given by  
 
𝑝𝑖 = 𝑝(𝑦𝑖 = 1|𝑥𝑖) =  exp (𝛽0 + 𝛽1𝑥𝑖1 + ⋯ ) 
 
and the probability of the absence of the event for each subject is: 
 
𝑝𝑖 = 𝑝(𝑦𝑖 = 0|𝑥𝑖) = 1 − exp(𝛽0 + 𝛽1𝑥𝑖1 + ⋯ ) 
 
Therefore, in the context of the independence of the observations, the likelihood function for 
each subject under binomial sampling distribution for data vector 𝑌  is given by (Savu, Liu 
and Yasui, 2010):  
 
𝐿( 𝑌; 𝛽) = ∏(𝑒𝛽0+ 𝛽1𝑥𝑖1 +⋯)𝑦𝑖(1 − 𝑒𝛽0+ 𝛽1𝑥𝑖1 +⋯)𝑛𝑖−𝑦𝑖
𝑛
𝑖=1
           (3.11) 
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or, equivalently, the log likelihood  
𝐿𝑜𝑔 𝐿(𝑌;  𝛽) = ∑[𝑦𝑖𝑥𝑖𝛽 + (1 − 𝑦𝑖)log (1 − exp(𝑥𝑖𝛽))
𝑛
𝑖=1
]                 (3.12) 
 
with 𝑛 denoting the number of independent observations and 𝑦𝑖the outcome responses (𝑖 =
1,2 … , 𝑛) indexes individual observations, the sampling distribution  for data 𝑦𝑖 given a 
vector of explanatory variables X, with corresponding regression coefficients β under the 
binomial model is given by  
 
𝑝(𝑌|𝛽, 𝑋) = (
𝑛
𝑦𝑖
) (𝑒𝛽0+ 𝛽1𝑥𝑖1 +⋯)𝑦𝑖(1 − 𝑒𝛽0+ 𝛽1𝑥𝑖1 +⋯)𝑛𝑖−𝑦𝑖      (3.13) 
 
and the parameter space is defined as  
 
𝛽0 +  𝛽1𝑥𝑖1 + ⋯ ≤ 0, 𝑖 = 1,2, . . , 𝑛                              (3.14)  
 
where 𝛽0 +  𝛽1𝑥𝑖1 + ⋯is the log-binomial model’s linear predictor, and 𝛽0, 𝛽1, 𝛽2 … is a vector 
of model parameters to be estimated from the data (Lumley et al., 2006; Deddens and Petersen, 
2008). Given 𝑥1  is a binary exposure of interest, exp(𝛽1)  is the adjusted prevalence ratio 
comparing the subjects exposed to the intervention with the non-exposed group while 
adjusting for the effects of other explanatory variables.  
 
Since 𝑝(𝑦𝑖 = 1|𝑥𝑖) is a probability, the model requires constraints on vector β so that fitted 
probabilities are always between 0 and 1; therefore, the parameter space for a log-binomial 
model is a convex cone (Deddens and Petersen 2008; Savu, Liu and Yasui, 2010). Thus, in log-
binomial models, the maximum likelihood estimates are derived by maximizing the 
parameters’ space 𝛽0 + 𝛽1𝑥𝑖1 + ⋯ ≤ 0 for each observation i (Wacholder, 1986; Skov et al., 
1998; Deddens and Petersen, 2008), and as such, the maximum likelihood estimator will only 
be asymptotically Normal if the true β is within the parameter space (Lumley et al., 2006).  
 
However, this restriction on the parameter space results in log-binomial models encountering 
convergence problems if the maximum likelihood estimates of the prevalence ratio (PR) 
parameters occur at the boundary of the restricted parameter space and the predicted 
probabilities are equal to 1 (Wacholder, 1986; Deddens et al., 2003). Hence, the iterative 
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procedures that maximize likelihood fail to converge, resulting in impermissible probabilities 
(Zocchetti et al., 1995; Nijem et al., 2005).  
 
Convergence problems 
Given the convergence problems of log-binomial models, Deddens et al. (2003) proposed the 
COPY method to approximate the maximum likelihood estimates of the prevalence ratios 
when log-binomial models fail to converge. The method involves expanding the original 
dataset to obtain copies large enough that the maximum likelihood estimates from the 
modified data approximate the maximum likelihood estimates in the original data. The 
resulting data set contains c-1 copies of the original data and 1 copy with dependent variable 
values interchanged. As noted by Lumley et al. (2006), this is equivalent to creating one copy 
of the original data set with weight w=(c-1/c)=0.999 and the other copy of the original data 
set with values interchanged with weight  1-w=0.001.  
 
 
In this instance, a weighted log-binomial regression maximising the likelihood is performed 
(Savu, Liu and Yasui, 2010): 
 
𝐿𝑤( 𝑌; 𝛽) = ∏(𝑒





or equivalently, the log likelihood  
 
𝑙𝑜𝑔 𝐿𝑤(𝑌, 𝛽) = ∑[𝑤𝑦𝑖 +
𝑛
𝑖=1
(1 − 𝑤)(1 − 𝑦𝑖)]𝑥𝑖𝛽 + [𝑤(1 − 𝑦𝑖) + (1 − 𝑤)𝑦𝑖]log (1 − exp(𝑥𝑖𝛽)     (3.15) 
 
This approach limits the need for adjusting the standard errors and the maximum likelihood 
estimates (MLE) from the modified data and allows direct estimation of likelihood ratio 
confidence intervals (Deddens and Petersen, 2008). The approach ensures that the MLE in the 
modified data is always within the restricted parameter space, yields estimates that are close 
to the true parameters and is superior to the Poisson and Cox proportional hazards models 
(Deddens et al. 2003 & 2008; Petersen and Deddens, 2006). A simulation study conducted by 




Yu and Wang (2008) proposed using the SAS Nonlinear Programming (NLP) procedure for 
estimating prevalence ratios. This procedure results in estimates being within an acceptable 
range as it explicitly imposes the constraints and, therefore, can be used as an alternative to 
the COPY method (Yu and Wang, 2008). When they compared the NLP procedure with PROC 
GENMOD using the log-binomial and COPY methods, they showed that the convergence 
rates, bias and mean square error estimates were comparable between the NLP procedure and 
the COPY method. However, the two methods share the same problem of data modification 
since the NLP procedure first uses the COPY method to generate initial values for the PROC 
NLP procedure and then uses PROC NLP to obtain the maximum likelihood estimates (Yu 
and Wang, 2008). Hence, the COPY method is preferred when the log-binomial model fails to 
converge.  
 
Skov et al. (1998) proposed a method based on logistic regression and robust estimation of 
standard errors, called ‘GEE-logistic’. According to Skov and colleagues, by duplicating every 
case in the data set to a non-case observation so that the new data set has three groups of cases 
as follows: cases, original non-cases and the new non-cases that have just been duplicated (e.g. 
if there were 50 cases and 100 non cases then the 50 cases would be duplicated and the final 
data set will be 50 cases, 100 original non-cases and 50 non-cases that have been duplicated 
making 150 non-cases), Schouten et al. (1993) proposed fitting the log-binomial model 
parameters using logistic regression such that 
 
𝑝(𝑦𝑖 = 1|𝑥𝑖) =
exp(𝛽0 +  𝛽1𝑥𝑖1 + ⋯ )
1 + exp(𝛽0 +  𝛽1𝑥𝑖1 + ⋯ )
     (3.16) 
 
where  𝑖 = 1, … , 𝑛 indexes the individual observations, 𝑥𝑖is a vector of covariates, β are the 
corresponding regression coefficients to be estimated.   
However, Skov et al. (1998) argued that due to correlations within the new data set, as a result 
of the case duplications, and the fact that the standard logistic model cannot maximize over 
the same parameter space that a log-binomial model uses to obtain maximum likelihood 
estimates, the generalized estimation equation approach must be used (Liang and Zeger, 
1986). Although the GEE-logistic models produced point estimates that were close to the true 
parameter (with negligible bias) and had correct type I error rates, the prevalence rates 
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produced were greater than one; therefore, Skov et al. (1998) preferred the log-binomial model 
for estimation of prevalence ratios. 
3.7 Analysis of clustered data using single level modelling approaches 
The generalised linear models framework presented in section 3.6.2 assumes that the 
observations of the response variable 𝑦𝑖 are independent of each other, which is not the case 
in clustered data because the within cluster correlation (intracluster correlation) is not zero. 
Ignoring the clustering of the data leads to underestimating the variance and thereby 
overstating the statistical significance (Omar and Thompson, 2000).  
 
Different techniques have been used in these single level models to address the 
underestimation of standard errors.  
 
Fixed effects approach 
In the fixed effect approach, dummy variables are included in the individual level model to 
account for the between cluster differences and allow intercepts and slopes to vary across 
clusters or covariates that are believed to influence individual responses. However, the 
regression approach used, in this case the Analysis of Co-variance (ANCOVA), is not feasible 
with many clusters, because we are adjusting for baseline measures which may result in too 
many parameters to be estimated. Furthermore, it does not permit an assessment of the 
association between cluster-level variables between clusters and how they influence the 
relationship between lower units and the response variable (Kreft and Leeuw, 1998). In 
addition, this approach may not fully account for cluster effects, as covariates at the cluster 
level may not be fully measured.  
 
Marginal effects approach  
In the marginal effects approach, design effects are used to adjust for standard errors and the 
construction of cluster level marginal models are used to address the dependencies between 
clusters (Liang and Zeger, 1986). In this approach, the GLM framework presented in section 
3.6.2 is extended to model correlated data by introducing second-order variance components 
into the generalised linear model’s estimating equation – a modelling approach also referred 
to as generalised estimation equations (GEE) which models the marginal or population 
averaged estimates (Liang and Zeger, 1986). Although the estimates of the coefficients and 
their standard errors in marginal models are fairly robust to misspecification of the correlation 
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structure (Liang and Zeger, 1986), the approach fails to investigate the nature of the between-
group variability (Breslow and Clayton, 1993). If the overall effect is of interest, then it is more 
appropriate to model the averaged marginal probabilities of success rates over all clusters 
being studied (Hu et al., 1998).  However, due to the limited number of clusters usually 
available in cluster randomised trials (Hayes et al., 2000), reliable asymptotic properties for 
robust standard errors may not be achieved leading to unreliable type I errors (Murray et al., 
1998a; Omar and Thompson, 2000).  
 
Thus, single level models are not suitable for cluster randomised trials because they do not 
model the variation in the outcome variable between clusters. The inherent correlations of 
observations resulting from cluster randomised trials or repeated measurements are better 
accounted for by using generalised linear mixed models (GLMM) or multilevel models 
(Breslow and Clayton, 1993) presented in Chapter 4.  
3.8 Conclusion 
The Chapter has provided an overview of cluster randomised designs and the challenges 
inherent in such designs. Furthermore, the Chapter has also given an overview of the 
approaches that have been used to mitigate the challenges, especially when only a limited 
number of clusters are available for randomisation. The statistical efficiency implications of 
the Triage Plus study have been highlighted and ways to avert the statistical challenges have 
been proposed. In particular, the use of multiple measurements within the clusters over time 
during the intervention period was suggested. The utility of this approach for analysing 
studies with cluster numbers as low as 3 is assessed in a series of simulations presented in 
Chapter 5.  
Furthermore, the Chapter has reviewed estimation approaches for prevalence (or risk ratios) 
in the evaluation of interventions. Although prevalence ratios are estimated directly when 
using log-binomial regression, it encounters convergence problems when the parameter 
estimates are at the boundaries of the parameter space. Instead, Poisson regressions models 
can be adapted to model prevalence ratios for cross sectional studies by ensuring a constant 
risk for all individuals or clusters (i.e. measurements in each cluster need to be taken at equal 
time intervals) and incidence rate ratios in longitudinal cohort designs.  Because the Triage 
Plus study primarily collected monthly count data during the study period, Poisson 
regression models with incidence rate ratios as measures for assessing the effectiveness of the 
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intervention (with some adjustments for over-dispersion by using robust standard errors) are 




GENERALISED LINEAR MIXED MODELS 
 
4.1 Introduction 
This thesis focuses on the assessment of the effectiveness of an integrated TB and HIV 
community intervention (Triage Plus) that used a cluster randomised design. The clusters 
were randomised into Early and Delayed intervention arms. Data on TB and HIV treatment 
initiations and testing uptake were repeatedly collected in each of the clusters at baseline and 
during the intervention period. Given that repeated observations from each cluster over time 
are more correlated than across clusters, this type of data is referred to as hierarchical or 
multilevel data. In this multilevel form, the repeated measurements (level 1) are nested within 
the clusters (level 2).  
 
As the data derived from this structure are correlated, the standard models, such as 
generalised linear models - a class of fixed effects models (McCullagh and Nelder, 1989) 
presented in section 3.6 in Chapter 3, cannot be used to analyse the data. To account for the 
correlations of these observations, generalised linear mixed model (GLMM) approaches have 
been proposed which have random effects incorporated in the linear predictor (Breslow and 
Clayton, 1993). The GLMM is an extension of the generalised linear model theory (McCullagh 
and Nelder, 1989). Generalised linear mixed models are also known as multilevel models 
(Goldstein and Rasbash, 1996) and generalised linear random effects models (Stiratelli, Laird 
and Ware, 1984).    
 
These multilevel models accommodate the extra-variability inherent in longitudinally 
repeated measures or cluster designs (Breslow and Clayton, 1993). The influence of cluster 
level explanatory variables is easily assessed in multilevel modelling while controlling for 
differences in explanatory variables in lower levels.  Thus, the use of generalised linear mixed 
modelling allows for the consideration of both epidemiological reasons, enabling the 
quantification of the need for contextual factors in assessing intervention effectiveness, and 
statistical reasons, improving estimation. Since the effects of the intervention may vary 
between clusters, the use of multilevel modelling resolves this problem by allowing an 
analysis of the effects that vary by cluster.  
63 
 
In this Chapter, the statistical models for analysing hierarchically structured data, specifically 
the repeated measurement data from a cluster randomised trial, are discussed. Furthermore, 
estimation approaches for these statistical models are also discussed. The aim of this Chapter 
is therefore to continue the review of statistical methods briefly presented in Chapter 3 with 
the aim of identifying the statistical models that can then be pursued in the simulations in 
Chapter 5 and the actual analysis of the Triage Plus study data in Chapter 6.  
 
This Chapter is organised as follows: section 4.2 presents a generalised linear mixed model 
framework in the context of a repeated measurement design within the clusters. Section 4.2 
also presents the GLMM representation of Poisson and Negative binomial models for the 
analysis of count data and log-binomial models for hierarchically structured data that are 
binomially distributed. Section 4.3 discusses estimation approaches for incidence rate ratios 
in multilevel models using likelihood approaches. Section 4.4 concludes the chapter. 
4.2 Generalised linear mixed model framework 
 
4.2.1 The generalised linear mixed model 
The generalised linear mixed model is an extension of the GLM theory where random effects 
are incorporated into the linear predictor (3.3) in Chapter 3. The resulting generalised linear 
mixed model includes the usual fixed effects for the regression coefficients and the random 
effects that model the correlations in the data. 
 
In data derived from a cluster randomised design denoted by (𝑦𝑖𝑗 , 𝑥𝑖𝑗)  , 𝑦𝑖𝑗 represents 
observations of the response measured in an individual 𝑖 = 1, … , 𝑛 in cluster 𝑗 = 1, … , 𝑁 , and  
𝑥𝑖𝑗is a vector of explanatory variables. For the repeated measurement data design within each 
cluster according to notation by Rabe-Hesketh et al., (2005), 𝑖 = 1, … , 𝑇 indexes the individual 
measurement time-points and 𝑗 = 1, … , 𝑁 indexes clusters in which repeated measurements 
are taken. Because the Triage Plus study adopted a repeated measurement design, the 
repeated measurement notation given by Rabe-Hesketh et al., (2005) has been used in this 
thesis. However, for the simulation studies carried in Chapter 5, the notation 𝑖 (𝑖 = 1, … , 𝑛) 
indexes the number of simulations in a given design condition investigated. Similar notation 
has also been used in Chapter 7 under the Future Work section (section 7.8) to denote the 
iterations (𝑖 = 1, … , 𝑛).   
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The generalised linear mixed model is composed of three parts:  
 
(i) A distribution component for the response variable. 
 
In the distribution component of the generalised linear mixed model, the conditional 
distribution of response 𝑦𝑖𝑗, given the covariates 𝑥𝑖𝑗 and the random intercepts 𝑢𝑗 for cluster 
𝑗, is assumed to follow a distribution from the exponential family of distributions (McCullagh 
and Nelder, 1989) with probability density function given as 
𝑓(𝑦𝑖𝑗|𝑥𝑖𝑗 , 𝜃𝑖𝑗, 𝑢𝑗,𝜙) = exp {
𝑦𝑖𝑗𝜃𝑖𝑗 − 𝑏(𝜃𝑖𝑗)
𝑎(𝜙)
+  𝑐(𝑦𝑖𝑗 , 𝜙)}               (4.1) 
 
where: 
functions b(.) and c(.)are known functions and are specific to the distribution of the 
exponential family (i.e. the same form for all 𝑦𝑖𝑗), 
𝜃𝑖𝑗 is the natural parameter and is the natural or canonical parameter for 𝑦𝑖𝑗,  
𝜙  is scale parameter,and 
𝑎(𝜙) is a fixed dispersion parameter, which is 1 for Poisson and binomially distributed data 
(Breslow, 1996).  
 
(ii) The structural assumptions specifying the conditional expectation of 𝑦𝑖𝑗, given the 
covariates and random effects, is given by   
 
𝜂𝑖𝑗  =  𝐸(𝑦𝑖𝑗|𝑥𝑖𝑗 , 𝑢𝑗,) = 𝑥𝑖𝑗𝛽 + 𝑢𝑗                    (4.2) 
 
where 𝑖 = 1, … , 𝑇  indexes the repeated measurement time points, 𝑗 = 1, … , 𝑁 indexes 
clusters,  𝑥𝑖𝑗 is a vector of explanatory variables, 𝛽 is a vector of corresponding regression 
coefficients, and 𝑢𝑗 is a random intercept for cluster 𝑗.   
 
(iii) A monotonic differentiable link function 𝑔(. ) converts the expected value mean 𝜇𝑖𝑗of 
the response variable 𝑦𝑖𝑗(ie 𝐸(𝑦𝑖𝑗|𝑥𝑖𝑗 , 𝑢𝑗 ) = 𝜇𝑖𝑗) to the linear predictor 𝜂𝑖𝑗 
 
𝑔(𝜇𝑖𝑗) =  𝜂𝑖𝑗                                              (4.3) 
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The inverse of the link function ℎ = 𝑔−1  is also called the ‘response function’, so that 𝜇𝑖𝑗 =
ℎ(𝜂𝑖𝑗).   
 
By transformation, the unit cumulant function 𝑏(. ) relates the natural parameter 𝜃𝑖𝑗  to the 
mean 𝜇𝑖𝑗 as well as to the variance of 𝑦𝑖𝑗 as 
 
𝜇𝑖𝑗 = 𝐸(𝑦𝑖𝑗|𝑥𝑖𝑗, 𝑢𝑗) = exp (𝜃𝑖𝑗) 
so that 
 




 𝑣(𝜇𝑖𝑗).  
 
where 𝜎2 is the variance of the responses 𝑦𝑖𝑗 given the covariates and random effects. 
 
 
Given 𝑔(𝜇𝑖𝑗) = 𝜃(𝜇𝑖𝑗) then 𝑔(. ) is the natural link function that yields 𝜃𝑖𝑗 = 𝜂𝑖𝑗.  
The parameters are determined as: 
 






𝜎2(𝜇𝑖𝑗) = 𝜙𝑣(𝜇𝑖𝑗) 
 






Thus, 𝑣𝑎𝑟(𝜇𝑖𝑗) has two components: one that depends on a scale parameter𝜙 and external 
factors, and the second that relates the variance to the mean 𝑣(𝜇𝑖𝑗), which determines the form 
of the distribution and is called the ‘unit variance function’.  
 
This implies that for a continuous response,𝑣(𝜇𝑖𝑗) = 1 indicates a Normal distribution with 
the mean 𝜇𝑖𝑗 and the scale parameter 𝜙 = 𝜎
2. In a discrete response, 𝑣(𝜇𝑖𝑗) =  𝜇𝑖𝑗  implies a 
Poisson distribution, and 𝑣(𝜇𝑖𝑗) =  𝜇𝑖𝑗(1 −  𝜇𝑖𝑗) implies a binomial distribution, with  𝑎(𝜙) =
𝜙 = 1 in both Poisson and binomial distributions (McCullagh and Nelder, 1989). Specifying a 
66 
variance structure in GLM or GLMM indicates that a distributional form is specified (Clark 
and Thayer, 2004).   
 
In addition to the distribution assumption (4.1), the structural assumption (4.2) and link 
function (4.3) of the cluster level random effects in a generalised linear mixed model are 
assumed to be independent and Normally distributed with mean  𝐸(𝑢𝑗) = 0  and with an 
unknown covariance matrix 𝑐𝑜𝑣(𝑢𝑗) = 𝐷(𝜃). 
 
4.2.2 Generalised linear mixed model representation in a repeated measurements design 
 
This section describes the generalised linear mixed model under the repeated measurements 
design. This is an extension of the previous equations under the generalised linear modelling 
framework that assumed the responses were independent (see section 3.6)  
 
Given 𝑦𝑖𝑗 is a response measured at time point 𝑖in cluster  𝑗,  𝑥𝑖𝑗 is a covariate vector with fixed 
effects (such as intervention status, measurement occasion variable, interaction terms between 
intervention and time, and cluster or individual level covariates) and 𝑊𝑖𝑗is a covariate vector 
associated with random effects  𝑢𝑗  (eg. random intercepts and random coefficients) the 
responses 𝑦𝑖𝑗 are conditionally independent with mean 𝐸(𝑦𝑖𝑗| 𝑢𝑗) = 𝜇𝑖𝑗  and 
variance  𝑣𝑎𝑟(𝑦𝑖𝑗|𝑢𝑗) = 𝜙𝑎𝑖𝑗
−1𝑣(𝜇𝑖𝑗) , where 𝑎𝑖𝑗  is a dispersion parameter,𝑣(. )  and 𝜙  are the 
unit variance functionand scale parameter respectively. According to Breslow and Clayton 
(1993), the general form of a generalised linear mixed model with repeated measurements is 
given by   
 
𝑔(𝜇𝑖𝑗)  = 𝑥𝑖𝑗𝛽 +  𝑊𝑖𝑗𝑢𝑗                              (4.4) 
 
The expectation of the conditional distribution of the response variable, given the random 
effects, is given by   
𝐸(𝑦𝑖𝑗|𝑢𝑗, 𝑥𝑖𝑗 , 𝛽) =  𝜇𝑖𝑗 = 𝑔
−1(𝑥𝑖𝑗𝛽 +  𝑊𝑖𝑗𝑢𝑗)        (4.5) 
 
The random effects 𝑢𝑗 are assumed to be independent and Normally distributed as 𝑁(0, 𝐷(𝜃)) 
i.e. mean 𝐸(𝑢𝑗) = 0, and unknown covariance matrix given as   𝑐𝑜𝑣(𝑢𝑗) = 𝐷(𝜃) and depends 
on an unknown vector 𝜃 of variance components.  The differentiable link function 𝑔(. ) is a 
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known monotonic function that relates the mean 𝜇𝑖𝑗 to the linear predictor  𝜂𝑖𝑗 = 𝑥𝑖𝑗𝛽 +  𝑊𝑖𝑗𝑢𝑗 
, with coefficient 𝛽 remaining constant over measurement time-points 𝑖. To account for the 
correlation of the repeated measurements within clusters as well as the overdispersion in the 
Poisson distributed data, the random effects 𝑢𝑖𝑗  for level one (i.e. repeated measurements) 
can be included in the model (see section 4.2.3.1 model (4.9)).  
 
The GLMM in (4.4) can be extended in two ways. First, if  𝑊𝑖𝑗 = 1, then the model is a random 
intercepts model that allows each cluster or group to have its own random intercept but same 
slope over time and is given as 
 
𝜂𝑖𝑗 = 𝑥𝑖𝑗𝛽 + 𝑢𝑗 
         (4.6) 
𝑢𝑗~ 𝑁(0, 𝜎
2) 
If 𝑊𝑖𝑗 = (1, 𝑥𝑖𝑗), then the GLMM has both random intercept and random slope parameters 
and is given as  
 
𝜂𝑖𝑗 = 𝑥𝑖𝑗𝛽 +  𝑢𝑗 + 𝑥𝑖𝑗𝑢𝑗 
          (4.7) 
𝑢𝑗~ 𝑁(0, 𝜎
2) 
If the coefficients of fixed effects 𝛽 are allowed to vary over the measurement time, then the 
GLMM becomes a generalised varying-coefficient mixed model (Hastie and Tibshirani, 1993; 
Lu and Zhang, 2009).  If the effect modifier is time, then the model in (4.4) is a time-varying 
coefficient model (Lee and Shaddick, (2007), indicating a special case of the varying-coefficient 
models of Hastie and Tibshirani (1993). 
 
4.2.3 Poisson and negative binomial models 
For the Triage Plus study, Poisson and or negative binomial regression models with mixed 
effects were the natural choice for analysis because the number of new TB and HIV cases 
accessing treatment and testing services over the intervention period were recorded each 
month.   
4.2.3.1 The Poisson models 
In modelling the Triage Plus study data, there are two possible model structures (random 
intercepts (see model (4.6) or random coefficients (see model (4.7)) that needed to be fitted to 
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the data to assess which of these models better fit the data. By using model selection criteria 
presented in section 4.4 for likelihood based model selection a correct model structure would 
be identified. Below is the description of the two model structures for the mixed effects 
Poisson models.  In addition, to the two model structures, marginal effects models would also 
be used to obtain population averaged estimates of intervention effectiveness.    
The random intercepts Poisson model 
Random intercepts Poisson models (see model (4.6) have been used to model correlations 
resulting from clustering effects and repeated observations in the same clusters, with the 
assumption that the effect of the intervention is the same across all clusters (Breslow and 
Clayton, 1993; Rabe-Hesketh and Skrondal, 2008). Therefore, in modelling longitudinal data, 
the levels are defined by the repeated measurement occasions nested within clusters (Snijders, 
1996).   
Given 𝑦𝑖𝑗 are the observed events at time point 𝑖in cluster 𝑗,  which are assumed to be Poisson 
distributed with mean  𝜇𝑖𝑗, and 𝑛𝑖𝑗is the number of people at risk in cluster 𝑗 at time 𝑖, then 
generalised linear random intercepts model for data that follow a Poisson distribution is given 
as:  
𝑦𝑖𝑗|𝑥𝑖𝑗, 𝑢𝑗~𝑃𝑜𝑖𝑠𝑠𝑜𝑛 ( 𝜇𝑖𝑗) 
𝑙𝑜𝑔  𝜇𝑖𝑗 = log(𝑛𝑖𝑗) +  𝛽0 + 𝛽1𝑥𝑖𝑗 + 𝑢𝑗    (4.8) 
𝑢𝑗~𝑁(0, 𝜎
2) 
where  𝑥𝑖𝑗 is a vector of covariates including interaction terms, 𝑢𝑗  is arandom interceptsfor 
cluster 𝑗, 𝛽0 is the mean number of events in the control arm,  𝛽1 is the regression coefficient 
for an intervention variable contrasting intervention clusters (treat=1) and control clusters 
(treat=0),and log(𝑛𝑖𝑗)  is an offset. The random effects (i.e. the random intercepts)capture the 
effects of unknown or unmeasured cluster level variables and are assumed to be independent 
across clusters. Thus, (𝛽0 + 𝑢𝑗) in the model is the random intercept for cluster 𝑗.  
 
 
To account for overdispersion and within cluster variations, a random intercept at level one 
(Breslow and Clayton, 1993) is included and the model in (4.8) is extended to  
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𝑦𝑖𝑗|𝑥𝑖𝑗, 𝑢𝑗, 𝑢𝑖𝑗~𝑃𝑜𝑖𝑠𝑠𝑜𝑛 ( 𝜇𝑖𝑗) 





where 𝛽0   and 𝛽1   are the intercept and intervention regression coefficients respectively,  
𝑢𝑗arethe between cluster random effects with variance 𝜎𝑗
2, 𝑢𝑖𝑗  are level one random effects 
with variance 𝜎𝑖𝑗
2 . The subscripts 𝑗 and 𝑖𝑗 are to distinguish cluster level and level one variance 
parameters respectively.  The level one random effects 𝑢𝑖𝑗  models both the extra-Poisson 
variability within clusters and level one variability due to repeated measurements, which are 
assumed to be independently Normally distributed (Gibbons et al., 2008). In random 
intercepts models, the cluster level error component remains constant across repeated 
measurements. However, the error resulting from repeated measurements varies between 
clusters and time points. The resulting intra-cluster correlation (ICC) between two repeated 
measurements within a cluster is given in section 3.2.2.2 as 





                 (4.10) 
where 𝜎𝑏
2 and 𝜎𝑤
2are the between and within cluster variance componentsrespectively. In a 
multilevel model for Poisson distributed data, 𝜎𝑏
2  is the variance of the random intercept 
denoted as 𝜎𝑗
2 in model (4.9) (Moineddin et al, 2007) and the within cluster variance 𝜎𝑤
2  is 
given as (Clark and Bachmann, 2009; Nakagawa and Schielzeth, 2010): 
𝜎𝑤







Using formula (4.10), the ICC in Poisson distributed data with overdispersion without 









                (4.11) 
where 𝜎𝑏
2 is the random intercepts variance, 𝜙 is the overdispersion scale parameter derived 
by dividing the Pearson chi-square by their degrees of freedom, and 𝑒𝑥𝑝(𝛽0) is the mean count 
of the outcome measure when all covariates are zero. Because of the inclusion of the intercept  
𝛽0 in the calculation of ICC for Poisson distributed data, the estimated ICC from Poisson data 
depends on the intercept 𝛽0 since a log transformation used in count data is not variance 
stabilising (Nakagawa and Schielzeth, 2010). 
If the ICC is close to 1, then this  reflects increased within-cluster variation, necessitating the 
need for using random effects models. This allows us to successfully quantify and remove the 
corresponding variability. Very low values of ICC close to zero, indicate low within-cluster 
variation and imply that the use of random effects models will not help improve the model. 
The random coefficients Poisson model  
In random intercepts models, the dependence of repeated observations within a cluster is well 
accounted for but it assumes that the effect of the actual intervention is constant in all clusters. 
However, to allow the effect of the intervention to vary randomly between clusters (see model 
in (4.7)), the random intercepts model (4.9) is extended to  
𝑦𝑖𝑗|𝑥𝑖𝑗, 𝑢𝑗~𝑃𝑜𝑖𝑠𝑠𝑜𝑛 ( 𝜇𝑖𝑗) 
𝑙𝑜𝑔  𝜇𝑖𝑗 = log(𝑛𝑖𝑗) + 𝛽0 + 𝛽1𝑥1𝑗 + 𝑢𝑖𝑗 + 𝑢𝑗𝑥1𝑗 + 𝛽2𝑥2𝑖𝑗     (4.12) 
where: 
𝑖  indexes the repeated measurements within cluster 𝑗 , with random effects  𝑢𝑖𝑗   and 𝑢𝑗  as 
defined in model (4.9)(Guo and Zhao, 2000 page 445; Thompson, Warn and Turner, 2004 page 
395), and the effect  𝛽1 + 𝑢𝑗 of the intervention (𝑥1𝑗) is allowed to vary over the clusters (Rabe-
Hesketh and Skrondal, 2008). 𝛽0 and 𝛽1 are regression coefficients as defined in model (4.8). 
The explanatory variables 𝑥1𝑗 and 𝑥2𝑖𝑗  represent the intervention and other explanatory 
variables measured at cluster level and at each time point within clusters respectively.The two 
random effects have bivariate Normal distribution with mean zero and unknown covariance 












2  is the variance of the random intercept, 𝜎22
2  is the variance of the random 
coefficients, 𝜎21
2  and 𝜎12
2  are the covariances between the random intercepts and random 
coefficients. In this context, 𝜎11
2  corresponds to the variance 𝜎𝑏
2  in model (4.10) and 𝜎𝑗
2  in 
model (4.9). Using the notation given in the covariance matrix D above, then the ICC term in 








              (4.13) 
where 𝑋 and 𝛽 are the vectors of covariates and coefficients respectively. 
According to Rabe-Hesketh and Skrondal (2008), the correlation between the random 







                      (4.14) 
where 𝜌21 is the correlation of the random intercept and slope.  
If there is no correlation between the two random effects, using the random coefficient model 
may not improve the model fit; when they are correlated, however, it may be necessary to fit 
the random coefficient model to obtain improved estimates since clusters with larger mean 
event counts per unit time tend to have larger slopes when the correlation is positive (Rabe-
Hesketh and Skrondal, 2008 page 160).  
4.2.3.2 The Negative Binomial Model 
Although the Poisson distribution is commonly used in modelling discrete events that are 
Poisson distributed, its restrictive assumption of equality of the mean and variance fails in 
certain situations, thereby leading to biased standard errors. This results in over-dispersion: 
the conditional variance exceeds the conditional mean.  To capture the extra variability 
associated with discrete count data, Poisson-gamma and negative binomial models are used 
to account for the greater than Poisson variability in estimating incidence rate ratios 
(Hausman, Hall and Griliches, 1984; Chin and Quddus, 2003; Ntzoufras, 2008 page 315). The 
two models are related in that the marginal likelihood of the negative binomial model (i.e. the 
marginal negative binomial model) is derived by integrating out the random effects of the 
Poisson-gamma model and the two models give similar results when fitted to the count data 
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with over-dispersion (Ntzoufras, 2008). Since the negative binomial models have a mixture of 
both Poisson and gamma distributions, the between-cluster variations are accounted for when 
a negative binomial model is fitted to the count data though variations resulting from time 
are not considered (Chin and Quddus, 2003). To adequately allow for cluster-speciﬁc 
variations and variations resulting from the repeated measures of count data, the random 
effect negative binomial model can be used (Chin and Quddus, 2003). This is achieved by 
introducing in the model a random effects term into the relationship between the expected 
numbers of events at a given time and the covariates (Chin and Quddus, 2003). 
 
Because the negative binomial and Poisson regression models have the same mean structure, 
the negative binomial is considered to be a generalisation of the Poisson model, and it has an 
extra dispersion parameter which is greater than zero for modelling the over-dispersion in 
count data. Usually the estimates of the coefficients under the Poisson and negative binomial 
models are similar but have different estimates of variance, with the negative binomial model 
having a wider sampling distribution leading to wider confidence intervals for the parameter 
estimates (Rabe-Hesketh & Skrondal, 2008). Since analysing mixed effects Poisson regression 
models with robust standard errors provides similar results to using negative binomial 
models (Rabe-Hesketh & Skrondal, 2012, page 712), the mixed effects Poisson regression 
model is preferred because it is relatively simpler to implement in Stata software. 
 
4.2.3.3 Marginal effects Poisson model 
Unlike in multilevel or hierarchical modelling where the dependence in the repeated 
measurements or clustered data is explicitly modelled by using random effects, marginal or 
population-averaged modelling usually estimates the model parameters as if the data was not 
clustered, and the clustering is only taken into account when estimating standard errors.  
The GLM framework used in non-correlated data presented in section 3.6.2 and the marginal 
modelling presented in section 3.7 were then used to model correlated data by introducing 
second-order variance components into the generalised linear model estimating equation – a 
modelling approach also referred to as generalised estimation equations (GEE) (Liang and 
Zeger, 1986). The GEE estimates marginal effects with corresponding robust sandwich-based 
standard errors while taking into account the dependence of the repeated measurements 
within clusters (Rabe-Hesketh and Skrondal, 2012). Fitting the generalised linear Poisson 
model (3.10) with robust standard errors when estimating marginal effects results in 
73 
comparable results (Rabe-Hesketh and Skrondal, 2012). In this thesis, therefore, the GLM with 
robust standard errors was used in marginal effects modelling. The regression coefficients and 
their standard errors in marginal models are fairly robust to misspecification of the correlation 
structure (Liang and Zeger, 1986). However, marginal modelling fails to investigate the nature 
of the between-group variability (Breslow and Clayton, 1993) which is correctly achieved 
when the random effects modelling is used. 
Because of this, model formulation in marginal modelling is slightly different from multilevel 
modelling. However, because of the similarity in expectations between marginal and 
conditional random effects models in Poisson models, the exponentiated regression 
coefficient exp(𝛽) has both marginal and cluster-specific interpretations as the incidence rate 
ratio (Rabe-Hesketh and Skrondal, 2008 page 381).  To improve the estimates in marginal 
effects models, robust standard errors are used to estimate all regression coefficients (Zou, 
2004). 
4.3 Likelihood based estimation methods for incidence rate ratios 
To make statistical inferences using the GLMM (4.4) involves the estimation of fixed effects 
and random effects variance components. However, the marginal likelihood of the response 
obtained by integrating out the random effects generally does not have a closed-form (Breslow 
and Clayton, 1993; Turtz et al., 2003). Several approximation methods for estimating the 
marginal likelihood have been used in literature. The most commonly used methods based 
on the likelihood estimation approach are numerical integration (Rabe-Hesketh, Skrondal and 
Pickles, 2005) or penalised quasi-likelihood (PQL) (Breslow and Clayton, 1993). More recently, 
Bayesian estimation using Markov chain Monte Carlo methods have been used (Zhao et al., 
2006). This section we present these various approximation methods in the estimation of 
incidence rate ratios for longitudinal data or prevalence ratios for cross-sectional data.    
 
 
4.3.1 Numerical integration 
Numerical integration methods based on Gauss- Hermite quadrature have been used to 
obtain an approximation for the marginal likelihood (Hartzel et al., 2001). This type of 
numerical integration requires more quadrature points to approximate the normal 
distribution (Rabe-Hesketh, Skrondal and Pickles, 2002). Numerical integration of the 
generalised linear mixed models using adaptive quadrature is computationally efficient, 
requiring fewer quadrature points to achieve accurate parameter estimation (Rabe-Hesketh, 
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Skrondal and Pickles, 2002). It performs better than the Gauss- Hermite quadrature in a 
variety of situations, including large cluster sizes and high intracluster correlations (Rabe-
Hesketh, Skrondal and Pickles, 2005).  
4.3.1.1 Maximum Likelihood Estimation of GLMM using adaptive and spherical 
quadrature 
 
Given a response𝑦𝑖𝑗measured at time point 𝑖 in cluster 𝑗is conditionally independent given 
the random intercepts 𝑢𝑗  and  𝑢𝑖𝑗  for clusters and repeated measurement time points 
respectively,  𝑥𝑖𝑗 is a vector of explanatory variables, the joint probability of the responses in 
a cluster is given by 
Pr(𝑦𝑖𝑗|𝑥𝑖𝑗 , 𝑢𝑗) =  ∏ 𝑝𝑟( 𝑦𝑖𝑗|𝑥𝑖𝑗 , 𝑢𝑗)
𝑇
𝑖=1
        (4.15) 
 
with 𝑦𝑖𝑗 , 𝑥𝑖𝑗 and 𝑢𝑗 as defined above.  However, for simplification purposes, only the cluster 
level random effects are considered in the above equation as well as the following equations 
for estimating the maximum likelihood of GLMM. The marginal joint probability of the 
responses 𝑦𝑖𝑗 in a given cluster and integrating out the random intercept is given by  
 
Pr(𝑦𝑖𝑗 |𝑥𝑖𝑗) = ∫ 𝜙(𝑢𝑗; 0, 𝜎
2) ∏ 𝑝𝑟( 𝑦𝑖𝑗|𝑥𝑖𝑗 , 𝑢𝑗)
𝑇
𝑖=1




2) is the normal density of random intercept 𝑢𝑗 with mean 0 and variance𝜎
2 (Rabe-
Hesketh, Skrondal and Pickles, 2002 & 2012). 
∏ 𝑝𝑟( 𝑦𝑖𝑗|𝑥𝑖𝑗, 𝑢𝑗)
𝑇
𝑖=1 is the conditional likelihood contribution (i.e. joint probability) of 𝑦𝑖𝑗 for 
cluster 𝑗, given the random effects and covariates. 
The marginal likelihood for all clusters is 
 
𝐿(𝛽, 𝜎2) = ∏ pr(𝑦𝑖𝑗 |𝑥𝑖𝑗)
𝑁
𝑗=1
               (4.17) 
 
The log-likelihood of 𝛽 is given by  
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𝑙𝑜𝑔𝐿(𝛽) = ∏ 𝑙𝑜𝑔 𝑝𝑟( 𝑦𝑖𝑗|𝑥𝑖𝑗)
𝑁
𝑗=1
        (4.18) 
 
Using a Newton-Raphson algorithm, the vector of model coefficients 𝛽 and random effects 
variance parameter𝜎2 are estimated by finding the values of the parameters that maximise 
the likelihood (Rabe-Hesketh, Skrondal and Pickles, 2012). 
 
When using the Gauss-Hermite quadrature, the random effects 𝑢𝑗 in (4.16) are substituted 
with Gauss-Hermite quadrature locations  𝑒𝑟  and the standardised normal density 
𝜙(𝑣𝑗 = 𝑢𝑗/𝜎)with weights 𝑤𝑟 for the 𝑟𝑡ℎ location(𝑟 = 1, … , 𝑅). That is, the integration is done 
over 𝑣𝑗 instead of 𝑢𝑗. The approximation of the marginal probability (4.15) at level 2 becomes  
 
Pr(𝑦𝑖𝑗 |𝑥𝑖𝑗) =  ∫ 𝜙(𝑣𝑗) ∏ 𝑝𝑟( 𝑦𝑖𝑗|𝑥𝑖𝑗 , 𝑣𝑗)
𝑇
𝑖=1






The method works well if Pr(𝑦𝑖𝑗 |𝑥𝑖𝑗) is a polynomial of degree up to 2𝑅 − 1. 
 
The procedure involves approximating the Normal distribution of the random effects with a 
discrete distribution with a given number of integration points. By taking into account the 
properties of the integrand 𝜙(𝑣𝑗) ∏ 𝑝𝑟( 𝑦𝑖𝑗|𝑥𝑖𝑗, 𝑣𝑗)
𝑇
𝑖=1 d𝑣𝑗 coupled with large sample sizes, the 
ratio of the integrand to the posterior density is well approximated by a low-degree 
polynomial (Rabe-Hesketh, Skrondal and Pickles, 2005).  
 
Pr(𝑦𝑖𝑗 |𝑥𝑖𝑗) =  ∫ 𝜙(𝑢𝑗; µ𝑗, 𝜎
2) (
𝜙(𝑣𝑗) ∏ 𝑝𝑟( 𝑦𝑖𝑗|𝑥𝑖𝑗, 𝑣𝑗)
𝑇
𝑖=1
𝜙(𝑢𝑗; µ𝑗 , 𝜎2)
) d𝑣𝑗           (4.20) 
where µ𝑗is the mean of the posterior density. By changing 𝑣𝑗 to 𝑢𝑗 = (𝑣𝑗 − µ𝑗)/𝜎 as variable 
for integration and applying standard quadrature rules  (Rabe-Hesketh, Skrondal and Pickles, 
2002, 2005), the model (4.19) gives  





    (4.21) 
 




) 𝜙(µ𝑗 + 𝑢𝑗𝑒𝑟)𝑤𝑟. 
 Rabe-Hesketh, Skrondal and Pickles (2002) generalised the adaptive quadrature to multilevel 
modelling including multilevel random coefficients models.    
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4.3.1.2 Estimation of random effects and regression coefficients 
 
Turtz and Kauermann (2003) estimated random effects 𝑢𝑗 using the posterior probability 
given data 𝑦𝑖𝑗and vector of regression coefficients𝛽 and vector of natural parameters 𝜃 as 
defined above in model (4.1) as 
 
𝑝(𝑢𝑗|𝑦𝑖𝑗 , 𝛽, 𝜃) =  
𝑝(𝑦𝑖𝑗|𝑢𝑗, 𝛽)𝑝(𝑢𝑗, 𝜃)
∫ 𝑝(𝑦𝑖𝑗|𝑢𝑗, 𝛽)𝑝(𝑢𝑗, 𝜃)𝑑𝑢𝑗
                                (4.22) 
 
with 𝑝(𝑢𝑗, 𝜃) being a density of the mixing normal distribution 𝑁(0, 𝜎
2) and the posterior 
mean of 𝑢𝑗 (Tutz and Kauermann, 2003; Rabe-Hesketh and Skrondal, 2008) defined as 
 
𝑢𝑗 =  ∫ 𝑢𝑗𝑝(𝑢𝑗|𝑦𝑖𝑗 ; 𝑥𝑖𝑗)𝑑𝑢𝑗              (4.23) 
 
which are then estimated using adaptive spherical quadrature. Once the random effects 
𝑢𝑗are known, the regression coefficients 𝛽 are then obtained by maximising the log-
likelihood (4.18).  
 
4.3.2 Penalised quasi-likelihood 
 
Marginal quasi-likelihood (MQL) has been used as an approximation procedure for likelihood 
(Goldstein & Rasbash, 1996). Breslow and Clayton (1993) proposed to approximate the 
likelihood using Laplace’s method for integral approximation commonly referred to as 
penalised quasi-likelihood (PQL). PQL is a modification of MQL that involves updating the 
random effects 𝑢𝑗 with their current estimates 𝑢𝑗
(𝑚) at iteration 𝑚. The PQL is an approximate 
inference technique for estimating generalised linear mixed models. It uses weighted least-
squares algorithms in the estimation of parameters in the mean together with likelihood 
equations from an approximating normal model in estimating variance components (Dean, 
Ugarte and Militino, 2004). Both the MQL and PQL rely on the Taylor expansion to achieve 
the approximation. 
4.3.2.1 Estimation of generalised linear mixed models using PQL 
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Given a response 𝑦𝑖𝑗 measured at time point 𝑖 in cluster 𝑗 that is conditionally independent 
given a vector of random effects 𝑢   that are assumed to be independent and Normally 
distributed as 𝑁(0, 𝐷(𝜃)) with unknown covariance matrix 𝐷 = 𝐷(𝜃) which depends on an 
unknown vector 𝜃 of variance components and 𝜙 is the dispersion parameter, the integrated 
quasi-likelihood function (Breslow and Clayton, 1993; Dean, Ugarte and Militino, 2004) used 
to estimate (𝛽, 𝜃) is  
 
|𝐷|−1/2 ∫ exp {−
1
2𝜙




−1𝑢} du              (4.24) 
where 








is a conditional deviance measure of fit for fixed effects 𝛽  given random effects 𝑢𝑗  and 
covariance matrix  𝑐𝑜𝑣(𝑢) = 𝐷  with 𝑣(. )  and 𝜇𝑖𝑗  being the variance function of the mean 
given the random effects and the mean at time 𝑖 and cluster 𝑗. The integrated quasi-likelihood 
in (4.24) is not tractable, and, therefore, an alternative is to use Laplace approximation to give 
a penalised quasi-likelihood as 
 
𝑃𝑄𝐿(𝛽, 𝑢) = −
1
2𝜙





−1𝑢        (4.25) 
 
Breslow and Clayton (1993) then replaced the PQL with its quadratic expansion of the 
exponent term of the integrand in the quasi-likelihood function (4.24) to find its maximum 
point before integration. This is to ensure that the term in the exponent of (4.24) has 
continuous second order partial derivatives with respect to random effects 𝑢𝑗.   
 
To ensure that an iterative weighted least-squares algorithm is employed to estimate fixed 
effects in the normal mixed effects model, Breslow and Clayton defined a vector 𝑌 with 𝑦𝑖𝑗 =
𝜂𝑖𝑗 + (𝑦𝑖𝑗 − 𝜇𝑖𝑗)𝑔






The associated normal theory model is given as  
 
𝑌 = 𝑥𝑖𝑗𝛽 +  𝑊𝑖𝑗𝑢𝑗 +  𝜀         (4.26) 
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where 𝜀 ~𝑁(0, 𝑍−1) , 𝑍 = 𝑑𝑖𝑎𝑔{𝑣𝑎𝑟(𝑦𝑖𝑗 |𝑢)[𝑔
′(𝜇𝑖𝑗)]
2
}−1 , 𝑢~𝑁(0, 𝐷) , with 𝜀  and 𝑢𝑗  
areindependent to each other.   
 
According to Breslow and Clayton (1993) using matrix terminology, the estimate of fixed 
effects 𝛽 is 
 
?̂? = (𝑋𝑇𝑉−1𝑋)−1𝑋𝑇𝑉−1𝑌         (4.27) 
 
and its estimated asymptotic variance is given by 
 
𝑣𝑎𝑟(?̂?) = (𝑋𝑇𝑉−1𝑋)−1                          (4.28) 
 
Given the data, the vector of random effects 𝑢 are estimated as empirical Bayes estimates of 
their posterior mean given the dataas 
 
?̂? = 𝐷𝑊𝑖𝑗
𝑇𝑉−1(𝑌 − 𝑋?̂?)              (4.29) 
 
where 𝑉 = 𝑍−1 +𝑊𝑖𝑗𝐷𝑊𝑖𝑗
𝑇,  𝑋  is the vector of covariates, the superscript T denotes the time at 
which measurement of the response variable is taken. 
 
Because the standard errors of the estimated ?̂?  do not take into account the additional 
variability that arises when estimating the unknown vector 𝜃 of variance components, the 
standard errors, therefore, may be underestimated (Breslow and Clayton, 1993; Dean, Ugarte 
and Militino, 2004).   
 
4.3.2.2 Estimation of variance components: 
 
In estimating variance components, Breslow and Clayton (1993) used restricted maximum 









𝑉−1(𝑌 − 𝑋?̂?) − 𝑡𝑟 (𝑃
𝜕𝑉
𝜕𝜃𝑘







2,   
𝐻 = 𝑉−
1
2𝑋(𝑋𝑇𝑉−1𝑋)−1𝑋𝑇𝑉−1/2 is a projection hat matrix.  
 












) , 𝑘, 𝑠 = 1,2,3, … (4.31). 
 
where ℐ is the Fisher information matrix, the subscripts k and s are the k, s-th element of the 
matrix taking values 1,2,3, .... 
 
In deriving the penalized quasi-likelihood and the corresponding equations shown above, 
Breslow and Clayton (1993) involved several adhoc adjustments and approximations which 
performed well because the equations are the REML equations under the normal theory linear 





The PQL was estimated using the iterative generalised least squares algorithm (Goldstein, 
1991); therefore, it consists of the following steps (Dean, Ugarte and Militino, 2004): 
 




, 𝜎2(0).   
2. The PQL then proceeds by first solving for (?̂?, ?̂?) iteratively using (4.28) and (4.30) for 
β and 𝑢 respectively while the variance components are fixed.  
3. Then, the variance components are updated.  
4. Steps 2 and 3 are repeated until the convergence of both estimates for fixed effects 
and variance components.  
 
Inferences for parameters are then made by comparing the standardised parameter estimates 
to the asymptotic standard normal distribution.   
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4.4 Likelihood based model selection 
In real life, there are many candidate models available for analysis of the given data. One is, 
therefore, faced with challenges in choosing the most suitable model among the candidate 
models. A common approach used in model selection is a stepwise strategy that involves 
comparing different model candidates on how well they predict the data when guided by 
tests based on approximate asymptotic P values or information criteria. The following model 
selection criteria were used in this dissertation during the analysis of the Triage Plus study 
presented in Chapter 6. 
4.4.1 Likelihood ratio tests 
In the likelihood framework, likelihood ratio tests have been used extensively for model 
selection because of their ability to test for multiple parameters and are often applied with 
large data sets (Berkhof and Snijders, 2001). The likelihood ratio test assesses the goodness-of-
fit between two models by comparing a relatively more complex model to a simpler model 
when fitting a given dataset.  
For instance, it can be used to assess whether the random coefficients model fits the data better 
than the random intercepts model. In terms of the variable selection process, then the more 
complex model is the one with more variables and or interaction terms are included in the 
model and the simpler model is the one with fewer variables or without interaction terms.   
Determination of the likelihood ratio test is based on the difference in the log-likelihoods 
between the complex and simpler model. Thus, the likelihood ratio test statistic is defined as:  
𝐿𝑅 =  2(𝐿1 − 𝐿0)                (4.32) 
with 𝐿0  and 𝐿1  being the maximised log-likelihood value estimates for the null (simpler 
model) and the alternative (complex or saturated) model respectively. The likelihood ratio test 
is asymptotically chi-square distributed with degrees of freedom equal to the number of 
additional parameters in the complex model (Berkhof and Snijders, 2001). However, since the 
test statistic does not have a chi-square distribution when testing variance parameters, and 
since variance parameters are nonnegative thereby making the p values conservative , the 
asymptotically correct p value of the likelihood ratio chi-square test is divided by 2 (Snijders 
and Bosker, 1999; Berkhof and Snijders, 2001). 
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Correct parameter estimation in random effects modelling depends on whether the data are 
better fitted using the random intercepts or random coefficients models. To select an 
appropriate model for the random effects modelling, the following sequential procedure is 
used. 
(i) Select an appropriate model structure (random intercepts or random coefficients) 
using likelihood ratio tests of the null hypothesis, that we have variance parameters of  
zero, at the 5% level of significance, and use model fit criteria after including all 
possible covariates of interest into the model  
(ii) Trim the model covariates through model variable selection and only include variables 
remaining statistically significant in subsequent model fittings. 
4.4.2 Akaike Information Criterion and Bayesian Information Criterion 
 
In likelihood based model selection, the Akaike Information Criterion (AIC) (Akaike, 1981) 
and Bayesian Information Criterion (BIC) (Schwarz, 1978) have also been popular in 
comparing maximum likelihood models; therefore, they have been used in model selection. 
Developed by Hirotsugu Akaike in 1971, the AIC was developed as an estimator of the 
Kullback-Leibler information function and is a measure of the loss of information when an 
incorrect model is fitted to the data. The AIC is, therefore, a measure of the goodness of fit of 
an estimated statistical model (Akaike, 1981; Hoeting et al., 2006). It is not necessarily a test of 
the model, as in hypothesis testing, but a test between models.  The AIC is given by 
  
𝐴𝐼𝐶 =  −2 ∗ 𝑙𝑛(𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑) +  2 ∗ 𝑝           (4.33) 
Unlike the AIC, which uses a constant 2 to weight the number of parameters 𝑝 in the model, 
the Bayesian Information Criterion uses the log of the number of observations to weight the 
parameters.  
The BIC is given by 
𝐵𝐼𝐶 =  −2 ∗ 𝑙𝑛(𝑙𝑖𝑘𝑒𝑙𝑖ℎ𝑜𝑜𝑑) +  𝑙𝑛(𝑁) ∗ 𝑝         (4.34) 
where 𝑝  is the number of parameters fitted in the model, thereby providing a trade-off 
between model fit and complexity (number of parameters). The best model for a given data 
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set is determined by ranking all the potential models according to their AIC or BIC, and the 
one with the lowest AIC or BIC is taken to be the best model.   
4.5 Conclusion 
 
In cluster randomised trials with a repeated measurement design within the same clusters, 
the use of multilevel modelling averts the challenges inherent in such designs and ably 
accommodates the correlations resulting from the cluster design as well as the repeated 
measurements within the same clusters. This is achieved by including random effects in the 
linear predictor.   
 
However, the use of multilevel modelling has brought its own challenges, such as the need 
for sophisticated statistical methods such as the numerical methods for nonlinear mixed 
models because of the intractability of the marginal likelihood (Breslow and Clayton, 1993, 
Hedeker and Gibbons, 2006). However, the development of statistical programmes has eased 
implementation of such methods.   
 
In the analysis of discrete data, such as counts or binomial data, the common likelihood based 
estimation methods presented in this chapter include numerical integration by adaptive 
quadrature and penalised quasi-likelihood. Although the PQL estimation is faster than 
adaptive quadrature, as it is implemented in the iterative generalised least squares algorithm, 
it has two shortcomings. First, in certain situations the approximations derived from PQL 
methods may underestimate both the random and fixed effects (Breslow and Lin, 1995), 
especially in binary response variables with small cluster sizes and high intracluster 
correlation (Rodriguez and Goldman, 2001). Second, as pointed out by Rabe-Hesketh, 
Skrondal and Pickles (2005), PQL estimation does not involve likelihood and, therefore, 
likelihood based inference, such as likelihood ratio tests and likelihood based confidence 
intervals, cannot be determined. Thus, in this dissertation, numerical integration based on 






STATISTICAL POWER ISSUES WITH CLUSTER RANDOMISED TRIALS 
 
5.1 Introduction 
Chapter 3 presented a review of cluster randomised designs and the challenges encountered 
when cluster randomised designs are used. In particular, challenges in achieving adequate 
statistical power due to a limited number of clusters available for randomisation, were 
highlighted. Different approaches for mitigating these challenges were briefly reviewed 
including use of a repeated measurement design. The chapter further reviewed statistical 
methods and appropriate measures for assessing the effectiveness of the intervention. These 
statistical methods were further reviewed and presented in Chapter 4.  
This chapter focuses on simulation methods for assessing the utility of the repeated 
measurement design in cluster randomised trials with limited number of clusters.  In 
particular, the simulation studies aim to assess statistical efficiencies for different design 
conditions in terms of statistical power and accuracy in parameter estimates when 
determining the effectiveness of complex interventions with a limited number of clusters.  In 
this way, the circumstances under which each of the statistical methods would be more robust 
in detecting significant intervention effects or providing accurate estimates of intervention 
effects, can be identified. 
The chapter is organised as follows: section 5.2 briefly reviews the issues concerning the 
number of clusters and participants per cluster; section 5.3 presents the details of the 
simulation study as well as the specific objectives of the simulations; section 5.4 presents the 
results of the simulations and the conclusions made.  
5.2 Number of clusters and numbers of participants per cluster: a literature review 
Data obtained from cluster randomised interventions are usually correlated; therefore, 
multilevel modelling approaches must be used for analysis (Breslow and Clayton, 1993; 
Murray, 1998a; Gelman and Hill, 2007). These multilevel models, also known as hierarchical 
models, are ideal for assessing how contextual factors affect the outcome of interest (O'Campo, 
2003). The maximum likelihood estimation methods commonly used in multilevel modelling 
are asymptotic, and these methods assume that the sample sizes will be large enough for 
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accurate estimates. However, in randomised studies that use cluster as the unit for treatment 
allocation, a common drawback is that the number of clusters available is usually limited, as 
evidenced by several studies (Murray, Varnell and Blitstein, 2004; Pals, Wiegand and Murray, 
2011; Simwaka et al., 2012). Adding more clusters may in itself raise distinct challenges, 
ranging from the increased costs incurred by the addition of clusters to problems of 
contamination (Torgerson, 2001; Borm et al., 2005) if the clusters are too small. Furthermore, 
it may not be possible to increase the number of clusters due to there being only a limited 
number of clusters in the study area, or the outcome of interest may have low prevalence or 
incidence necessitating larger clusters to achieve an adequate sample size in each cluster. 
However, it is an inescapable fact that having only a limited number of clusters raises 
questions about the statistical power as well as the accuracy of the effect size estimates and 
their standard errors obtained in such studies (Moineddin, Matheson and Glazier, 2007). 
To counteract the problem of a limited number of clusters, researchers have tended to opt for 
using a small number of clusters with a sufficiently large number of individuals sampled per 
cluster: the aim is to compensate for the limited number of available clusters as pointed out 
by Feldman, McKinlay, and Niknian (1996). However, simulation studies using multilevel 
modelling have suggested that the number of clusters per intervention arm is more important 
than the sample sizes within the clusters for achieving adequate statistical power and the 
correct estimation of parameters and their variance components (Mass and Hox, 2004; 
Moineddin, Matheson and Glazier, 2007). Although fixed effects regression coefficients are 
not biased, the estimated standard errors and variance components are biased, with non-
coverage rates above the nominal value in the presence of only a small number of clusters 
(Bennett, Parpia and Cousens, 2002; Moineddin, Matheson and Glazier, 2007), thereby 
affecting type I error rates.  Other simulation studies have indicated that a minimum of 30 
clusters may be needed for adequate statistical power and valid parameter estimates 
(Moineddin, Matheson and Glazier, 2007; Maas and Hox, 2005).    
Despite the clear relationship between number of clusters used and statistical efficiency, 
cluster randomised interventions with a small number of clusters continue to be reported in 
the literature (Donner et al., 1990; Simpson, Klar, and Donner, 1995; Varnell et al., 2004; 
Murray et al., 2008; Pals, Wiegand and Murray, 2011) because of the challenges involved in 
having more clusters (as was the case for the Triage Plus study with 3 clusters per arm 
described in Chapter 2). Statistical power and robustness problems have been reported in 
intervention studies with a small number of clusters (Bennett, Parpia and Cousens, 2002; 
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Murray et al., 1998b). Most of the studies that have assessed statistical power have involved 
one or two time intervals for the outcome measurement and at least 5 clusters per intervention 
arm. However, little is known about cluster randomised studies with a panel data structure 
with only 3 clusters per arm and with low incidence disease conditions (e.g. TB). In such 
longitudinal studies, the analytical levels are defined by the measurement occasions at a lower 
level nested within clusters at a higher level (Murray et al., 1998b; Heo and Leon, 2009; Heo 
et al., 2013). There is limited research into the minimum number of clusters, measurement 
occasions, detectable effect sizes and disease prevalence / incidence necessary to achieve 
optimal statistical efficiency in terms of power and accuracy of parameter estimates in the 
context of multilevel modelling. There is a clear need, therefore, for further investigations into 
the required design conditions necessary for achieving optimal statistical efficiency to guide 
the statistical analysis of such studies when the number of clusters is small. 
In this dissertation, simulation studies have been used to assess statistical efficiencies under 
different design conditions such as a varied number of clusters, measurement occasions, effect 
sizes and prevalence/ incidence of the outcomes of interest. Although simulation studies have 
inherent limitations, such as being sensitive to assumptions about the variability of the 
outcome and the statistical Normality of random effects (Arnold et al., 2011), the results found 
in these simulations may inform the analytical approach for actual data derived from studies 
with limited number of clusters (and in particular the analysis of the Triage Plus study data). 
5.3 Simulation study 
Because the findings of the simulation studies were intended primarily to inform which 
analytical approach should be used for the actual data derived from the Triage Plus study, 
and as the primary outcome in this study was a count variable, the Poisson generalised linear 
mixed models presented in Chapter 4 were used to assess statistical efficiencies under 
different design conditions. In particular, the relative efficiencies of Poisson GLMM regression 
methods were evaluated using likelihood estimation approaches in the estimation of 
intervention effect size. To run the simulations, the baseline dataset was used as a ‘training 
dataset’ to generate the random sample datasets to obtain the desired parameter specifications 
such as the ICC and mean response per group (see Appendix 8.5 for the simulation code).  
The Triage Plus study described in Chapter 2 used only 3 clusters per arm, and the design 
involved the collection of repeated observations in each cluster over time. The simulation 
studies reported below generated time-series cross-sectional panel data over a 12 month 
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intervention period in line with the Triage Plus study. Thus, the maximum units of analysis 
used were 3 x 12 = 36 cluster-months per intervention arm (varying from 3x2 to 3x12 cluster-
months for 2 to 12 repeated measurement occasions respectively).  These simulations were 
used to investigate the likely statistical power and efficiencies of the Triage Plus study design 
and then used in the actual analysis of the Triage Plus study to assess the effectiveness of 
community engagement in improving access to TB and HIV services.  
The simulations were then extended to involve other likely scenarios for comparison. Since  
simulation studies sometimes use design conditions that  may not be applicable in field study 
situations, they do not only allow for estimation of accuracy measures of the parameter 
estimates of interest  compared to the known true estimates; but they may also provide a better 
understanding of the intended statistical approach to be used (Hodgson and Burke, 2000). The 
simulations implemented in this Chapter provided a broader understanding of the analytical 
approaches needed for the analysis of the data derived from the Triage Plus study.   
5.3.1 Rationale and objectives 
Given the limited number of clusters used in the Triage Plus study, the objective of the current 
study was to use simulation methods to investigate the relative statistical efficiencies of 
different cluster configurations, in terms of statistical power, and the accuracy of parameter 
estimates and variance components.  Additionally, the statistical efficiencies of different 
statistical methods for the estimation of relative risks or prevalence ratios were investigated 
under different design conditions for cluster randomised trials. 
Specifically, the objectives of the simulation studies were to: 
i. determine the optimal design conditions of cluster randomised trials with only a 
limited number of clusters available, such as Triage Plus, as well as the statistical 
power and accuracy of parameter estimates for fixed effects parameters and 
variance components (with their corresponding standard errors).  
 
ii. determine the effect of disease prevalence, under different statistical 
configurations, on the statistical power and accuracy of parameter estimates in 
cluster randomised trials with a limited number of clusters. 
 
5.3.2 Simulation procedures 
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Generation of data 
To correspond closely with the Triage Plus study, simulations were constructed with repeated 
measurements in each cluster using desired parameter specifications. The distributions and 
parameters specified included the mean response per group and the desired effect size. Since 
the simulations represented a cluster randomised trial design with repeated measurements, 
covariate correlation structures, which summarised a correlation between clusters, and 
repeated measurements within clusters were also specified (Arnold et al., 2011). More 
specifically, the parameter specifications in the statistical models were estimated from the real 
data obtained from the Triage Plus study and used to generate the random sample data sets 
by fitting the model (5.3) without covariates to obtain the model intercept and the standard 
deviation of the random intercept parameter √𝜎11
2 . To induce overdispersed data within the 
clusters, an overdispersion scale parameter 𝜙 obtained from the baseline data was specified 
during the generation of the data (see section on generation of Poisson outcome data below).  
The random outcome 𝑦𝑖𝑗  representing the outcome of interest for the 𝑖
𝑡ℎ measurement 
occasionin 𝑗𝑡ℎcluster was generated in the context of multilevel modelling. The covariates 
considered in the simulation were the intervention and the secular trends. A separate 
indicator variable, treat, was used to indicate whether the cluster received the intervention 
(treat=1) or control (treat=0) and for secular trend, denoted by variable time, for the repeated 
measurements (time=2, 3, 4, 5, 6, 9, 12). The number of clusters was equally distributed 
between intervention and control arms during the simulation. For the reproducibility of the 
simulated data, the response variables were generated using the same seed number in Stata by 
including a Stata command ‘seed(3321)’ as option in the simulation syntax.  
To generate the random outcome, a generalised linear mixed model (GLMM) framework was 
used to account for the correlations resulting from the randomised cluster design as well as 
the repeated measurements from each cluster.  
The general form of the GLMM framework used is given in (4.4) in section 4.2.2 and repeated 
here as 
𝑔(𝜇𝑖𝑗)  = 𝑥𝑖𝑗𝛽 +  𝑊𝑖𝑗𝑢𝑗                           (5.1) 
 where 𝜇𝑖𝑗  is the expectation of response outcome  𝑦𝑖𝑗  given a covariate vector with fixed 
effects  𝑥𝑖𝑗  and a covariate vector 𝑊𝑖𝑗 with random effects 𝑢𝑗 (in our case we used a random 
intercept where 𝑊𝑖𝑗 = 1). Use of the random intercepts model reduced the simulation time 
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needed; more importantly, this approach was adequate to answer the simulation questions 
investigated, making random coefficients modelling less necessary in our case. The function 
𝑔(. ) is a differentiable link function that relates the expectation  𝜇𝑖𝑗 with the linear predictor 
of the model. The random effects  𝑢𝑗 are Normally distributed with mean zero and unknown 
variance-covariance structure. 
 
Generation of Poisson outcome data 
To be in line with the Triage Plus cross-sectional panel structure, conditional Poisson 
distributed outcome data were generated in Stata version 11.2. Given 𝑦𝑖𝑗  is an outcome 
response at repeated measurement occasion 𝑖  ( 𝑖 = 2, … , 𝑇 ) indexing time points within 
clusters, 𝑗(𝑗 = 1, … , 𝑁) indexing clusters, which is conditionally Poisson and distributed with 
mean 𝜇𝑖𝑗, the statistical model used in the simulations is given in model (4.9) in Chapter 4 
section 4.2.3.1 repeated here as 
 
𝑦𝑖𝑗|𝑥𝑖𝑗, 𝑢𝑗, 𝑢𝑖𝑗~𝑃𝑜𝑖𝑠𝑠𝑜𝑛 ( 𝜇𝑖𝑗) 






𝑦𝑖𝑗  denotes the number of events measured at time point𝑖 in cluster𝑗 and is conditionally 
Poisson distributed. The time points were varied from 2 to 12.  
 𝜇𝑖𝑗is the mean count for cluster 𝑗 at time point 𝑖,  
log(𝑛𝑖𝑗) is an offset with a constant coefficient of 1, 
𝛽0 is the mean number of events in the control arm at baseline time point, 
𝛽1 is the estimated intervention effect comparing intervention clusters and control clusters, 
𝑥𝑖𝑗  is a covariate for intervention status (i.e. treated or not), 
𝑢𝑗  is a random effect for individual cluster 𝑗 with a variance 𝜎𝑗
2  to model between cluster 
variation  
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𝑢𝑖𝑗  is a random effect with variance 𝜎𝑖𝑗
2  at time point 𝑖  and cluster 𝑗  to model both extra-
Poisson and variability within clusters due to repeated measurements.  The subscripts 𝑗 and 
𝑖𝑗 are used to distinguish cluster level and level one variance parameters respectively. 
The random effects are assumed to be Normally distributed with a mean of zero and a known 
standard deviation.   
 
The intracluster correlations (ICC)resulting from these random effects affect statistical power 
as well as the accuracy of the parameter estimates (Moineddin, Matheson and Glazier, 2007; 
Parker, Evangelou and Eaton, 2005).  The ICC was then estimated using the formula (4.13) 










2  is the random intercepts variance, 𝜙 is the overdispersion scale parameter derived 
by dividing the Pearson chi-square by their degrees of freedom, and 𝑒𝑥𝑝(𝛽0) is the mean count 
of the outcome measure.  
For the simulation studies, four different ICC values were considered in total.  The first two 
values, 0.00154 and 0.081, were the smallest and largest values found in the baseline data from 
the Triage Plus study; in order to test a very wide, but also realistic, range of ICC values in the 
simulations, two additional, much larger ICC values (0.321 and 0.699) were taken from other 
similar studies (see below). The estimated standard deviation of the random intercepts 
parameter √𝜎11
2 , overdispersion scale parameter 𝜙 and the model intercept 𝛽0 were 0.005, 0.5 
and 2.71 respectively for the ICC of 0.00154. For the ICC of 0.081, the estimated standard 
deviation of the random intercepts parameter √𝜎11
2 , overdispersion scale parameter 𝜙 and the 
model intercept were 0.1405, 3.493 and 2.71 respectively. The Stata analysis output below 
shows the parameters that were used in the calculation of baseline ICCs using the formula in 




To investigate the effect of varying intracluster correlation coefficients on statistical power, 
further simulations were run using the baseline ICC of 0.081 compared to other ICC scenarios 
of 0.321 and 0.699. The standard deviations of the random intercept parameters √𝜎11
2  for the 
ICCs (0.081, 0.321 and 0.699) were 0.1405, 0.140, and 1.459 respectively. The overdispersion 
scale parameter 𝜙  and the within cluster variances were determined as described above and 
the corresponding ICCs were determined using formula (4.13). As pointed out in section 2.5 
in Chapter 2, the ICC of 0.081 was based on the baseline data from the Triage Plus study. The 
ICC of 0.321 was based on a cluster randomised trial to assess the effect of an education 
intervention on TB case detection and primary care of respiratory diseases in South Africa 
which was reanalysed by Clark and Bachmann, 2009.  The ICC of 0.699 was based on the high 
ICCs implemented by Stryhn et al (2006). This high ICC was applied here to assess power 
issues when there are very high ICCs.   
Thus, to generate the outcome variable 𝑦𝑖𝑗 , the fixed effects parameters and the standard 
deviations for the random intercepts parameter √𝜎11
2 , and an estimate of the overdispersion 
scale parameter 𝜙 were specified. The overdispersion parameter was specified in the model 
in order to generate an overdispersed count data. The intervention effect size 𝛽1 was specified 
based on pre-determined intervention effects of 20%.  
To estimate the remaining 2 parameters (𝛽0, and 𝜎11), baseline datasets for the Triage Plus 
study was used to estimate the parameters by fitting a model without covariates (Arnold et 
al., 2011) as 
𝑦𝑖𝑗|𝑥𝑖𝑗, 𝑢𝑗, 𝑢𝑖𝑗~𝑃𝑜𝑖𝑠𝑠𝑜𝑛 ( 𝜇𝑖𝑗) 
𝑙𝑜𝑔  𝜇𝑖𝑗 = log(𝑛𝑖𝑗) +  𝛽0 + 𝑢𝑖𝑗 + 𝑢𝑗 (5.3) 
In the model (5.2),parameter 𝛽1 is the parameter of interest, while the constant 𝛽0 represents 
the average mean count of events in the control clusters at baseline time point.  
 
Once the desired parameters were estimated, 12 repeated measurements, datasets and 
random effects were then generated. Cluster level data was created by expanding the data 
sets to the required number of clusters, and corresponding random effects were generated for 
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each cluster. The outcome response 𝑦𝑖𝑗was then simulated using models (5.2), and Poisson 
mixed effects regression models (5.2) were fitted to the data set with indicators contrasting the 
intervention or control specified in the model. Regressions coefficients were saved for further 
analysis.  
Design conditions investigated 
In the simulation of data sets, the following factors were allowed to vary: number of clusters 
per arm, effect size in the intervention arm, number of repeated measurement points and 
incidence rate ratios as follows: 
i. The number of clusters per arm was set at 3, 4, 5, 6, 9, and 12, with the 3 clusters per 
arm case corresponding to the Triage Plus study. The remaining cases represent the 
common number of clusters used in intervention studies and investigated in similar 
simulation studies involving hierarchical modelling.  
 
ii. The intervention effect sizes were based on incidence rate ratio (IRR) and specified 
as 1.1, 1.2, 1.3, 1.4, 1.5, 1.6 and 1.8 by varying the regression coefficient of the variable  
contrasting intervention and control (the effect size of 1.2 or 20%increase in uptake 
represented the desired effect of the intervention in the Triage Plus study). The 
maximum of an IRR of 1.8 was considered to be the highest effect size that can be 
obtained in such interventions (though in certain instances, higher effect sizes than 
the 1.8 may arise). The other intervention effect sizes were included for comparison. 
These intervention effects were fixed during each of the simulations which were then 
compared to the estimated intervention effects after 1000 simulations. In 
investigating the effect of varying ICCs on statistical power estimation and the 
accuracy of parameter estimates, effect sizes of 1.2, 1.4, 1.6 and 1.8 are reported for 
better clarity in comparing the different ICCs in the same table.  
 
iii. As the risk of encountering estimation problems increases as the number of data 
collection (time)points increases (due to the reduced number of potential 
observations at each fixed time) (Turtz and Kauermann, 2003), the intervention’s 
effect was evaluated at time points for repeated outcome measurement, set at 2, 3, 4, 
6 and 12. Basic baseline and post-intervention study design were represented by 2 
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measurement points: 12 measurement points represent the desired 12 month period 
for the project implementation used in Triage Plus.  
 
iv. There were four different outcome measures investigated in the Triage Plus study 
(TB and ART treatment initiation rates as primary outcomes, HIV and TB testing 
uptake rates as secondary outcomes) with varied incidence rates. Incidence (or 
prevalence) of the investigated outcomes affects the statistical power required to 
detect a significant effect of the intervention and the accuracy of the parameter 
estimates (Raudenbush and Liu, 2000; Moineddin, Matheson and Glazier, 2007). 
Statistical power and the accuracy of the parameter estimates and their standard 
errors were also assessed by varying disease incidence based on the actual data 
derived from Triage Plus study (Dean et al. 2004; Burton et al., 2006, Arnold et al., 
2011). This was done by varying the mean number of events (new or incident cases 
of TB and HIV treatment initiation rates) in the control clusters (Delayed arm), which 
corresponded to the intercept of the regression model. Because the incidence of TB 
treatment initiations is very low in Malawi and that TB testing uptake is higher4, for 
the simulations TB treatment initiations and TB testing uptake were considered to be 
examples of low incidence and high incidence disease events. Therefore, the baseline 
number of new cases of TB treatment initiations and testing uptake of 15 and 70 
respectively were used in the simulations. 
 
Number of simulations 
Although Burton et al (2006) provided formulae for determining the required number of 
simulations, the required number of replications in this study was determined by gradually 
increasing this number until no further changes in the parameter estimates were observed.  In 
general, about 500 simulations were required to achieve adequately converged parameter 
estimates, but 1000 simulations were finally adopted and used for each of the conditions 
investigated in order to align with most reported simulations (Maas and Hox, 2005; 
Moineddin, Matheson and Glazier, 2007; Heo et al., 2013).  All simulated data sets were then 
saved for further analysis.   
 
                                                          
4 Only 20% of cases who take up TB diagnosis (which is TB smear microscopy) are eventually diagnosed 
TB cases in Malawi, and only a (variable and unknown) proportion of these proceed to start treatment. 
 
93 
Quantities of interest in each simulation 
The parameters of interest stored after fitting Poisson mixed effects regression models 
included fixed effects regression coefficients (𝛽𝑖) assumed to be constant across time points 
and their associated simulation standard errors ( 𝑆𝐸𝑖 ). The mean estimate 𝛽  over the 𝑛  
simulations conducted were obtained under each of the conditions investigated as a measure 
of the true estimate of interest given as 




where 𝑖 (𝑖 = 1, … , 𝑛) in this caserepresents number of simulations conducted to estimate the 
regression coefficients of the intervention variable (in our case, n=1000) in a given design 
condition investigated.  
The mean estimates derived from the regression coefficients were then exponentiated to 
obtain incidence rate ratios.   To show the levels of uncertainty around these estimates, 
empirical standard errors (calculated as the standard deviation of the parameter estimates 
over all the simulations) and the mean of the within simulation standard errors of the 
parameter estimates were calculated according to Burton et al. (2006).  
The empirical standard error was calculated as  
𝑆𝐸(?̂?) =  √[
1
𝑛 − 1




and the within simulation standard errors as 
 




In addition, non-parametric summary measures of uncertainty using the 5% and 95% 
percentiles of distribution were obtained.  
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5.3.3 The Simulation Algorithm 
In implementing the simulation study, the procedures described by Arnold et al (2011) and 
Heo and Leon (2009) were adopted. The covariates for each of the simulations were fixed by 
simulating them once. 
 
The steps used can be summarised as follows: 
1. Generate data by specifying the underlying hierarchical model with sample sizes, 
covariates, expressed parameters and random effects that are Normally distributed with 
mean zero and known variance-covariance structure.   
 
a. Generate a set of clusters with half of them assigned to the intervention arm and 
half to the control arm.  
 
 
b. Generate cluster-level random effects using mean zero and a known variance-
covariance structure (i.e. using ICCs of 0.00154  and 0.081) based on the baseline 
data sets (i.e. training datasets) for the Triage Plus study (see section 5.3.2). 
 
 
c. Generate a repeated measurement data structure with corresponding random 




d. Estimate the mean of the outcome (𝛽0) in the control areas using the baseline data 
sets. 
e. Fit the generalised linear mixed effects Poisson model (xtmepoisson) to the 
simulated data while fixing the intervention effect estimate.  
 
 
2. Simulate the response outcome (yij) for each of the cluster and measurement occasions 
using the appropriate model as described in section 5.3.2 after specifying the effect size 
and number of repeated measurement time points. After each simulation, store the 
appropriate parameters and standard errors (see in (e) above) for future analysis. 
 
3. Repeat steps 1 and 2 a total of 1000 times. 
a. Estimate the statistical power (section 5.3.4)by calculating the test statistic (z test) 
and p-value. The test statistic is derived by dividing the parameter estimate by its 
standard error and using normprob function in Stata to obtain p-values. Thus, the 
p-value for a two-sided significant test is calculated using: 




 and Φ is the standard normal cumulative distribution function. 
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b. Estimate power by calculating the proportion of the total observations for which 
the p-value is ≤ 0.05.  
c. Check if the simulations were calculated correctly by simulating the Null case to 
ensure that the statistical power is shown to be a specified significance level and 
that the distribution of the p- values is uniform.   
d. Determine the accuracy of the parameter estimates by calculating all indicators for 
statistical efficiency using the formulae described in section 5.3.6.  
 
5.3.4 Assessment of statistical power estimation for different design conditions 
Lack of statistical significance in any particular evaluation could occur either because the 
intervention was not effective in producing the desired impact (i.e. the true effect size was 
smaller than anticipated) or because the study design made it unlikely that a biologically real 
effect would be detected. Hence, estimation of the actual statistical power of a study is critical 
in distinguishing between these two alternatives in the presence of statistical non-significance. 
Statistical power, defined as the probability of obtaining a statistically significant effect size 
estimate given that there is a biologically real effect in the population being studied, is 
dimensionless and as such is a better design parameter for comparing different designs using 
different outcome measures. Due to the design challenges of the Triage Plus study, where 
there were only 3 clusters in the intervention arm and 3 clusters in the control arm, the 
statistical power of the Triage Plus intervention was investigated through a simulation study.   
The parameter estimates of the 1000 saved simulations completed under each of the studied 
design conditions were used to calculate test statistics (z test) and p-values as described by 
Arnold et al (2011).  Statistical power for each design condition was then estimated as a 
proportion of the total observations for which the p-value is less than the conventional 
significance level of 5% (α = 0.05).  
5.3.5 Diagnostics and sensitivity analysis of simulation procedures 
The formal development and evaluation of new diagnostic procedures for simulation 
methods is not within the remit of this dissertation.  Nevertheless, the statistical methods for 
the simulations conducted may be sensitive to the different parameter values and covariates 
used in their evaluation. Hence, it is necessary to test or monitor the behaviour patterns of the 
parameter estimates to ensure that the models used are reasonably acceptable. Sensitivity 
analysis involves carrying out a series of diagnostic tests in which different parameter values 
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are adjusted to see how the changes affect the posterior results. By showing how the model 
responds to changes in the parameters used, sensitivity analysis is a useful tool in model 
evaluation. Thus, sensitivity analysis refers to the estimation and adjustment of model 
parameters, and it allows for interactions to improve agreement between model output and 
the data set. 
To confirm that the simulations were correctly done, a simulation of a Null case (H0: B1=0) 
was carried out to demonstrate that the distribution of the p-values was uniform. In general, 
the simulations with a Null case were uniformly distributed despite having some minor 
variations at around a p value of 0.8 and 1 (see Figure 5). 
 
Figure 5: Distribution of p-values after running 1000 simulations when the effect of the 
intervention was set to a Null case 
 
 
5.3.6 Assessing performance of the different statistical methods 
As statistical efficiency may vary with design conditions, statistical efficiency under different 
design conditions using various performance measures was assessed (Maas & Hox, 2005; 
Moineddin, Matheson & Glazier, 2007; Burton et al., 2006; Arnold et al., 2011; Collins, Schafer 
and Kam, 2001). Performance measures used to evaluate efficiencies in parameter estimation 
included bias, mean square error, the average length of the 95% confidence intervals of 
parameters estimates and the coverage of the 95% confidence intervals as applied in similar 
studies. The simulated results were compared against the true values used to generate the 
data.  Measures used to evaluate the performance of the statistical methods under varying 
design conditions are presented below. 
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In assessing the accuracy of the statistical methods in parameter estimation, percentage 
relative bias as well as the standardised bias as described by Burton et al (2006) were 
calculated.  If ?̂? is the estimate of the true population parameter 𝛽, the percentage relative bias 








where ?̂?  is the mean estimate over 𝑛  simulations. According to Collins et al (2001), any 
standardized bias greater than 40% is considered significant. In this thesis, only the percentage 
relative bias is used in assessing the accuracy in parameter estimation as it is commonly 
reported in simulation studies (see Moineddin, Matheson and Glazier, 2007). 
 
The 95% coverage of standard errors 
The accuracy of the standard errors of the parameter estimates was assessed by establishing 
the coverage of the 95% confidence interval of the asymptotic standard normal distribution in 
each simulated data set. The 95% coverage is a proportion of the times the 95% confidence 
interval of an estimate of interest includes the true population estimate.  The coverage 
indicator was calculated and set to 1 if the confidence interval contained the true value and 0 
if otherwise (Maas and Hox, 2005; Moineddin, Matheson and Glazier, 2007; Burton et al., 
2006). Correct coverage should be within two standard errors of the nominal coverage 
probability (Gelman and Hill, 2007) given as: 
?̂?𝑖 ± 𝑍1−𝛼/2𝑆𝐸(?̂?𝑖) 
The mean square error 
Because mean square error determination incorporates both bias and uncertainty around the 
parameter estimates, it provides an overall measure of the accuracy of parameter estimates 
(Burton et al., 2006; Collins, Schafer and Kam, 2001). The smaller the MSE estimate (ideally 
less than 5% of the estimate) the better the fit. Because the mean square error is not commonly 
reported in simulation studies, it was not used in this thesis. The MSE is given as: 
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(?̂? − 𝛽)2  + (𝑆𝐸(?̂?))2 
Average length of confidence interval 
The average length of the 95% confidence interval for the parameter estimate was used to 
assess efficiency in the estimation of parameter estimates. The shorter the average length of 
the interval, the more precise the estimates, hence the greater the efficiency and statistical 
power (Collins, Schafer and Kam, 2001; Burton et al., 2006). The average length of the 95% 
confidence interval is given by: 








Convergence rate was defined as the proportion of simulations that converged, and its 
properties were investigated under different scenarios. Model convergence rates were high 
overall in all scenarios investigated and varied from 99.2% to 100%. Unsurprisingly, there 
was no clear pattern in convergence rates after varying the number of clusters per arm, 
number of repeated measurements, effect size and/or incidence of the disease conditions and 
ICC confirming the findings of previous studies (Moineddin, Matheson and Glazier, 2007). 
Moineddin and colleagues found that convergence rates increased to 100%, regardless of the 
correlations structure, when group size was at least 30 individuals. In general, convergence 
rates increased with increasing ICC, number of groups and group sizes (Moineddin, 
Matheson and Glazier, 2007). However, subtle observations were noted in this study, in that 
increasing the number of clusters per arm still produced slight convergence failure rates 
(<1%) especially when the incidence of the disease conditions and repeated measurement 
times increased in a situation when the ICC was 0.00154 (Table 3). For ICC values of 0.081 
and above, similar high convergence rates were observed when the number of clusters per 
arm and effect sizes were varied (Tables 4 & 5). It is interesting to note that overall 
convergence rates were high even when effect sizes were as low as 10% and with high ICC 
levels due to increased background incidence rate as the ICC increases leading to improved 
convergence rates (Amatya, Bhaumik and Gibbons, 2013). However, there was a convergence 
problem noted at the effect size of 10% when 12 clusters were used in low incidence disease 
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conditions such as TB treatment uptake rates when the ICC was 0.00154 (Table 3). Further 
simulation work to investigate this finding will be needed in future. However, this 
observation was not observed when the ICCs were 0.081 and above potentially due to the 
increased background incidence rate noted by Amatya, Bhaumik and Gibbons (2013).  
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Mean monthly outcome measure in control clusters of 15 
cases 
Mean monthly outcome measure in control clusters of 70 
cases 
Effect size (incidence rate ratio) Effect size (incidence rate ratio) 
1.1 1.2  1.3 1.4 1.5 1.6 1.8 1.1 1.2  1.3 1.4 1.5 1.6 1.8 
3 clusters per arm              
2 100 100 100 99.8 100 99.8 99.9 100.0 100.0 100 100.0 99.9 99.9 100.0 
3 100 100 100 100 100 99.8 99.9 100.0 99.9 99.8 100.0 99.8 100.0 100.0 
4 100 100 99.8 99.8 100 100 100 100.0 100.0 99.9 99.9 100 100.0 100.0 
6 100 99.8 100 100 100 100 100 100.0 99.9 99.6 99.9 99.9 99.8 99.8 
12 100 100 99.8 100 100 100 100 99.7 99.8 99.8 99.9 99.9 99.8 99.8 
4 clusters per arm              
2 100 100 100 100 100 100 99.9 99.9 99.9 100 99.9 100 100 99.9 
3 100 99.9 100 99.9 100 100 100 99.8 99.9 100 100 99.9 99.9 99.8 
4 100 100 99.8 99.9 99.9 100 100 100 100 100 99.9 100 99.9 100 
6 100 100 100 100 100 100 100 99.8 99.8 99.5 99.9 99.6 100 99.9 
12 99.9 99.8 99.9 100 99.9 99.8 99.9 99.8 99.8 99.9 99.7 99.9 99.8 99.8 
5 clusters per arm              
2 100 100 100 99.9 100 100 100 99.7 100 100 99.9 99.7 100 99.7 
3 99.8 100 100 100 99.9 99.9 99.9 99.9 100 99.8 99.7 99.9 100 100 
4 99.8 99.9 99.9 99.8 99.9 100 100 99.9 99.9 99.8 99.9 99.9 99.9 100 
6 100 99.8 99.6 99.9 100 100 99.7 99.9 99.8 99.6 99.9 99.7 99.9 99.8 
12 100 100 99.9 100 99.9 100 99.9 99.9 99.9 99.7 99.9 100 99.9 99.4 
6 clusters per arm              
2 100 100.0 100 100.0 100 99.9 99.9 100.0 100.0 100 100.0 99.9 99.9 99.9 
3 100 99.9 99.9 100.0 99.9 100.0 99.9 100.0 99.9 100 100.0 100 99.8 99.6 
4 99.8 99.9 100 100.0 99.9 99.9 99.9 100.0 99.9 99.8 99.8 99.8 99.5 99.9 
6 99.9 99.9 99.9 99.7 100 100.0 100.0 99.5 99.6 99.8 99.4 99.9 99.8 99.9 
12 99.9 99.9 100 99.9 99.6 99.8 99.9 99.7 99.7 99.7 99.6 100 99.8 99.7 
9 clusters per arm              
2 99.9 99.9 100 99.8 99.9 100.0 99.8 99.9 100.0 99.9 99.9 100 100.0 99.9 
3 99.9 99.8 100 100.0 100 100.0 100.0 99.9 99.8 100 99.9 99.8 100.0 99.8 
4 99.8 100.0 100 100.0 100 99.9 100.0 99.8 100.0 99.6 99.9 99.8 99.9 99.9 
6 99.9 100.0 99.7 99.9 100 99.7 100.0 99.6 99.7 99.4 99.2 99.9 99.8 99.4 
12 100.0 99.5 99.8 99.7 99.8 100.0 99.8 99.7 99.9 99.4 99.3 99.5 99.1 99.8 
12 clusters per arm*            
2 - 100.0 100 100.0 100 99.8 99.8 99.9 100.0 99,9 100.0 99.5 99.7 99.5 
3 - 100.0 100 100.0 100 99.9 99.9 100.0 100.0 99.8 99.8 99.7 99.9 99.7 
4 - 99.9 99.9 99.7 99.9 99.9 99.9 99.8 99.8 99.8 99.8 99.8 99.9 99.7 
6 - 99.9 99.9 99.9 99.7 99.9 99.9 99.9 99.6 99.8 99.4 99.5 99.6 99.8 
12 - 99.8 99.8 100.0 99.7 99.7 100.0 99.4 99.5 99.7 99.0 99.6 99.2 99.7 
 ICC=0.00154 




Table 4: The effect of the ICC, number of groups, effect size and repeated measurements on convergence rate, based on 1000 
simulated data sets when the disease incidence is low: Mean outcome measure in control clusters of 15 cases per month 
  ICC=0.081 ICC = 0.321 ICC = 0.699 
  Effect size (incidence rate ratio) Effect size (incidence rate ratio) Effect size (incidence rate ratio) 
  Effect  1.2 1.4 1.6 1.8 1.2 1.4 1.6 1.8 1.2 1.4 1.6 1.8 
3 clusters Time                    
  2 99.8 100.0 100.0 100.0 100.0 100.0 100.0 100.0 99.9 100.0 100 100.0 
 3 100.0 99.9 99.8 99.9 100.0 100.0 100.0 100.0 99.9 100.0 100 100.0 
  4 100.0 99.9 100.0 100.0 100.0 100.0 100.0 100.0 100 100.0 100 100.0 
  6 100.0 99.9 99.9 100.0 100.0 100.0 100.0 100.0 99.9 100.0 100 99.9 
  12 99.9 99.9 99.8 99.8 100.0 100.0 100.0 99.9 99.9 100.0 99.9 100.0 
4 clusters               
  2 100.0 99.9 100.0 99.8 100.0 100.0 100.0 100.0 99.9 100.0 100.0 99.9 
  3 99.7 100.0 100.0 99.9 100.0 100.0 100.0 100.0 99.9 100.0 100.0 100.0 
  4 100.0 99.9 100.0 99.7 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
  6 100.0 100.0 100.0 99.9 100.0 100.0 100.0 100.0 99.9 100.0 100.0 99.9 
  12 99.9 100.0 99.8 99.8 99.9 100.0 100.0 100.0 99.9 100.0 100.0 100.0 
5 Clusters               
  2 100.0 99.9 99.9 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 99.9 
  3 99.9 100.0 99.9 99.9 100.0 100.0 100.0 100.0 100.0 99.8 99.9 100.0 
  4 99.9 99.9 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 99.9 
  6 99.7 100.0 99.9 100.0 100.0 100.0 100.0 100.0 99.9 99.8 100.0 99.9 
  12 100.0 99.7 99.9 99.8 100.0 100.0 100.0 100.0 99.9 100.0 100.0 100.0 
6 Clusters               
  2 99.9 99.9 100.0 100.0 100.0 100.0 100.0 100.0 99.9 99.9 100.0 100.0 
  3 100.0 100.0 100.0 99.9 100.0 100.0 100.0 100.0 99.9 100.0 99.8 99.9 
  4 99.9 100.0 100.0 99.8 100.0 100.0 100.0 100.0 100.0 100.0 99.9 100.0 
  6 99.9 100.0 99.9 99.9 100.0 100.0 100.0 100.0 99.9 99.9 100.0 100.0 
  12 99.9 99.9 99.8 99.5 99.8 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
9 Clusters               
  2 100.0 100.0 99.9 99.9 100.0 100.0 100.0 100.0 100.0 99.9 100.0 99.9 
  3 99.9 100.0 99.9 100.0 100.0 100.0 100.0 100.0 99.9 99.9 100.0 100.0 
  4 100.0 100.0 99.6 99.9 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
  6 99.6 100.0 99.9 99.9 100.0 100.0 100.0 100.0 99.9 100.0 99.7 99.9 
  12 99.5 100.0 99.6 99.7 99.9 99.6 100.0 100.0 99.9 99.9 99.9 99.9 
12 Clusters               
  2 100.0 99.9 100.0 100.0 100.0 100.0 100.0 100.0 100.0 99.9 99.9 100.0 
  3 100.0 99.9 99.9 100.0 100.0 99.9 100.0 100.0 100.0 99.9 100.0 100.0 
  4 100.0 100.0 99.9 100.0 100.0 100.0 100.0 100.0 100.0 100.0 99.9 100.0 
  6 99.9 99.8 99.9 100.0 100.0 100.0 100.0 100.0 100.0 100.0 99.7 100.0 




Table 5: The effect of the ICC, number of groups, effect size and repeated measurements on convergence rate, based on 1000 
simulated data sets when the disease incidence is high: Mean outcome measure in control clusters of 70 cases per month 
  ICC=0.081 ICC = 0.321 ICC = 0.699 
  Effect size (incidence rate ratio) Effect size (incidence rate ratio) Effect size (incidence rate ratio) 
  Effect  1.2 1.4 1.6 1.8 1.2 1.4 1.6 1.8 1.2 1.4 1.6 1.8 
3 clusters Time                    
  2 100.0 99.8 99.9 99.7 100.0 100.0 99.9 99.9 99.9 99.9 99.9 99.9 
 3 99.8 99.8 99.4 100.0 99.9 99.9 99.8 100.0 100.0 100.0 100.0 99.9 
  4 99.9 99.8 99.6 100.0 100.0 100.0 100.0 100.0 100.0 99.9 100.0 99.9 
  6 99.8 99.8 99.5 99.6 99.8 100.0 99.9 100.0 100.0 99.7 99.9 100.0 
  12 99.8 98.3 97.9 97.0 99.8 100.0 100.0 100.0 100.0 99.9 99.8 99.6 
4 clusters               
  2 99.9 99.8 100.0 99.9 100.0 100.0 100.0 100.0 100.0 100.0 99.9 100.0 
  3 99.8 99.7 99.5 99.8 99.9 99.8 100.0 100.0 100.0 100.0 99.9 99.7 
  4 99.9 99.6 99.8 99.3 100.0 100.0 100.0 100.0 100.0 100.0 100.0 99.9 
  6 99.3 99.6 99.5 99.1 99.7 99.8 100.0 99.9 99.8 99.8 99.9 99.9 
  12 98.7 98.5 97.6 98.0 100.0 100.0 100.0 100.0 99.7 99.6 99.6 99.9 
5 Clusters               
  2 99.8 100.0 100.0 99.9 100.0 99.8 99.8 100.0 99.9 100.0 100.0 100.0 
  3 99.9 99.9 99.6 99.9 100.0 99.9 100.0 99.9 100.0 100.0 99.9 100.0 
  4 99.7 99.7 99.4 99.6 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
  6 99.4 98.9 99.7 99.4 99.9 100.0 100.0 100.0 100.0 99.9 99.8 99.9 
  12 98.1 98.3 97.9 98.3 100.0 100.0 100.0 100.0 99.8 99.9 99.7 99.8 
6 Clusters               
  2 99.9 99.8 100.0 99.8 99.9 99.9 99.9 100.0 99.9 100.0 100.0 100.0 
  3 100.0 99.9 99.9 99.9 99.9 100.0 100.0 99.7 100.0 99.8 99.9 100.0 
  4 99.4 99.9 99.9 99.5 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 
  6 99.3 99.5 99.6 98.2 100.0 100.0 99.8 99.9 99.8 99.4 99.9 99.7 
  12 98.2 98.2 98.0 96.9 100.0 100.0 100.0 100.0 99.9 99.8 100.0 100.0 
9 Clusters               
  2 99.9 99.8 100.0 100.0 99.8 99.9 100.0 100.0 99.9 100.0 99.8 100.0 
  3 99.6 99.9 99.5 99.6 99.8 99.9 99.9 99.8 99.8 100.0 99.9 100.0 
  4 99.6 99.5 99.3 99.3 100.0 100.0 100.0 100.0 100.0 100.0 99.7 99.9 
  6 99.5 99.5 99.2 99.1 100.0 99.9 99.8 99.7 99.6 99.8 99.7 99.9 
  12 98.1 95.8 97.3 96.4 100.0 100.0 100.0 99.9 99.8 100.0 99.8 99.9 
12 Clusters               
  2 100.0 100.0 100.0 100.0 100.0 99.9 99.8 99.9 99.7 99.8 100.0 100.0 
  3 99.9 99.6 99.8 99.7 100.0 100.0 99.9 100.0 99.8 100.0 100.0 99.8 
  4 100.0 100.0 100.0 99.9 100.0 100.0 100.0 100.0 100.0 100.0 99.8 100.0 
  6 99.7 99.8 99.5 99.1 99.9 99.9 99.9 99.9 99.8 99.6 99.7 99.7 






5.4.2 Power estimation 
Statistical power determination was calculated as the proportion of the total observations for 
which the observed p value was ≤ 0.05. Conventionally, when detecting a significant effect a 
power of at least 80% is considered adequate (Cohen, 1992).  
 
The results for estimating statistical power for different scenarios are presented in Tables 6 - 
9. As statistical properties vary according to the prevalence or incidence of the conditions 
being studied (Moineddin, Matheson and Glazier, 2007), the results are presented according 
to the incidence levels of the studied disease conditions, which is in line with the different 
study outcomes of the Triage Plus study. The disease conditions are categorised as low 
incidence (e.g. TB treatment initiation rates) and high incidence (access rates to HIV testing, 
TB testing or ART treatment initiation rates). Statistical power estimates for ICCs of 0.081 and 
higher are presented in Tables 8 and 9 for low and high incidence diseases respectively. 
5.4.2.1 Power estimates when the incidence of the outcome is low and ICC is 0.00154 
The Triage Plus study had 3 clusters per arm and a desired effect size of 20%.  Under these 
circumstances, the simulation study indicates that the Triage Plus study would have had only 
24% statistical power to detect a 20% improvement in the detection and initiation of TB 
treatment if only 2 repeated measurement times had been used in each cluster: a pre- and 
post- evaluation design. However, statistical power would have increased with increasing 
effect sizes and the number of repeated measurement times. For instance, at least 80% 
statistical power would have been attained with an effect size of at least 50% and only 2 time 
points. The same percentage of power (>80%) would also be achieved with the desired effect 
size of 20% if there are 12 repeated measurement times. However, with an effect size as low 
as 10%, inadequate power is achieved even with 12 repeated measurement times (37% power 
at 12 measurements).  
 
With an effect size of 20% and two assessment time points, varying the number of clusters 
per intervention arm produced an improvement in estimated power from 24% with 3 clusters 
to 34%, 36%, 42%, 61% and 70% for 4, 5, 6, 9 and 12 clusters respectively. Estimated power 
increased to at least 80% when the number of repeated measurement times was set at 6 or 12 
with 5 or 6 clusters per arm. Thus, using 9 or12 clusters per arm required less repeated 
measurement times (i.e. 4 and 3 measurement times for 9 and 12 clusters per arm respectively) 
to achieve adequate power to detect an effect size of 20%.  
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By increasing the effect size to >20%, adequate power was achieved with less repeated 
measurement times: the minimum number of assessment times required decreased as the 
number of clusters per arm increased. With an effect size of 10%, none of the design 
conditions gave adequate power even with an increased number of clusters per arm or 
repeated measurement times (Table 6).  
 
Table 6:The effect of the number of clusters, repeated measurement times and effect size on the statistical 
power of the study design (% p value<0.05) based on 1000 simulated data sets under low disease incidence 
– The mean outcome measure in control clusters is 15 cases per month. 
Clusters and 
time points 
Effect size (incidence rate ratio) 
3 clusters per arm  1.1 1.2  1.3 1.4 1.5 1.6 1.8 
2 9.8 24.0 46.2 68.3 83.7 92.2 98.7 
3 12.3 35.5 64.7 85.1 94.4 97.6 99.9 
4 15.8 41.9 76.5 93.1 98.5 99.6 100 
6 20.2 58.7 88.9 98.4 99.9 100.0 100.0 
12 37.0 88.9 99.8 100.0 100.0 100.0 100.0 
4 clusters per arm        
2 11.8 33.9 58.1 79.4 90.8 96.1 99.8 
3 15.3 45.0 77.4 90.7 98.0 99.5 100.0 
4 18.5 54.4 86.5 97.3 99.7 99.9 100.0 
6 26.2 74.1 95.4 99.6 100.0 100.0 100.0 
12 45.2 94.5 99.8 100.0 100.0 100.0 100.0 
5 clusters per arm        
2 12.3 36.2 67.2 84.7 95.1 98.2 99.7 
3 17.2 51.6 84.8 96.9 99.8 100.0 100.0 
4 22.4 64.9 93.0 99.3 100.0 100.0 100.0 
6 30.8 82.7 98.2 100.0 99.9 100.0 100.0 
12 54.0 98.7 100.0 100.0 100.0 100.0 100.0 
6 clusters per arm        
2 15.6 41.9 75.7 88.9 97.2 99.3 100.0 
3 23.5 61.3 88.1 97.9 99.5 100.0 100.0 
4 25.6 72.2 95.7 99.7 100.0 100.0 100.0 
6 38.2 89.2 99.1 100.0 100.0 100.0 100.0 
12 65.2 99.3 100.0 100.0 100.0 100.0 100.0 
9 clusters per arm        
2 20.7 60.5 88.1 97.6 99.3 99.9 100.0 
3 29.4 77.4 96.7 99.7 100.0 100.0 100.0 
4 40.5 87.1 99.1 100.0 100.0 100.0 100.0 
6 50.9 97.0 100.0 100.0 100.0 100.0 100.0 
12 79.1 99.5 100.0 100.0 100.0 100.0 100.0 
12 clusters per arm*       
2 - 69.6 94.5 99.1 100.0 100.0 100.0 
3 - 86.1 99.2 100.0 100.0 100.0 100.0 
4 - 94.9 99.7 100.0 100.0 100.0 100.0 
6 - 99.2 100.0 100.0 100.0 100.0 100.0 
12 - 100.0 100.0 100.0 100.0 100.0 100.0 
 ICC=0.00154 
* No convergence was achieved at the effect size of 10%, hence no estimates are given  
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5.4.2.2 Power estimates when incidence of the outcome is high and ICC is 0.00154 
The Triage Plus study also included outcome measures for disease conditions with different 
incidence rates over the intervention period (e.g. TB testing uptake rates, ART initiation rates 
among eligible HIV positives individuals, HIV testing uptake rates, etc.), power was therefore 
also assessed for high incidence conditions. Without loss of generality, the effect of the 
intervention for improving uptake rates of TB testing, in terms of presumptive TB cases newly 
accessing TB microscopy testing, was evaluated as a proxy for high incidence outcomes.  
 
Using TB microscopy testing uptake rates as the outcome measure of interest, with a mean 
number of presumptive TB cases accessing TB testing = 70 in the control clusters (based on 
the baseline sample), the simulation results showed that 3 clusters per arm provided over 
77% power to detect a 20% improvement in uptake when two repeated measurement times 
were used. Statistical power increased to >95% when the effect size was increased to >20% 
even with only two repeated measurement times and 3 clusters per arm. Estimated power 
was at least 90% with an effect size of 20% when 3 or more repeated measurements times 
were used. However, with an effect size of 10% and just 3 clusters per arm, adequate power 
was only achieved when 12 repeated measurement times were used. 
 
When the number of clusters per arm was varied, an estimated power level of 80% or greater 
was achieved with 2 repeated measurements and an effect size >20%. With an effect size of 
only 10%, estimated power of ≥80% was achieved with 4 - 12 repeated measurements for 4 or 
more clusters per arm.   
 
Thus, in high incidence outcomes, adequate power to detect an intervention effect of 20% or 
greater can be achieved even when the number of clusters per study arm is as low as 3; more 
clusters per arm or repeated measurement times are required when the effect size is below 
20% (Table 7). 
 
The relationship between estimated power and the number of repeated measurement points 
in the 3 clusters per arm study design for different effect sizes is presented in Figure 6 for low 
incidence diseases and Figure 7 for high incidence diseases. Figure 6 clearly shows that with 
a true effect size of up to 20% (e.g. improving service access to TB treatment), statistical power 
of at least 80% can only be achieved with at least 12 repeated measurements times; however, 
with effect sizes of ≥40%, power levels of 80% or greater can be achieved with only 3 repeated 
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measurement times. With high incidence conditions (e.g. access to TB microscopy testing) 
shown in Figure 7, adequate statistical power of 80% or greater is achieved with 12 repeated 
measurements for effect sizes of 10%,  but fewer repeated measurements times (in some 
situations as few as 3 times) may be required when the effect size is 20% or greater . 
 
Table 7:The effect of the number of clusters, repeated measurement times and effect size on the statistical power 
of the study design based on 1000 simulated data sets under high disease incidence. The mean outcome measure 
in control clusters is 70 cases per month. 
Clusters and measurement 
times 
Effect size (incidence rate ratio) 
3 clusters per arm 1.1 1.2  1.3 1.4 1.5 1.6 1.8 
2 28.7 77.4 96.0 99.3 99.9 100.0 100.0 
3 43.6 90.1 99.3 100.0 100.0 100.0 100.0 
4 52.3 95.7 100.0 99.9 100.0 100.0 100.0 
6 69.1 99.2 100.0 100.0 100.0 100.0 100.0 
12 95.1 100.0 100.0 100.0 100.0 100.0 100.0 
4 clusters per arm        
2 36.0 87.0 98.5 99.8 100.0 100.0 100.0 
3 51.9 95.2 99.9 100.0 100.0 100.0 100.0 
4 63.6 99.3 100.0 100.0 100.0 100.0 100.0 
6 80.7 99.9 100.0 100.0 100.0 100.0 100.0 
12 98.3 100.0 100.0 100.0 100.0 100.0 100.0 
5 clusters per arm        
2 44.6 91.0 99.7 99.8 99.9 100.0 100.0 
3 63.5 98.1 100.0 100.0 100.0 100.0 100.0 
4 73.1 99.8 100.0 100.0 100.0 100.0 100.0 
6 87.1 100.0 100.0 100.0 100.0 100.0 100.0 
12 99.0 100.0 100.0 100.0 100.0 100.0 100.0 
6 clusters per arm        
2 52.9 95.2 99.7 99.9 100.0 100.0 100.0 
3 68.0 98.7 100.0 100.0 100.0 100.0 100.0 
4 82.7 99.8 100.0 100.0 100.0 100.0 100.0 
6 93.4 100.0 100.0 100.0 100.0 100.0 100.0 
12 99.9 100.0 100.0 100.0 100.0 100.0 100.0 
9 clusters per arm        
2 67.4 98.3 100.0 100.0 100.0 100.0 100.0 
3 85.6 99.7 100.0 100.0 100.0 100.0 100.0 
4 92.4 100.0 100.0 100.0 100.0 100.0 100.0 
6 90.0 100.0 100.0 100.0 100.0 100.0 100.0 
12 99.9 100.0 100.0 100.0 100.0 100.0 100.0 
12 clusters        
2 76.9 99.8 100.0 100.0 100.0 100.0 100.0 
3 91.3 100.0 100.0 100.0 100.0 100.0 100.0 
4 97.7 100.0 100.0 100.0 100.0 100.0 100.0 
6 99.7 100.0 100.0 100.0 100.0 100.0 100.0 
12 100 100.0 100.0 100.0 100.0 100.0 100.0 





Figure 6 Power curves when the disease incidence is low: 
The power curves show the relationship between power and the number of repeated measurement 
time points at different effect sizes (10%, 20%, 30%, 40%, 50% and 60%) when 3 clusters per arm are 
used using 1000 simulated datasets, when incidence is low.  The power curves indicate that statistical 
power increases as the number of repeated measurement times increases and the increase is higher 
when the effect size is at least 20%.  
 
 
Figure 7 Power curves when the disease incidence is high. 
 The power curves show the relationship between power and the number of repeated measurement 
time points at different effect sizes (10%, 20%,  40% and 60%) when 3 clusters per arm are used using 
1000 simulated datasets, when incidence is high. The curves indicate that statistical power increases as 
the number of repeated measurement times increases. With high incidence diseases, adequate statistical 
power is achieved even at low effect sizes of 10% after 12 measurement time points. 
 
 
5.4.2.3 Effect of varying ICC on power estimation 
To investigate the effect on statistical power estimation due to increasing the intracluster 







































0.081 to 0.699. In general, statistical power decreased with increasing ICCs and decreasing 
number of clusters. With a very high ICC (0.699), no adequate statistical power was achieved 
in all scenarios investigated. For an ICC of 0.321, adequate statistical power was achieved 
when the number of clusters was 12 and the effect size was 60%. The statistical power 
increased with increasing number of repeated measurement times (Table 8). With an ICC of 
0.081, adequate statistical power was achieved with 4 repeated measurement time points and 
an effect size of 40% in a 3 cluster per arm design. For lower effect sizes (20% and below), 
adequate statistical power was achieved when the number of clusters was 9 with 12 repeated 
measurement times (Table 8).   
 
In high incidence disease situations (70 events per month), no adequate statistical power was 
achieved in all scenarios investigated when the ICC was 0.699. However, when the ICC was 
varied up to just 0.321, higher statistical power was achieved with high effect sizes and 
adequate power was attained when the number of clusters was 6 with 3 repeated 
measurement time points at an effect size of 80%. For an effect size of 60%, 12 clusters per 
arm were needed to achieve adequate statistical power. No adequate statistical power was 
achieved when the effect size was 40% or less even after increasing the number of clusters to 
12 per arm (Table 9). With an ICC of 0.081, adequate statistical power was achieved with only 
3 repeated measurement time points in a 3 cluster per arm design when the effect size was 
40%. For an effect size of 20%, a minimum of 9 clusters per arm and 6 repeated measurement 




Table 8: The effect of the ICC, number of groups, effect size and repeated measurements on the statistical power, based on 
1000 simulated data sets when the disease incidence is low: Mean outcome measure in control clusters of 15 cases per month 
  ICC=0.081 ICC = 0.321 ICC = 0.699 
  Effect size (incidence rate ratio) Effect size (incidence rate ratio) 
Effect size (incidence rate 
ratio) 
  Effect  1.2 1.4 1.6 1.8 1.2 1.4 1.6 1.8 1.2 1.4 1.6 1.8 
3 clusters Time                    
  2 30.7 63.3 81.0 89.3 20.6 30.8 44.6 60.3 16.7 20.1 22.8 23.4 
 3 36.1 71.2 89.2 95.4 21.6 33.0 47.2 57.9 16.8 19.7 20.9 24.0 
  4 44.6 79.7 92.8 97.7 24.8 36.6 51.6 61.4 18.7 20.4 23.5 25.9 
  6 47.6 83.6 96.3 99.6 25.4 37.2 48.2 62.8 17.4 18.9 22.6 24.4 
  12 50.9 87.8 98.0 99.6 22.6 39.6 50.8 63.8 18.7 21.5 24.7 25.5 
4 clusters               
  2 36.1 68.3 84.9 93.2 20.0 34.0 50.4 66.1 12.1 15.9 19.4 22.6 
  3 41.7 78.4 92.9 97.2 19.4 32.1 51.4 67.9 12.0 14.2 19.4 22.7 
  4 45.8 84.6 96.2 99.3 21.4 35.0 50.3 63.7 14.9 17.6 18.3 18.6 
  6 51.1 90.4 98.7 99.8 20.0 39.6 56.0 70.9 15.7 16.5 18.0 23.0 
  12 55.6 93.9 99.5 100.0 21.1 35.9 52.5 69.2 15.0 15.6 16.5 23.3 
5 Clusters               
  2 39.0 76.1 89.1 94.2 20.8 38.7 52.1 68.3 10.5 12.4 17.3 18.0 
  3 43.6 86.1 95.6 98.7 16.4 35.3 55.4 73.6 13.1 15.8 15.7 21.3 
  4 51.5 90.1 97.6 99.6 19.4 38.5 55.9 72.7 12.0 14.0 16.8 21.1 
  6 54.1 93.7 99.5 100.0 19.1 39.2 57.0 71.9 12.8 13.3 14.4 19.6 
  12 57.0 96.3 100.0 100.0 18.6 39.1 58.1 75.0 12.6 13.7 15.9 19.2 
6 Clusters               
  2 40.1 79.1 91.0 94.9 18.3 36.3 59.6 74.9 11.0 13.9 17.8 18.4 
  3 52.5 87.7 96.9 99.0 19.5 37.8 60.9 81.2 9.1 14.1 15.1 21.4 
  4 52.5 91.2 98.3 99.7 20.2 41.4 62.5 76.8 12.1 12.4 15.2 19.7 
  6 62.4 97.6 99.8 100.0 18.3 41.8 61.9 78.4 11.7 15.5 16.2 19.9 
  12 65.7 97.9 100.0 100.0 20.6 42.8 63.0 79.5 10.7 14.9 16.7 20.4 
9 Clusters               
  2 52.1 86.7 94.5 98.6 20.2 48.2 69.9 88.9 8.9 12.8 16.9 23.6 
  3 64.7 93.5 98.8 99.8 22.5 45.3 75.8 91.6 9.2 13.1 15.6 22.0 
  4 70.6 98.0 99.8 99.9 22.0 48.2 73.6 90.5 9.0 13.4 17.7 22.4 
  6 75.3 99.3 100.0 100.0 21.8 49.7 76.0 91.8 9.8 14.2 17.4 24.1 
  12 80.0 99.9 100.0 100.0 22.2 56.1 79.3 92.0 9.8 13.0 17.2 23.6 
12 Clusters               
  2 59.4 93.7 96.9 98.8 18.7 55.1 81.7 95.7 9.6 13.6 20.0 25.6 
  3 70.8 96.9 99.7 99.6 23.5 58.9 84.7 95.1 8.8 15.2 16.0 26.8 
  4 73.1 99.0 99.8 100.0 25.0 59.7 86.2 96.4 9.8 12.1 18.3 25.4 
  6 81.8 100.0 100.0 100.0 23.3 61.8 87.6 97.3 9.9 13.1 18.1 24.9 
  12 86.9 100.0 100.0 99.7 27.0 63.1 86.1 96.2 8.8 12.9 18.1 28.3 
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Table 9: The effect of the ICC, number of groups, effect size and repeated measurements on the statistical power, based on 
1000 simulated data sets when the disease incidence is high: Mean outcome measure in control clusters of 70 cases per 
month 
  ICC=0.081 ICC = 0.321 ICC = 0.699 
  Effect size (incidence rate ratio) Effect size (incidence rate ratio) 
Effect size (incidence rate 
ratio) 
  Effect  1.2 1.4 1.6 1.8 1.2 1.4 1.6 1.8 1.2 1.4 1.6 1.8 
3 clusters Time                    
  2 42.8 79.1 95.3 98.3 22.8 39.2 48.3 62.3 15.8 20.4 21.3 23.7 
 3 46.5 84.3 97.0 99.4 24.4 37.9 49.6 66.5 21.1 19.7 24.3 23.2 
  4 51.9 87.9 98.1 99.8 23.7 35.7 53.0 65.4 20.5 20.5 21.8 21.7 
  6 51.3 89.8 98.4 99.9 23.3 35.2 54.3 63.8 18.6 23.9 21.4 23.8 
  12 51.0 87.7 98.4 99.8 23.1 38.4 51.5 63.6 18.8 18.4 21.6 27.1 
4 clusters               
  2 49.2 85.5 96.8 99.2 21.5 34.3 56.6 69.6 14.9 17.0 17.7 22.1 
  3 49.6 91.0 99.7 99.7 21.0 35.0 56.2 70.6 16.4 17.2 19.6 21.5 
  4 55.5 93.1 99.3 100.0 19.9 37.0 53.0 72.3 15.3 16.1 17.3 19.4 
  6 56.9 91.8 99.8 100.0 23.8 37.9 55.2 70.8 14.5 17.5 19.7 22.4 
  12 56.9 94.5 99.7 100.0 22.9 38.4 54.7 68.6 14.2 18.0 17.6 23.1 
5 Clusters                           
  2 52.4 91.8 98.1 99.6 19.6 40.7 56.6 75.3 13.5 13.4 16.4 19.4 
  3 60.8 94.3 99.7 100.0 19.7 43.2 59.4 75.7 11.7 14.8 15.9 19.3 
  4 58.8 96.4 99.9 100.0 22.0 35.1 58.0 75.2 14.4 14.4 18.1 19.9 
  6 59.2 96.7 99.9 100.0 18.4 40.4 61.2 76.3 14.6 14.1 16.2 20.1 
  12 63.3 96.5 99.9 100.0 20.9 40.6 59.2 75.6 13.7 15.3 17.4 22.0 
6 Clusters                           
  2 57.5 93.4 98.3 99.6 17.7 40.4 62.5 78.0 13.9 12.6 16.3 19.7 
  3 62.5 97.2 99.8 100.0 23.4 41.9 66.9 81.8 10.4 13.4 16.5 20.0 
  4 64.0 97.1 100.0 100.0 20.5 43.0 67.4 80.6 11.7 14.9 14.9 20.8 
  6 67.3 98.2 99.8 100.0 19.5 42.7 64.3 82.7 11.7 12.1 17.0 21.2 
  12 66.6 98.6 100.0 100.0 22.1 40.7 63.6 82.4 12.0 12.4 14.3 21.2 
9 Clusters                           
  2 69.9 96.9 99.6 99.8 21.4 50.7 78.2 90.9 10.6 13.4 18.4 25.1 
  3 76.4 99.2 100.0 100.0 22.4 53.3 78.8 92.0 8.9 12.7 16.9 22.1 
  4 77.1 99.7 100.0 100.0 21.4 54.9 78.2 91.3 10.4 13.6 17.8 22.5 
  6 80.7 99.8 100.0 100.0 23.3 53.4 79.4 92.8 11.4 13.6 17.0 20.6 
  12 82.2 100.0 100.0 100.0 22.5 54.0 77.5 92.0 9.7 13.7 21.0 22.2 
12 Clusters                           
  2 77.8 99.3 100.0 100.0 23.8 59.5 86.2 96.1 9.5 12.8 18.2 26.0 
  3 84.0 99.7 100.0 100.0 24.9 60.7 87.8 97.2 9.9 15.0 18.0 28.1 
  4 85.7 100.0 100.0 100.0 23.3 62.9 87.0 95.5 9.1 13.2 18.3 25.6 
  6 90.1 100.0 100.0 100.0 27.9 62.9 87.0 97.0 9.5 13.8 19.2 24.5 





5.4.3 Assessment of accuracy of parameter estimates 
5.4.3.1 Parameter estimates and precision when the ICC was 0.00154 
To better understand the statistical issues relating to different design scenarios, probabilistic 
simulations were used to assess the accuracy of parameter estimates (Gelman & Hill, 2007). 
These simulations showed negligible bias (deviation from a true estimate) in the estimation 
of fixed effects parameters of <1% in all scenarios evaluated for high incidence disease 
conditions of 70 events per month (Table 10). In low incidence diseases of 15 events per 
month, rates of bias of up to 2% were observed especially in a 3 cluster per arm design with 
2 measurements times (Table 10).The results are similar to simulation studies done by Mass 
& Hox (2005) and Bennett et al (2002) who also found negligible bias in the estimation of fixed 
effects parameters. However, Moineddin et al (2007) found biases for fixed effect parameters 
as high as 3.7% using multilevel logistic regression models. 
However, in an assessment of 95% confidence intervals and 5% and 95% percentiles, the 
results from this study indicated a clear pattern, with the precision of parameter estimates 
(based on the widths of 95% confidence intervals and 5% and 95% percentiles) improving as 
the number of clusters per arm was increased and as the number of measurement times in 
each cluster was increased (Tables 11 - 13). To clearly show how precision was related to 
different design conditions, Table 13 presents the average length of the 95% confidence 
intervals of the parameter estimates calculated as an absolute difference between the upper 
and lower limits of the confidence intervals around the estimate. The overall precision of 
parameter estimates improves with an increased number of clusters and repeated 
measurements times and a higher incidence of the studied disease condition.  
Average 95% confidence interval length improved from 0.729 to 0.275 in low disease 
incidence using 3 clusters per arm, an effect size of 20% and 2 to 12 repeated measurement 
times. For high disease incidence, precision improved from 0.332 to 0.128. The greatest 
reductions in average 95% confidence interval length occurred using 12 repeated 
measurements and 12 clusters (0.137 for low incidence outcomes, 0.064 for high incidence 
outcomes). 
It is important to note that the average length of the 95% confidence intervals increased with 
increasing effect size and was more evident in low incidence outcomes. With a low incidence 
outcome, 3 clusters per arm and 6 measurement occasions, the average length of the 95% 
confidence intervals increased from 0.368, when the effect size was 10%, to 0.541, when the 
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effect size was 80%. Similarly, when there was a high incidence outcome and 3 clusters per 
study arm, the average length of the 95% confidence intervals increased from 0.171, when the 
effect size was 10%, to 0.252, when the effect size was 80%.  
The findings from these simulations show that to achieve precise estimates, which will in turn 
provide gains in statistical efficiency and hence statistical power, at least 6 repeated 
measurement times are required to improve precision by 50% and that the gain in precision 







Table 10: The effect of the number of groups, time points and the effect size on  how accurately the estimated effect size is close to the fixed estimate size and how the precision of the estimated effect size improves based on the  95% 
confidence interval after 1000 simulated data sets (using ICC=0.00154) 
 Low incidence outcomes- Mean outcome measure in control clusters of 15 cases per month High  incidence  outcomes- Mean outcome measure in control clusters of 70 cases per month 
 Effect size (incidence rate ratio)* Effect size (incidence rate ratio)* 
 1.1 1.2 1.3 1.4 1.5 1.6 1.8 1.1 1.2 1.3 1.4 1.5 1.6 1.8 
3 clusters per arm 
 













































































































































4 clusters per arm 
 













































































































































5clusters per arm  
 
















































































































































 Low incidence outcomes- Mean outcome measure in control clusters of 15 cases per month High incidence outcomes- Mean outcome measure in control clusters of 70 cases per month 
 Effect size (incidence rate ratio) Effect size (incidence rate ratio) 
 1.1 1.2 1.3 1.4 1.5 1.6 1.8 1.1 1.2 1.3 1.4 1.5 1.6 1.8 
6clusters per arm 
 













































































































































9clusters per arm 
 













































































































































12 clusters per 
arm** 
             


































































































































* Incidence rate ratios (1.1 to 1.8) on top row were specified and therefore were fixed, the incidence rate ratios with 95% confidence intervals in brackets for the measurements times of 2 – 12 were estimated using the 1000 simulations for 
accessing accuracy of the estimation of the specified intervention effect sizes based on the 95% confidence intervals. 
 
* *No convergence was achieved at the effect size of 10%, hence no estimates are given 
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Table 11: The effect of the number of groups, time points and the effect size on how accurately the effect sizes were estimated based on 5% and 95% percentiles of the estimated effect size after 1000 simulated data sets. 
 Low incidence outcomes- Mean outcome measure in control clusters of 15 cases per month High incidence outcomes- Mean outcome measure in control clusters of 70 cases per month 
 Effect size (incidence rate ratio)* Effect size (incidence rate ratio)* 
 1.1 1.2 1.3 1.4 1.5 1.6 1.8 1.1 1.2 1.3 1.4 1.5 1.6 1.8 






















































































































































































































































































































































































































































































































































































 Low incidence outcomes- Mean outcome measure in control clusters of 15 cases per month High incidence outcomes- Mean outcome measure in control clusters of 70 cases per month 
 Effect size (incidence rate ratio) Effect size (incidence rate ratio) 
 1.1 1.2 1.3 1.4 1.5 1.6 1.8 1.1 1.2 1.3 1.4 1.5 1.6 1.8 













































































































































12 clusters per arm**             



































































































































* Incidence rate ratios (1.1 to 1.8) on top row were specified and therefore were fixed, the incidence rate ratios with 95% confidence intervals in brackets for the measurements times of 2 – 12 were estimated using the 1000 simulations for 
accessing accuracy of the estimation of the specified intervention effect sizes based on the 5% and 95% percentiles. 
 







Table 12: The effect of the number of groups and repeated measurements on the accuracy of the estimated effect size based on 
the mean length of 95% confidence interval, based on 1000 simulated data sets 
 Low incidence outcomes- Mean outcome measure in 
control clusters of 15 cases per month 
High incidence outcomes- Mean outcome measure in 
control clusters of 70 cases per month 
    Effect size (incidence rate ratio)    Effect size (incidence rate ratio) 
 1.1 1.2  1.3 1.4 1.5 1.6 1.8 1.1 1.2  1.3 1.4 1.5 1.6 1.8 
3 clusters per arm             
2 0.682 0.729 0.778 0.830 0.870 0.919 1.00 0.305 0.332 0.350 0.370 0.387 0.411 0.451 
3 0.539 0.574 0.612 0.650 0.685 0.725 0.800 0.245 0.263 0.278 0.293 0.315 0.327 0.360 
4 0.460 0.492 0.524 0.553 0.587 0.618 0.677 0.212 0.223 0.241 0.253 0.270 0.283 0.311 
6 0.368 0.391 0.418 0.443 0.493 0.492 0.541 0.171 0.184 0.194 0.202 0.218 0.227 0.252 
12 0.257 0.275 0.293 0.310 0.328 0.343 0.379 0.119 0.128 0.136 0.143 0.152 0.159 0.176 
4 clusters per arm             
2 0.580 0.622 0.661 0.700 0.738 0.781 0.856 0.268 0.288 0.301 0.318 0.338 0.357 0.391 
3 0.464 0.496 0.529 0.561 0.592 0.625 0.685 0.215 0.227 0.239 0.257 0.271 0.285 0.313 
4 0.395 0.419 0.447 0.478 0.503 0.526 0.583 0.183 0.195 0.208 0.221 0.231 0.245 0.268 
6 0.319 0.341 0.363 0.387 0.409 0.431 0.472 0.147 0.159 0.166 0.178 0.188 0.198 0.217 
12 0.224 0.240 0.254 0.269 0.285 0.300 0.329 0.103 0.111 0.118 0.125 0.132 0.140 0.153 
5 clusters per arm             
2 0.512 0.549 0.585 0.616 0.654 0.687 0.758 0.239 0.257 0.272 0.285 0.306 0.320 0.349 
3 0.415 0.444 0.471 0.500 0.529 0.558 0.615 0.191 0.203 0.216 0.229 0.245 0.255 0.278 
4 0.354 0.378 0.401 0.427 0.449 0.476 0.523 0.164 0.175 0.186 0.199 0.207 0.218 0.341 
6 0.286 0.308 0.327 0.346 0.362 0.382 0.422 0.133 0.141 0.151 0.159 0.168 0.179 0.195 
12 0.200 0.214 0.232 0.243 0.255 0.269 0.295 0.093 0.99 0.105 0.111 0.118 0.124 0.136 
6 clusters per arm             
2 0.478 0.510 0.537 0.572 0.600 0.631 0.692 0.219 0.235 0245 0.261 0.278 0.289 0.321 
3 0.378 0.404 0.429 0.455 0.481 0.505 0.554 0.173 0.187 0.197 0.208 0.220 0.231 0.255 
4 0.322 0.345 0.367 0.389 0.411 0.431 0.478 0.149 0.158 0.170 0.180 0.188 0.199 0.218 
6 0.261 0.278 0.297 0.313 0.331 0.350 0.382 0.120 0.129 0.138 0.145 0.153 0.161 0.177 
12 0.183 0.195 0.208 0.220 0.232 0.245 0.268 0.085 0.091 0.096 0.101 0.107 0.113 0.124 
9 clusters per arm             
2 0.393 0.419 0.444 0.471 0.499 0.525 0.576 0.176 0.188 0.198 0.212 0.225 0.235 0.260 
3 0.308 0.329 0.353 0.373 0.393 0.409 0.450 0.141 0.150 0.161 0.170 0.181 0.190 0.209 
4 0.261 0.279 0.297 0.314 0.332 0.351 0.386 0.121 0.130 0.138 0.147 0.154 0.162 0.177 
6 0.213 0.228 0.243 0.258 0.272 0.287 0.314 0.098 0.104 0.112 0.118 0.126 0.133 0.144 
12 0.149 0.159 0.170 0.180 0.190 0.199 0.218 0.069 0.074 0.079 0.082 0.088 0.092 0.102 
12 clusters arm*             
2 - 0.354 0.377 0.401 0.423 0.445 0.487 0.153 0.162 0.172 0.183 0.194 0.205 0.222 
3 - 0.282 0.300 0.319 0.337 0.355 0.391 0.122 0.130 0.139 0.149 0.155 0.164 0.180 
4 - 0.241 0.256 0.274 0.289 0.304 0.337 0.104 0.112 0.119 0.126 0.133 0.141 0.154 
6 - 0.197 0.209 0.222 0.234 0.247 0.270 0.085 0.091 0.096 0.102 0.108 0.114 0.125 
12 - 0.137 0.160 0.155 0.163 0.172 0.190 0.059 0.064 0.068 0.072 0.076 0.080 0.088 
 ICC=0.00154 
* No convergence was achieved at the effect size of 10%, hence no estimates are given 
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Table 13:The effect of the number of clusters, time points and the effect size on the percentage relative bias of how the estimated effect size differed from the 
fixed effect size and non-coverage of the asymptotic 95% confidence interval of the estimated effect size. 
 Low incidence- Mean count in control clusters of 15 cases per month High incidence - Mean count in control clusters of 70 cases per month 
 Bias (% Relative bias (
?̂?−𝜽
𝜽




 Effect size (incidence rate ratio) Effect size (incidence rate ratio) 
 1.1 1.2 1.3 1.4 1.5 1.6 1.8 1.1 1.2 1.3 1.4 1.5 1.6 1.8 




















































































































































































































































0.0 (0.0) 0.0  
(-0.01) 
0.0 (0.0) 0.003 
(0.16) 




















































































































































































































































































































































































































































12 clusters per arm*             

































































































































* No convergence was achieved at the effect size of 10%, hence no estimates are given 
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5.4.3.2 Effect of varying ICC on the accuracy of parameter estimates 
To assess the effect of varying ICC values on the accuracy of parameter estimates, the average 
length of the 95% confidence intervals of the parameter estimates were used; these showed 
clear patterns when the design conditions were varied (see section 5.4.3.1). In general, the 
accuracy of parameter estimates decreased with increasing ICCs (Table 14). Within a given 
ICC, the accuracy of parameter estimates improved with increasing number of clusters, time 
points and effect size. This was most evident when the ICC was 0.081. The average length of 
the 95% confidence intervals reduced on average by 50% when the measurement time points 
were changed from 2 to 12 for any given number of clusters and when the ICC was 0.081. 
However, with ICCs of 0.321 and higher, there were minimal changes in the average length 
of the 95% confidence intervals even after varying the number of clusters, measurement time 
points and effect sizes (Table 14).  These findings suggest that precise estimates of the 
estimated parameters can only be achieved if the ICCs are not too high and that at least 12 
repeated measurement times are required to improve precision by 50% (Table 14).    
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Table 14: The effect of the ICC, number of groups, effect size and repeated measurements on the accuracy of the estimated effect size based the mean length of 95% 
confidence interval, based on 1000 simulated data sets 
  
Low incidence outcomes- Mean outcome measure in control clusters of 15 
cases per month 
High incidence outcomes- Mean outcome measure in control clusters 
of 70 cases per month 
  ICC=0.081 ICC = 0.321 ICC = 0.081 ICC = 0.321 
  Effect size (incidence rate ratio) Effect size (incidence rate ratio) Effect size (incidence rate ratio) Effect size (incidence rate ratio) 
  Effect  1.2 1.4 1.6 1.8 1.2 1.4 1.6 1.8 1.2 1.4 1.6 1.8 1.2 1.4 1.6 1.8 
3 clusters Time                        
  2 0.985 1.033 1.142 1.268 1.375 1.706 1.896 2.109 0.544 0.641 0.722 0.821 1.244 1.477 1.728 1.977 
 3 0.679 0.751 0.881 0.923 1.362 1.547 1.829 2.035 0.489 0.559 0.625 0.714 1.256 1.469 1.663 1.894 
  4 0.566 0.642 0.727 0.788 1.328 1.560 1.739 1.987 0.451 0.536 0.616 0.676 1.294 1.478 1.713 1.869 
  6 0.501 0.572 0.645 0.724 1.315 1.532 1.720 1.868 0.439 0.516 0.591 0.666 1.258 1.487 1.726 1.850 
  12 0.453 0.515 0.590 0.661 1.303 1.476 1.693 1.858 0.434 0.501 0.583 0.657 1.256 1.433 1.633 1.869 
4 clusters                       
  2 0.816 0.869 1.010 1.132 1.317 1.518 1.742 1.939 0.495 0.590 0.647 0.726 1.176 1.359 1.573 1.739 
  3 0.596 0.671 0.755 0.377 1.282 1.414 1.639 1.845 0.442 0.514 0.580 0.645 1.165 1.344 1.564 1.733 
  4 0.517 0.581 0.671 0.274 1.213 1.431 1.611 1.796 0.425 0.490 0.569 0.631 1.163 1.348 1.529 1.782 
  6 0.461 0.517 0.603 0.220 1.192 1.392 1.534 1.800 0.415 0.479 0.554 0.621 1.150 1.339 1.559 1.757 
  12 0.414 0.498 0.556 0.203 1.153 1.347 1.520 1.727 0.405 0.473 0.536 0.607 1.155 1.344 1.507 1.722 
5 Clusters                       
  2 0.762 0.881 0.905 1.071 1.187 1.427 1.554 1.760 0.475 0.546 0.613 0.672 1.088 1.274 1.439 1.608 
  3 0.538 0.609 0.706 0.753 1.123 1.293 1.515 1.687 0.407 0.474 0.552 0.609 1.097 1.252 1.401 1.595 
  4 0.462 0.545 0.602 0.671 1.113 1.299 1.502 1.656 0.394 0.453 0.525 0.591 1.061 1.223 1.406 1.594 
  6 0.431 0.495 0.558 0.623 1.095 1.281 1.412 1.626 0.384 0.448 0.509 0.572 1.058 1.238 1.400 1.588 
  12 0.391 0.452 0.520 0.584 1.071 1.265 1.414 1.572 0.381 0.438 0.502 0.571 1.059 1.240 1.420 1.609 
6 Clusters                       
  2 0.645 0.706 0.828 0.938 1.100 1.279 1.447 1.619 0.430 0.494 0.553 0.625 1.022 1.165 1.325 1.500 
  3 0.485 0.562 0.637 0.718 1.087 1.227 1.370 1.566 0.386 0.447 0.506 0.568 1.005 1.179 1.367 1.480 
  4 0.438 0.498 0.560 0.633 1.020 1.191 13.84 1.527 0.375 0.429 0.493 0.553 0.990 1.159 1.336 1.460 
  6 0.393 0.452 0.518 0.579 1.004 1.183 1.358 1.529 0.361 0.421 0.475 0.533 0.965 1.486 1.316 1.469 




 Low incidence outcomes- Mean outcome measure in control clusters of 15 
cases per month 
High incidence outcomes- Mean outcome measure in control clusters 
of 70 cases per month 
  ICC=0.081 ICC = 0.321 ICC = 0.081 ICC = 0.321 
  Effect size (incidence rate ratio) Effect size (incidence rate ratio) Effect size (incidence rate ratio) 
Effect size (incidence rate ratio) 
  Effect  1.2 1.4 1.6 1.8 1.2 1.4 1.6 1.8 1.2 1.4 1.6 1.8 1.2 1.4 1.6 1.8 
9 Clusters                       
  2 0.524 0.603 0.792 0.770 0.915 1.077 1.198 1.344 0.366 0.414 0.476 0.532 0.849 0.973 1.127 1.277 
  3 0.412 0.465 0.526 0.587 0.886 1.020 1.165 1.315 0.319 0.373 0.429 0.48 0.830 0.963 1.102 1.231 
  4 0.358 0.418 0.475 0.542 0.866 1.004 1.151 1.288 0.314 0.365 0.412 0.461 0.820 0.977 1.101 1.232 
  6 0.336 0.388 0.443 0.492 0.844 0.982 1.116 1.262 0.308 0.354 0.407 0.456 0.829 0.959 1.099 1.225 
  12 0.310 0.362 0.414 0.460 0.819 0.988 1.114 1.236 0.299 0.350 0.399 0.449 0.810 0.967 1.073 1.213 
12 Clusters                       
  2 0.439 0.479 0.572 0.636 0.796 0.927 1.060 1.173 0.316 0.357 0.405 0.461 0.736 0.858 0.974 1.090 
  3 0.354 0.416 0.467 0.518 0.771 0.892 1.014 1.153 0.286 0.330 0.375 0.427 0.729 0.835 0.961 1.093 
  4 0.325 0.371 0.429 0.475 0.740 0.877 0.995 1.125 0.277 0.322 0.369 0.415 0.723 0.849 0.964 1.069 
  6 0.293 0.342 0.391 0.435 0.739 0.869 0.978 1.111 0.269 0.313 0.359 0.404 0.725 0.842 0.953 1.091 
  12 0.276 0.321 0.367 0.411 0.733 0.841 0.963 1.081 0.266 0.307 0.353 0.397 0.715 0.828 0.957 1.077 
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5.4.3.3 Coverage rates of Standard errors when ICC was 0.00154 
The accuracy of the simulated data parameter estimates were evaluated using coverage rates; 
95% confidence intervals were computed for the parameter estimates from each data set 
obtained from the different scenarios studied. The coverage rate was defined as the 
proportion of times the true parameter was within the specified (95%) confidence intervals 
(Burton et el, 2006). 'Adequate coverage' was thus defined as a coverage rate equal to or 
greater than the specified 95% (see Collins, Schafer and Kam, 2001). Using this coverage rate, 
the failure rate of the true specified parameter (non-coverage) was defined as 5%. 
 
Table 15 presents the non-coverage rates of the asymptotic 95% confidence intervals of the 
parameter estimates of interest based on 1000 simulated data sets for each of the studied 
scenarios. Overall, the effects of varying the number of clusters, measurement times, effect 
size and incidence of the outcomes were small, with non-coverage rates ranging from 2.8% 
to 6%. With 3 clusters per arm, non-coverage rates were approximately close to the 5% 
nominal value across most of the different effect sizes when the number of measurement 
times was 4 and the outcome measure incidence was low (range 4.2% to 5.0%) and also when 
the number of measurement times was 3 and the outcome measure incidence was high (range 
3.5% to 5.1%).  
 
In general, the close clustering of the non-coverage rates around the 5% nominal value clearly 
demonstrates that the standard errors were correctly estimated for each of the different 
scenarios investigated.   
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Table 15: The effect of number of clusters, time points and the effect size on the non-coverage of the 95% confidence intervals of 
parameter estimates (regression coefficients) based on 1000 simulated data sets. 
 % non-coverage of standard errors based on low incidence 
conditions of 15 cases per month 
% non-coverage of standard errors based on high incidence 
conditions of 70 cases per month 
 Effect size (incidence rate ratio) Effect size (incidence rate ratio) 
 
1.1 1.2 1.3 1.4 1.5 1.6 1.8 1.1 1.2 1.3 1.4 1.5 1.6 1.8 
3 clusters per arm             
2 4.8 4.0 4.4 4.1 3.9 4.3 4.2 4.4 4.6 4.7 4.1 4.1 4.4 4.1 
3 4.1 4.0 4.1 4.2 4.3 3.3 3.8 4.6 3.9 3.7 4.9 5.1 4.8 3.5 
4 4.5 4.2 4.8 4.8 4.2 4.3 5.0 3.4 4.2 4.2 3.8 2.8 4.4 4.0 
6 3.8 4.0 5.1 4.5 4.1 4.4 4.4 4.1 4.7 5.2 4.6 3.9 4.4 4.1 
12 4.7 3.7 4.1 3.4 3.0 4.1 3.6 4.0 3.5 3.6 4.4 4.6 5.8 3.9 
4 clusters per arm             
2 3.8 4.8 4.6 4.9 5.0 4.3 4.6 3.6 4.7 4.7 4.6 4.3 4.0 4.0 
3 3.9 4.8 5.9 5.7 5.0 5.0 5.0 4.4 4.1 5.2 3.9 3.9 3.9 4.1 
4 4.2 3.5 4.3 4.6 2.8 4.1 4.2 5.0 4.7 3.3 3.9 3.1 5.9 4.1 
6 4.0 4.1 5.0 4.2 4.3 4.2 3.5 4.1 3.4 5.1 3.4 3.6 3.2 3.8 
12 4.3 3.9 4.6 3.8 3.9 3.3 4.1 3.6 4.1 4.2 5.1 4.1 3.7 5.4 
5 clusters per arm             
2 4.2 4.1 3.8 4.6 4.5 4.3 4.0 3.8 4.8 3.7 5.4 5.8 4.5 3.9 
3 3.9 4.1 3.7 4.2 4.1 4.2 3.6 3.2 3.8 4.8 5.0 5.1 4.1 4.6 
4 4.4 5.2 4.6 4.6 4.4 4.4 4.4 4.8 4.7 4.1 3.8 3.9 3.0 4.5 
6 4.3 4.1 4.3 5.7 4.4 4.2 3.7 4.4 4.0 3.4 5.2 4.6 3.4 4.8 
12 3.3 3.5 4.3 3.0 3.1 3.3 3.9 4.4 4.0 3.7 3.1 4.0 4.3 3.2 
6clusters per arm             
2 4.4 4.3 4.7 5.7 5.3 4.5 4.8 3.6 4.3 4.3 3.7 5.4 4.8 5.7 
3 5.0 4.3 4.4 4.2 4.9 4.2 5.6 4.5 5.4 5.5 3.5 3.9 4.0 4.5 
4 4.8 4.9 6.0 4.7 4.0 4.4 3.9 4.2 3.3 3.7 3.5 4.3 4.1 3.5 
6 5.1 4.1 4.6 4.5 5.1 4.0 4.6 4.5 3.9 5.4 4.8 3.9 4.6 3.9 
12 3.8 3.7 4.4 3.5 4.9 4.6 4.0 3.4 3.5 3.8 3.7 4.1 4.1 4.1 
9 clusters per arm             
2 4.7 4.1 4.1 4.0 4.2 3.8 4.5 4.2 4.4 5.3 3.3 5.6 5.2 4.3 
3 4.7 4.9 4.0 4.0 4.3 4.8 4.7 4.4 4.8 5.2 4.3 5.0 4.4 3.1 
4 4.6 3.8 4.5 4.7 3.8 4.0 4.9 5.1 5.3 4.5 3.9 4.4 5.3 5.4 
6 3.2 3.2 3.0 3.8 3.1 4.4 3.1 4.0 4.1 4.5 4.1 4.3 3.7 3.7 
12 4.5 4.0 3.6 4.8 4.6 4.2 3.4 4.6 4.5 4.3 5.5 4.9 4.4 4.4 
12 clusters per arm*             
2 - 3.8 4.5 4.1 4.1 3.7 4.5 6.0 5.8 4.6 4.8 4.2 4.9 4.1 
3 - 3.9 2.9 5.0 4.5 3.8 3.7 4.3 4.2 3.8 5.6 5.2 4.7 5.3 
4 - 3.9 3.5 4.1 3.3 3.2 4.1 3.8 4.6 5.0 4.0 4.5 4.7 4.9 
6 - 4.1 3.6 3.8 4.1 4.1 3.9 3.9 4.7 3.8 4.3 3.9 3.5 4.2 
12 - 5.0 4.4 3.7 4.2 4.0 4.5 4.3 3.0 3.3 5.0 3.8 4.2 4.4 
ICC=0.00154 






This Chapter has investigated the conceptual and practical issues relating to the attainment of 
adequate statistical power and efficiency for a range of cluster randomised study designs.  The 
simulation studies presented provide a wealth of findings that will help to inform the choice 
of design conditions for a cluster randomised study in circumstances where the number of 
clusters is both limited and small. By using simulation approaches, different design conditions 
could be investigated in a way that would not normally be possible using real field trials.   
It was apparent that there was no gain in evaluating the different design conditions of interest 
within the context of the Triage Plus study using different statistical approaches (e.g. using 
negative binomial models for count data), so this option was not pursued.  In particular, 
random effects models analysed with Poisson regression models and robust standard error 
would provide similar results to using negative binomial models. Use of robust standard 
errors reduces the over-dispersion usually encountered in Poisson regression models (Rabe-
Hesketh & Skrondal, 2012, page 712). As highlighted in section 4.2.3.2, the estimates of the 
regression coefficients in Poisson and negative binomial models are similar but differ in 
variance estimates, and therefore use of the robust standard errors in marginal effects models 
corrects the difference (Rabe-Hesketh & Skrondal, 2008). The only drawback of using the 
Poisson models is that they may give rise to predicted probabilities that are greater than 1 
when the estimates are on or are very close to the boundaries of the parameter space (Deddens 
and Petersen, 2004); this problem was resolved in this study by simply increasing the number 
of iterations used to reduce high rates of non-convergence rates (Table 15). 
Furthermore, because the primary outcome measure collected in the Triage Plus study was a 
count, the use of log-binomial regression models, presented under the Future Work section 
7.8.2 in Chapter 7,would not have been ideal in the current study despite producing efficient 
estimates and accurate measures of statistical uncertainty in estimating prevalence or risk 
ratios (Wacholder, 1986; Zocchetti, 1995; Skov et al., 1998; Savu, Liu & Yasu, 2010). 
The simulation study findings reported here show that the gain in statistical efficiency and 
power varied considerably under the different design conditions investigated. As expected, 
nominal non-coverage rates as well as negligible biases in the estimation of regression 
coefficients of fixed effect parameters were observed in all scenarios investigated, including 
the 3 cluster per arm design.  However, in order to achieve precise estimates that would in 
turn provide some gains in statistical efficiency and hence power, if at least 6 repeated 
measurement times are used with an ICC of 0.00154, precision improves by as much as 50% 
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compared to using just two time points, and this gain in precision is greatest for high incidence 
outcomes. In high incidence disease conditions, with effect sizes of as low as 10%, adequate 
power is still achievable, particularly if at least 6 repeated measurements are taken over time.  
By contrast, the simulations also clearly show that more measurement times are required to 
achieve adequate power (≥80%) with effect sizes of 20% or lower in low incidence situations. 
With effect sizes of 10% or lower in low incidence disease conditions, no adequate power 
levels or efficient parameter estimates were achieved in any of the design conditions 
investigated, implying a substantial (and probably totally unacceptable) risk of a statistical 
type II error (i.e. of drawing a wrong negative conclusion) when analysing the effectiveness 
of an intervention using a small number of clusters when both the population effect size and 
disease incidence are low.  Possibly the most surprising finding was that, in low incidence 
disease conditions and with an effect size of 10%, the simulations encountered convergence 
problems even when the number of measurement times was increased to 12; these challenges 
are likely to be even more severe with very low effect sizes (<10%). Moineddin, Matheson 
and Glazier (2007) also encountered lowest convergence rates at disease prevalence rates of 
10%. Further research will be needed in future to investigate this finding. However, for ICC 
values ≥0.081, such convergence challenges were not observed potentially due to the fact that 
larger values of the between cluster variance increase the background incidence rate leading 
to improved convergence rates (Amatya, Bhaumik and Gibbons, 2013).  
 
Simulations carried out to investigate the effect of varying the intracluster correlations on 
statistical power estimation indicated that statistical power decreased with increasing ICC. 
With an ICC of 0.699, the simulations indicated that no adequate statistical power could be 
achieved when the number of events per month was ≤70. However, with ICCs of ≤0.081, 
adequate statistical power could be achieved with 4 repeated measurement time points and 
an effect size of 40% in a 3-cluster per arm design when the disease incidence rate was low, 
and with only 3 repeated time points when the mean number of events per month was 70. At 
effect sizes of ≤20%, adequate statistical power was achieved when the number of clusters 
was 9 with 12 measurement time points for low incidence disease rates and 6 time points for 
high incidence disease rates.  
 
Although the simulations reported in this dissertation did not assess the effect of varying 
group level explanatory variables on power and parameter estimation accuracy, the results 
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obtained are comparable to previous studies (Bennett et al., 2002; Moineddin, Matheson and 
Glazier, 2007). However, unlike previous studies, our study has further demonstrated that by 
employing a repeated measurement approach in the design of the cluster randomised trials, 
adequate statistical properties (e.g. statistical power) can be achieved in situations where only 
a limited number of clusters is available for randomisation provided the incidence of the 
outcome of interest is not too small and the ICC is not too high. In the simulations, estimates 
of variance components and model intercepts from baseline samples from the actual Triage 
Plus study were used. Assessment of various explanatory variables would have been essential 
in assessing statistical efficiency, but these analyses were not included. Including them in the 
simulations would have meant adding more computer processing time considering the varied 
conditions considered in the simulations.   
The findings presented in this Chapter have a number of implications worth noting:  
1. In situations where the number of available clusters is both small and limited, study designs 
that do not involve a longitudinal data structure (i.e. do not involve several post-intervention 
assessment times) risk being considerably underpowered and are likely to provide poor 
estimates of the effectiveness of the intervention (effect size). Some researchers avert the 
challenge of a limited number of clusters by analysing the data as if it were not derived from 
a cluster randomised design (i.e. derived from a conventional individual-participant 
randomised design), a practice that risks overstating the significance of the interventions 
effects (Murray, 1998a), resulting in wrong decisions and poorly informed policy directions.   
It is worth noting that it is only necessary to increase the number of clusters to about 6 in each 
arm of the study and to have more than one post-intervention assessment time to achieve 
optimal statistical properties. However, although the use of random effects modelling with 
variable adjustments accounted for the heterogeneity and unknown confounding effects, the 
use of more clusters is recommended to ensure an even spread of covariates between the 
treatment arms (and hence to ensure internal validity).   
2. Power estimation in conjunction with the use of the average length of the 95% confidence 
intervals of parameter estimates (calculated as an absolute difference between the limits 
around the estimate) was found to be critical in assessing the varied design conditions. Using 
power estimation alone did not provide clear patterns in determining optimal design 
conditions especially when the ICCs were moderate. The simulations showed that precise 
estimates were achieved with increasing the number of clusters and measurement times for 
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each of the effect sizes and disease incidence and decreased with increasing intracluster 
correlations.  
3. Given that statistical efficiency is most affected by the incidence of the disease condition and 
the intervention effect size, especially in rare disease conditions such as TB treatment 
initiations, when the number of clusters is limited the use of more measurement times can 
achieve optimal statistical efficiency and power in the context of large cluster sizes as pursued 
here (the Triage Plus study, from which the baseline data sets were derived, used large cluster 
sizes).   
4. However, because there is often (financial and other) constraints that will limit the actual 
number of post-intervention assessment times available for random effects modelling (Best, 
Mason and Li, 2011), in order to ensure internal validity of the trial results, the findings of 
this simulation study suggest that a minimum of 9 clusters per arm and a minimum of 4 
measurement times in low incidence diseases and low ICC (in our case an ICC of 0.00154) are 
needed with an effect size of ≤20% to obtain valid estimates using mixed effects Poisson 
models. However, for high incidence outcomes, as low as 3 clusters per arm and at least 3 
measurement times may be adequate to achieve statistical power of at least 80%. With an ICC 
of 0.081, more clusters and measurement times were needed to achieve adequate statistical 
power in both high and low incidence disease conditions. 
5. In complex study designs requiring a number of factors to be considered for sample size 
determination, sample size calculations cannot be conducted using the existing formulae and 
extended formulae may prove to be too complex to be of practical value. Simulation methods, 
such as those employed in this study, may need to be used to overcome these issues where 




STATISTICAL ANALYSIS OF THE TRIAGE PLUS STUDY 
 
6.1 Introduction 
Different statistical methods were presented in Chapters 3 and 4. Some of these methods were 
used in the simulation studies presented in Chapter 5. In this Chapter, the analytical 
framework is applied, which the simulation methods showed to be optimal, on the Triage 
Plus integrated TB-HIV community cluster-randomised intervention study. In particular, the 
robustness of the statistical methods in assessing the effectiveness of the Triage Plus 
intervention were assessed by using marginal and random effects models. The circumstances 
under which the statistical methods would be more robust in detecting significant 
intervention effects when applied to real situations are assessed.   
Given that the second part of the thesis focuses on assessing the effectiveness of engaging 
informal healthcare providers in integrated TB and HIV interventions at community level, the 
chapter further presents results of the Triage Plus study as well as its implications for TB and 
HIV control.  As the phased intervention approach was used in implementing the Triage Plus 
intervention (see section 2.3.3.5 in Chapter 2), the results presented in this Chapter are 
presented according to the phases. This Chapter further presents a summary of the findings 
concerning the involvement of informal health care providers in TB and HIV community 
interventions.  This Chapter concludes with the statistical implications of the Triage Plus 
study findings and gives cautious interpretations of the non-significant findings.   
6.2 Analytical approach 
 
6.2.1 Unit of analysis and the need for repeated measurements 
In cluster randomised interventions, analysis is usually done at the cluster level. Since the 
number of events (e.g. TB treatment initiations) at cluster level on each of the different 
measurement occasions were recorded, our unit of analysis is the measurement occasion 
within each cluster (i.e. cluster x measurement occasions units). Cluster level summaries are 
usually robust and provide valid results, unlike individual level analysis (Hayes and Moulton, 
2009).  Using cluster- measurement occasion summaries improves statistical power, especially 
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in studies with a limited number of clusters as observed in the simulation studies presented 
in Chapter 5. 
When there is only a moderate number of clusters, Thompson, Warner and Turner (2004) 
noted that inferences made from asymptotic approximations are less robust. Considering that 
multilevel modelling is most attractive with more clusters (Feldman, McKinlay, and Niknian, 
1996; Maas and Hox, 2005; Moineddin, Matheson and Glazier, 2007; Snijders and Bosker, 1999) 
and that the Triage Plus study has only limited number of clusters, the repeated-measurement 
nature of our data improves the number of degrees of freedom and, therefore, the statistical 
power, especially when marginal or random intercepts models are used (Murray et al., 1998b).  
As pointed out by Murray et al (1998b), power still improves in random coefficients models, 
even though the degrees of freedom remain constant with the increasing number of repeated 
measurements from the same clusters.  By using the longitudinal structure of data collection 
as described by Feldman, McKinlay, and Niknian (1996), as shown in the simulation studies 
presented in Chapter 5 that statistical power and efficiency in parameter estimations can be 
increased without necessarily increasing the number of clusters, especially in high incidence 
outcomes  such as ART initiation rates.  
The use of repeated measurements, sometimes called time-series cross-sectional data, in the 
same clusters in the context of a mixed effects framework has the advantage of allowing the 
assessment of whether or not the effect of the intervention increases over time as the 
intervention becomes established in the community (Gelman and Hill, 2007).  
In such modelling approaches, the incorporation of separate, random intercept and slope 
terms for each time point may be necessary to distinguish intervention effects from secular 
trends (Hayes and Moulton, 2009). The approach allows for greater flexibility in modelling 
(studying) cluster-level and time effects when accounting for correlations resulting from the 
clustering and repeated measurements (Gelman and Hill, 2007). As pointed out by 
Gueorguieva and Krystal (2004), the flexibility in modelling correlation and variance patterns 
is necessary since variations in response outcomes between clusters may occur over time and 
during the implementation of the intervention: variations may be greater immediately after 
the initiation of the intervention or later in the study when the intervention  has had an 
opportunity to ‘bed-in’ (i.e. if there is a lag between intervention implementation and first 
signs of effect).   
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6.2.2 The matched-pair design analysis 
The matched-pair design implemented in the Triage Plus study was meant to minimise 
differences in baseline characteristics between intervention arms which improves precision 
and statistical power as well as trial results credibility. However, the matching on surrogate 
variables that were expected to be correlated with the outcome measures was not effective in 
minimising between-group variation in baseline outcome measures such as TB and ART 
treatment initiation rates (see Table 18). The pair-matching was less robust due to there being 
only a limited number of clusters (Diehr et al., 1995; Hayes and Moulton, 2009).  
The matched-pair design analysis usually decreases statistical power, especially when the 
number of pairs is less than 10 (Diehr et al., 1995, Klar and Donner, 1997; Feng et al., 2001). 
Klar and Donner (1997) noted that with a limited number of matched-pairs (as in the Triage 
Plus study) obtaining balanced matches on all potential factors may be difficult. Therefore, 
small differences, though important in the context of TB and HIV community interventions, 
may be missed if a matched (conditional) analysis is conducted. In simulation studies, which 
sought to compare the performance of unmatched (unconditional) and matched (conditional) 
analysis methods on data from a matched study design, Diehr et al (1995) concluded that the 
use of unmatched methods was more efficient in the presence of fewer than 10 cluster-pairs.  
In contrast, Donner, Taljaard and Klar (2007), in their investigation of the effect of individual-
level risk factors on outcomes of interest in data arising from a matched-pair design, showed 
that unmatched analyses may result in biased estimates of the regression coefficients. They 
argued, however, that in community intervention trials with a small number of large clusters, 
using unmatched analysis would generally be valid and efficient. Therefore, since Triage Plus 
had only 3 matched-pairs (giving it only 2 degrees of freedom for testing the effect of the 
intervention), the loss of degrees of freedom associated with matched analysis outweighs the 
reduction in variance thereby resulting in reduced power compared with an unmatched 
design. The matched design would only provide increased power if the matching was highly 
effective due to the high correlation of outcome measures within matched pairs (Hayes and 
Moulton, 2009). Assessing the variation of the effect of the intervention in matched pairs is 
not possible as it depends on effect size and the intrinsic between-cluster variability which 
cannot be separated without additional assumptions (Hayes and Moulton, 2009). Given that 
the matching done in the Triage Plus study did not match on the baseline outcome measures 
(i.e. TB and HIV treatment initiations and testing uptake rates) and that the matching carried 
out on the surrogate variables was less effective, the use of unmatched analysis methods was 
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clearly optimal for the Triage Plus study data analysis; the matching done only increased the 
face validity of the study (Klar and Donner, 1997; Feng et al., 2001). Bennett et al (2002) also 
noted that point estimates of the intervention effect size derived from paired and unpaired 
analyses were similar. Thus, unmatched analyses were used  to improve the statistical power 
of the Triage Plus study data analysis, as this study was effectively a large scale community 
intervention trial with a small number of clusters (Donner, Taljaard and Klar, 2007; Feng et 
al., 2001; Diehr et al., 1995).  The matching, conducted at the randomisation stage of the study, 
did help to balance the two arms of the study with respect to population size but not 
necessarily across the baseline outcome measures, as evidenced by the lack of homogeneity 
between the matched pairs on these measures (Table 18).  
6.3 Statistical methods 
 
6.3.1 Analysis plan 
As the intervention clusters only received the intervention package after baseline data was 
collected from each cluster-pair for at least 12 months prior to the intervention, the beginning 
of the intervention period was defined as the month when one of the clusters in a cluster-pair 
initiated intervention activities. The intervention was implemented in the cluster in each 
matched pair assigned to the Early intervention arm during the first 12 months of the study 
period, while the other cluster in each matched pair was by definition assigned to the Delayed 
intervention arm; clusters in the Delayed intervention arm received the intervention in the 
final 11 months of the study period. Due to time constraints, the Delayed clusters could not 
receive the intervention for the 12 months period. Monthly data on number of TB and ART 
patients starting treatment (primary outcomes)was repeatedly measured in all 6 clusters: 
overall, each cluster had 23 data measurements which corresponded to the monthly data 
collection (i.e. 12 months in Phase I and 11 months in Phase II). The repeated measurements 
in each cluster allowed for the implementation of multilevel modelling with repeated 
measurements nested within clusters. 
Because the Early intervention arm received the intervention package in the first 12 months 
while the Delayed intervention arm acted as a control arm, our analysis is conducted in two 
phases. First, the first 12 months’ data are used to estimate the effect of the intervention by 
comparing treatment initiation rates and testing uptake rates between the two arms adjusted 
for the baseline data and cluster-level characteristics. Second, the next 11 months’ data are 
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used to assess if the estimated intervention effect changed with the introduction of the 
intervention to the Delayed intervention arm.  Thus, two scenarios are possible: 
1. If the effect of the intervention peaks early within the first few months, then there would 
be a reduced effect size between the first 12 months and the next 11 months because the 
introduction of the intervention to the Delayed intervention arm narrows the gap in the 
effect size or remains constant.  
2. If the effectiveness of the intervention is established with time, then the narrowing effect 
in effect size reduction would be less pronounced between the two study arms. 
 
Guided by the primary and secondary outcomes of the Triage Plus study, as defined at the 
study design stage (section 2.5), and by the need for clarity, the results for the primary 
outcome measures are presented first followed by those for the secondary outcome measures. 
Our intervention was expected to promote uptake rates for TB and HIV testing through TB 
and HIV community sensitisations and referrals made at the community level by the informal 
health care providers. These increased testing uptake rates were then expected to eventually 
lead to improved TB and HIV treatment initiation rates. The primary outcome measures 
considered in the first phase are therefore TB and ART treatment initiation rates. Uptake rates 
for TB and HIV testing are the secondary outcome measures in the analysis.  
Marginal effects Poisson regression models as well as random intercepts and random 
coefficients generalised linear mixed effects Poisson models were used in order to identify the 
most appropriate model for assessing the impact of the intervention in regards to improving 
TB and ART treatment initiation rates. The relative effect of each covariate on the outcome of 
interest was assessed while adjusting for all the covariates in the model. Random effects 
(generalised linear mixed modelling) methods are adopted because of their suitability in the 
presence of repeated measurements and clustering effects in cluster randomised designs 
(Murray et al., 1998b; Best, Mason and Li, 2011).  Such models are usually used for large 
numbers of clusters with a small number of repeated measurement times, but are used here 
to increase the degrees of freedom and to improve statistical power as demonstrated in 
Chapter 5.   
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6.3.2 Adjustment for baseline outcome data and cluster-level covariates 
Because only a limited number of clusters were used in the Triage Plus study, the cluster 
randomisation process did not adequately achieve an even distribution of either the baseline 
outcome measures or cluster level covariates between the two study arms (Table 
17).Adjustment for the estimated intervention effects for baseline data collected over 12 
months prior to the implementation of the intervention was therefore made to control for any 
baseline imbalances in outcome measures between the intervention arms. This adjustment 
reduces between cluster variation in the study outcome measure thereby increasing study 
power and precision in the estimated effect sizes (Hayes and Moulton, 2009). The most robust 
method for adjusting for baseline differences in outcome measures is to include the baseline 
variable in the regression model as an independent covariate (Hayes and Moulton, 2009). 
However, for the cluster level covariates, baseline adjustment only included covariates in the 
regression model that improved log likelihood estimation (see section 4.4.1 in Chapter 4).   
6.3.3 Statistical modelling 
To estimate the effectiveness of community engagement in improving TB and HIV services 
access, concurrent comparisons of the outcome measures between the intervention arms using 
likelihood based approaches were performed. Estimation of the effectiveness of the 
intervention and investigation of heterogeneity in cluster level TB and ART treatment 
initiations rates as well as TB and HIV testing uptake rates were investigated using 
generalised linear mixed effects Poisson models with some adjustment for cluster level 
covariates. Because observations from the same cluster are usually correlated, cluster level 
random effects to account for the autocorrelation between observations were included. This 







The statistical model 
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If 𝑦𝑖𝑗  is an outcome response for cluster 𝑗(𝑗 = 1, … ,6) at measurement time point 𝑖  ( 𝑖 =
1, … , 12), which is conditionally Poisson and distributed with mean  𝜇𝑖𝑗, the general statistical 
model used to assess effectiveness of the intervention is given by 
𝑦𝑖𝑗|𝑥𝑖𝑗, 𝑢𝑗, 𝑢𝑖𝑗~𝑃𝑜𝑖𝑠𝑠𝑜𝑛 ( 𝜇𝑖𝑗) 
 
log ( 𝜇𝑖𝑗) = 𝑙𝑜𝑔(𝑛𝑖𝑗) +  𝛽0 + 𝛽1𝑡𝑟𝑒𝑎𝑡𝑖𝑗 + 𝛽2𝐵𝑎𝑠𝑒𝑖𝑗 + 𝛽3𝑇𝑖𝑚𝑒𝑖𝑗 + 𝛽4𝑡𝑟𝑒𝑎𝑡𝑖𝑗 ∗ 𝑇𝑖𝑚𝑒𝑖𝑗 + 𝛽5𝐶𝑖𝑗 + 𝑢𝑗
+ 𝑢𝑗𝑡𝑟𝑒𝑎𝑡𝑖𝑗 + 𝑢𝑖𝑗     (6.1) 
where: 
 𝜇𝑖𝑗 is the mean count at time i for cluster j;  
the constant  𝛽0 is the grand mean count when all covariates and random effects terms are 
zero (Omar and Thompson, 2000);  
𝑡𝑟𝑒𝑎𝑡𝑖𝑗 is a variable indicating the intervention status for the cluster and takes values 1 for an 
Early intervention cluster and 0 for a Delayed intervention cluster; 
the fixed effects 𝐵𝑎𝑠𝑒𝑖𝑗 are the baseline ART and TB treatment initiation rates or testing uptake 
rates for HIV and TB at time 0 (i.e. at baseline) in cluster j are the systematic differences 
between intervention groups existing at baseline and persisting throughout the intervention; 
𝑇𝑖𝑚𝑒𝑖𝑗 is the repeated measurement time variable at a given time point within a cluster and 
therefore measures both time trends for repeated measurements and secular trends occurring 
in both intervention groups over the intervention periods (Feldman, McKinlay and Niknian, 
1996); 
the 𝑡𝑟𝑒𝑎𝑡𝑖𝑗 ∗ 𝑇𝑖𝑚𝑒𝑖𝑗 isan interaction term representing intervention effects that develop over 
time during intervention. 
In this specification, if there are only two time intervals, the design reverts to the standard 
pre-post intervention design with pre-post measures nested within clusters. 
To compare the longitudinal trends between two intervention arms in either TB and ART 
treatment initiation rates or TB and HIV testing uptake rates, an interaction term between 
intervention status and time is included in the model.  Thus, 𝛽1 and 𝛽4 in the model are the 
coefficients of interest as they represent the intervention effect after adjusting for the other 
covariates and random effects.  
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In our analyses, just like other cluster level covariates, intervention status, time and 
interactions between time and intervention status were treated as fixed effects.  
Because there were different cluster-level population sizes, log (𝑛𝑖𝑗) is an offset (covariate with 
regression coefficient set to 1) used to obtain model based cluster-specific estimates taking 
into account the cluster-level population (Rabe-Hesketh and Skrondal, 2012, page 724). The 
random cluster-level intercept 𝑢𝑗 accounts for between cluster variations resulting from the 
repeated measurements within each cluster and the cluster randomised design respectively 
(Hayes and Moulton, 2009; Hu et al., 1998).  The random intercept 𝑢𝑖𝑗  models the 
overdispersion in the count data. All the random effects were assumed to be Normally 
distributed with mean zero and an unknown variance-covariance matrix. The 𝐶𝑖𝑗 represents 
any cluster level covariates considered in the model that are likely to affect the outcome of 
interest (e.g. distribution of health facilities, gender distribution). Therefore,  𝛽5 in model (6.1) 
is a vector of regression coefficients for the covariates included in the 𝐶𝑖𝑗, and fixed effects 
𝛽0to 𝛽4are single estimates. Appendix 8.6 details the Stata analysis programme used. 
Instead of using generalised estimating equations in determining marginal models, Poisson 
generalised linear models with robust variance estimators were used to adjust for clustering 
because of the robustness issues of using generalised estimating equations with a small 
number of clusters (Donner, Eliasziw and Klar, 1994; Moore and Tsiatis, 1991; Zou, 2004).  
With 12 measurement times, there are adequate degrees of freedom (about 44) to ensure 
asymptotic properties of the sandwich estimators to avert the misspecification of the 
covariance matrix (Liang and Zeger, 1986).  
Although economic status, the distance a person has to travel to health facilities and gender 
all affect access rates to services (in particular TB initiation rates) (Storla et al., 2008, Kemp et 
al., 2007; Needham et al., 2001), the 𝐶𝑖𝑗 only included gender distribution and the distribution 
of health facilities (i.e. number of health facilities offering TB and HIV services in each of the 
6 clusters were documented and this actedas a proxy for service proximity) as covariates in 
the model. In addition, factors such as poor living and working conditions (associated with a 
high risk of TB transmission), prevalence of HIV (HIV impairs the host’s defences against TB 
infection and disease), prevalence of malnutrition, smoking, diabetes, alcohol abuse and 
indoor air pollution (Lönnroth et al., 2009) were also not considered.  This is because the 
primary outcome data was collected from health registers that do not capture such risk factors 
as economic status and actual distance travelled by all patients.  
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To improve convergence and accuracy in the estimation of parameters, covariates are 
standardised to mean zero and standard deviation 1 by centering each covariate about its 
mean (Gelman and Hill, 2007). This standardisation was unfeasible for the likelihood based 
approaches in the Stata software, as the centering of covariates around mean zero was found 
to be impossible because the covariates were averaged and fixed across time points, and 
therefore centering of such covariates within clusters would result in having zeros in each 
time point. Likewise, centering the embedded time variable that indexes repeated 
measurement occasions in Stata did not offer any improvement in any of the parameter 
estimates (see Appendix 8.4 for the data layout used for final analysis).  
 
Monthly and cumulative treatment initiations and testing uptake rates 
In addition to the statistical modelling used in assessing the effectiveness of community 
engagement in increasing access to TB and HIV treatment initiations and testing uptake, 
monthly and cumulative access rates for TB and HIV services between the two arms were also 
calculated and plotted using cluster level populations as denominators.  The graphical 
presentation of the monthly and cumulative treatment and testing uptake rates over time 
helped to show the differences in TB and HIV treatment initiations and testing uptake rates 
between the study arms. These were then confirmed by fitting the marginal and random 
effects statistical models with covariate adjustments. 
6.4 Summary of characteristics of clusters 
The Consort diagram shown in Figure 8 summarises the overall cluster characteristics and the 
outcome measures (i.e. number of individuals starting TB and ART as well as those accessing 
testing services for TB and HIV) between the Early and Delayed arms.  A detailed description 
of the results of the Triage Plus study follows. 
6.4.1 Baseline demographic and distribution of health facilities 
Table 16 summarises the baseline demographic characteristics by cluster (including the 
gender distribution usually associated with service access) in the two study intervention arms 
(clusters for the Early arm were 1, 3 and 4; clusters for Delayed arm were 2, 5 and 6).  
Overall, the gender distribution at baseline for each of the outcome measures was similar 
across clusters.  However, the proportion of female TB patients starting treatment at baseline 
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was high in cluster 4 compared to the other clusters. The proportion of females accessing HIV 
testing was higher in cluster 2 than the other clusters.  
Mean cluster population was greater in the Delayed intervention areas (209,564) than the Early 
intervention areas (200,714). Cluster level population ranged from 166,702 to 243,826 in the 
Early intervention areas and from 167,074 to 232,433 in the Delayed intervention areas.  
 
Table 16: Comparison of the baseline demographic characteristics between Early intervention and Delayed 
intervention arms 
  Early Intervention Delayed Intervention 
 Defined Clusters with the traditional authorities in each cluster 
Demographic factors 1 3 4 2 5 6 
Gender distribution for total 
TB cases starting treatment 
at baseline (% females) 
 46.5 34.7 53.1  48.3  46.9 43.6  
Gender distribution for TB 
testing uptake at baseline 
(% females) 
52.0 47.0 52.0 51.0 53.0 53.0 
Gender distribution for 
ART patients starting 
treatment at baseline  
(% females) 
 60.4 59.8  65.3  60.6  60.3  63.0  
Gender distribution for HIV 
testing uptake at baseline 
(% females) 
54.3 53.5 49.4 64.8 45.1 51.6 
Mean cluster catchment 
population at baseline 




























Strengthening of data recording in patient registers for ART, 
HIV testing, TB treatment and diagnosis by training health 
workers.  
Excluded  (n= 0 clusters  ) 
 Not meeting inclusion criteria (n=0 clusters) 
Declined to participate (n=0 clusters) 
Other reasons (n= 0 clusters) 
 
Analysed in first 12 months of intervention: 
Treatment initiations (ART=1,565; TB=670); Tested 
(TB=2637; HIV=29,087);  
Not assigned for both arms: ART=81; TB 
treated=20; TB testing: All assigned 
 
Training of IHPs and implementation of 
intervention (n= 3 clusters ) 
Allocated to Early arm (n= 3 clusters ) 
 Received allocated intervention (n=3 clusters) 
 Did not receive allocated intervention (n= 0 clusters) 
 Total population=602,143; mean=200,714 
 No of sites (TB testing=7, HIV testing=20,TB treatment 
initiation=2, ART initiation=3) 
No intervention (n= 3 clusters ) 
Allocated to Delayed arm (n=3 clusters  ) 
 No intervention (n= 3 clusters ) 
 Did not receive allocated intervention(n= 0 clusters) 
 Total population=628,691; mean=209,564 
 No of sites (TB testing=9, HIV testing=18,TB treatment 
initiation=4, ART initiation=6) 
 
Analysed/assigned in first 12 months of 
intervention: 
Treatment initiations (ART=1,519; TB=902); Tested 
(TB=2,658; HIV=24,288) 
Not assigned for both arms: ART=81; TB 
treatment=20; TB testing: All assigned 





Randomized (n= 6 clusters ) 
Enrolment 
Assessed clusters for eligibility (N= 6 Clusters) 
 
Implementation of intervention and supervision (n= 
3 clusters ) 
Training of IHPs and implementation of 
intervention (n= 3 clusters ) 
 Blinded allocation of patients to clusters (n= 3 
clusters )  




 Blinded allocation of patient data to study clusters 
(n= 3 clusters )  
 Simulations using baseline data parameters 
  
Baseline data: Months 1 - 12 
collectionDataEnrollment 
Figure 8: Flow diagram 
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In terms of the distribution of health facilities offering TB and HIV services, Figures 8, 9 and 
10 summarise the distribution of health facilities offering TB and HIV services in the study 
areas. At baseline, the number of health facilities initiating treatment for TB and ART in the 
Early arm were two and three sites respectively (Figure 8);  in the Delayed arm, four health 
facilities initiated TB treatment and ART was initiated in six health facilities. The number of 
health facilities offering HIV testing in the rural areas was twice that of TB testing (Figure 
8).After the first 12 months of the study period, new health facilities, which were also evenly 
spread between intervention arms, were opened to offer ART treatment initiation services. 
Both of the intervention arms were served by urban health facilities such as Bwaila Hospital, 
Light House and Martin Preuss, as well as by other private and public health facilities.  
Figure 9 shows the distribution of health facilities offering TB and ART treatment initiation 
services during the first 12 months of the Triage Plus study, and Figure 10 shows the 
distribution of health facilities when new ART initiation sites were opened between the two 
intervention arms. 
 
Because the disparity in the distribution of health facilities offering TB and ART treatment 
initiation and testing services was likely to affect service access rates, this imbalance was 
adjusted for by including number of sites as a covariate in all models used in subsequent 




Figure 9: Map showing the distribution of TB and ART treatment initiation sites in the first 12 months. 
The pink background represents clusters in the Early intervention arm and the orange background 
represents clusters in the Delayed intervention arm.  The circles in green background represent health 
facilities initiating ART treatment and the squares with red background represent health facilities 




Figure 10: Map showing the distribution of new ART initiation sites.  
The pink background represents clusters in the Early intervention arm and the orange background 
represents clusters in the Delayed intervention arm. The circles with blue background are the new 
health facilities initiating ART and the circles in green background are the old ART initiating sites. 
The sites shown in red colour initiate both TB and ART treatment.  
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6.4.2 Baseline measurement of outcome measures between intervention arms 
Tables 17 and 18 summarise the unadjusted estimates of incidence rate ratios (IRR) and the 
mean counts for baseline TB and ART treatment initiation rates by intervention arm and by 
cluster-pair. The incidence rate ratio for smear-positive TB cases starting treatment was 0.847, 
suggesting some imbalance in this rate at the baseline between the two intervention arms with 
the Early arm having lower smear-positive TB cases starting treatment than the Delayed arm, 
but baseline total TB and ART treatment initiation rates were similar between the two 
intervention arms (IRR = 0.904 and 1.039 respectively).    
Because of the observed baseline differences in treatment initiation rates between the 
intervention arms (especially for smear- positive TB cases), TB and ART treatment initiation 
rates between matched cluster-pairs were further explored. Clear variability was detected 
between cluster-pairs, with cluster-pair 2 having lower incidence rate ratios than both of the 
other cluster-pairs. TB treatment initiation rates varied from an IRR of 0.663 in pair 2 to 1.318 
in pair 3. This again necessitated baseline adjustments in subsequent analyses when 
estimating the effect of the intervention.    
 
Table 17: Comparison of baseline crude mean counts and incidence rate ratios for TB and 
ART treatment initiation rates between intervention arms 
 Mean number of new 
cases/month (SD) 











Total TB cases starting  
treatment at baseline 
15.0 (4.97) 17.3 (5.02) 111.93 123.75 0.904 
Smear-positive TB cases 
starting treatment at 
baseline 
4.1 (0.85) 5.2 (1.20) 31.39 37.06 0.847 
ART cases starting 
treatment at baseline 
32.97 (6.43) 33.2 (8.29) 245.95 236.68 1.039 
* Early intervention arm cluster IDs: 1,3, & 4; Delayed arm cluster IDs: 2,5,& 6 





Table 18: Comparison of baseline cluster-pair TB and ART treatment initiation rates between intervention arms 
 Incidence rateper 100,000 population 
 























TB cases starting  
treatment at baseline 
68.89 84.65 0.814 104.17 157.03 0.663 172.76 131.08 1.318 
Smear-positive TB cases 
starting treatment at 
baseline 
23.48 31.85 0.737 24.20 43.02 0.562 50.99 35.91 1.420 
ART cases starting 
treatment at baseline 
213.45 195.48 1.092 257.56 282.66 0.911 266.34 229.24 1.162 
* Cluster IDs 1,3 and 4 are Early arm clusters and clusters IDs 2.5 and 6 are delayed arm clusters. 
** Incidence Rate Ratio (IRR) = incidence rate in Early intervention/incidence rate in Delayed intervention. 
 
 
6.4.3 Assessment of the effectiveness of the intervention in the first 12 months using 
unadjusted incidence rate ratios 
 
Tables 19 and 20 summarise the TB and ART treatment initiation rates over the first 12 months 
of the intervention. In the first 12 months, a key feature of these results is the high variability 
between clusters-pairs and between intervention arms in the unadjusted TB and ART 
treatment initiation rates. Overall, TB treatment initiation incidence rate ratios were <1 
indicating less TB cases starting treatment in the Early intervention arm than the Delayed 
intervention arm. There was an increase in number of patients starting ART (IRR = 1.221).  
 
Unadjusted analyses of the TB and ART treatment initiation rates in the first 12 months of the 
intervention between the cluster-pairs (Table 20) show similar patterns of variability. Cluster-
pair 2 reported low incidence rate ratios, especially for TB treatment initiation rates, compared 
to the other pairs. This suggests that TB and ART treatment initiation rates were low in the 
Early intervention cluster compared to the Delayed intervention cluster in this cluster-pair.   
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Table 19: Comparison of crude mean  counts and incidence rate ratios in TB and ART treatment initiation rates  
between interventions arms in the first 12 months of intervention 
 Mean number of new 
cases/month (SD) 










TB cases starting  treatment  in the first 
12 months 
15.0 (5.0) 19.0 (10.2) 106.79 138.38 0.772 
Smear-positive TB cases starting  
treatment in the first 12 months 
3.6 (2.2) 6.0 (3.2) 25.91 41.51 0.624 
ART patients starting treatment s 36.2 (13.7) 33.5 (11.3) 4711.34 3859.13 1.221 
* Early intervention arm cluster IDs: 1,3, & 4; Delayed arm cluster IDs: 2,5,& 6 
** Incidence Rate Ratio (IRR) = incidence rate in Early intervention/incidence rate in Delayed intervention 
 
 
Table 20: Comparison of cluster-pair incidence rate ratios for TB and ART treatment initiation between intervention arms in 
the first 12 months of the intervention 
 Incidence rate per 100,000 population 




















TB cases starting  
treatment in first 12 
months 
101.77 87.27 1.166 84.90 189.73 0.447 144.57 127.49 1.134 
Smear-positive TB cases 
starting  treatment in 
first 12 months 
24.53 40.58 0.604 20.51 47.33 0.433 35.39 32.92 1.075 
ART patients starting 
treatment in first 12 
months 
278.68 183.70 1.517 262.48 282.23 0.930 223.75 266.35 0.840 
* Cluster IDs 1,3 and 4 are Early arm clusters and clusters IDs 2.5 and 6 are delayed arm clusters. 
** Incidence Rate Ratio (IRR) = incidence rate in Early intervention/incidence rate in Delayed intervention 
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6.5 Impact evaluation based on the generalised linear mixed modelling 
Examination of the intervention effects between cluster-pairs (Table 20) revealed considerable 
variation in TB and ART treatment initiation rates, suggesting that the effect of the 
intervention varied between cluster-pairs. It has already been widely recognised that 
statistical approaches that take into account the observed variability between clusters are 
necessary in the assessment of the effectiveness of the intervention (Thompson, Warn and 
Turner, 2004; Donner  and  Klar, 2000; Murray, 1998a; Omar and Thompson, 2000). 
Generalised linear mixed effects models presented in Chapter 4 were therefore used to 
account for the observed variability in intervention effect between cluster-pairs while 
adjusting for cluster-level baseline TB and ART treatment initiation rates and characteristics. 
Final estimates for the effect of the intervention are based on the appropriate model that better 
fitted the data based on the model selection criteria given below (see also section 4.4 in Chapter 
4) and the pairing of clusters is not taken into account in the analysis. 
Model selection criteria used to identify models that best fit the data 
To identify the appropriate model, model selection procedures presented in section 4.4 of this 
dissertation were used, including likelihood ratio tests, BIC and AIC. Different models were 
fitted for assessing the effectiveness of the intervention, in regards to TB and ART treatment 
initiation rates, using generalised linear mixed Poisson models described in section 4.2.1.  
Appropriate model structures were selected by fitting models based on marginal effects or 
population averages, and random effects models.  Random intercepts and random coefficients 
models were used in the random effects modelling. The appropriate model was selected based 
on the model selection criteria presented in section 4.4. 
The covariates considered in the model selection process included baseline treatment 
initiation rates or testing uptake rates, gender distribution and the distribution of health 
facilities physically located in the study areas. The covariates were averaged and fixed across 
time points (see Appendix 8.4 for sample data used for the analysis).In addition, interaction 
terms between the intervention indicator and time were also included to assess if the effect of 
the intervention changed with time. All covariates that were significant or affected the 
estimates of the intervention were included in the final model. 
 
In selecting the appropriate model, the results for TB treatment initiation rates showed no 
differences in model fitting between the marginal models and random effects models. All 
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model selection criteria using either likelihood ratio tests, AIC or BIC were similar for the 
different models with similar log likelihood estimates. Fitting the random coefficients model 
did not make any (statistically significant) difference compared to the random intercepts 
model (likelihood ratio test 𝜒2 = 2.44, p=0.118). Similarly, when fitting the random effects 
models to assess ART treatment initiation rates, no improvement was gained over the 
marginal model (likelihood ratio test 𝜒2 = 1.68, p=0.642). However, because of the clustering 
effects in studies involving repeated measurements and with cluster designs and the 
improvements noted in the estimated standard errors when the random intercepts models 
were fitted (compared to the marginal models), the random effects models were the most 
preferred. In all marginal models, standard errors and confidence intervals of the fixed effects 
were estimated based on sandwich estimators to account for repeated measurement occasions 
in the data as well as over-dispersion (Liang and Zeger, 1986).   
 
6.5.1 Impact on TB and ART treatment initiation rates in the first 12 months of the 
intervention 
In this section, the results from the first 12 months of the study period are presented, during 
which only the Early intervention arm received the intervention and the Delayed intervention 
arm continued to have standard care. The incidence rate ratios determined here assesses the 
actual effect of engaging informal healthcare providers in integrated TB and HIV community 
interventions.     
6.5.1.1 Impact on TB treatment initiation rates 
For TB treatment initiation rates (new TB cases registered for treatment in the first 12 months), 
the marginal effects model with a single covariate for intervention status estimated the 
incidence rate ratio (IRR) for the effect of the intervention as 0.824 (95% CI: 0.513 to 1.34). This 
is slightly higher than the unadjusted incidence rate ratios of 0.772 shown in Table 19 
potentially due to differences in use of the cluster level populations: Table 19 used cluster level 
populations directly to estimate the incidence rate ratios while the current estimate 
(IRR=0.824) was derived using monthly counts of new TB cases with differences in cluster 
level populations fixed when the offset was used. Using a random intercepts and random 
coefficients models, the IRR were 0.876 (95% CI:0.583 to 1.315) and 0.876 (95% CI: 0.586 to 
1.316) respectively.   
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Thus, using the marginal model without adjusting for covariates revealed that persons in 
Early intervention clusters were on average 17.6% less likely (per month) to initiate TB 
treatment than their counterparts in the Delayed intervention clusters, but this difference was 
not significant at the 5% level (p=0.424 for marginal model). Using the random intercepts 
model, TB patients starting treatment (per month and per cluster) were 12.4% less likely to 
initiate treatment (again, not statistically significant). The standard deviation of the random 
intercepts parameter (√𝜎11
2 ) was estimated to be 0.243 (95% CI: 0.132 to 0.488).  
When baseline TB treatment initiation rates were considered, the incidence rate ratios based 
on the marginal effects and random intercepts were respectively 0.938 (95% CI: 0.650 to 1.354) 
and 0.963 (95% CI: 0.695 to 1.333), neither of which were statistically significant. A reduction 
in the variability of the impact estimate was observed when the baseline TB treatment 
initiation rates were adjusted for the random intercepts standard deviation of 0.180 (95% CI: 
0.093 to 0.350). The log likelihood, AIC and BIC values were respectively -236.788, 481.575, 
and 490.682. 
When the baseline gender distribution and the distribution of health facilities initiating TB 
treatment in rural areas were included in the model, the effect size estimates based on the 
marginal and random intercepts models were respectively 1.07 (95% CI: 0.803 to 1.413) and 
1.08 (95% CI: 0.787 to 1.476), suggesting about 7 - 8% more cases per month were detected in 
the Early intervention areas.  Inclusion of baseline gender distribution and the distribution of 
health facilities offering TB treatment initiations in the model resulted in a further reduction 
in the variability of the impact estimate in the random intercepts model with standard 
deviation of 0.112 (95% CI: 0.050 to 0.253), suggesting an improvement in the model fit. The 
corresponding log likelihood, AIC and BIC values were respectively -234.554, 481.108, and 
494.768. 
To assess whether the effect of the intervention varied over the duration of intervention, 
interaction terms between measurement occasion and intervention status were included in 
the model; the results obtained are presented in Table 21. This inclusion did not produce a 
marked improvement in the model fit (values for log likelihood, AIC and BIC were 
respectively -234.554, 481.108, and 494.768). The corresponding fixed effects interaction term 
was not statistically significant. Using the marginal model, the IRR for the intervention 
increased from 1.07 to 1.18 (i.e. 1.204 * 0.981) after adjusting for the covariates (including the 
interaction terms). This suggests that the intervention increased the likelihood of initiating 
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treatment for TB cases in the Early intervention group by 18% compared to the Delayed 
intervention group, although this estimated effect size remained statistically non-significant. 
Nevertheless, this does give a clear indication that a model that allows for the effect of the 
intervention to vary with measurement occasions is superior to one that assumes that the 
effect of the intervention is constant over duration of the intervention.   
Only baseline TB treatment initiation rates and the distribution of the health facilities 
remained statistically significant, indicating that increase in number of health facilities 
offering TB treatment initiations was also associated with an increase in TB treatment 
initiations, which in turn, depended on the baseline TB treatment initiations in each cluster. 
The intervention effect size estimate slightly improved when a random intercepts model was 
fitted: IRR increased from 1.18 to IRR 1.20 (1.219*0.981), suggesting a 20% increase in the 
number of TB cases starting treatment in the Early intervention areas compared to the Delayed 
intervention areas (Table 21). No further improvement over the random intercepts model was 
detected when a random coefficients model was fitted (Table 21). In both the random 
intercepts and random coefficients models, the distribution of health facilities and baseline TB 
treatment initiation rates were significantly associated with TB treatment uptake rates.  
To determine the level of clustering of the outcome measures (i.e. TB treatment initiation 
rates), the intracluster correlation coefficients were estimated using the formula given in (4.13) 











2  is the random intercepts variance, and 𝜙  is the overdispersion scale parameter 
derived by dividing the Pearson chi-square by its degrees of freedom. Using the estimated 
standard deviation of the random intercepts parameter √𝜎11
2  of  0.112 and the overdispersion 
scale parameter 𝜙  of 3.478, the intracluster correlation coefficient was 0.067 (Table 21) 
suggesting moderate clustering of the outcome measures. The estimated ICC in TB treatment 
initiations is comparable to the based ICCs (i.e. 0.00154 and 0.081) used in the simulation 
studies presented in Chapter 5. 
 
Using the random intercepts model, a unit increase in the number of health facilities was 
associated with an estimated 24% increase in the TB treatment initiations per cluster while 
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controlling for the other covariates.   An extra TB case initiated on TB treatment at baseline 
was associated with an estimated 3% increase in TB treatment initiations per cluster. The 
results also suggest that female gender distribution was associated with an 18% increase in 
TB treatment initiations though not significant and that the TB treatment initiations did not 
change much with increased time of the intervention (0.4%), controlling for the other 
covariates and was again not significant at the 5% level.   
6.5.1.2 Impact on smear- positive TB treatment initiation rates 
To assess whether the engagement of informal healthcare providers increased the number of 
new smear-positive TB patients starting treatment during the first 12 months of the 
intervention, marginal, random intercepts and coefficients models were fitted to the data. 
Covariate adjustment was made for baseline smear-positive TB treatment initiation rates, 
gender and health facility distribution. In addition, an interaction term between intervention 
status and time was included in the model as well as a time to see if there was any change in 
the smear-positive TB treatment initiation rates over time (Table 22). The IRRs for the 
marginal, random intercepts and coefficients models were all identical; variation between 
clusters was zero while the correlation between the two random effects was 0.422, suggesting 
the need for fitting the random coefficient model despite model fit indices being similar across 
the three models fitted (Table 22).  
When the effect of the intervention was assessed by using the marginal, random intercepts 
and random coefficients models with a single covariate for intervention status estimated the 
incidence rate ratio for the effect of the intervention as 0.622 (95% CI: 0.427 to 0.905) for the 
marginal effects model, 0.647 (95% CI: 0.450 to 0.930) for the random intercepts and 0.646 (95% 




Table 21: Adjusted incidence rate ratios for intervention effects using the marginal effects, random intercepts, and 
random coefficients models for measuring TB treatment initiation rates in the first 12 months of the intervention 
 Marginal effects Poisson Random intercepts Poisson Random coefficients Poisson 
Fixed part IRR1 95% CI2 P3 IRR1 95% CI2 P3 IRR1 95% CI2 P3 
Treat4 1.204 0.957, 1.515 0.112 1.219 0.835, 1.779 0.305 1.239 0.881,1.744 0.218 
Base5 1.025 1.003, 1.048 0.025 1.027 1.001, 1.053 0.040 1.025 1.000,1.050 0.046 
Occasion6 1.004 0.978, 1.031 0.748 1.004 0.983, 1.026 0.694 1.004 0.983,1.026 0.694 
Gender  1.255 0.306, 5.140 0.752 1.181 0.084, 16.50 0.902 0.912 0.107,7.743 0.932 
Treat*Month7 0.981 0.944, 1.012 0.335 0.981 0.950, 1.014 0.253 0.981 0.950,1.014 0.253 
H. facility8 1.247 1.096, 1.419 0.001 1.244 1.053, 1.470 0.010 1.248 1.067,1.458 0.005 
Random part9          
√𝜎11
2  
    0.112   0.000  
√𝜎22
2  
       0.179  
ICC10        0.0674  
Model fit 
indices 
         
Log likelihood -236.975   -233.781   -232.561  
AIC 483.952   481.108   483.123  
BIC 495.335   494.768   503.613  
1 Incidence Rate Ratio (IRR) = rate in Early intervention/rate in delayed intervention; 2 Confidence interval (CI); 3 p-
value; 4 Intervention status (Early/Delayed);  5 Baseline TB treatment initiation rates; 6 Repeated measurement time;                 
7 interaction between intervention status and measurement time; 8 Distribution of health facilities offering TB 
treatment initiations; 9 𝜎11
2  is the between cluster variance and 𝜎22
2  is the slope  variance; 10 ICC=Intracluster correlation. 
 
When all the covariates were included in the model (baseline smear-positive TB treatment 
initiations, time, gender, distribution of health facilities initiating TB treatment and interaction 
terms),the results indicate that the intervention significantly reduced TB smear-positive cases 
starting treatment on average by 28% (IRR=0.722*1.002 = 0.723, p<0.05) when the marginal 
effects model was fitted, suggesting that fewer smear-positive cases were detected in the Early 
intervention arm than in the Delayed arm (potentially due to more health facilities initiating 
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TB treatment (see Figure 8 in section 6.4.1)) . However, using the random intercepts and 
random coefficients models, the reductions in smear-positive cases starting treatment were 
not significant at the 5% level (Table 22). In the marginal model, all covariates included in the 
model were significantly associated with the number of smear-positive TB cases starting TB 
treatment except for the interaction terms between intervention status and time (Table 22).   
When the random intercepts model with all covariates were included, the standard deviation 
of the random intercepts parameter √𝜎11
2  was 0.0 and the estimated intracluster correlation 
coefficient was 0.0, suggesting no between cluster variation in smear-positive TB treatment 
initiations rates (Table 22). The estimated overdispersion scale parameter 𝜙 for the smear-
positive TB treatment initiations was 3.085. 
Using the random effects models, only baseline TB treatment initiation rates and time period 
of the intervention were significantly associated with smear-positive TB patients starting 
treatment with an estimated 20% increase and 5% decrease respectively. Although a unit 
increase in female gender distribution was associated with approximately a four times 
increase in number of smear-positive TB cases starting treatment per cluster, the increase had 
a borderline statistical significance (p=0.07) for the two random effects models after 
controlling for the other covariates.  Increasing the number of health facilities initiating TB 
treatment did not result in increasing the number of smear-positive TB cases starting 
treatment (Table 22).  
6.5.1.3 Impact on ART treatment initiation rates 
To assess the effect of the intervention on ART treatment initiation rates, the first 12 months 
data following the intervention were used. Employing the marginal effects, random intercepts 
and random coefficients models with only intervention status fitted showed that the 
intervention increased ART treatment initiation rates by 12.8% (IRR=1.128; 95% CI: 0.895 to 
1.422; p=0.308) in the marginal model, and 11.2% (IRR=1.112; 95% CI: 0.891 to 1.389; p=0.34) 
for the random intercepts and random coefficients models. These estimated effect sizes 
slightly improved to 13.1% (IRR=1.131; 95% CI: 0.919 to 1.391; p=0.244) in the marginal model 
and 11.5% (IRR=1.115; 95% CI: 0.907 to 1.370; p=303) for both the random intercepts and 
random coefficients models when baseline ART initiation rates were added to the model. 
Finally, when an improved model was fitted with intervention status, baseline ART initiation 
rates, gender distribution and distribution of health facilities, the incidence rate ratios were 
1.301 (95% CI: 1.101 to 1.536, p=0.002), 1.286 (95% CI: 1.060 to 1.559, p=0.011) and 1.316 (95% 
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CI: 1.086 to 1.1595, p=0.005) for the marginal model, random intercepts and random 
coefficients models respectively. Thus, the intervention was associated with an estimated 
30.1%, 28.6% and 31.6% increase in ART treatment initiations when the marginal, random 
intercepts and random coefficients models were fitted after controlling for the other 
covariates.     
Table 22: Adjusted incidence rate ratios for intervention effects using the marginal effects, random intercepts, and 
random coefficients models for measuring access rates to TB treatment services among smear positive patients in the 
first 12 months of the intervention 
 Marginal effects Poisson Random intercepts Poisson Random coefficients Poisson 
Fixed part  IRR1 95% CI2 P3 IRR1 95% CI2 P3 IRR1 95% CI2 P3 
Treat4 0.722 0.540, 0.967 0.029 0.722 0.452, 1.154 0.174 0.722 0.452, 1.154 0.174 
Base5 1.198 1.113, 1.289 <0.001 1.198 1.067, 1.344 0.002 1.198 1.067, 1.344 0.002 
Occasion6 0.952 0.921, 0.985 0.005 0.952 0.916, 0.990 0.014 0.952 0.916, 0.990 0.014 
Gender  3.912 1.640, 9.335 0.002 3.913 0.883, 17.327 0.072 3.913 0.883, 17.327 0.072 
Treat*Month7 1.002 0.926, 1.085 0.959 1.002 0.940, 1.068 0.949 1.002 0.940, 1.068 0.949 
H. facility8 0.932 0.879, 0.987 0.017 0.932 0.803, 1.080 0.348 0.932 0.803, 1.080 0.348 
Random part9          
√𝜎11
2  
    0.000   0.000  
√𝜎22
2  
       0.000  
ICC10       0.000  
Model fit indices         
Log likelihood -157.203   -157.203   -157.203  
AIC 324.406   330.406   334.406  
BIC 335.790   348.620   357.173  
1 Incidence Rate Ratio (IRR) = rate in Early intervention/rate in delayed intervention; 2 Confidence interval (CI); 3 p-
value; 4 Intervention status (Early/Delayed);  5 Baseline smear positive TB treatment initiation rates; 6 Repeated 
measurement time;                 7 interaction between intervention status and measurement time; 8 Distribution of 
health facilities offering TB treatment initiations; 9 𝜎11
2  is the between cluster variance and 𝜎22
2  is the slope variance; 10 
ICC=Intracluster correlation coefficient. 
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Using these marginal, random intercepts and random coefficients models, the distribution of 
health facilities and intervention status were the only covariates that were significantly 
associated with ART initiation rates. A unit increase in number of health facilities was 
associated with a 19.4% (IRR=1.194, 95% CI: 1.069 to 1.333, p=0.002), 20% (IRR=1.200, 95% CI: 
1.030 to 1.399, p=0.020) and 23.3% (IRR=1.233, 95% CI: 1.104 to 1.378, p<0.001)increase in the 
number of ART patients starting treatment (p=0.002) for the marginal, random intercepts and 
random coefficients models. 
To assess whether the effect of the intervention varied with time, an interaction term was 
included in the model between time and intervention status.  The overall incidence rate ratio 
increased from 1.301 to 1.347 (IRR=1.356*0.993=1.347) using the marginal model, from 1.286 
to 1.332 (IRR=1.341*0.993=1.332) in the random intercepts model and from 1.316 to 1.362 
(IRR=1.372*0.993) in the random coefficients model and were significant at the 5% level (Table 
23). Only the distribution of health facilities initiating ART was significantly associated in 
increasing the number of patients starting ART for all the three models. However, fitting the 
random coefficients model and the inclusion of an interaction term did not improve the model 
fit (see model fit indices in Table 23).  
The intracluster correlation coefficient estimated after fitting the random intercepts model 
adjusting for all covariates was 0.0402, suggesting moderate correlation in ART treatment 
initiation rates which is comparable to the baseline ICCs used in the simulation studies (Table 
23). The corresponding standard deviation for the random intercept parameter √𝜎11
2  and the 
overdispersion scale parameter 𝜙 used to estimate the ICC were 0.056 and 3.486 respectively.  
In all the three models fitted, baseline ART initiation rates and time period of the intervention 
were less likely to be associated with number of patients starting ART and were only 
associated with an estimated 0.3% increase and 0.8% decrease in the number of patients 
starting ART respectively.  The results further suggest that female gender distribution was 
associated with reduced access to ART initiations and ranged from an estimated 67% when 
the marginal model was fitted to 91% reduction for a random coefficients model but was not 
significant at 5% level.  
  
155 
Table 23: Adjusted incidence rate ratios for intervention effects using the marginal effects, random intercepts, and 
random coefficients models for measuring access rates to ART services in the first 12 months 
 Marginal effects Poisson Random intercepts Poisson Random coefficients Poisson 
Fixed part IRR1 95% CI2 P3 IRR1 95% CI2 P3 IRR1 95% CI2 P3 
Treat4 1.356 1.003, 1.833 0.048 1.341 1.053, 1.706 0.017 1.372 1.078, 1.746 0.010 
Base5 1.003 0.993, 1.013 0.567 1.003 0.994, 1.011 0.545 0.998 0.989, 1.008 0.741 
Occasion6 0.992 0.962, 1.024 0.619 0.992 0.976, 1.008 0.344 0.992 0.976, 1.008 0.344 
Gender  0.319 0.002, 44.68 0.650 0.328 0.002, 59.145 0.674 0.086 0.00, 37.145 0.429 
Treat*Month7 0.993 0.949, 1.040 0.778 0.993 0.971, 1.016 0.572 0.993 0.971, 1.016 0.572 
H. facility8 1.194 1.069, 1.333 0.002 1.200 1.030, 1.399 0.019 1.233 1.104, 1.378 <0.001 
Random part9          
√𝜎11
2  
    0.056   0.000  
√𝜎22
2  
       0.108  
ICC 10        0.0402  
Model fit indices         
Log likelihood -285.874   -285.034   -283.855  
AIC 581.748   586.068   587.710  
BIC 593.131   604.281   610.477  
1 Incidence Rate Ratio (IRR) = rate in Early intervention/rate in delayed intervention; 2 Confidence interval (CI); 3 p-
value; 4 Intervention status (Early/Delayed);  5 Baseline ART initiation rates; 6 Repeated measurement time;                 
7 interaction between intervention status and measurement time;  8 Distribution of health facilities offering ART 
treatment initiations; 9 𝜎11
2  is the between cluster variance and 𝜎22




6.5.2 Impact on secondary outcome measures in the first 12 months 
In this section, the secondary outcome measures of the intervention are analysed. The 
secondary outcome measures recorded included the number of new clients/patients who 
accessed TB and HIV testing services. All health facilities in the rural areas offered HIV testing 
and counselling services, but TB microscopy testing is done only in selected health facilities 
in rural and urban areas.  
Numbers of presumptive TB cases were obtained from all TB testing sites. Individuals 
accessing TB testing were allocated to the study clusters based on their residential address. 
However, because HIV testing registers do not record an individual's personal residential 
address, data collection for this measure was mainly confined to sites located in rural areas.  
Thus, HIV testing registers from health facilities in the rural areas were used and the 
individuals accessing HIV testing in such health facilities were allocated to the study clusters 
where the respective health facilities were located. 
6.5.2.1 Impact on TB and HIV testing access rates in the first 12 months of intervention 
In this section, results for the analysis using data for the first 12 months are presented for the 
TB and HIV testing uptake rates.  
6.5.2.2 Impact on TB testing uptake rates in the first 12 months of the intervention 
As some components of the intervention involved increasing awareness about TB in the 
community, including the recognition and referral of TB cases, an investigation was made to 
see if these activities generally increased the number of presumptive TB cases accessing TB 
testing services. Using the first 12 months’ data with a marginal model with baseline 
presumptive TB testing uptake rates, intervention status, distribution of testing sites, gender 
distribution, time, and an interaction term between intervention status and time included as 
cluster-level covariates, all the covariates were significantly associated with TB testing uptake 
rates (Table 24).  
The effect of the intervention on increasing TB testing uptake rates among presumptive TB 
cases was estimated at 1.152 (IRR=1.215*0.948=1.152) after adjusting for all covariates 
considered in the model when a marginal model was fitted. This suggests that there was a 
15.2% increase in the number of presumptive TB cases accessing TB testing services in the 
Early intervention arm compared to the Delayed arm.  Only baseline TB testing uptake was 
significantly associated with increased uptake rates following the intervention with an 
estimated 0.4% increase. The results further suggest that being female was more associated 
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with reduced TB testing uptake rate by 97% after controlling for all covariates considered in 
the model.   
When the random effects models (random intercepts and random coefficients models) were 
fitted, all the variables except the baseline outcome measurements were significantly 
associated with testing uptake rates after controlling for the other covariates (see Table 24).  
The interaction effect between intervention status and time was significantly associated with 
TB testing uptake when all the models were fitted, suggesting that the effect of the 
intervention depended on the duration of the intervention. When the random intercepts 
model with all covariates was fitted, the estimated intracluster correlation coefficient was 
0.0192 suggesting that there was minimal clustering effects in the TB testing uptake rates. The 
corresponding standard deviation for the random intercepts parameter √𝜎11
2   and the 
overdispersion scale parameter 𝜙 used to estimate the ICC were 0.0386 and 5.12 respectively 
(Table 24).  Fitting the random effects models did not improve much compared to the marginal 
effects model (see model fit indices in Table 24). 
A graphical presentation of the effect of the intervention in increasing TB testing uptake, 
monthly and cumulative uptake rates suggested that the numbers of TB cases accessing 
testing services in the first 12 months showed slightly more presumptive TB cases in the Early 
intervention arm accessing TB testing services compared to the Delayed arm (Figure 14 shown 
in section 6.6.2). When the intervention was rolled out to the Delayed intervention arm, there 
was no difference in cumulative rates towards the end of the second phase (11 month) of the 
intervention period described in section 6.6.2. 
Of the presumptive TB cases which accessed testing sites in the first 12 months, 8.6% 
(375/4384) were identified as smear-positive 7.5% (165/2189) in the Early intervention arm 
and 9.6% (210/2,195) in the Delayed intervention arm. The effect of the intervention in 
increasing smear-positive cases was then assessed by fitting marginal, random intercepts and 
coefficients models adjusted for intervention status, baseline smear-positive cases in the 
testing sites, gender distribution, time and distribution of TB microscopy sites and an 
interaction term for intervention status and time.  
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Table 24: Adjusted incidence rate ratios for intervention effects using the marginal effects, random intercepts, and 
random coefficients models for measuring access rates to testing services for presumptive TB cases in the first 12 
months 
 Marginal effects Poisson Random intercepts Poisson Random coefficients Poisson 
Fixed part IRR1 95% CI2 P3 IRR1 95% CI2 P3 IRR1 95% CI2 P3 
Treat4 1.215 1.071, 1.379 0.003 1.215 1.001, 1.475 0.049 1.215 1.001, 1.475 0.049 
Base5 1.004 1.004, 1.004 <0.001 1.004 0.998, 1.010 0.187 1.004 0.998, 1.010 0.187 
Occasion6 0.940 0.906, 0.975 0.001 0.940 0.908, 0.973 <0.001 0.940 0.908, 0.973 <0.001 
Gender  0.028 0.028, 0.029 <0.001 0.028 0.003, 0.233 0.001 0.028 0.003, 0.233 0.001 
Treat*Month7 0.948 0.913, 0.986 0.013 0.948 0.902, 0.998 0.040 0.948 0.902, 0.998 0.040 
testing  sites8 0.920 0.919, 0.921 <0.001 0.920 0.848, 0.999 0.045 0.920 0.848, 0.999 0.045 
Random part9          
√𝜎11
2  
   0.0386    0.000  
√𝜎22
2  
       0.004  
ICC10        0.0192  
Model fit indices         
Log likelihood -165.317  -165.63    -165.82  
AIC 340.635  347.268    349.642  
BIC 348.553  359.936    363.893  
1 Incidence Rate Ratio (IRR) = rate in Early intervention/rate in delayed intervention; 2 Confidence interval (CI); 3 p-
value; 4 Intervention status (Early/Delayed);  5 Baseline TB testing uptake rates; 6 Repeated measurement time; 7 
interaction between intervention status and measurement time; 8 Distribution of TB testing sites;  9 
𝜎11
2  is the between cluster variance and 𝜎22
2  is the slope  variance; 10 ICC=Intracluster correlation. 
 
The results for the marginal and random intercepts models were similar.  Fitting the random 
intercepts or coefficients models did not greatly improve the model fit (similar log likelihoods, 
AIC and BIC) (Table 25). However, there was an attenuation of the effect size when the 
random coefficients model was used (Table 25).  The intervention resulted in an increase in 
TB smear-positive cases detected at the testing sites of 11.7% (IRR=1.123*0.995=1.117) when 
the marginal and random intercepts models were fitted; however, this effect was not 
statistically significant at the 5% level for either the marginal or random intercepts models 
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owing to the small sample sizes available for this analysis as demonstrated in the simulations 
presented in Chapter 5. None of the covariates included in the model were significantly 
associated with the number of smear positive TB cases detected in all the three models(Table 
25).  When the model with all covariates was fitted using the random intercepts model, the 
estimated intracluster correlation coefficient was 0.0 and the corresponding random intercept 
parameter √𝜎11
2  and the overdispersion scale parameter 𝜙  used to estimate the ICC were 
respectively 0.0 and 3.09,  suggesting no between cluster variability in presumptive TB testing 
uptake rates (Table 25).  
Table 25: Adjusted incidence rate ratios for intervention effects using the marginal effects, random intercepts, and 
random coefficients models for smear -positive TB  cases identified at testing sites during the first 12 months 
 Marginal effects Poisson Random intercepts Poisson Random coefficients Poisson 
Fixed part IRR1 95% CI2 P3 IRR1 95% CI2 P3 IRR1 95% CI2 P3 
Treat4 1.123 0.700, 1.803 0.631 1.123 0.686, 1.840 0.645 1.073 0.608, 1.891 0.809 
Base5 1.176 0.963, 1.436 0.113 1.176 0.947, 1.459 0.142 1.149 0.879, 1.503 0.309 
Occasion6 0.982 0.961, 1.004 0.107 0.982 0.945, 1.021 0.365 0.982 0.945, 1.021 0.365 
Gender  0.421 0.045, 3.915 0.447 0.421 0.014, 13.10 0.622 0.490 0.013, 18.213 0.699 
Treat*Month7 0.995 0.963, 1.027 0.738 0.995 0.938, 1.054 0.854 0.995 0.938, 1.054 0.854 
Testing  sites8 1.048 0.793, 1.385 0.741 1.048 0.805, 1.364 0.727 0.996 0.681, 1.458 0.985 
Random part9          
√𝜎11
2  
    0.000   0.001  
√𝜎22
2  
       0.106  
ICC10        0.000  
Model fit indices         
Log likelihood -161.624   -161.624   -161.587  
AIC 333.247   339.247   341.174  
BIC 344.631   357.461   361.664  
1 Incidence Rate Ratio (IRR) = rate in Early intervention/rate in delayed intervention; 2 Confidence interval (CI); 3 p-
value; 4 Intervention status (Early/Delayed);  5 Baseline smear positive TB testing uptake rates; 6 Repeated 
measurement time; 7 interaction between intervention status and measurement time; 8 Distribution of TB testing 
sites; 9 𝜎11
2  is the between cluster variance and 𝜎22
2  is the slope  variance; 10 ICC=Intracluster correlation. 
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6.5.2.3 Impact on HIV testing uptake rates 
To assess whether the engagement of informal health care providers in sensitising 
communities to the need for voluntary HIV testing improved uptake rates, the HIV testing 
uptake rates between the Early and Delayed intervention arms were compared.  
At baseline, 43% of HIV tests (28,792/66,612) were registered in HIV testing sites in the 
Delayed intervention areas while the remaining 57% (37820/66612) were registered in the 
Early intervention areas. After the first year of the study, 54.5% (29,087) of HIV testing cases 
were reported in the Early arm, a slight decline in the relative proportion of HIV tests before 
adjusting for the potential confounders. 
To assess the effect of the intervention on HIV testing uptake rates in the first 12 months of 
the intervention, marginal, random intercepts and random coefficients models were fitted. 
When only the variable for intervention status was fitted, the intervention increased HIV 
testing uptake by 22.1% (IRR=1.221; 95% CI: 0.810 to 1.839; p=0.340), 19.8% (IRR=1.198; 95% 
CI: 0.755 to 1.900; p=0.443) and 19.8% (IRR=1.198; 95% CI: 0.755 to 1.899; p=0.444) for the 
marginal, random intercepts and random coefficients models respectively. Using intervention 
status, baseline HIV testing uptake rates, gender distribution, HIV testing sites, measurement 
occasion and an interaction term between intervention status and measurement occasion as 
covariates, the HIV testing uptake rate significantly increased by 61.0% 
(IRR=1.626*0.990=1.61, p=0.001) when the marginal and random effects models were used 
(Table 26).  
Comparison of the log likelihood values between the marginal and random effects models 
indicated that the model with a random effects specification better fitted the data 
(deviance=181.352, chi-square distribution with 1 degree of freedom, p<0.001). This suggests 
that the intercepts of the random effects varied significantly between the clusters.  
The intracluster correlation coefficient estimated after fitting the random intercepts model 
adjusting for all covariates was 0.1287, suggesting a slightly higher between cluster variability 
in HIV testing uptake rates than the other outcome measures (Table 26). The corresponding 
standard deviation for the random intercept parameter √𝜎11
2  and the overdispersion scale 
parameter 𝜙 used to estimate the ICC were 0.0987 and 115.326 respectively, suggesting a very 
high overdispersion in HIV testing uptake rates which was accounted for by use of robust 
estimates. The estimated ICC was slightly higher than the ICC of 0.081 from the baseline data 
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from the Triage Plus study used in the simulation studies presented in Chapter 5 though the 
statistical power was still maintained due to the high effect size of 61%.  
All covariates in the models, except baseline HIV testing measurements, were significantly 
associated with HIV testing uptake rates in the marginal model. However, for the two random 
effects models, only the baseline HIV testing uptake was not significantly associated with HIV 
testing uptake rates. 
In all the models, the distribution of HIV testing sites (a proxy measure for geographical 
proximity) was significantly associated with increasing HIV testing uptake rates (estimated 
increase of 13.4% in the marginal model). A unit increase in the number of health facilities 
offering HIV testing was associated with an estimated 11.8% increase in the HIV testing 
uptake per cluster while controlling for the other covariates when the random intercepts and 
random coefficients models were fitted.   The results also suggest that female gender 
distribution was associated with a decreased service access for HIV testing by over 98% in all 
the three models fitted, suggesting that females were less likely to access HIV testing 
compared to males.   
With the interaction term between intervention status and time being significantly associated 
with HIV testing uptake when the random effects models were fitted suggests that the effect 
of the intervention varied with time of the intervention.  When plots for the unadjusted 
monthly and cumulative HIV testing uptake rates over the first 12 months were plotted, the 
results showed a consistent increase in the number of new clients testing for HIV in the Early 
intervention arm compared to the Delayed intervention arm (Figure 11). This suggests that 
the intervention was most effective in increasing the numbers of persons being tested for HIV 
in the community. However, due to challenges noted in the data after 12 months where some 
sites registered very few cases, which was atypical for these sites and that some registers could 
not be traced in some sites for specific months especially in sites with outreach services (see 
section 2.6.1), the data from 12 months onward was not considered.  
 
 
Table 26: Maximum likelihood estimates for intervention effects using the marginal effects, random intercepts, and 
random coefficients models for measuring access rates to HIV testing in the first 12 months 
 Marginal effects Poisson Random intercepts Poisson Random coefficients Poisson 
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Fixed part IRR1 95% CI2 P3 IRR1 95% CI2 P3    
Treat4 1.626 1.443,1.832 <0.001 1.622 1.221,2.155 0.001 1.622 1.221,2.155 0.001 
Base5 0.999 0.999,0.9998 0.016 1.000 0.999,1.000 0.279 1.000 0.999,1.000 0.279 
Occasion6 0.949 0.934,0.964 <0.001 0.949 0.945,0.953 <0.001 0.949 0.945,0.953 <0.001 
Gender  0.011 0.003,0.039 <0.001 0.018 0.002,0.183 0.001 0.018 0.002,0.183 0.001 
Treat*Month7 0.990 0.960,1.020 0.489 0.990 0.984,0.995 <0.001 0.990 0.984,0.995 <0.001 
H.facility8 1.134 1.079,1.193 <0.001 1.118 1.046,1.195 0.001 1.118 1.046,1.195 0.001 
Random part9         
√𝜎11
2  
    0.0987   0.098  
√𝜎22
2  
       0.000  
ICC10        0.1287  
Model fit indices         
Log likelihood -1933.180   -1751.828   -1752.943  
AIC 3876.360   3519.656   3523.885  
BIC 3887.308   3537.173   3543.592  
1 Incidence Rate Ratio (IRR) = rate in Early intervention/rate in delayed intervention; 2 Confidence interval (CI); 3 p-
value; 4 Intervention status (Early/Delayed);  5 Baseline HIV testing uptake rates; 6 Repeated measurement time; 7 
interaction between intervention status and measurement time; 8 Distribution of HIV testing sites in rural areas; 9 
𝜎11
2  is the between cluster variance and 𝜎22





Figure 11: Monthly and cumulative HIV testing uptake rates per 1,000 adults. 
Results in individuals aged 12 years and above over the first 11 months of the intervention before the scale up of the Delayed intervention arm are shown. The 
line graphs represent the cumulative HIV testing uptake rates. The purple cubed line graph indicates the Delayed intervention arm and the green triangle line 
graph the Early intervention arm. The solid bar graphs represent the monthly HIV testing uptake rates per 1,000 adults for every month over the 11 months of 
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6.6 Impact on TB and ART treatment initiation and testing uptake rates in the second 
phase (11 months) of the intervention 
In this section, results based on the second half (11 months) of the study period are presented, 
during which time both the Delayed and Early arms received the intervention (see Figure 3 in 
section 2.3.3.5). Thus, the incidence rate ratios determined here compare the incidence rates 
in the Early arm against those in the Delayed intervention group when both of these groups 
were receiving the intervention (but for different lengths of time).   In all the analyses, same 
baseline covariates were used when assessing the effectiveness of the intervention. 
6.6.1 Impact on TB and ART treatment initiation rates in the second phase (11 months) of 
the intervention 
In this section, results for the analysis using data for the next 11 months after scaling up the 
intervention to the Delayed arm are presented for the TB and HIV treatment initiation rates.  
6.6.1.1 Impact on TB treatment initiation rates in the second phase (11 months) of the 
intervention 
The effect size estimate based on the marginal effects model with a single covariate contrasting 
intervention status was IRR = 0.758 (95% CI: 0.445 to 1.290).  This is slightly lower than the 
IRR of 0.824 (95% CI: 0.513 to 1.24)obtained in the first 12 months. When baseline TB treatment 
initiations were adjusted for, the incidence rate ratio increased to 0.909 (95% CI: 0.645 to 1.280), 
which was similar to the IRR of 0.938 (95% CI: 0.650 to 1.354), obtained during the evaluation 
of the first 12 months of the study period.  
Using the random intercepts and random coefficients models, the effect size estimate with a 
single covariate contrasting intervention status was IRR = 0.821 (95% CI: 0.516 to 1.306) for the 
random intercepts model and IRR = 0.824 (95% CI: 0.520 to 1.307) for the random coefficients 
model.  These results were slightly lower than the IRR of 0.876 (95% CI: 0.583 to 1.313) for the 
random intercepts and 0.878 (95% CI: 0.585 to 1.316) for the random coefficients models 
obtained in the first 12 months. When baseline TB treatment initiations were adjusted for, the 
incidence rate ratios were 0.931 (95% CI: 0.686 to 1.264) and 0.924 (95% CI: 0.669 to 1.274) for 
the random intercepts and random coefficients models respectively, which were slightly 
lower than the IRR of 0.963 (95% CI: 0.695 to 1.333) for the random intercepts and 0.990 (95% 
CI: 0.723 t0 1.357) for the random coefficients model obtained during the first 12 months of 
the study. 
When the most improved model was fitted,  with gender, distribution of health facilities, time, 
same baseline TB treatment initiation rates used in the first 12 months and interaction terms 
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between time and intervention status (as implemented in the first 12 months’ data), the 
incidence rate ratio comparing the Early intervention and Delayed intervention were 0.552 
(0.529 * 1.044), 0.555 (0.532*1.044) and 0.562 (0.538*1.044) for the marginal, random intercepts 
and random coefficients models which were lower than the estimates obtained in the first 12 
months (see Table 21), suggesting that the intervention was effective in initiating more TB 
treatment in the Delayed intervention arm when the intervention was scaled up in this arm.  
The intracluster correlation coefficient estimated after fitting the random intercepts model 
adjusting for all covariates was 0.0073, suggesting low clustering in TB treatment initiation 
rates in the next 11 months of the intervention (Table 27). The corresponding standard 
deviation for the random intercept parameter √𝜎11
2  and the overdispersion scale parameter 𝜙 
used to estimate the ICC were 0.046 and 3.497 respectively. Fitting the random coefficients 
model did not greatly improve the model fit when compared to the random intercepts model 
(see the log likelihood, AIC and BIC in Table 27). 
All covariates considered in the marginal model were significantly associated with TB 
treatment initiation rates (Table 27). Using the random intercepts and random coefficients 
models, no significant improvements in the effect of the intervention were observed 
[IRR=0.555 (0.532*1.044) for the random intercepts model, IRR=0.562 (0.538*1.044) for the 
random coefficients model, neither of which were statistically significant] (Table 27).  Thus, 
(numerically) the effect of scaling up the intervention to the Delayed arm compared to the 
Early arm was associated with a 45% reduction in the number of new TB patients starting 
treatment in the Early arm when the marginal model was used and about 44% reduction when 
the random intercepts model was used.  
In the random effects models only baseline TB treatment initiations, time, interaction effect 
and distribution of health facilities initiating treatment were significantly associated with TB 
treatment initiation rates. Using the random intercepts model, only the distribution of health 
facilities, baseline TB treatment initiations and interaction effect were associated with 
increasing number of TB cases starting treatment with an estimated magnitude of 27%, 3.8% 
and 4.4% respectively. The results also indicate that being female was associated with reduced 
TB treatment initiation rates by 69% as observed in the first 12 months (Table 27).  
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Table 27: Adjusted incidence rate ratios for intervention effects using the marginal effects, random intercepts, and 
random coefficients models for measuring overall access rates to TB treatment initiation rates using the data from the 
second phase of the intervention (11 months) 
 Marginal effects Poisson Random intercepts Poisson Random coefficients Poisson 
Fixed part IRR1 95% CI2 P3 IRR1 95% CI2 P3 IRR1 95% CI2 P3 
Treat4 0.529 0.387, 0.722 <0.001 0.532 0.247, 1.145 0.106 0.538 0.249, 1.161 0.114 
Base5 1.038 1.021, 1.054 <0.001 1.038 1.020, 1.057 <0.001 1.038 1.017, 1.059 <0.001 
Occasion6 0.974 0.959, 0.989 0.001 0.974 0.948, 0.999 0.049 0.974 0.948, 0.999 0.049 
Gender  0.320 0.117, 0.874 0.026 0.314 0.046, 2.139 0.237 0.274 0.039, 1.931 0.194 
Treat*Month7 1.044 1.027, 1.062 <0.001 1.044 1.003, 1.088 0.036 1.044 1.003, 1.088 0.036 
H.facility8 1.269 1.155, 1.395 <0.001 1.268 1.123, 1.431 <0.001 1.268 1.111, 1.447 <0.001 
Random part9          
√𝜎11
2  
    0.046   0.041  
√𝜎22
2  
       0.114  
ICC10        0.0073  
Model fit indices         
Log likelihood -190.639   -190.541   -189.999  
AIC 391.279   397.083   397.980  
BIC 402.227   414.600   417.687  
1 Incidence Rate Ratio (IRR) = rate in Early intervention/rate in delayed intervention; 2 Confidence interval (CI); 3 p-
value; 4 Intervention status (Early/Delayed);  5 Baseline TB treatment initiation rates; 6 Repeated measurement time;                 
7 interaction between intervention status and measurement time; 8 Distribution of health facilities offering TB 
treatment initiations; 9 𝜎11
2  is the between cluster variance and 𝜎22
2  is the slope  variance; 10 ICC=Intracluster correlation. 
 
When TB patients starting treatment were assessed in terms of monthly and cumulative TB 
treatment initiation rates (computed per 10,000 adults aged 12 years and above), both the 
unadjusted monthly treatment initiation rates and the cumulative treatment initiation rates 
were high in the Delayed intervention group compared to the Early intervention group. When 
the intervention was added to the Delayed intervention arm in the 13th month, a widening 
gap was observed between the two arms in terms of cumulative TB treatment initiation rates 
(Figure 12) potentially due to the high number of health facilities in the Delayed arm 
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compared to the Early arm (2 health facilities in Early arm and 4 health facilities in the Delayed 
arm as shown in Figure 8 in section 6.4.1). At baseline (i.e. the preceding 12 months before the 
intervention) similar trends were observed with more cases in the Delayed arm than in the 
Early arm (Table 17). Thus, with more health facilities initiating TB treatment in the Delayed 
arm compared to the Early arm coupled with a widening gap in the cumulative TB treatment 
initiation rates after scaling the intervention to the Delayed arm (increased number of TB cases 
starting treatment in Delayed arm), it would appear that the effect of the intervention 
depended on the distribution of health facilities between the two intervention arms. 
6.6.1.2 Impact on smear- positive TB treatment initiation rates in the second phase (11 
months) of the intervention 
When the smear-positive TB patients starting treatment were analysed over the final 11 
months of the intervention, the effect size based on the marginal effects model with a single 
covariate contrasting intervention status was estimated as IRR = 0.781 (95% CI: 0.551 to 1.107), 
which is slightly higher than the IRR = 0.622 (95% CI: 0.427 to 0.905) obtained when the first 
12 months’ data were used. Using the random intercepts and random coefficients models, the 
incidence rate ratios for the next 11 months were 0.799 (95% CI: 0.575 to 1.110) and 0.804 (95% 
CI: 0.585 to 1.105) respectively. These estimates were slightly higher than the 0.647 (95% CI: 
0.450 to 0.930) for the random intercepts model and 0.646 (95% CI: 0.448 to 0.931) for the 
random coefficients model obtained when the first 12 months were used (see section 6.5.1.2), 
suggesting that the number of smear-positive cases starting TB treatment slightly increased in 
the Early arm compared to the Delayed arm before controlling for other covariates. 
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Figure 12: Monthly and cumulative TB treatment initiations rates per 10,000 adults. 
Results in individuals aged 12 years and above over the 23 months of the intervention are shown. The line graphs represent the cumulative TB treatment 
initiation rates.  The green triangle line graph indicates the Early Intervention arm and the purple cubed line graph indicates the Delayed Intervention arm.  
The solid bar graphs represent the monthly TB treatment initiation rates per 1,000 adults for each month of the intervention. The blue bars represent the Early 
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After adjusting for baseline smear-positive TB treatment initiation rates, the IRR increased to 
1.016 (95% CI: 0.896 - 1.152), which was a marked increase compared to the IRR of 0.778 (95% 
CI: 0.591 - 1.023) obtained when the first 12 months were used, although neither estimate was 
statistically significant.  
After fitting the most improved model with gender, time, distribution of large health facilities, 
baseline smear- positive TB treatment initiation rates and interaction terms between time and 
intervention status as covariates, there was an increased attenuation of the effect of the 
intervention. Using the marginal model, the effect of the intervention was estimated as IRR = 
0.384 (0.362 * 1.061), which is almost half the IRR value of 0.723 obtained when the first 12 
months’ data was used. Thus, using data from the second 11 month period, the Early 
intervention areas experienced a reduction in TB smear-positive cases of 61.6%, although this 
was not significant at the conventional 5% level due to a small number of smear- positive TB 
cases detected later in the intervention (Table 28). Only baseline smear positive TB treatment 
initiation rates and the distribution of health facilities were significantly associated with the 
rate at which smear-positive TB patients started treatment (Table 28).  
When the random effects models were fitted, the effect of the intervention was estimated as 
IRR = 0.384 (0.362 * 1.061) for both the random intercepts and random coefficients models and 
these were similar to that obtained using the marginal model, suggesting a 61.6% reduction 
in TB treatment initiations per cluster in the Early arm when the random effects models were 
fitted. Thus, when the intervention was scaled up in the Delayed arm, more smear-positive 
TB cases were detected than in the Early arm (i.e. with more health facilities in the Delayed 
arm as shown in Figure 8 in section 6.4.1 coupled with the scaling up of the intervention in 
this arm led to increased treatment initiations of smear-positive TB patients). Only baseline 
smear positive TB treatment initiation rates was significantly associated with TB treatment 
initiations among smear-positive TB patients in both the random intercepts and random 
coefficients models. There was no clustering in the smear positive TB treatment initiation rates 
(ICC=0.0) and the random intercepts parameter √𝜎11
2   was approximately 0.0 and the 
overdispersion scale parameter 𝜙 used to estimate the ICC was 5.024. Fitting of the random 
coefficients model did not improve the model fit when compared to the random intercepts 
model (Table 28). 
In both the random effects and marginal effects models, baseline smear positive TB treatment 
initiations, distribution of health facilities initiating TB treatment and the interaction effect 
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were associated with increased TB treatment initiations (Table 28). Being female was 
associated with decreased TB treatment initiations among the smear-positive TB cases as 
noted when the first 12 months data was used. 
Table 28:  Adjusted incidence rate ratios for intervention effects using the marginal effects, random intercepts, and 
random coefficients models for measuring overall access rates in smear positive TB treatment initiation rates using 
the second phase (11 months) of the intervention 
 Marginal effects Poisson Random intercepts Poisson Random coefficients Poisson 
Fixed part IRR1 95% CI2 P3 IRR1 95% CI2 P3 IRR1 95% CI2 P3 
Treat4 0.362 0.102, 1.288 0.117 0.362 0.089, 1.483 0.158 0.362 0.089, 1.483 0.158 
Base5 1.191 1.162, 1.220 <0.001 1.191 1.053, 1.346 0.005 1.191 1.053, 1.346 0.005 
Occasion6 0.987 0.933, 1.045 0.663 0.987 0.940, 1.037 0.616 0.987 0.940, 1.037 0.616 
Gender  0.762 0.576, 1.009 0.058 0.762 0.147, 3.958 0.747 0.762 0.147, 3.958 0.747 
Treat*Month7 1.061 0.988, 1.139 0.102 1.061 0.984, 1.144 0.125 1.061 0.984, 1.144 0.125 
H. facility8 1.070 1.049, 1.091 <0.001 1.070 0.897, 1.276 0.452 1.070 0.897, 1.276 0.452 
Random part9          
√𝜎11
2  
    0.000   0.000  
√𝜎22
2  
       0.006  
ICC10        0.000  
Model fit indices         
Log 
likelihood 
 -140.457   -140.457   -140.457  
AIC  290.915   296.915   298.915  
BIC  301.863   314.432   318.621  
1 Incidence Rate Ratio (IRR) = rate in Early intervention/rate in delayed intervention; 2 Confidence interval (CI); 3 p-
value; 4 Intervention status (Early/Delayed);  5 Baseline smear positive TB treatment initiation rates; 6 Repeated 
measurement time;                 7 interaction between intervention status and measurement time; 8 Distribution of 
health facilities offering TB treatment initiations; 9 𝜎11
2  is the between cluster variance and 𝜎22





6.6.1.3 Impact on ART treatment initiation rates in second phase (11 months) of the 
intervention period 
When ART treatment initiation rates, based on the second phase (the next 11 months) of the 
intervention period were assessed, the marginal effects model with a single variable 
contrasting intervention status showed that ART treatment initiation rates significantly 
reduced by 20.1% (IRR=0.799; 95% CI:0.664 to 0.960, p=0.016) in the Early arm compared to 
the Delayed arm. This is in contrast to the IRR of 1.128 obtained when the first 12 months’ 
data was used. No improvement in effect size was noted after adjusting for baseline ART 
treatment initiation rates (IRR=0.798; 95% CI:0.665 - 0.958, p=0.015).  
However, using the random effects models with only a variable contrasting intervention 
status, ART treatment initiation rates increased 20.6% (IRR=0.794; 95% CI: 0.670 to 0.940, 
p=0.007) in the Early arm compared to the Delayed arm using the random intercepts model 
and 20.6% (IRR=0.794; 95% CI: 0.670 to 0.940, p=0.008) using the random coefficients model. 
These results are lower than the 11.2% (IRR=1.112; 95% CI: 0.890 to 1.389) for both random 
intercepts and random coefficients models (see section 6.5.1.3), suggesting an increased ART 
treatment initiations in the Delayed arm after rolling out the intervention.   
When an improved model with intervention, baseline ART initiation rates, gender, and 
distribution of large health facilities but without an interaction term between intervention 
status and time was fitted, the IRR was 0.873 (0.794 - 0.959, p=0.005). However, when an 
interaction between intervention and time was allowed for, the overall effect size estimate 
increased to IRR= 0.924 (0.927*0.997), which was not statistically significant. This estimate was 
considerably lower than the IRR=1.347 obtained when first 12 months’ data was used.  
Similar reductions in ART initiation rates were noted when the random intercepts and 
coefficients models were fitted (Table 29). The estimated intracluster correlation coefficient 
was 0.0 and the corresponding random intercepts parameter √𝜎11
2  and overdispersion scale 
parameter 𝜙 used to estimate the ICC were respectively 0.0 and 6.843, suggesting no between 
cluster variability in ART initiation rates in the next 11 months of the intervention. Fitting of 
the random coefficients model was not superior to the random intercepts model based on the 
model fit indices (Table 29), suggesting that the results from the random intercepts model 
were adequate. 
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Only ART baseline initiation rates, time and distribution of health facilities were significantly 
associated with ART initiation rates when both marginal and random effects models were 
fitted. 
Using the 11 months’ data from the second phase of the intervention, ART treatment initiation 
rates in the Early intervention areas reduced by 8% compared to the areas that received the 
Delayed intervention which was not significant at 5% level after using both marginal and 
random effects models. This suggests that the addition of the intervention in the Delayed arm 
narrowed the effect size of the intervention observed in the first 12 months. Hence, the fact 
that the difference between Early and Delayed intervention arms diminished after rolling out 
the intervention clearly demonstrates that the intervention was effective in increasing ART 
treatment initiation rates in the community. In fact, the intervention was effective in increasing 
ART treatment initiation rates even within a shorter time period.   
When the monthly and cumulative ART treatment initiation rates over the whole study period 
were computed and plotted, the monthly and cumulative rates initially showed an increase 
in number of ART cases starting treatment in the Early intervention arm in the first 12 months 
compared to the Delayed intervention arm (Figure 13). As the intervention was rolled out to 
the Delayed arm, there was a narrowing gap between the two intervention arms. 
173 
Table 29: Adjusted incidence rate ratios for intervention effects using the marginal effects, random intercepts, and 
random coefficients models for measuring overall ART initiation rates using the second phase (11 months) of the 
intervention 
 Marginal effects Poisson Random intercepts Poisson Random coefficients Poisson 
Fixed part IRR1 95% CI2 P3 IRR1 95% CI2 P3 IRR1 95% CI2 P3 
Treat4 0.927 0.389, 2.205 0.863 0.927 0.588 , 1.459 0.742 0.927 0.588, 1.459 0.742 
Base5 0.994 0.990, 0.999 0.011 0.994 0.989, 0.999 0.025 0.994 0.989, 0.999 0.025 
Occasion6 1.08 1.062, 1.100 <0.001 1.08 1.064, 1.098 <0.001 1.081 1.064, 1.098 <0.001 
Gender  1.476 0.128,16.960 0.755 1.476 0.063, 34.817 0.809 1.476 0.063, 34.763 0.809 
Treat*Month7 0.997 0.949, 1.047 0.898 0.997 0.974, 1.020 0.789 0.997 0.974, 1.020 0.789 
H. facility8 1.146 1.093,  1.201 <0.001 1.146 1.050 , 1.250 0.002 1.146 1.050, 1.250 0.002 
Random part9          
√𝜎11
2  
    0.000   0.000  
√𝜎22
2  
       0.0191  
ICC10        0.000  
Model fit indices         
Log 
likelihood 
 -285.478   -286.111   -286.485  
AIC  580.956   588.223   590.969  
BIC  591.904   605.740   610.676  
1 Incidence Rate Ratio (IRR) = rate in Early intervention/rate in delayed intervention; 2 Confidence interval (CI); 3 p-
value; 4 Intervention status (Early/Delayed);  5 Baseline ART initiation rates; 6 Repeated measurement time;   7 
interaction between intervention status and measurement time; 8 Distribution of health facilities offering ART 
treatment initiations; 9 𝜎11
2  is the between cluster variance and 𝜎22
2  is the slope  variance; 10 ICC=Intracluster correlation. 
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Figure 13: Monthly and cumulative ART treatment initiations rates per 10,000 adults. 
Results in individuals aged 12 years and above over the 23 months of the intervention are shown. The line graphs represent the cumulative ART initiation rates. 
The green triangle line graph indicates the Early Intervention arm and the purple cubed line graph indicates the Delayed Intervention arm. The solid bar graphs 
represent the monthly ART initiation rates per 1,000 adults for every month of the intervention.  The blue bars represent the Early Intervention Arm while the 
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6.6.2 Impact on TB testing uptake rates in the second phase (11 months) of the 
intervention 
To investigate the effect of scaling up the intervention to the Delayed intervention arm on the 
number of people accessing TB testing services, marginal and random effects models were 
fitted using data from the second phase of the trial (11 months). The results from the marginal 
effects models showed that there were reductions in the number of presumptive TB cases 
accessing testing services when compared to the first 12 months’ data (IRR=0.659=0.648*1.017 
i.e. an 34% reduction in the 11 months’ data vs IRR=1.215*0.948=1.152 i.e. a 15.2% increase in 
the preceding12 months’ data; p<0.05). Using the random effects models, the number of 
presumptive TB cases accessing TB testing reduced by 34% (IRR=0.659=0.648*1.017) for the 
random intercepts model and 34% (IRR=0.660=0.649*1.017) for the random coefficients model. 
When the random intercepts model was fitted, the estimated intracluster correlation 
coefficient was 0.004 and the corresponding random intercepts parameter √𝜎11
2  and the 
overdispersion scale parameter 𝜙 used to estimate the ICC were respectively 0.021 and 4.406 
(Table 30). Fitting the random coefficients model did not improve the model fit when 
compared to the random intercepts model (Table 30). 
The 34% reduction in uptake rates in the marginal, random intercepts and random coefficients 
models were all significant after adjusting for baseline access to TB testing services, 
distribution of testing sites, gender, time and an interaction term between intervention status 
and time as cluster-level covariates (Table 30).  
In the second phase (11 months) of the trial, all the covariates except the interaction effect were 
significant at the 5% level in the marginal, random intercepts and random coefficients models. 
The distribution of health facilities, gender and the interaction effect were the only covariates 
associated with increasing the number of presumptive cases accessing TB testing sites in all 
the models fitted.   In general, approximately 7 times more females than males were accessing 
TB testing in the next 11 months of the intervention compared to treatment initiation rates 
reported in both the first 12 months and the next 11 months of the intervention potentially 
due to embedding of the intervention. The reduction in the effect size observed when the TB 
testing uptake rates were compared between Early and Delayed intervention arms suggests 
that the intervention also improved the TB testing uptake rate in the Delayed intervention 
arm. Similar observations are noted in monthly and cumulative rates shown in Figure 14. 
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Table 30: Adjusted incidence rate ratios for intervention effects using the marginal effects, random intercepts, and  
coefficients models for measuring presumptive TB testing uptake rates in the second phase (11 months) of the 
intervention. 
 Marginal effects Poisson Random intercepts Poisson Random coefficients Poisson 
Fixed part IRR1 95% CI2 P3 IRR1 95% CI2 P3 IRR1 95% CI2 P3 
Treat4 0.648 0.445,0.943 0.023 0.648 0.438,0.961 0.031 0.649 0.436,0.966 0.033 
Base5 0.993 0.988,0.998 0.008 0.992 0.987, 0.998 0.003 0.993 0.986,0.999 0.030 
Occasion6 0.963 0.959,0.967 0.002 0.963 0.949, 0.978 <0.001 0.963 0.949,0.978 <0.001 
Gender  6.997 2.421,20.231 <0.001 7.092 0.946,53.17 0.057 8.213 1.104,61.11 0.040 
Treat*Month7 1.017 0.992, 1.043 0.180 1.017 0.996, 1.039 0.118 1.017 0.996,1.039 0.118 
H.facility8 1.119 0.757,0.876 <0.001 0.814 0.755, 0.877 <0.001 0.816 0.745,0.892 <0.001 
Random part9          
√𝜎11
2  
    0.021   0.020  
√𝜎22
2  
       0.0197  
ICC10        0.004  
Model fit indices         
Log 
likelihood 
 -325.555   -327.068   -327.592  
AIC  661.110   670.136   673.185  
BIC  672.058   687.653   692.892  
1 Incidence Rate Ratio (IRR) = rate in Early intervention/rate in delayed intervention; 2 Confidence interval (CI); 3 p-
value; 4 Intervention status (Early/Delayed);  5 Baseline TB testing uptake rates; 6 Repeated measurement time; 7 
interaction between intervention status and measurement time; 8 Distribution of TB testing sites; 9 
𝜎11
2  is the between cluster variance and 𝜎22





Figure 14: Monthly and cumulative TB testing uptake rates per 10,000 adults. 
Results in individuals aged 12 years and above over the 23 months of the intervention are shown. The line graphs represent the cumulative TB testing uptake 
rates.  The green triangle line graph indicates the Early Intervention arm and the purple cubed line graph indicates the Delayed Intervention arm.  The solid 
bar graphs represent the monthly TB testing uptake rates per 1,000 adults for each month of the intervention. The blue bars represent the Early Intervention 
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6.7 Summary and conclusion 
 
In this chapter, results from the analysis of the Triage Plus study that employed informal 
health care providers to implement TB and HIV community interventions were presented. 
The results from this chapter can be summarised as: 
 The adjusted analysis showed that involvement of the informal providers significantly 
increased the number of presumptive TB cases accessing testing sites by 15.2% 
(p=0.003) and the number of TB patients starting treatment by 18%, 19.6% and 21.5% 
for the marginal, random intercepts and random coefficients models in the first 12 
months of the intervention but not significant at 5% level.  In the next 11 months of the 
intervention, the number of presumptive cases accessing testing services were similar 
between the two intervention arms. In the second phase (11 months) of the 
intervention, the number of TB treatment initiations were significantly reduced by 45% 
(p<0.001) in the Early intervention compared to the Delayed arm, suggesting that 
rolling out of the intervention to the Delayed arm resulted in increased TB treatment 
initiations in the Delayed arm.  
 
 For smear- positive TB, the number of patients starting TB treatment in the Early 
intervention areas in the first 12 months were 28% (p=0.02) less than the Delayed arm. 
In the second phase (11 months) of the intervention, the number of smear-positive TB 
patients starting treatment in the Early arm fell by 61%, though this was not 
statistically significant at the 5% level.  
 
 In regards to the adjusted analysis for the HIV services access rates, the involvement 
of informal healthcare providers significantly increased the number of patients 
starting ART in the Early arm by 34.7% (p=0.048) during the first 12 months of the 
intervention. In the next 11 months of the intervention, the number of patients starting 
ART were similar between the two intervention arms (IRR = 0.924 with 95% CI: 0.389, 
2.205, p=0.863). The HIV testing uptake rates in the Early arm increased by 61% (RR 





Thus, the results of the study clearly demonstrate that engaging informal health care 
providers was effective in improving TB and HIV testing uptake and also increased ART 
initiation. This reinforces the need for community participation in integrated TB and HIV 
interventions to combat the two diseases. However, for these providers to be effective in 
promoting TB treatment initiation, numbers of sites offering TB testing and treatment 
initiation in rural areas should be increased.  
Furthermore, the results of the study demonstrate that the effectiveness of engaging informal 
health care providers in improving access to TB and HIV services was dependent on the 
gender distribution. In general, access to TB and HIV services was lower in females than in 
males due to gender related structural barriers such as poverty (Storla et al., 2008). It is worth 
noting that TB testing uptake increased by approximately 7 times more in females compared 
to males in the next phase of the intervention potentially due to more women being exposed 
to the intervention over time although this did not lead to improved TB treatment initiations. 
However, the assessment of the effectiveness of the intervention over time (based on the 
analysis of time treatment interactions) showed no significant effect on time treatment 
interactions overall. This absence of statistical significance is mainly due to the low statistical 
power of the significance test for the interaction terms (a common problem in statistical 
analysis).  
6.8 Statistical implications of the findings of the Triage Plus study 
 
Due to the fact that the 3 clusters per arm study design was used in the Triage Plus study, the 
results, especially in regards to the TB outcome measures, needed to be interpreted 
cautiously.  For example, the adjusted effect size in increasing TB treatment initiations was 
18% but was not statistically significant at the 5% significance level. This supports the 
findings from the simulation studies that clearly showed that with a true effect size of < 20% 
in low incidence disease conditions, such as TB in our case, no adequate power would be 
achieved even after increasing the number of repeated measurement times to 12 points. 
However, with effect sizes ≥ 20%, such as that found in smear-positive TB patients starting 
treatment, adequate power was available to detect significant differences in TB initiation rates 
between the two arms. The findings from the analysis of the Triage Plus study therefore 
confirm the conclusions made in the simulations studies presented in Chapter 5 that no 
adequate power would be achieved in low incidence disease conditions with an effect size 
less than 20% even after 12 measurement time points. 
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For the high incidence outcomes of ART initiation rates and testing uptake rates for TB and 
HIV, achieving adequate statistical power in assessing the differences between the two arms 
was not difficult. For example, the simulation studies presented in Chapter 5 showed that in 
high incidence outcomes adequate power could be achieved even with the number of clusters 
as low as 3 clusters per arm but with at least 3 measurement time points when the ICC was 
0.00154. With an ICC of 0.081, adequate statistical power was achieved with effect sizes >40% 
in a 3 cluster per arm design. 
 
Overall, the ICCs obtained in the final analysis of the Triage Plus study were comparable to 
those used in the simulation studies presented in Chapter 5. This, therefore, suggests that the 
interpretation of the main outcome measures and the statistical power for the final analysis 
of the Triage Plus study data using the repeated monthly counts over the intervention period 






GENERAL DISCUSSION, POLICY IMPLICATIONS AND CONCLUSIONS 
 
7.1 Introduction 
This final Chapter provides a discussion of the research findings, strengths and possible 
limitations of both the simulation and Triage Plus intervention studies. To begin with, the true 
statistical power of the Triage Plus study is explored based on the findings of the simulation 
study. The limitations of both are also reviewed because of the power issues within each 
study. The methodological conduct of the Triage Plus study is then considered, including a 
review of the implications of the study’s key findings on the policy implications for 
community engagement intervention in the promotion of TB and HIV testing and treatment. 
7.2 Statistical power and parameter estimation in a cluster randomised trial with a limited 
number of clusters but adopting a repeat observation design 
In simulation studies of a cluster randomised intervention design consistent with that of 
Triage Plus, it was clear that any correlations arising from the study design had to be 
accounted for in the analysis. Mixed effects models, such as the Poisson mixed effects model, 
help to capture such correlations, but they also limit the power and the precision of parameter 
estimates as the analysis is done at the cluster level, a major problem when there are only 
limited numbers of clusters available for analysis. The extensive Monte Carlo simulations 
implemented in Chapter 5 using baseline data sets from the Triage Plus study (i.e. using 
baseline mean TB treatment initiations, actual estimates of intracluster correlations from the 
Triage Plus study and the 3 clusters per arm) indicated that adequate power would have been 
difficult to achieve if a basic pre- and post- evaluation design was used.  
Thus, by using a repeated measurement design with a small number of clusters, a similar level 
of statistical power was achieved when compared to the cross-sectional design with more 
clusters enrolled (Hedeker and Gibbons, 2006). This is because the repeated measurements in 
the same cluster are not perfectly correlated (which is the case in community interventions 
which usually have low ICC (see Gulliford, Ukoumunne, and Chinn, 1999).   As a result, the 
repeated measurements in the same clusters provide more independent data than in cross- 
sectional designs such as pre- and post- evaluations (Hedeker and Gibbons, 2006). 
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Thus, the findings of the simulation studies reported in Chapter 5, relating to the power and 
accuracy of parameter estimates and to the variance components in cluster randomised 
studies with small numbers of clusters, are considered to be critical in several respects.  
The population incidence of the studied disease was found to be critical in determining 
statistical efficiency— a finding noted also by Moineddin, Matheson and Glazier (2007). The 
simulation study showed that in low incidence disease conditions such as TB treatment 
initiation rates, achieving adequate statistical power and precise estimates required more 
clusters and repeated measurement times. With effect sizes of less than 10%, no adequate 
power could be achieved regardless of the number of clusters and measurement times (see 
Table 6, 8 & Figure 6).   
In contrast, in high incidence disease conditions such as HIV testing / treatment initiation and 
TB testing, the simulations showed that at an effect size of 10%, adequate power could be 
achieved even in a 3 cluster per arm design but only by having more repeat observations (in 
our case 12 time points for the 3 clusters per arm), when the ICC was low (ICC=0.00154). With 
an ICC of 0.081, adequate statistical power could only be achieved with an effect size of at 
least 40% in a 3 cluster per arm design. The required number of repeat observations to achieve 
adequate power decreased with the increasing number of clusters per arm (see Table 7 & 9). 
However, when the effect size was at least 20%, the simulation studies showed that in the low 
incidence disease conditions adequate statistical power could be achieved after more repeat 
observations. At effect size of 20%, about 12 repeat observations were needed to achieve 
adequate power of at least 80% in a 3 cluster per arm design when the ICC was 0.00154. 
However, with an ICC of 0.081, at least 9 clusters with 6 measurement times were needed. In 
general, the number of repeat observations decreased with the increasing number of clusters 
and effect sizes in both low and high incidence disease conditions (see Tables 6 - 9, Figures 6 
& 7). Increasing the ICC resulted in decreased statistical power as also observed in other 
simulation studies (Amatya et al., 2013). 
The findings from the simulations in general showed that statistical power is affected by 
several factors such as disease incidence, number of clusters, effect size, and repeated 
measurements and ICC (see Tables 6 - 9, Figure 6 & 7). These simulations, therefore, allowed 
exploration of complex designs that often arise in practice but for which conventional power 
calculation formulae are inadequate.  
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Although previous simulations have recommended a minimum of 30 groups per arm (for 
example Maas and Hox, 2005; and Moineddin et al., 2007), our simulations clearly showed 
that the statistical power of cluster randomised trials with only a limited number of clusters 
available per arm (such as the Triage Plus study) can be improved considerably by increasing 
the number of measurement times and can be applicable in high prevalence or incidence 
disease conditions with moderate ICCs (Murray et al., 1998b; Heo and Leon, 2009; Moineddin 
et al., 2007; Amatya et al., 2013).  
The simulation methods used in this dissertation are universally applicable to determine the 
optimal number of clusters and the design conditions needed to obtain valid estimates 
(Murray et al., 1998b; Arnold et al., 2011; Burton et al., 2006; Bennett et al., 2002; Moineddin et 
al., 2007).    
However, the simulation studies presented in Chapter 5 were limited to cluster randomised 
designs with repeated measurements nested within clusters when assessing statistical 
efficiencies in terms of power and parameter estimate precision. The design adopted a 
situation where repeated measurements were taken from the same clusters and not 
necessarily from the same individuals in the group (i.e. cross-sectional design). Thus, the 
findings of this study are most applicable to similar study designs—but as pointed out by 
Murray et al. (1998b), the findings may also be applicable to cohort studies collecting repeated 
measurements in the same clusters as well as for individuals within the clusters.      
7.3 Statistical power of the Triage Plus study 
The positive effects of the Triage Plus intervention were intended to persist in the 
communities and increase as the intervention progressed. In this way, more patients in the 
community would be more aware of the signs and symptoms of TB and HIV which would 
necessitate them seeking care from health centres (Storla et al., 2008). With the limited number 
of clusters used in the Triage Plus study, coupled with the effects of the intervention persisting 
over a longer duration, a parallel cluster randomised approach was therefore appropriate. 
Thus, all 3 clusters in each arm were simultaneously allocated either to an Early intervention 
arm or to a Delayed intervention arm - consistent with other parallel designs (see Corbett et 
al., 2010).  
 
The Triage Plus intervention used what could be termed a ‘semi stepped wedged design’ in 
that the scheduling of the implementation of the intervention within the Early arm clusters 
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was randomly drawn, and, based on the randomisation process, the implementation was 
sequential. In addition, the Triage Plus intervention also adopted a phased intervention: after 
implementing the intervention in the Early intervention arm for the first 12 months, the 
intervention package was also implemented in the Delayed arm for the following 11 months, 
which acted as both control and intervention clusters as in a stepped wedged design (The 
Gambia Hepatitis Study Group, 1987; De Allegri et al., 2008).  Though analysis based on the 
pure stepped wedge design has the advantage of allowing internal comparisons (the clusters 
all experience both the control and intervention conditions to act as their own controls) which 
can lead to improved power, this design is only valid when there is a relatively large number 
of clusters and the clusters receive the intervention sequentially; hence, the pure stepped 
wedge design is not applicable to our study (Hussey and Hughes, 2007), and  the  design was 
not considered in any further detail. 
The sequential and phased cluster randomised design used in the Triage Plus study allowed 
efficient project implementation and also removed the ethical concern of withholding the 
intervention from the control clusters (Hussey and Hughes, 2007). The study design further 
allowed us to assess how the effects of the intervention changed over the intervention period 
when the Delayed arm clusters received the intervention. When the intervention is scaled to 
the Delayed intervention clusters, the direction of the effect size provides valuable 
information regarding the effectiveness of the intervention. If the intervention is effective, an 
effect size and direction similar to that found in the first phase of the study would be 
anticipated, if this does not happen, a more thoughtful interpretation of effect may be needed. 
However, such analyses may require more statistical power than is available when there are 
only a small number of clusters, as evidenced in the lack of statistical significance when the 
effectiveness of the intervention was assessed after the Delayed arm received the intervention: 
a reduction in smear positive TB treatment initiation rates by 61% was not statistically 
significant (see Table 28).  This may be due to the earlier intervention arm depleting much of 
the smear-positive TB cases during the first phase of the intervention (in the first 12 months), 
but more cases are detected in the newly scaled interventions (as a result of the intervention), 
leading to huge differences between the two arms in terms of the estimated incidence rate 
ratio. Very few smear-positive TB cases detected in the second phase of the intervention in the 
Early intervention areas resulted in having small mean counts per month but with an 
increased variance around this estimate that affected the statistical power (see also in 
Moineddin et al., 2007).   
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Thus, the analytical design used in Triage Plus was efficient in attaining adequate statistical 
power for HIV outcomes (ART treatment initiation rates and HIV testing uptake rates) 
because they were very common. In addition, outcome measures related to testing uptake 
rates among presumptive TB cases were also adequately powered. However, TB treatment 
initiation outcome measures were inadequately powered for small effective sizes of less than 
20% even after using the repeated measurements design (see Table 21). Findings from the 
simulation study in Table 6 & 8 also indicated that no adequate power could be achieved at 
an effect size less than 20%. Ideally, therefore, more clusters were needed in the Triage Plus 
intervention to achieve adequate statistical power across all important outcome measures as 
well as to derive valid and precise estimates of effect size for the intervention on the TB 
treatment initiation rates.   
7.4 How the Triage Plus study was conducted and its limitations 
7.4.1 Research design 
The use of multiple measurements in a cluster randomised intervention trial substantially 
improves statistical power (Murray et al., 1998b; Hedeker and Gibbons, 2006), as also 
demonstrated in Chapter 5. Using multiple measurements also allows for concurrent 
comparison of outcome measures over time. Together, these provide a clearer measure of 
intervention effectiveness than could be obtained through before-after evaluation methods 
that may fail to account for indirect effects such as secular trends. In general, there is a 
downward trend in TB in Malawi (Glynn, 2004) and an upward trends in ART uptake rates 
(Cook et al., 2010). Our approach was, therefore, robust in accounting for these secular trends. 
Applying a repeated measurement design (i.e. collecting data from the same clusters over 
several time points) allowed us to compute better estimates of the effectiveness of the 
intervention. With repeat observations, the general trend in the effectiveness of the 
intervention over time was clearly demonstrated by using cumulative rates in treatment 
initiations rates for TB and ART as well as uptake rates in TB and HIV testing (see Figures 11 
to 14 in Chapter 6).      
However, using the repeated measurement design necessitated sophisticated statistical 
methods requiring numerical integration approaches to evaluate the likelihood of the 
generalised linear mixed regression models for the mixed effects Poisson regression (Breslow 
and Clayton, 1993).  
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In the cluster randomised design, it is acknowledged that the randomisation process could 
have resulted in two alternative scenarios. In an extreme scenario, the randomisation process 
may have achieved the complete balancing of known and unknown confounding variables, 
in which case the assessment of the effect of the intervention can be implemented without 
adjusting for covariates and without necessarily affecting the trial conclusions (Bennett et al., 
2002; Corbett et al., 2010).  In a more moderate scenario, our randomisation process may have 
resulted in the moderate imbalance of some confounding factors due to the limited number 
of clusters available. Our matching of clusters at the randomisation stage was intended to 
ensure an even distribution of confounding factors between the two arms. However, the 
statistical comparisons made showed clear differences between the two study arms in terms 
of baseline TB and HIV services access rates (see Tables 17 & 18). In addition, there was uneven 
distribution of health facilities initiating TB and ART treatment between the two arms (see 
Figure 8). Thus, model adjustment for confounding variables when assessing the effectiveness 
of an intervention was imperative.   
Bennett et al. (2002), in their simulation studies, observed that the adjustment for a confounder 
with moderate imbalance but having a large effect on the intervention effect was robust even 
with a very small number of clusters. Thus, in the analysis of the Triage Plus study, statistical 
modelling, adjusting for covariates, was undertaken. This permitted controlling for effects 
resulting from an uneven distribution of factors, such as the number of large health facilities 
between the two intervention arms. Furthermore, the effects of clustering and the repeated 
measurements from the same clusters were adjusted for by our use of random effects 
modelling approaches (Breslow and Clayton, 1993). 
By using mixed effects Poisson regression models and repeated measurements from the same 
clusters in the analysis of the Triage Plus study, the challenges in type I error rates usually 
encountered in cluster randomised trials were averted, referred to as ‘Cornfield penalties’ 
(Cornfield, 1978).   By incorporating random effects in the models, the design addressed the 
extra-variation problem due to clustering and overdispersion. Given the small number of 
clusters available in the Triage Plus study, the use of repeated measurement design provided 
the additional degrees of freedom necessary for a valid estimation of intervention 
effectiveness (Murray et al., 1998b; Hedeker and Gibbons, 2006). 
7.4.2 Study limitations 
Despite the strength provided by the multiple measurements within a limited cluster 
randomisation and the use of random effects modelling, the study had its inherent limitations.  
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First, the evaluation process depended on routine data recorded in patient registers in health 
facilities; therefore, potentially inaccurately recorded patient address details were used to 
locate patients.  Use of both active and routine data collection methods for impact evaluation 
would be necessary. The use of routine data may have contributed to biased estimates of the 
intervention effect for several reasons: 
i) Patients who received treatment in urban areas while temporarily residing with relatives 
due to their illness may have been less likely to mention their actual place of residence 
and, therefore, may have been missed in our database, which only collected patients with 
rural addresses,  leading to an underestimation of the number of TB or HIV cases in the 
rural areas. No specific direction of the bias could be determined as this was likely to 
occur on all intervention arms.   
ii) Failure to accurately identify the actual villages that are in rural or urban areas (especially 
those bordering the urban areas) may also have led to the misallocation of patients to 
clusters for analysis. This occurred randomly between the two arms as they all shared 
boundaries with the urban areas. 
iii) As the intervention improved the community's knowledge of TB and HIV and the 
relationship between the two, a certain proportion of patients may have either avoided 
seeking health care services for fear of being labelled HIV positive (Moller et al., 2011) or 
used other names and wrong addresses in the course of seeking health care for fear of 
being identified and traced. This may have lowered the effect size of the intervention. 
iv) As routine health services data were used for this evaluation, some addresses were so 
poorly recorded that we were unable to properly assign them to either intervention arm 
in about 1.8% of cases (0.8% for TB and 2.2% for ART). However, the failure to assign the 
patients occurred randomly, and there was no consistent pattern to the missing 
residential addresses, so this bias was probably small. 
 
Second, although the use of repeated measurements might have addressed the statistical 
power issues in terms of having adequate degrees of freedom, the limited number of clusters 
used in the randomisation might not have evenly spread the unmeasured confounding factors 
(Donner and Klar, 2000; Murray 1998; Varnell et al., 2001) as observed in the uneven 
distribution of health facilities initiating both ART and TB treatment between the two arms 
(see Figure 8). Although other, smaller health facilities offering TB and HIV testing and/ or 
ART services were, however, evenly distributed between the two arms, there may have been 
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other unmeasured confounding factors. Because of the limitations of pair-matched design 
especially when there are few clusters for randomisation and the difficulty in predicting in 
advance the effectiveness of the matching process, alternative approaches needed to be 
considered in future such as stratified designs in which there are more than two clusters in 
each stratum (Klar and Donner, 1997; Hayes and Moulton, 2009). 
7.5 Effectiveness of the Triage Plus study 
7.5.1 Intervention effect on ART treatment initiation rates and HIV testing uptake rates 
The findings of the Triage Plus intervention indicate that the involvement of unpaid informal 
health care providers in HIV community awareness, disease recognition and referral has 
contributed significantly in ART treatment initiation rates and HIV testing uptake rates. By 
the end of the first phase (the first 12 months), HIV testing uptake  and ART treatment 
initiation rates had increased by more than 61%  and 34% respectively in the Early intervention 
arm compared to the Delayed arm (see Tables 23 & 26). In addition, there was no difference 
in ART treatment initiation rates between the two arms in the second phase (the next 11 
months) of the intervention (see in Table 29).  
Furthermore, the differences in cumulative ART treatment initiation rates and HIV testing 
uptake rates increased over time, with higher rates in the Early arm than in the Delayed arm 
in the first 12 months (for treatment and testing) followed by a reduction in these differences 
in the second phase for ART treatment (the next 11 months) (see Figures 11 & 13). This major 
improvement in ART treatment initiation rates and HIV testing uptake following intervention 
suggests that the intensification of the engagement of informal healthcare providers in the 
delivery of HIV services in such under-served rural areas could likely lead to improved 
service access and, therefore, reduce HIV related deaths and transmission (Cohen et al., 2011).    
Our results are consistent with other studies done in the region. A community based 
intervention in a rural district in KwaZulu-Natal, South Africa, involving paid community 
care workers to provide  an integrated TB/HIV/PMTCT, showed improved uptake rates  for 
HIV testing (92% acceptance rates) and screening of sexually transmitted infections (32%) 
compared to sexually transmitted infections screening rates of 7%  in control areas (Uwimana 
et al., 2012).  
7.5.2 Intervention effect on TB treatment initiation rates and testing uptake rates 
The results indicate that the involvement of unpaid informal health care providers in HIV 
community awareness, disease recognition, support in sputum collection and referral 
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significantly increased TB testing uptake rates. In addition, there was a non-significant 
increase in TB treatment initiation rates. Results from the first 12 months showed that the 
engagement of informal healthcare providers increased the number of presumptive TB cases 
accessing testing sites in the Early arm by 15% (p=0.003), but there was no difference between 
the intervention arms in the next 11 months when the intervention was rolled out to the 
Delayed arm (see Tables 24 & 30). Studies conducted within the region involving informal 
healthcare providers have shown similar results (Datiko and Lindtjorn, 2009; Simwaka et al., 
2012). In Ethiopia, the engagement of informal healthcare providers (called extension health 
workers) in the identification of presumptive TB cases, sputum collection and transportation 
to smear microscopy sites resulted in an increase in TB case detection by 122.2% in 
intervention areas compared to 69.4% in control areas (Datiko and Lindtjorn, 2009). In Malawi, 
the use of this type of provider (in this case storekeepers) in referring presumptive TB cases 
significantly increased the number of smear-positive TB case notifications in the intervention 
areas after one year of the intervention (0.6 per 1000 people in the control areas vs. 1.2 per 1000 
in the intervention areas) (Simwaka et al., 2012). 
On the other hand, TB treatment uptake rates in the Early arm increased by 18% after the first 
12 months, which was not significant (possibly because of inadequate statistical power) (see 
Table 6). At this effect size in low incidence disease conditions like TB, the simulation findings 
showed that achieving adequate power is a problem (see Table 6).         
In contrast, despite the significant increase in uptake rates of TB testing observed in the first 
12 months of the intervention, there was a significant reduction in the number of smear-
positive TB cases starting treatment in the Early arm compared to the Delayed arm (see Table 
22). These results are also consistent with the fact that many of the cases in Malawi are smear- 
negative because of the high HIV burden that increases the number of smear- negative TB 
patients (NAC, 2007 & 2010) 
In implementing Triage Plus, a number of activities were implemented by informal healthcare 
providers including patient referrals and sputum collection and delivery to the nearest testing 
sites, an intervention known to improve TB case detection rates (Xiong et al., 2007; Simwaka 
et al., 2012). Presumptive TB cases consequently were started on treatment, an intervention 
known to reduce TB incidence.  
However, it is not clear whether the observed significant reduction in smear- positive TB 
patients starting treatment in areas that received the intervention early could be attributed to 
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the reduction in infectious TB incidence in the study areas following the intervention.  Thus, 
there are two interpretations of the effect of engaging informal health care providers on smear- 
positive TB cases commencing treatment: 
First, engaging informal health care providers was not effective because there was a 
significant reduction in smear- positive TB treatment initiation rates following intervention. 
The number of smear-positive TB cases starting treatment in the Early arm in the first 12 
months was 28% less than those starting treatment in the Delayed arm (see Table 22).  
If this is the direction one would take, then one would argue that with chronic cough being a 
cardinal sign for TB, which was emphasised during community awareness interventions 
conducted by informal health care providers, meant that the intervention was to greatly affect 
individuals with pulmonary TB, convincing them to start TB treatment. Thus, the reductions 
in smear-positive TB cases as well as all types of TB cases starting treatment would suggest 
that the intervention was counterproductive: more individuals with TB did not access the TB 
services because of the TB and HIV integration (see Moller and Erstad, 2007). The TB and HIV 
integration might have led to increased stigmatisation because in some instances TB is usually 
equated with HIV (Skordis-Worrall, Hanson and Mills; 2010). At community level, TB and 
HIV sensitisation messages meant to address the two diseases were given as a package. The 
messages highlighted the association between TB and HIV with a view to promote testing and 
eventual treatment initiations for the two diseases.   This association has shown to be a major 
source for stigmatisation and affected timely presentation for TB treatment in high HIV 
prevalence areas (Moller and Erstad, 2007). In a community survey exploring attitudes to TB 
in South Africa showed that the majority of the respondents (89%) cited fear of learning one's 
HIV-positive at health clinics and the belief that almost all TB patients are HIV positive and 
that only people who are HIV positive get TB were found to be the most important barrier for 
timely TB case detection (Moller et al., 2011). 
Given that there were improved uptake rates of TB and HIV testing in the Early arm in the 
first 12 months suggests that the notion that TB and HIV integration might have led to other 
individuals seeking care from other sources because of their fear of an HIV positive result 
(Moller et al., 2011) or the stigma associated with HIV (Moller and Erstad, 2007) is not feasible 
in this case. If individuals were going elsewhere for testing, there should have been a 
corresponding significant reduction in the uptake rates of TB and HIV testing because these 
cases would be seeking care from alternative sources.  
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A second possible explanation was a falling TB incidence over the time period of the study.  
Community interventions using participatory approaches have led to major reductions in 
latent TB incidence rates within a few years (O’Donnell et al., 2012). O’Donnell and colleagues 
observed a sustained reduction in the incidence of latent TB infection among all racial groups 
in a community based participatory intervention. Incidence of latent TB infection reduced by 
50 % from the baseline levels over a 3 year period. Using active case finding strategies in high-
density residential suburbs in Harare, Corbett and colleagues (2010) observed a 40% reduction 
in smear- positive TB cases from the baseline at the end of 3 years. However, TB incidence in 
our study could only have been reduced as a consequence of the intervention in the Early arm 
if TB treatment initiation had been significantly increased. If TB incidence was already falling 
in both the Early and Delayed arms as a result of background effectiveness of the TB 
programme, then the intervention should still have resulted in a detectable increase in TB 
treatment initiation. 
Overall, therefore, the most likely explanation relates to the extent to which TB testing and 
HIV testing are available in the rural areas.  HIV testing was available at 20 sites in the Early 
intervention arm and 18 sites in the Delayed arm.  This compares with TB testing which was 
only available at 7 sites in the Early arm and 9 sites in the Delayed arm (see Figure 1).  Thus, 
a more likely explanation for the lack of increase in TB treatment initiation is that people in 
this poor, rural area will have used substantial resources (including for travel) to access the 
infrequently available TB testing sites (Kemp et al., 2007). Kemp and colleagues found that TB 
patients in peri-urban Lilongwe use between 2 and 5 times their monthly income in reaching 
a TB diagnosis and starting treatment. By contrast, patients accessing the more frequently and 
locally available HIV testing facilities will have used a smaller percentage of their available 
resources.  In support of this, work in Malawi suggests that patients accessing ART spend less 
than their monthly income in care-seeking (Namakhoma et al submitted). Furthermore, there 
is evidence that linkage between HIV testing and ART initiation is hindered when treatment 
initiation is less accessible (Mac Pherson et al, 2012). Overall, therefore, we hypothesise that 
people who have accessed TB testing will frequently have depleted their resources to the 
extent that going on to access TB treatment initiation will have been beyond their means.  By 
contrast, people who have accessed HIV testing will not have depleted their reserves to the 
same extent and will have found it easier to travel to, and access the HIV treatment initiation 
sites. Similar numbers of HIV and TB treatment initiation sites were available in both arms of 
the study: 3 and 2 respectively in the Early arm and 4 and 6 respectively in the Delayed arm. 
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Our findings reinforce recent policy recommendations on the integration of TB and HIV 
services in order to reduce the burden of TB and HIV in co-infected patients (WHO, 2004). 
Integration of TB and HIV services in health facilities has greatly improved treatment 
initiation and success rates (Hermans et al., 2012).  
 
7.5.3 Flexibility of the intervention 
To ensure the scalability of the intervention by the national programmes,   implementation of 
the intervention was flexible, in terms of types of informal health care providers engaged and 
as well as the nature of activities implemented by them. Implementing the intervention in 
such a way that it could be undertaken by national programmes enhances its chances of being 
adopted and scaled up nationally. The Triage Plus study used a variety of informal healthcare 
providers to implement the various components of the intervention, thereby enabling national 
programmes to use any of these informal health care providers in the national level 
programmes without restricting the program to a specific type of informal provider. In 
addition, by allowing the informal health care providers to implement specific intervention 
activities, which they were capable of doing or were currently doing as part of their existing 
community work, meant that concerns regarding the sustainability of the interventions would 
be minimised.  For instance, store keepers engaged in recognising and referring presumptive 
TB cases during their encounters with clients when buying medication are more likely to 
continue identification and referral even after the intervention study because of the 
knowledge gained through training.   
Follow up visits by the research team to check on the progress of informal health care 
providers participating in the intervention project was minimised to only two visits in each 
year to be consistent with the pragmatic nature of the intervention and to reflect what the 
study team thought would be sustainable in the long term. To reduce costs, supervisory visits 
were done only for providers where challenges were observed.   
However, the fact that several players are engaged in this intervention presents difficulties in 
isolating the effectiveness of the intervention: it is difficult to determine what is attributed to 
the specific activities implemented by the informal health care providers and other 
stakeholders sensitised in the intervention areas.  Thus, the effects of the different components 
of the intervention, such as community awareness meetings and support in sputum collection 
by informal health care providers on one hand, and engagement coupled with orientation of 
health surveillance assistants to support project implementation on the other, cannot be 
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isolated in terms of the effectiveness of the intervention, and this was not the intention of the 
project.  It is worth noting that it would be difficult practically in the long term to implement 
targeted interventions with only one type of informal care provider or one type of engagement 
(e.g. sputum submission without any additional raising of general awareness or training on 
infection control). Thus, the holistic approach adopted was realistic in real field conditions.    
7.6 Policy implications 
The findings from the Triage Plus study have several policy implications in improving TB and 
HIV services access and disease control. They are as follows:  
7.6.1 Policy implications on TB control 
The observed improvements in TB testing uptake rates due to engaging informal healthcare 
providers means that the scaling up of such interventions to many districts through national 
programmes would increase TB case detection and timely treatment initiation, thereby 
reducing transmissions in the general population, as most transmissions occur outside 
households (Verver et al., 2004).  
Furthermore, the rapid reduction of smear- positive TB cases initiating treatment due to the 
depletion of infectious cases in the community following the intervention, as shown elsewhere 
(Corbett et al., 2010), suggests that a decline in the rates of new TB infections can be achieved 
within a reasonable number of years if the intervention is successfully implemented in the 
general population nationally. 
7.6.2 Policy implications on HIV transmission prevention 
The fact that the intervention was able to improve ART and HIV services access in the general 
community within one year, suggests that by engaging informal health care providers in 
community interventions, national HIV programmes are able to reach even those who 
normally would have not accessed the services. The increase in number of people tested for 
HIV and in starting ART coupled with timely ART initiation means that HIV transmission 
rates can greatly be reduced over a shorter period of time because of the protective effect of 
the ART (Cohen et al., 2011).   
As more people accessed HIV testing following the community sensitisation meetings 
conducted by the informal healthcare providers as part of the intervention, the increase, in 
turn, leads to improved changes in risky behaviour,  thereby reducing HIV incidence in the 
general population (Bello et al., 2011; Hallet et al., 2006). This means scaling the intervention 
to other areas would result in a reduction in HIV transmission in the general population.  
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7.7 Conclusions 
In this section, conclusions regarding the simulation studies and the actual analysis of Triage 
Plus are given.  
Findings of the simulation studies 
1. The simulations show that there are many factors that need to be considered when 
designing and powering a cluster randomised trial where the outcome measure is a 
count of events: minimum detectable effect size, ICC - between cluster variability and 
within cluster correlation), incidence of outcome measure (this will be related to the 
unit length of time used for each observation point), and number of observation times 
for which data are collected.  These will primarily influence the optimal number of 
clusters needed, but prevalence or incidence will directly affect the size of each cluster 
(to ensure sufficient events per cluster). 
 
2. Previous recommendations may be overly pessimistic as to the minimum number of 
clusters needed, which could be as small as 3-4 per intervention group, provided the 
incidence of the outcome event is reasonably high and ICC is moderate. Adding more 
assessment times may compensate for a small incidence and/or limitation in the 
number of available clusters. 
 
3. Pairing clusters for randomisation will help to balance confounding factors, but will 
only be partially successful when the number of clusters available per group is small 
– for this reason, it may be optimal to use unconditional statistical methods that ignore 
the pairing structure with the inclusion of an adjustment to the effect size for all known 
confounding factors. This may be as good as or probably even better, in terms of 
statistical efficiency, than conditional analyses as there are more degrees of freedom 
available in the analysis. 
 
4. In complex study designs, sample size calculations cannot be computed using the 
existing formulae, and extended formulae may prove to be too complex to be of 
practical value.  It may be necessary to use simulation methods to overcome these 
issues.   
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5. In conclusion, cluster randomised trials with a count outcome measure ideally need a 
minimum of 3 clusters per group with at least 12measurement times for effect size of 
20% (or higher) in low incidence diseases with low ICCs. However, for high incidence 
outcomes, as few as 3 measurements times with 3 clusters per arm may be adequate 
to achieve statistical power of at least 80%. With moderate ICCs (in our case ICC of 
0.081), at least 9 clusters were needed to achieve adequate statistical power of 80% with 
an effect size of 20% and using 6 and 12 measurement time points respectively for high 
and low incidence disease conditions. For an effect size of 40%, at least 3 clusters per 
arm were needed to achieve adequate statistical power with 4 repeated measurement 
times in low incidence diseases and 3 measurement times for high incidence diseases. 
Thus, having more clusters is not necessarily that advantageous and adequate 
statistical power can still be obtained with fewer clusters per group provided the 
incidence of the outcome of interest is not too small, and it is possible to take multiple 
measurements (replicates) over time within each intervention phase  
 
Findings from the Triage Plus study 
 The Triage Plus intervention showed that the engagement of the informal health care 
providers at the community level in sputum collection, TB and HIV sensitisation and 
awareness campaigns was effective in improving  HIV services access rates (both 
testing uptake and treatment initiation) and TB testing uptake rates. But more clusters 
were needed to more accurately evaluate the impact of the intervention in improving 
TB treatment initiations.  
 Our conclusions on the effectiveness of engaging informal healthcare providers in TB 
and HIV services access are made more likely based on the following reasons: 
 First, because the data used for evaluation, which showed improvement in 
services access for HIV and TB testing, is facility based and followed 
standardised management guidelines for patients in testing for TB and HIV, 
but similar improvements were not seen in the Delayed arm in the first 12 
months. In addition, baseline ART treatment initiation rates and testing 
uptake rates, especially for presumptive TB cases, were similar between the 
intervention arms. 
 Second, the fact that TB testing uptake rates increased in areas that received 
the Early intervention and then were followed by a reduction in smear- 
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positive TB treatment initiation rates, a trend which was not seen in the 
Delayed intervention areas.   
 Assessment using both TB and HIV testing uptake rates and treatment initiation rates 
in our study provided a clearer measure of intervention effectiveness than could be 
obtained from treatment initiation rates alone. The use of TB testing uptake rates, for 
instance, allowed a better interpretation of the observed reductions in smear- positive 
TB initiating treatment, a finding that would be difficult to discern if treatment 
initiations rates were the sole outcome measure.  
 The intracluster correlation coefficients estimated after fitting the random intercepts 
models adjusting for all covariates obtained in the final analysis of the Triage Plus 
study were comparable to the ICCs used in the simulation studies presented in 
Chapter 5. However, the estimated ICC for HIV testing uptake was slightly higher 
than the ICC of 0.081 from the baseline data from the Triage Plus study. With the high 
effect size of 61% and the fact that the mean count for HIV testing uptake per month 
was high, the slightly higher ICC levels did not lead to reduced statistical power. This, 
therefore, suggests that the interpretation of the main outcome measures and the 
statistical power for the final analysis of the Triage Plus study data using the repeated 
monthly counts over the intervention period were not affected by changes in the ICCs 
for the main outcome measures.   
 We, therefore, finally conclude that an effective approach to TB and HIV control is to 
engage informal health care providers in order to reach those failing to access TB and 
HIV services due to a number of factors including poverty, poor TB and HIV 
knowledge, geographical barriers and perceived attitudes towards disease prevention 
and control. 
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7.8 Future work 
7.8.1 Introduction 
Although the Triage Plus study data were monthly counts measured over the duration of the 
intervention and therefore Poisson models presented in 4.2.3 were the ideal models. However, 
an alternative approach for assessing the effectiveness of the intervention would have been to 
conduct multiple household surveys to obtain data required for the evaluation of the Triage 
Plus. In this way, individuals would be interviewed to assess if they have had an outcome of 
interest in a specified time period (e.g. access to ART or TB treatment). These surveys, 
therefore would generate binomial data. Section 7.8.2 briefly presents the log-binomial 
regression methods to model of such data using the same notations used in Poisson model 
formulations (where 𝑖 indexes repeated measurements in a cluster 𝑗) presented in Chapter 4. 
 
In addition to the likelihood based estimation approaches using numerical integration 
presented in section 4.3, Bayesian estimation methods presented in section 7.8.3 can be used 
to estimate the generalised linear mixed models presented in Chapters 4-6. They are presented 
here as an alternative approach to the analysis of the Triage Plus study.  
 
7.8.2 Hierarchical model for binomial data 
 
The log-binomial random intercepts model 
Given𝑦𝑖𝑗   is the observed number of events (e.g. TB treatment initiations) out of the 𝑛𝑖𝑗 
(subjects in cluster 𝑗 and time point 𝑖); 𝑝𝑖𝑗  are the true probabilities of success at repeated 
measurement time point 𝑖  in cluster 𝑗, 𝑥𝑖𝑗 is a vector of explanatory variables including the 
intervention status variable, 𝛽  is a vector of regression coefficients, and 𝑢𝑗  is the random 
intercept for cluster 𝑗; then the random intercepts log-binomial model for clustered data is 
defined as  (Thompson, Warner and Turner, 2004, p393) 
 
𝑦𝑖𝑗|𝑥𝑖𝑗, 𝑢𝑗~𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑛𝑖𝑗, 𝑝𝑖𝑗) 





The random effects 𝑢𝑗 at time 𝑖 for cluster 𝑗are random intercepts and follow the truncated 
half-Normal distribution, with mean zero and variance 𝜎2 (Turner, Omar and Thompson, 
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2001), in order to be consistent with the probability laws of within [0, 1) for model 
convergence.  
 
The parameter space is defined as  
{
𝛽𝑥𝑖𝑗 ≤ 0 
𝛽𝑥𝑖𝑗 + 𝑢𝑗 ≤ 0 
                               (7.2) 
where 𝑢𝑗 is the cluster level random effect, assumed to be independent, and follows a Normal 
distribution with mean zero and variance 𝜎2 (variance of cluster-specific probabilities). 
 
Since the random effect 𝑢𝑗 is drawn from a Normal distribution with mean zero and variance 
𝜎2, it can take any value in the range (−∞, ∞). Thus, it is symmetrically distributed around a 
defined point. To ensure that the probability 𝑝 is within [0, 1), two approaches are possible.  
 
First, the log-binomial method may be used, and if convergence is not achieved, the COPY 
Method as described in section 3.6.2.3 in Chapter 3 can be employed when using likelihood 
based estimation approaches.  
 
Second, the Bayesian analysis approach may be used, where 𝑢𝑗   is confined to the interval 
(𝛽𝑥𝑖𝑗  ≤ 𝑢𝑗 ≤ −(𝛽𝑥𝑖𝑗))  as suggested by Thompson, Warn and Turner (2004), so that the 
parameter space can be defined as  
 
{
𝛽𝑥𝑖𝑗  ≤ 0
𝛽𝑥𝑖𝑗  ≤ 𝑢𝑗 ≤ −(𝛽𝑥𝑖𝑗)





Using the notation in model (4.13) for the random intercepts variance parameters, the extent 











2  is the between cluster variance and 𝜋2/3 is the residual variance on logit scale 
within clusters (Nakagawa and Schielzeth, 2010). 
 
The log-binomial random coefficients model 
To investigate whether the effect of the intervention varies across clusters over the duration 
of the intervention, random coefficients log-binomial model is fitted by including a random 
coefficients as follows:  
 
𝑦𝑖𝑗|𝑥𝑖𝑗, 𝑢𝑗, 𝑢𝑖𝑗~𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙 (𝑛𝑖𝑗, 𝑝𝑖𝑗)    
 
log(𝑝𝑖𝑗) =  𝛽𝑥𝑖𝑗 + 𝑢𝑖𝑗 + 𝑢𝑗𝑥𝑖𝑗 < 0 (7.5) 
 
and the parameters’ space defined in (7.2) becomes  
 
{
𝛽𝑥𝑖𝑗 ≤ 0 
𝛽𝑥𝑖𝑗 + 𝑢𝑗𝑥𝑖𝑗 ≤ 0 
                                          (7.6) 











2  and 𝜎22
2  as variances for random intercepts and random coefficients respectively, 𝜎21
2  
and 𝜎12
2  are the covariances between the random intercepts and random coefficients. 
 
In a two arm intervention study like the Triage Plus, the random intercepts uij represents 
between-cluster variability in control areas, and the random intercepts plus random 
coefficients effects (uij + uj) represent between-cluster variability in intervention areas. They 
respectively, therefore, represent deviations of a specified cluster from the mean intercept and 
the average slope for the intervention variable coefficient in all the scenarios discussed.    
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7.8.3 Bayesian estimation of incidence rate ratios 
7.8.3.1 Introduction: 
Bayesian methods were introduced by the Reverend Thomas Bayes (1702-1761), and Bayesian 
estimation, first used by La Place in 1786, is increasingly used in the analysis of different 
models because of its distinctive advantages.  Bayesian approaches are currently growing in 
popularity for the following reasons: 
 Uncertainty in variance components is easily accounted for, and the use of prior 
information in the parameter estimation process is allowed (Spiegelhalter, 2001; 
Turner, Omar & Thompson, 2001).  
 Flexibility in estimating prevalence ratios or risk ratios when log-binomial models are 
used, and the adjustment of the domain of parameter estimation is only required to 
ensure non permissible probabilities greater than 1 do not occur (Thompson, Warner 
and Turner, 2004). In addition, they are flexible in modelling individual or cluster level 
covariates and variance structure as pointed out by Thompson, Warner and Turner, 
(2004).  
 Marginal likelihood obtained by integrating out random effects is generally 
intractable, but it is easily implemented using Bayesian estimation methods such as 
the Markov chain Monte Carlo methods (MCMC) (see Zhao et al., 2006).  
 
7.8.3.2 The Bayesian paradigm 
Given 𝑦𝑖𝑗 are the observed data at measurement time 𝑖 and in cluster 𝑗, θ are the parameters 
of the probability model, and the prior probability is denoted by 𝜋 (θ). The posterior 
distribution in Bayesian analysis is given by   
𝑝(𝜃|𝑦𝑖𝑗) =  
𝑝(𝑦𝑖𝑗|𝜃)𝜋(𝜃)
𝑝(𝑦𝑖𝑗)
                     (7.7) 
where 
𝑝(𝑦𝑖𝑗) = 𝑝(𝑦𝑖𝑗|𝜃)𝜋(𝜃)𝑑𝜃  is the normalising constant of 𝜋(𝜃) which iscalled the‘marginal 
distribution’; 𝑝(𝑦𝑖𝑗|𝜃)is the likelihood function of θ (the probability of observing the data 
𝑦𝑖𝑗given the model with parameter θ). In this case the posterior distribution 𝑝(𝜃|𝑦𝑖𝑗)provides 
the parameter estimates of interest (e.g. regression coefficients of covariates).  
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Thus, in a Bayesian framework, the key elements are the likelihood function 𝑝(𝑦𝑖𝑗|𝜃) and the 
prior distribution 𝜋(𝜃). The likelihood function reflects information about the parameters 
contained in the data while the prior distribution quantifies what is known about the 
parameters before observing the data. Therefore, the larger the values of the likelihood, the 
more the parameters are supported by the data (Glickman and Dyk, 2007). 
7.8.3.3 Computation of posterior distributions 
In regards to more general problems, the joint posterior distribution 𝑝(𝜃|𝑦𝑖𝑗) in (7.7) is usually 
complex, high dimensional (or not available in closed form) and posterior quantities cannot 
be obtained analytically.  Therefore, numerical integration techniques using Markov chain 
simulations are widely used to obtain reliable posterior estimates. A discussion of the major 
methods for approximating integrals, with special emphasis on Bayesian integration 
problems, is provided by Evans and Swartz (1995).  
Among the Markov chain techniques, the Markov chain Monte Carlo (MCMC), first proposed 
by (Metropolis et al., 1953), is among the best known simulation techniques that have been 
used in numerical integration. Of the MCMC techniques, the Metropolis-Hastings algorithm 
(M-H) (Metropolis et al., 1953, Hastings, 1970)and the Gibbs sampler (Geman and Geman, 
1984; Gelfand and Smith, 1990)are the widely used MCMC methods. The development of 
modern statistical software, including WinBugs (Lunn et al., 2000), made the computation of 
complex models using MCMC simulation methods very easy. Below is a brief description of 
the common MCMC methods used in the simulation of posterior distributions.   
Metropolis-Hastings algorithm 
The Metropolis-Hastings (M-H) algorithm, named after Nicholas Metropolis and W. Keith 
Hastings, is a Markov chain Monte Carlo method that generates observations from a posterior 
distribution without computing the normalisation factor, which is a major aspect of the 
algorithm (Metropolis et al., 1953; Hastings, 1970).  
The algorithm starts with the objective distribution (𝜃(1), … . , 𝜃(𝑖−1))  in order to generate 
observations from a proposed distribution 𝑞(𝜃, 𝜃(𝑖−1)) that depends on the current state to 
generate the new proposed sample.   If a sample of size 𝑛 with a posterior distribution𝑝(𝜃|𝑦𝑖𝑗), 
and 𝜃𝑖, a vector of generated values in 𝑖 iterations is to be generated, then the algorithm is 
summarised as follows:  
1. Set initial values 𝜃(0) 
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2. For 𝑖 = 1, … , 𝑛repeat the following steps 
a. Set 𝜃 =  𝜃(𝑖−1) 
b. Generate a new parameter value 𝜃′ from a proposal distribution 𝑞(𝜃′, 𝜃) 
 
c. This generated value is accepted with acceptance rate 
 


















d. Obtain the new value 𝜃𝑡 =  𝜃′   with probability ℎ  ; otherwise set  𝜃𝑖 = 𝜃  with 





 represents the likelihood ratio between the proposed new value 𝜃′ and the 
previous value 𝜃 ;  
𝑞(𝜃|𝜃′)
𝑞(𝜃′|𝜃)
 is the ratio of the proposed density function for 𝜃′  given the 
previous value 𝜃. The superscript 𝑖 denotes the iterations. The desired acceptance rate ℎ (the 
fraction of the proposed samples accepted among the previous samples) depends on the target 
distribution for efficient estimation. The algorithm requires starting values 𝜃(0)  to start 
simulations. The choice of starting values affects the rate of convergence if the value chosen is 
outside the range covered by the posterior distributions (Lunn et al., 2000).   
The Gibbs sampling 
The Gibbs sampling algorithm, first introduced by Geman and Geman (1984), is a special case 
of the Metropolis-Hastings algorithm which generates a Markov chain by sampling from 
posterior distributions that condition upon all other model parameters and the data (full 
conditional distributions) with 100% acceptance rate. With the development of adaptive 
rejection sampling (Gilks and Wild, 1992), the Gibbs sampling algorithm efficiently samples 
from any conditional distribution with log concave density functions (e.g. the log-binomial 
and Poisson models, and most common priors and likelihood functions).  
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Given that there are three regression coefficients 𝛽0,𝛽1and 𝛽2 for a vector of 
explanatoryvariables 𝑥𝑖𝑗that are to be estimated using Gibbs sampling, then the following 
steps are used: 







2) Generate a new value 𝛽0
(𝑖)
for 𝛽0 from its posterior distribution conditioning on the 
data 𝑦𝑖𝑗 and the current values for 𝛽1 and 𝛽2. 
3) Generate a new value 𝛽1
(𝑖)
for 𝛽1  from its posterior distribution conditioning on the 
data 𝑦𝑖𝑗 and the current values for 𝛽0 and 𝛽2. 
4) Generate a new value 𝛽2
(𝑖)
for 𝛽2 from its posterior distribution conditioning on the 
data 𝑦𝑖𝑗 and the current values for 𝛽0 and 𝛽1. 
5) Repeat steps 1- 4 several times while increasing 𝑖 by 1 each time until convergence is 
achieved. 
 
Although the development of adaptive rejection sampling to effectively sample from 
conditional distributions whose density functions are not log-concave (Gilks and Wild, 1992), 
routine use is limited. Therefore, Neal (2003) proposed a sampling technique called ‘slice 
sampling’ that is implemented for both univariate and multivariate distributions and can be 
used to sample from any continuous distribution.  
7.8.3.4 Diagnosing the convergence of posterior distributions 
Due to the iterative and Monte Carlo nature of the MCMC techniques, there is a need to assess 
the convergence of the MCMC methods. Procedures for diagnosing convergence in MCMC 
methods have been proposed (Brooks and Gelman, 1998). The main issues considered in 
MCMC methods include how quickly the simulated chains converge to a target posterior 
distribution (i.e. the required number of ‘burn-in’ iterations that are excluded before making 
necessary inferences) and how efficiently the posterior quantities are estimated from the 
sample chains.   
Built-in statistical and graphical tools can be used for checking convergence (Brooks and 
Gelman, 1998). Convergence can also be ascertained by monitoring the Monte Carlo errors for 
estimates with small values of this error, indicating the parameter estimate of interest is 
estimated with precision (Ntzoufras, 2009).  
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When convergence is achieved, plots of samples of parameters show a random scatter around 
a stable mean value in no specific pattern, and there is much overlap of the trace plots chains, 
which indicate independence in the samples (as an example see Figure 15 showing 
convergence after 10,000 iterations with 1000 iterations as 'burn-in' for the coefficient for the 
intervention variable measuring effect size using TB treatment initiations data from the Triage 
plus study.  The two chains show overlapping patterns indicating convergence is achieved). 
However, if the samples are not largely independent, then there may be autocorrelation 
between samples, which can be addressed by generating additional samples (Spiegelhalter et 
al., 2003). More iterations should be made after convergence to obtain posterior inference after 
discarding the burn-in iterations. To reduce burn-in period, different starting values for model 











Figure 15: History plots for the converged chains. 
The history plots for the coefficient for the intervention variable measuring effect size using TB 
treatment initiations data from the Triage plus study.  The two chains show overlapping patterns 
indicating convergence is achieved. 
 
The Monte Carlo standard error (MC error), an estimate of the difference between the mean 
of sampled values and the true posterior mean of a parameter,  is used to evaluate the 
efficiency of the MCMC methods (MC error measures the extent simulation error contributes 
to uncertainty in mean estimation) and is usually reduced by generating more samples. The 
efficiency of the posterior estimates is guaranteed if the MC error is less than 5% of the 
posterior standard deviation of the parameter estimate (Spiegelhalter et al., 2003).  
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7.8.3.5 Prior distributions 
To carry out Bayesian analysis, prior distributions of the model parameters need to be 
specified. Best knowledge about the parameters is used to make a selection; otherwise, non-
informative priors are usually adopted. The correct choice of the priors can be ascertained 
easily if the posterior distributions are relatively stable (see Figure 16), an indication that the 
data contains sufficient information. When the correct prior for the model and inference has 
been correctly determined, it can then be used to carry out analysis for the model and 
inference.   
Different priors are available and have been used in the literature for Bayesian analysis. The 
choice of priors might be guided by two approaches.  Firstly, ‘informative priors’ are selected 
based on a strong prior belief regarding the distribution of the parameters of interest in which 
subjective prior information is available. Informative priors tend to show impact on the 
posterior distributions and are dominated by the likelihood. Secondly, when no prior belief is 
available, objective priors are used and analysis is conducted without the influence of prior 
information (Spiegelhalter, 2001; Turner, Omar and Thompson, 2001).   
 
alpha.Treat chains 1:2 sample: 34002
-2.0E+3 -1.0E+3     0.0 1.00E+3





Figure 16: Density plot for the posterior distribution for the coefficient of the intervention using TB 
treatment initiations data from the Triage plus study. The x-axis is the log of the coefficient of variable 
treat (i.e. log of incidence rate ratio for variable treat) and the y-axis is the posterior density of the log of 
the coefficient of variable treat. 
 
Prior assumptions 
In the Bayesian paradigm, model formulation is complete when priors for model parameters 
are specified, which accounts for all available knowledge about the parameters. In the random 
effects models considered here, the prior distributions will often depend on higher level 
Log of β 
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parameters called ‘hyperparameters’, in which case additional hyper priors have to be 
specified.   
Prior distributions of fixed effects parameters 
Guided by the need for priors to have minimal impact on the posterior distribution and due 
to the lack of previous knowledge on the size of intervention effects (in our case effect in 
regards to engaging informal health care providers), prior distribution for fixed effects vector 
𝛽 takes the form 
𝛽~ 𝑁(0, 𝐷(𝜃)) 
for some covariance matrix 𝐹 as given by Zhao et al. (2006).  By making the covariance matrix 
𝐷(𝜃)  diagonal with large variance of 100,000 coupled with appropriate choices of variance 
components, a proper joint posterior distribution of parameters can be achieved (Zhao et al., 
2006).  The commonly used prior distributions for analysis of fixed effects parameters are 
𝛽~ 𝑁(0, 100000). For Bayesian analysis the precision is expressed as an inverse of the variance 
and therefore the fixed effects parameters are instead expressed as  𝛽~ 𝑁(0, 0.00001). 
Prior distributions for variance parameters: 
Inverse-gamma  
The common prior density for variance parameters often used in generalised linear mixed 
models for random effects precision is the inverse-gamma (0.001, 0.001)  proper prior 
distribution (Spiegelhalter et al., 2003) for single variance components and the inverse Wishart 
distribution for a variance-covariance matrix because of the conjugacy properties with the 
Normal distribution for random effects (Zhao et al., 2006).  
Uniform prior 
When prior information is not available or cannot subjectively be specified for model 
parameters, uniform priors, also known as ‘flat priors’, are the common choice for non-
informative priors. Generally, relatively uniform proper prior distributions that integrates to 
1, (for binomial distributions, the uniform prior is given as 𝜋 (𝑝) = 1) are desired. Among the 
set of relatively flat distributions, the choice of prior makes no difference if the data contains 
adequate information about the parameters of interest (Glickman ME, and Dyk DA, 2007).  
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The uniform prior, with large standard deviation and 0 lower bound (i.e. U(0,1000), has been 
suggested in the literature as the prior for random effects variance parameters (Gelman, 2006). 
According to Gelman (2006), the uniform (0, ∞) prior usually yields limiting proper posterior 
distributions. However, it leads to a heavy-tailed posterior distribution that result in 
overestimating 𝜎, especially in small numbers of clusters (Gelman, 2006). This results in less 
than optimal shrinkage for estimating group level random effects (Gelman, 2006).   
Posterior quantities: 
In Bayesian model estimation, posterior mean or median and the variance of the estimated 
posterior means for the model parameters are the primary quantities of interest. The median 
has been preferred at times because of its stability (Thompson, Warn and Tanner, 2004).  
Given 𝐺(𝜃) is a function of a parameter of interest 𝜃 estimated after generating a sample size 
(iterations) 𝑖 iterations, the maximum number of iterations excluding burn-in iterations, the 
posterior mean of the estimate is given by 






                               (7.8) 








              (7.9) 
The MC error is given as a measure of the efficiency of posterior estimation. Hence, to calculate 
the parameter of interest with increased precision, the MC error has to be low as it measures 
the variability of the estimate due to the simulation process and is achieved by having a 
sufficient number of iterations. To estimate the MC error, two methods have commonly been 
used: the batch mean method and the window estimator method.   Although the window 
estimator method is more precise, the batch mean method is more popular and easier to 






In Bayesian analysis, credible intervals and the highest posterior density (HPD) are derived 
as part of the posterior quantities (Ntzoufras, 2009). The credible interval estimates are 
derived as the interval of the ordered sample as follows: 
Given an MCMC sample{𝜃𝑖, 𝑖 = 1,2, … . 𝑛},   
i. Obtain the ordered values of  𝜃(1) ≤ 𝜃(2) ≤ ⋯ ≤ 𝜃(𝑛) by sorting{𝜃𝑖, 𝑖 = 1,2, … . 𝑛}. 
ii. Compute the 100(1-α)% credible intervals for each of the MCMC sample. 
iii. The smallest interval of the credible intervals in (ii) is the 100(1-α)% highest posterior 
density (HPD) interval given the same density for the two boundaries of unimodal 
distributions.  
7.8.3.6 Bayesian model selection 
Just as in the likelihood based approaches, identifying an appropriate model that fits the given 
data may be challenging. This is especially true when there is a given set of potential statistical 
models that can be used for the given data. In Bayesian analysis, approaches such as the 
Akaike Information Criterion (AIC) (Akaike, 1981), Bayesian Information Criterion (BIC) 
(Schwarz, 1978), Deviance Information Criterion (DIC) (Spiegelhalter et al., 2002) and Bayes 
Factor (Kass and Raftery, 1995) have been used in determining the best model. However, 
when none of the models show clear superiority, Bayesian model averaging (Hoeting et al. 
1999) may be used to find the appropriate model. A brief description of the model selection 
methods is given.  
7.8.3.6.1   Model selection with Bayes factors   
Bayes factors have dominated the model selection process because not only are they easy to 
calculate and do not require models to be nested, but also because they enable external 
information to be incorporated when assessing a hypothesis. Kass and Raftery, (1995) provide 
a detailed review of the Bayes factors and other model selection approaches.   
Definition of a Bayes factor:  
Given two models, M0 and M1, arising from data 𝑦𝑖𝑗 , with probability densities (marginal 
likelihood) p(𝑦𝑖𝑗|M0) and p(𝑦𝑖𝑗|M1) respectively, and assuming posterior probabilities for 
models M0 and M1 are p(M0|𝑦𝑖𝑗 ) and p(M1|𝑦𝑖𝑗 ) respectively, the model that maximises 
p(Mk|yij) is normally chosen (where k=0,1) according to Wasserman (2000).  
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Given prior probabilities being p(M0) and p(M1) for model M0 and M1 respectively, then 
according to Bayes’ theorem as presented in Kass and Raftery (1995 page 776), the posterior 
probabilities are obtained as: 
𝑝(𝑀1|𝑦𝑖𝑗) =  
𝑝(𝑦𝑖𝑗|𝑀1)𝑝(𝑀1)
𝑝(𝑦𝑖𝑗|𝑀0)𝑝(𝑀0) + 𝑝(𝑦𝑖𝑗|𝑀1)𝑝(𝑀1)
,               (7.10) 






                                                      (7.11)    
 










                 (7.12) 
The Bayes factor is, therefore, the posterior odds in favour of M1 divided by the prior odds in 
favour of M0, and it measures the relative agreement of the data for the two models being 
compared (M1 versus M0) over the parameter space and summarises the evidence in support 
of M1 against M0 provided by the data (Raftery, 1996). If the prior odds for the two models are 
equal, which is usually the case, then the posterior odds of the two models is equal to the 
Bayes factor (Wasserman, 2000), in which case p(M1) = p(M0)=0.5 and p(M1) + p(M0)=1.  
Given the marginal likelihood of data 𝑦𝑖𝑗  for model 𝑀𝑘  as 𝑝(𝑦𝑖𝑗|𝑀𝑘), which is obtained by 
integration (Kass and Raftery, 1995) as shown by:  
𝑝(𝑦𝑖𝑗|𝑀𝑘) =  ∫ 𝑝(𝑦𝑖𝑗|𝜃𝑘, 𝑀𝑘)𝑝(𝜃𝑘|𝑀𝑘) 𝑑𝜃𝑘             (7.13) 
where 𝜃𝑘 is the parameter to be estimated under model 𝑀𝑘 for 𝑘 = 0 and 1, 𝑝(𝜃𝑘|𝑀𝑘) is a prior 
distribution for 𝜃𝑘 under 𝑀𝑘 and 𝑝(𝑦𝑖𝑗|𝜃𝑘 , 𝑀𝑘) is the likelihood function for 𝜃𝑘 .  
Then the Bayes factor, BF, can be rewritten as the ratio of the marginal probabilities of 𝑀1 and 
𝑀0 as: 
𝐵𝐹10 =  
𝑝(𝑀1|𝑦𝑖𝑗)
𝑝(𝑀0|𝑦𝑖𝑗)







∫ 𝑝(𝑦𝑖𝑗|𝜃1, 𝑀1)𝑝(𝜃1|𝑀1) 𝑑𝜃1
∫ 𝑝(𝑦𝑖𝑗|𝜃0, 𝑀0)𝑝(𝜃0|𝑀0) 𝑑𝜃0
                  (7.14) 
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However, when more than two models are under consideration, according to Raftery (1996 
page 253), then each model M1, .. Mk is compared against model M0 in turn, yielding 
corresponding Bayes factors BF10, .. BFk0. Using the notation by Raftery (1996 page 253), the 
posterior probability that Mk is true and takes into account model uncertainty is given by 





                            (7.15) 
with  𝛼𝑘 = 𝑝(𝑀𝑘)/𝑝(𝑀0) being the prior odds for Mk against M0, and with equal prior odds 
assumed therefore𝛼𝑘 = 1.  
For the purposes of model selection, if 2𝑙𝑛(𝐵𝐹10 ) >5, then 𝑀1  is substantially in better 
agreement with the data (Kass and Raftery, 1995).  
The integration of the posterior normalising constant  𝑝(𝑦𝑖𝑗|𝜃𝑘 , 𝑀𝑘)𝑝(𝜃𝑘|𝑀𝑘)  requires a 
numerical evaluation that is difficult for models with high-dimensional parameters and the 
fact that the estimates of the marginal densities from the MCMC samples may be unstable 
(Albert and Chib 1993 cited by Carlin and Chib, 1995). However, according to Diciccio et al 
(1997), by combining simulation and asymptotic approximations, simulated versions of 
methods such as Laplace, Bartlett correction or importance sampling can be used to calculate 
Bayes factors efficiently, provided the posterior distribution has a single dominant mode and 
direct calculation of the posterior normalising constant is avoided.  
Calculation of Bayes Factors 
Given that there are two models 𝑀1 and 𝑀0, to be compared and recall that the normalising 
constant 𝑝(𝑦𝑖𝑗1)  for model M1 is given as 𝑝(𝑦𝑖𝑗1) = 𝑓1(𝑦𝑖𝑗) =   ∫ ℎ (𝜃|𝑦𝑖𝑗1) 𝑑𝜃 , where 
ℎ(𝜃|𝑦𝑖𝑗) = 𝑝(𝑦𝑖𝑗|𝜃)𝜋(𝜃) with parameter 𝜃 ∈  Ω, the Ω  denotes the parameter space for 𝜃 . 
Another constant is 𝑝(𝑦𝑖𝑗0) =  𝑓0(𝑦𝑖𝑗) =   ∫ 𝑞 (𝜃|𝑦𝑖𝑗 0) 𝑑𝜃, with 𝑦𝑖𝑗0 being part of 𝑦𝑖𝑗 , 𝜃 ∈  Ω0. 
The subscripts 1 and 0 stand for model M1 and model M0.The Bayes factor in support of M1 
against M0 is given as the ratio of the constants:  






]                     (7.16) 
where 𝐸0isthe expectation with respect to the posterior distribution of model 𝑀0. To estimate 
the Bayes factor using importance sampling, suppose {𝜃(𝑖), 𝑖 = 1, … , 𝑛} is a random sample 
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drawn from a simulated distribution G with a probability density 𝑞, then the importance 
sampling estimate of the Bayes factor BF10 is given by 









                       (7.17) 
When density 𝑞 is properly chosen such that it is similar to h in order to reduce the ratio 
ℎ(𝜃𝑖|𝑦𝑖𝑗1/𝑞(𝜃
𝑖|𝑦𝑖𝑗0), the 𝐵?̂?10 is an unbiased and consistent estimator of 𝐵𝐹10.  
By using the sampling-importance sampling algorithm, the posterior sample from the 
posterior distribution for model M1 may be obtained as follows. A new sample with 
probability proportional to the ratio ℎ(𝜃𝑖|𝑦𝑖𝑗1/𝑞(𝜃
𝑖|𝑦𝑖𝑗0) should be drawn from a simulated 
sample 𝜃𝑖 so that it is approximately distributed according to the model M1 posterior (Albert, 
1996). 
To avert problems in computing integrals for the Bayes factors, Carlin and Chib (1995) 
proposed the inclusion of model M in the sampling process to obtain a sample from the 
marginal posterior distribution for M and regard the prior distributions 𝑝(𝜃𝑘), 𝑘 = 1, … 𝐾,  as 
part of model specification. Given model 𝑀𝑘  with a likelihood  𝑝(𝑦𝑖𝑗|𝜃𝑘, 𝑀𝑘)  and a 
prior𝑝(𝜃𝑘|𝑀𝑘) and data 𝑦𝑖𝑗 with 𝜃𝑘′𝑠 conditionally independent given the model M, Carlin 
and Chib (1995) completed the model specification by choosing ‘pseudopriors’ 𝑝(𝜃𝑘|𝑀 ≠ 𝑘) 
such that: 
𝑝(𝑦𝑖𝑗|𝑀𝑘) =  ∫ 𝑝(𝑦𝑖𝑗|𝜃, 𝑀𝑘)𝑝(𝜃|𝑀𝑘)𝑑𝜃 = ∫ 𝑝(𝑦|𝜃𝑘,𝑀𝑘)𝑝(𝜃𝑘|𝑀𝑘)𝑑𝜃𝑘 ,      (7.18) 
 
from the conditional independence assumptions. According to Carlin and Chib (1995), the 
joint distribution of 𝑦𝑖𝑗 and 𝜃 when 𝑀 = 𝑘 given the model prior probability 𝑝(𝑀𝑘 ) is  
𝑝(𝑦𝑖𝑗 , 𝜃, 𝑀𝑘) =  𝑝(𝑦𝑖𝑗|𝜃𝑘 , 𝑀 = 𝑘) {∏ 𝑝(𝜃𝑘|𝑀𝑘)
𝐾
𝑘=1
} 𝑝(𝑀𝑘 ) .               (7.19) 
 
and the full conditional distributions for each 𝜃𝑘is given as 
𝑝(𝜃𝑘|𝜃, 𝑀, 𝑦𝑖𝑗) ∝  {
𝑝(𝑦𝑖𝑗|𝜃𝑘 , 𝑀 = 𝑘)𝑝(𝜃𝑘|𝑀 = 𝑘),                𝑀 = 𝑘,
𝑝(𝜃𝑘|𝑀 ≠ 𝑘),                                        𝑀 ≠ 𝑘,
        (7.20) 
212 
where k denotes the candidate models. In this specification, M=k then the Gibbs sampler 
generates the usual full conditional distributions for the model k. However, if the 𝑀 ≠ 𝑘  
Carlin and Chib (1995) proposed to generate from the linking density he called 
pseudopriors.Using the MCMC methods, the routine generation of model M is given by 
𝑝(𝑀 = 𝑘|𝜃, 𝑦𝑖𝑗) =  
𝑝(𝑦𝑖𝑗|𝜃𝑘 , 𝑀 = 𝑘){∏ 𝑝(𝜃𝑘|𝑀 = 𝑘)
𝐾
𝑘=1 }𝑝(𝑀𝑘 ),
∑ 𝑝(𝑦𝑖𝑗|𝜃𝑘, 𝑀 = 𝑘)
𝐾
𝑘=1 {∏ 𝑝(𝜃𝑘|𝑀 = 𝑘)
𝐾
𝑘=1 }𝑝(𝑀𝑘 )
     (7.21) 
The MCMC algorithm will produce samples from correct posterior distributions because all 
the full conditional distributions are well defined.  According to Carlin and Chib (1995), the 
ratio ?̂?(𝑀 = 𝑘|𝑦𝑖𝑗) provides a ratio that could be used to estimate Bayes factor between any 
two models.  
However, if there is an extreme imbalance in one of the 𝑝(𝑀 = 𝑘|𝑦𝑖𝑗),  then the model 
probability 𝑝(𝑀𝑘 ) is adjusted before retaining samples for estimation of Bayes factors (Carlin 
and Chib, 1995).  Corresponding standard errors are obtained from the MCMC outputs, and 
it is assumed independent samples and batching techniques can be used in cases of 
autocorrelation (Carlin and Chib, 1995, p 478). 
7.8.3.6.2 Deviance Information Criterion  
The Deviance Information Criterion (DIC) proposed by Spiegelhalter et al. (2002) is a 
generalisation of the AIC that is used as a measure of model fit and complexity and as an 
approach for model selection. Classical deviance for model assessment is based on the 
difference in the log-likelihoods between the fitted and saturated model as defined in (4.31) 
for the likelihood ratio test. Using the Bayesian approach, the model in (4.32) is given as:  
𝐷(𝜃) =  −2 log (𝑝(𝑦𝑖𝑗|𝜃)) + 2 log(𝑝(𝑦𝑖𝑗|𝜃)        (7.22) 
where 𝐷(𝜃) is the Bayesian deviance, log (𝑝(𝑦𝑖𝑗|𝜃)) is the log likelihood for the saturated 
model,   log 𝑝(𝑦𝑖𝑗|𝜃) is the log likelihood for the fitted model. Using this specification, the L1 
and L0 in model (4.31) is represented by the log (𝑝(𝑦𝑖𝑗|𝜃))  and log 𝑝(𝑦𝑖𝑗|𝜃) respectively.  
The DIC as a model selection criterion was based on the posterior distribution of the Bayesian 
deviance and is given as: 
DIC = ?̂? + PD             (7.23) 
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where 
?̂? = 𝐸[𝐷(𝜃)]  is the Bayesian measure of goodness of model fit; 
PD is the effective number of parameters that measures the complexity of the model and is 
defined as the difference between the posterior mean of the deviance and the deviance 
evaluated at the posterior mean 𝜃 of the posterior distribution as:  
𝑃𝐷 = ?̂? − 𝐷(𝜃) = 𝐸[𝐷(𝜃)] −  𝐷(𝐸(𝜃))                                        (7.24) 
Thus by rearranging (7.24) to ?̂? = 𝐷(𝜃) +  𝑃𝐷, gives  
   𝐷𝐼𝐶 = 𝐷(𝜃) + 2𝑃𝐷                             (7.25) 
The smaller the DIC for a given model, the better the model fits the data and the better the 
model will be for making predictions. More complex models fit the data better, and thus, have 
smaller values of ?̂?. Differences of DIC>10 are regarded as substantial and differences of DIC 
< 5 may be negligible (Best, Mason and Li, 2011).  
7.8.3.6.3 Bayesian model averaging (BMA) 
However, when none of the models show clear superiority, Bayesian model averaging 
(Hoeting et al., 1999) is superior to the single models in terms of its predictive performance. 
The predictions are a result of weighted single model predictions that provide posterior mean 
expectations (Hoeting et al., 1999) where model uncertainty is present.  
Given M={ 𝑀1, … , 𝑀𝑘 ) is a set of all models under consideration and 𝜃  representsthe 
parameters of interest (Hoeting, Raftery and Madigan, 2002; Hoeting et al. 1999) for data 𝑦𝑖𝑗, 
the Bayesian model averaging is given as 
𝑝(𝜃|𝑦𝑖𝑗) =  ∑ 𝑝(𝜃|𝑀𝑘 , 𝑦𝑖𝑗)𝑝(𝑀𝑘|𝑦𝑖𝑗)
𝐾
𝑘=1
       (7.26) 
that averages posterior model distributions under each model weighted by corresponding 
model probabilities to account for model uncertainty (Madigan and York, 1995; Hoeting et al., 
1999; Hoeting, Raftery and Madigan, 2002). While the posterior model probability for model 






               (7.27) 
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where 
𝑝(𝑦𝑖𝑗|𝑀𝑘) = ∫ 𝑝(𝑦𝑖𝑗|𝜃𝑘, 𝑀𝑘)𝑝( 𝜃𝑘|𝑀𝑘)𝑑𝜃𝑘 is the marginal likelihood for model 𝑀𝑘 , 
𝑝(𝑀𝑘)is the prior probability for model 𝑀𝑘. 
𝜃𝑘is a vector of parameters (Hoeting et. 1999).  
Therefore, the posterior mean and variance of 𝜃 given the data 𝑦𝑖𝑗(as described by Hoeting et 
al. 1999 page 383) is given by 
𝐸[𝜃|𝑦𝑖𝑗] =  ∑ 𝜃𝑘𝑝(𝑀𝑘|𝑦𝑖𝑗)
𝐾
𝑘=1
                  (7.28) 
and   






)              (7.29) 
 
 Implementing Bayesian Model Averaging  (BMA) 
However, because there may be a great number of candidate models, including the BMA, 
resulting from an increased number of covariates in (7.26), computation of posterior 
probabilities for each model might not be practical (Hoeting, Raftery and Madigan, 2002). 
Therefore, Markov chain Monte Carlo model composition proposed by Madigan and York 
(1995)is used to directly approximate the equation in(7.26)with considerable flexibility and 
provides improved predictive performance against any single best model.  
If M is a class of models under consideration, then in constructing a simulated Markov chain 
{M(i), i= 1,...,n} with a given state space and equilibrium distribution p(𝑀𝑘|𝑦𝑖𝑗) a sequence of 
model observations 𝑀𝑘 must be obtained. For any function g(𝑀𝑘), according to Madigan and 







             (7.30) 
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converges to give an estimate of E(g(M) as N→∞ (Smith and Roberts 1993 as cited by Hoeting, 
Raftery and Madigan, 2002). Madigan and York recommended setting g(M) = p(𝜃 |M, 𝑦𝑖𝑗) in 
order to compute equation in (7.26).  
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7.8.4 Future simulation work 
 
The simulation study findings reported in Chapter 5 showed that statistical efficiency and 
power varied in the different design conditions investigated including the 3 clusters per arm 
design. However, the simulations did not assess the potential impact on statistical power and 
the accuracy of the parameter / effect size estimates of varying the group level explanatory 
variables. The ICCs considered in this dissertation represented situations of low to high 
correlations between clusters. The simulation studies presented in Chapter 5 showed that the 
size of the intracluster correlation affected both statistical power and the accuracy of 
parameter estimates (see Tables 8 & 9) when intervention status was used as the only group 
level explanatory variable.  
Thus, future simulation studies are needed as a matter of priority to assess the effect of varying 
intracluster correlation and group level explanatory variables on statistical power and 
accuracy of parameter estimates.  Less urgently, but still importantly, further simulation 
studies are needed to more fully evaluate the optimum numbers clusters and repeated 




Appendix 8.1: A statement of declaration of the contributions made by me and other 
people in the whole study 
 
I write to declare that my key contributions in the whole study were contributing to refining 
the study conceptual framework of engaging informal healthcare providers in TB and HIV 
community interventions to improve TB and HIV service uptake rates as well as designing a 
proper cluster randomised trial with more than one cluster per arm (i.e. I changed the original 
study design of assigning one cluster per study arm to a design with multiple clusters). 
However, because the study was limited to one district due to cost and the administrative 
logistics of having the study done in multiple districts, only a small number of clusters could 
be defined in order to limit the possible contamination between study arms (in this case 3 
clusters per arm).  To ensure that adequate statistical power was achieved in the final analysis 
of the study given the limited number of clusters, I conducted simulation studies that 
informed the appropriate design conditions that were then pursued in the evaluation of the 
actual Triage Plus intervention. In addition, implementation of the study design, interventions 
and quality data management procedures was ensured in order to align to standard cluster 
randomised trials (e.g. blinding patient allocation to clusters) and this work was accepted for 
oral presentation at the 2013 Union Conference (see Appendix 8.7). 
 My supervisors namely Prof Bertel Squire, Dr Brian Faragher and Rachael Thomson from the 
Liverpool School of Tropical Medicine were key in the initial conceptualisation of the 
intervention as well as obtaining funding for the implementation of the study, whose final 
results forms part of this thesis. They provided technical support throughout the 
implementation of the Triage Plus study. The technical support included in the definition of 
the clusters and randomisation process, support in the definitions of the study objectives and 
outcome measures, presentation of the results as well as the structure of the thesis and 
continuously reviewing each stage of the thesis development until it was submitted. 
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Appendix 8.2: Data recording/collection forms 
 
Appendix 8.2.1: TB treatment registration form-sample 
 
Facility 
















Area 25 19/01/2012 12 2 79 Chitukula   Area 25 P New Negative        0 
Area 25 21/02/2012 22 2 20 Chimutu Kamlembo Area 25 P New Negative  24/04/2012     1 
Area 25 2/3/2012 25 1 56 Mtema Mzungu Ngoni P New Negative        0 
Area 25 2/3/2012 29 1 62 Chitukula   Area 25 P New Negative  16/05/2012     0 
Area 25 8/3/2012 30 2 27 Chitukula   Area 25 EP New Negative        0 
Area 25 9/3/2012 31 2 31 Kabudula Mngwangwa  Area 25 P New Negative        1 
Area 25 15/03/2012 33 2 75 Njewa Chikhuthe Area 25 P New Positive        0 
Area 25 16/03/2012 38 1 29 Mtema Mtsukwa Area 25 EP New Negative        0 
Bwaila 5/1/2012 14 2 19 Chimutu Mseche Chiwamba  EP New Negative        0 
Bwaila 6/1/2012 17 2 33 Kabudula Malovu Chizu EP New Negative        0 
Bwaila 9/1/2012 26 1 60 Mtema Chule Ngoni P New Negative        0 
Bwaila 9/1/2012 28 1 57 Kabudula Chiswentche Chikowa P New Negative  4/1/2012     0 
Bwaila 9/1/2012 46 2 46 Chadza Sanjiko Bwaila P New Negative  5/1/2012     1 
Bwaila 12/1/2012 60 1 45 Tsabango Chiuzira Bwaila P New Negative  10/1/2012     1 
Bwaila 17/01/2012 75 1 49 Chimutu Kaomba Area 18 P New Negative        1 
Bwaila 17/01/2012 78 2 26 Malili   Chitedze P New Negative        0 
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ART KS E e 
ART Starting 
Date 
 Kabudula 626 06.01.2009 F 25 Khongoni Kaluzi TI 3       01.02.2008 
Kabudula 627 06.01.2009 F 27 Kalolo Sani FT 3       06.01.2009 
Kabudula 628 06.01.2009 M 40 Kalolo Sani FT 3       06.01.2009 
Kabudula 629 13.01.2009 F 30 Kabudula Kawiya TI 4       18.04.2008 
Kabudula 630 13.01.2009 M 39 Kabudula   FT 3       13.01.2009 
Kabudula 631 13.01.2009 M 47 Khongoni Chilowa FT 3   Default 
01.06.200
9 13.01.2009 
Kabudula 632 13.01.2009 M 68 Khongoni Chilowa FT 3       13.01.2009 
Kabudula 633 13.01.2009 F 54 Kabudula Katutula FT 3       13.01.2009 
Kabudula 634 13.01.2009 F 33 Kabudula Kadala FT 3   Default 
30.08.200
9 13.01.2009 
Kabudula 635 13.01.2009 F 30 Khongoni Chimbayo FT 3     
01.12.200
9 13.01.2009 
Kabudula 636 13.01.2009 F 40 Kalolo Phandula FT 3   Transfer 
04.03.200
9 13.01.2009 
Kabudula 637 13.01.2009 F 33 Kabudula Lundu FT 3       13.01.2009 
Kabudula 638 13.01.2009 M 56 Kabudula Kambudzi FT 3       13.01.2009 
Kabudula 639 13.01.2009 F 54 Kabudula Kambudzi FT 3       13.01.2009 
Kabudula 640 13.01.2009 F 40 Khongoni   FT 3       13.01.2009 
Kabudula 641 14.01.2009 M 41 Kabudula Mavele FT 3   Transfer   14.01.2009 
Kabudula 642 20.01.2009 F 32 Kabudula Chipeni FT 3       20.01.2009 
Kabudula 643 20.01.2009 F 39 Kabudula Kadiya FT 4       20.01.2009 
Kabudula 644 20.01.2009 F 30 Khongoni Chizu FT 3       20.01.2009 
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Appendix 8.2.3: Presumptive TB testing registration form 
 
Facility 
Name Lab SN Date Sex Age Treatment Unit TA Village Sputum  
 Specimen 
results 
ABC 3 06.01.2009 F 36 ABC Njewa   New Negative 
ABC 7 09.01.2009 M 10 ABC     New Negative 
ABC 18 29.01.2009 M 39 Mtsiliza Clinic Njewa   New Negative 
ABC 38 17.02.2009 F 21 Mtsiliza Clinic Njewa Muzu New Negative 
ABC 39 17.02.2009 M 43 Mtsiliza Clinic Chimutu Salambula New Negative 
ABC 48 24.02.2009 F 69 Mtsiliza Clinic Njewa Lusi New Negative 
ABC 50 24.02.2009 F 23 Mtsiliza Clinic Njewa Nsanje New Negative 
ABC 55 05.03.2009 M 40 Mtsiliza Clinic Chitukula Chisusu New Negative 
ABC 61 16.03.2009 M 39 Mtsiliza Clinic Njewa Chilota New Negative 
ABC 63 19.03.2009 M 36 ABC Chitukula Chatata New Positive 
ABC 74 01.04.2009 M 52 ABC Njewa Chagonga New Negative 
ABC 75 01.04.2009 M 23 Mtsiliza Clinic Chitukula Mwenela New Negative 
ABC 82 20.04.2009 M 40 ABC Njewa Chimombo New Negative 
ABC 86 22.04.2009 F 70 Mtsiliza Clinic Njewa Kanthache New Negative 
ABC 93 06.05.2009 F 27 ABC Njewa Chikwawo New Negative 
ABC 94 06.05.2009 M 50 ABC Kalolo Nsundwe New Negative 
ABC 121 12.06.2009 F 59 Mtsiliza Clinic Njewa Chimombo 2 New Negative 
ABC 122 12.06.2009 F 51 Mtsiliza Clinic Njewa Nsanje New Negative 
ABC 134 27.06.2009 M 76 ABC Masumbankhunda   New Negative 
ABC 174 31.08.2009 M 49 Mtsiliza Clinic Chitukula Mwenela New Negative 
ABC 176 01.09.2009 M   ABC Kabudula Mdzibwa New Negative 
ABC 182 02.09.2009 F 39 Mtsiliza Clinic Chitukula Mwenela New Negative 
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Appendix 8.2.4: HIV testing registration form 
 
Facility Name Date 
Patient 
ID 
Number Sex  Age Ever had HIV test 
Name of Testing 
Unit Final result 
Chimbalanga 02.01.2009 1 FNP 39 Y Chimbalanga Negative 
Chimbalanga 02.01.2009 2 M 49 Y Chimbalanga Negative 
Chimbalanga 02.01.2009 3 FP 16 N Chimbalanga Negative 
Chimbalanga 02.01.2009 4 FP 20 Y Chimbalanga Negative 
Chimbalanga 02.01.2009 5 M 27 Y Chimbalanga Negative 
Chimbalanga 02.01.2009 6 M 47 Y Chimbalanga Negative 
Chimbalanga 02.01.2009 7 FNP 20 Y Chimbalanga Negative 
Chimbalanga 02.01.2009 8 FNP 20 Y Chimbalanga Negative 
Chimbalanga 05.01.2009 9 FP 22 Y Chimbalanga Negative 
Chimbalanga 05.01.2009 10 FNP 33 Y Chimbalanga Negative 
Chimbalanga 05.01.2009 11 M 25 Y Chimbalanga Negative 
Chimbalanga 05.01.2009 12 FP 22 Y Chimbalanga Negative 
Chimbalanga 05.01.2009 13 FP 19 N Chimbalanga Negative 
Chimbalanga 05.01.2009 14 FNP 58 N Chimbalanga Negative 
Chimbalanga 05.01.2009 15 FP 23 Y Chimbalanga Negative 
Chimbalanga 05.01.2009 16 FP 27 N Chimbalanga Negative 
Chimbalanga 05.01.2009 17 FNP 22 N Chimbalanga Negative 
Chimbalanga 05.01.2009 18 M 26 Y Chimbalanga Negative 
Chimbalanga 05.01.2009 19 M 23 Y Chimbalanga Negative 
Chimbalanga 05.01.2009 20 M 25 N Chimbalanga Negative 
Chimbalanga 12.01.2009 61 FP 26 Y Chimbalanga Negative 
Chimbalanga 12.01.2009 62 FP 32 Y Chimbalanga Positive 
Chimbalanga 12.01.2009 63 FNP 45 Y Chimbalanga Negative 
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Appendix 8.3 Cluster level population sizes 
 
Cluster-pair 
(cluster IDs)* Early arm Delayed arm 
  Total Male Female Total Male Female 
1 (3 & 5) 191615 91,962 99,653 229184 111,387 117797 
2 (1 & 6) 243826 120,388 123,438 232433 114,152 
           
118,281  
3 (4 & 2) 166702 80,414 86,288 167074 82,023 85051 
Total 602143 292764 309,379 628691 307562 321129 
*Cluster IDs 3, 1, 4 are for the Early arm and Cluster IDs 5,6,2 are for the Delayed arm 
 
223 
Appendix 8.4: Sample of dataset layout for TB treatment initiations (similar layout used 
for ART initiations, HIV testing and TB testing) 
 
Clustid time y treat Base Sites ptfemale clpop timecenter treat_time y-center 
1 1 13 1 16.9 1 0.465 243826 -10 1 -1.25 
1 2 16 1 16.9 1 0.465 243826 -8 2 1.75 
1 3 24 1 16.9 1 0.465 243826 -6 3 9.75 
1 4 13 1 16.9 1 0.465 243826 -4 4 -1.25 
1 5 19 1 16.9 1 0.465 243826 -2 5 4.75 
1 6 18 1 16.9 1 0.465 243826 0 6 3.75 
1 7 13 1 16.9 1 0.465 243826 0 7 -1.25 
1 8 11 1 16.9 1 0.465 243826 2 8 -3.25 
1 9 11 1 16.9 1 0.465 243826 4 9 -3.25 
1 10 10 1 16.9 1 0.465 243826 6 10 -4.25 
1 11 12 1 16.9 1 0.465 243826 8 11 -2.25 
1 12 11 1 16.9 1 0.465 243826 10 12 -3.25 
2 1 16 0 13.7 2 0.347 167074 -10 0 2.58 
2 2 12 0 13.7 2 0.347 167074 -8 0 -1.42 
2 3 10 0 13.7 2 0.347 167074 -6 0 -3.42 
2 4 11 0 13.7 2 0.347 167074 -4 0 -2.42 
2 5 17 0 13.7 2 0.347 167074 -2 0 3.58 
2 6 13 0 13.7 2 0.347 167074 0 0 -0.42 
2 7 18 0 13.7 2 0.347 167074 0 0 4.58 
2 8 11 0 13.7 2 0.347 167074 2 0 -2.42 
2 9 7 0 13.7 2 0.347 167074 4 0 -6.42 
2 10 12 0 13.7 2 0.347 167074 6 0 -1.42 
2 11 18 0 13.7 2 0.347 167074 8 0 4.58 
2 12 16 0 13.7 2 0.347 167074 10 0 2.58 
3 1 16 1 9.4 3 0.531 191615 -10 1 1.33 
3 2 11 1 9.4 3 0.531 191615 -8 2 -3.67 
3 3 7 1 9.4 3 0.531 191615 -6 3 -7.67 
3 4 12 1 9.4 3 0.531 191615 -4 4 -2.67 
3 5 13 1 9.4 3 0.531 191615 -2 5 -1.67 
3 6 20 1 9.4 3 0.531 191615 0 6 5.33 
3 7 30 1 9.4 3 0.531 191615 0 7 15.33 
3 8 20 1 9.4 3 0.531 191615 2 8 5.33 
3 9 10 1 9.4 3 0.531 191615 4 9 -4.67 
3 10 15 1 9.4 3 0.531 191615 6 10 0.33 
3 11 7 1 9.4 3 0.531 191615 8 11 -7.67 
3 12 15 1 9.4 3 0.531 191615 10 12 0.33 
4 1 12 1 18 0 0.483 166702 -10 1 -4 
4 2 22 1 18 0 0.483 166702 -8 2 6 
  
224 


















































Akaike H, 1981. Likelihood of a model and information criteria. Journal of Econometrics, 16, 3 - 
14. 
Allen JD, Stoddard AM, Mays J, and Sorensen G, 2001. Promoting breast and cervical cancer 
screening at the workplace: results from the Woman to Woman Study. Am J Public Health, 91, 
584–590. 
Anglemyer A, Rutherford GW, Baggaley RC, Egger M, and Siegfried N, 2011. Antiretroviral 
therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database 
Syst Rev.,  8, CD009153. doi: 10.1002/14651858.CD009153.pub2. 
Arnold BF, Hogan DR, Colford jr JM, and Hubbard AE, 2011. Simulation methods to estimate 
design power: an overview for applied research [online]. BMC Medical Research Methodology, 
11:94. Available at Http://www.biomedcentral.com/1471-2288/11/94. 
Atienza AA, and King AC, 2002. Community-based Health Intervention Trials: an Overview 
of Methodological Issues. Epidemiol Rev., 24 (1), 72-79. 
Austin PC, 2007. A comparison of the statistical power of different methods for the analysis 
of cluster randomisation trials with binary outcomes. Statist. Med., 26, 3550-3565. 
Aveyard P, Sherratt E, Almond J, Lawrence T, Lancashire R, Griffin C, and Cheng KK, 2001. 
The change-in-stage and updated smoking status results from a cluster randomized trial of 
smoking prevention and cessation using the trans-theoretical model among British 
adolescents. Prev Med., 33, 313–324. 
Axelson O, Fredricksson M, and Ekberg K, 1994. Use of the prevalence ratio v the prevalence 
odds ratio as a measure of risk in cross sectional studies. Occup Environ Med., 51, 574. 
Ayles H, Schaap A, Nota A, Sismanidis C, Tembwe R, De Haas P, Muyoyeta M, and Beyers 
N, 2009. Prevalence of tuberculosis, HIV and respiratory symptoms in two Zambian 
communities: implications for tuberculosis control in the era of HIV. PLoS ONE, 4(5), e5602. 
doi: 10.1371/journal.pone.0005602. 
Ayles H, Muyoyeta M, Du Toit E, Schaap A, Floyd S, Simwinga M, Shanaube K, Chishinga N, 
Bond V, et al.,2013. Effect of household and community interventions on the burden of 
tuberculosis in southern Africa: the ZAMSTAR community-randomised trial. Lancet , 382: 
1183–94. 
 
Bandura A, 1971. Social Learning Theory. Morristown, NJ: General Learning Corporation. 
Bandura A, 1986. Social foundations of thought and action: a social‐cognitive theory. Englewood 
Cliffs, NJ: Prentice Hall. 
237 
Barros AJ, and Hirakata VN, 2003. Alternatives for logistic regression in cross-sectional 
studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC 
Medical Research Methodology, 3:21. Available at http://www.biomedcentral.com/1471-2288/3/21. 
Barter DM, Agboola SO,  Murray MB, and Bärnighausen T, 2012. Tuberculosis and poverty: 
the contribution of patient costs in sub-Saharan Africa – a systematic review. BMC Public 
Health,12, 980. doi:  10.1186/1471-2458-12-980. 
Bartholomew LK, Parcel GS, Kok G, Gottlieb NH,  and Fernandez ME, 2006. Planning health 
promotion programs: an Intervention Mapping approach. San Francisco, CA: Jossey‐Bass. 
Bartholomew LK, Parcel GS, Kok G, Gottlieb NH, and Fernandez ME, 2011. Planning health 
promotion programs: an Intervention Mapping approach. San Francisco, CA: Jossey‐Bass. 
Beckwith CG, Flanigan TP, del Rio C, Simmons E, Wing EJ, Carpenter, CCJ, and Bartlett JG, 
2005. It is time to implement routine, not risk-based, HIV testing. Clin Infect Dis., 40(7),1037-
1040. 
Bello G, Simwaka B, Ndhlovu T, Salaniponi F, and Hallet TB, 2011. Evidence for changes in 
behaviour leading to reductions in HIV prevalence in urban Malawi. Sex Transm Infect; 87(4), 
296-300.  
Bennett S, Parpia T, Hayes R, and Cousens S, 2002. Methods for the analysis of incidence rates 
in cluster randomised trials. International Journal of epidemiology, 31, 839-846. 
Benson T, Kaphuka J, Kanyanda S, and Chinula R, 2002.  Malawi : an atlas of social statistics, 
Zomba, Malawi. 
 
Berkhof J, and Snijders TAB, 2001. Variance component testing in multilevel models. Journal 
of education and behavioural statistics, 26(2), 133-152. 
Best N, Mason A, and Li P, 2011. Bayesian Hierarchical Modelling using WinBUGS. Short Course, 
Feb 17–18 [online]. Imperial College. Available at:  http://www.bias-project.org.uk. 
Blizzard L, and Hosmer DW, 2006. Parameter estimation and goodness-of-fit in log binomial 
regression. Biometrical J., 48, 5–22. 
Borgdorff MW, Floyd K, and Broekmans JF, 2002. Interventions to reduce tuberculosis 
mortality and transmission in low- and middle-income countries. Bulletin of the World Health 
Organization, 80 (3), 217-227.   
Borm GF, Melis RJF, Teerenstra S, and Peer PG, 2005. Pseudo cluster randomization: a 
treatment allocation method to minimize contamination and selection bias. Statist. Med., 24, 
3535–3547. 
Brechtl JR, Breitbart W, Galietta M, Krivo S, and Rosenfeld B, 2001. The use of Highly Active 
Antiretroviral Therapy (HAART) in patients with advanced HIV‐infection: Impact on 
medical, palliative care, and quality of life outcomes. Journal of Pain and Symptom Management, 
21, 41‐51. 
238 
Breslow NE, and Clayton DG, 1993. Approximate inference in generalised linear mixed 
models. Journal of the American Statistical Association, 88 (421), 9-25. 
Breslow NE, and Lin X, 1995. Bias correction in generalized linear mixed models with a single 
component of dispersion. Biometrika,82, 81-91. 
Breslow NE, 1996. Generalised linear models: checking assumptions and strengthening 
conclusions [online]. Prepared for Congresso Nazionale Societa’ Italiana di Biometrica Centro 
Convegni S.Agostino, Cortona, 16-17 June, 1995. 
Broekmans J, 1994. Control strategies and programme management. In: Porter JDH, McAdam 
KPWJ, editors. Tuberculosis— back to the future. Chichester: John Wiley & Sons. 
Brooks SP, and Gelman A, 1998. General Methods for Monitoring Convergence of Iterative 
Simulations. Journal of Computational and Graphical Statistics, 7(4), 434–455. 
Brown CH, Wyman PA, Guo J, and Peňa J, 2006.  Dynamic wait-listed designs for randomised 
trials: new designs for prevention of youth suicide. Clinical Trials, 3, 259-271.  
Burton A, Altman DG, Royston  P, and Holder RL, 2006. The design of simulation studies in 
medical statistics. Statist. Med., 25, 4279-4292. 
Cai Z, Fan J, and Li R, 2000. Efficient Estimation and Inferences for Varying-coefficient Models.  
Journal of the American Statistical Association, 95, 888–902. 
Campbell MK, Elbourne DR,  and Altman DG, 2004. CONSORT statement: extension to 
cluster randomised trials. BMJ, 328, 702-708. 
Campbell CH Jr, Marum ME, Alwano-Edyegu M, Dillon BA, Moore M, and Gumisiriza E, 
1997. The role of HIV counselling and testing in the developing world. AIDS Educ Prev., 
9(Suppl B), 92-104. 
Campbell M, Fitzpatrick R, Haines A, Kinmonth AL, Sandercock P, Spiegelhalter D, and Tyrer 
P, 2000. Framework for design and evaluation of complex interventions to improve health. 
BMJ, 321:694. 
Carlin BP, and Chib S, 1995. Bayesian model choice via Markov Chain Monte Carlo Methods. 
Journal of the Royal Statistical Society, Series B, 57, 473 - 484. 
Castilla J, Sobrino P, De La Fuente L, Noguer I, Guerra L, Parras F, 2002. Late diagnosis of HIV 
infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. 
AIDS, 16(14), 1945-1951. 
Central Statistical Agency [Ethiopia] and ICF International, 2012. Ethiopia Demographic and 
Health Survey 2011. Addis Ababa, Ethiopia and Calverton, Maryland, USA: Central Statistical 
Agency and ICF International. 
Chavasse DC, Shier RP, Murphy OA, Huttly SRA, Cousens SN, and Akhtar T, 1999. Impact of 
fly control on child diarrhoea in Pakistan: community-randomised trial. Lancet, 353, 22 – 25.  
239 
Chiang CY, Chang CT, Chang RE, Li CT, and Huang RM, 2005. Patient and health system 
delays in the diagnosis and treatment of tuberculosis in Southern Taiwan. Int J Tuberc Lung 
Dis., 9(9), 1006-1012. 
Chin HC and Quddus MA, 2003. Applying the random effect negative binomial model to 
examine traffic accident occurrence at signalized intersections. Accident Analysis and 
Prevention, 35, 253–259. 
Clark AB and Bachmann MO, 2009. Bayesian methods of analysis for cluster randomized trials 
with count outcome data. Statist. Med. 29, 199-209. 
Clark DR, and Thayer CA, 2004. A Primer on the Exponential Family of Distributions on 
generalised linear models. Discussion Paper Program Casualty Actuarial Society - Arlington, 
Virginia, 2004, 117-148. 
Cohen J, 1992. A power primer. Psychol Bull., 112(1), 155-159. 
Cohen C, Revicki DA, Nabulsi A, Sarocco PW,  and Jiang P, 1998. A randomized trial of the 
effect of ritonavir in maintaining quality of life in advanced HIV disease. AIDS, 12, 1495‐1502. 
Cohen MS, and Gay CL, 2010. Treatment to prevent transmission of HIV-1. Clin Infect Dis., 50 
(Supplement 3), S85-S95.   
Cohen MS, Chen YQ, McCauley M, et al, 2011. Prevention of HIV-1 infection with early 
antiretroviral therapy. N Engl J Med., 365:493-505.  
Collins LM, Schafer JL, and Kam C, 2001. A comparison of inclusive and restrictive strategies 
in modern missing data procedures. Psychological Methods, 6(4), 330-351. 
Colombo M, Mosso C, and De Piccoli N, 2001. Sense of community and participation in urban 
contexts. J. Commun. Appl. Soc. Psychol., 11, 457–464. 
Cook GS, Frank C Tanser FC, Bärnighausen TW, and Newell M, 2010. Population uptake of 
antiretroviral treatment through primary care in rural South Africa [online]. BMC Public 
Health, 10, 585 doi:10.1186/1471-2458-10-585. 
Corbett EL, Bandason T, Duong T, Dauya E, Makamure B, Churchyard GJ, Williams BG, 
Munyati SS, Butterworth AE, Mason PR, Mungofa S, and Hayes RJ, 2010. Comparison of two 
active case-finding strategies for community-based diagnosis of symptomatic smear-positive 
tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster 
randomised trial. Lancet, 376, 1244-1253. 
Corbett EL, Churchyard GJ, Charambos S, Samb S, Moloi V, Clayton TC, Grant AD, Murray 
J, Hayes RJ, and De Cock KM, 2002. Morbidity and mortality in South African gold miners: 
impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis, 34(9), 1251-
1258. 
240 
Corbett EL, Marston B, Churchyard GJ, and De Cock KM, 2006. Tuberculosis in sub-Saharan 
Africa: opportunities, challenges and change in the era of antiretroviral treatment. Lancet, 
367,926–37. 
Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, and Dye C, 2003. The 
Growing Burden of Tuberculosis: global trends and interactions with the HIV epidemic. 
Archives of Internal Medicine,163, 1009–1021. 
Corkery E, Palmer C, Foley M E, Schechter C B, Frisher L, and Roman S H, 2007. Effect of a 
bicultural community health worker on completion of diabetes education in a Hispanic 
population. Diabet Care, 20, 254–257. 
Cornfield J, 1978. Randomization by group: a formal analysis. Am J Epidemiol.108, 100–102. 
Coutinho LMS, Scazufca M, and Menezes PR, 2008. Methods for estimating prevalence ratios 
in cross sectional studies. Rev Saúde Pública,  2008;42(6), 992-998. 
Creek TL, Ntumy R, Seipone K, Smith M, Mogodi M, Smit m, Legwaila K, Molokwane I, 
Tebele G, Mazhani L, Shaffer N, and Kilmarx PH, 2007. Successful Introduction of Routine 
Opt-Out HIV Testing in Antenatal Care in Botswana. J. Acquir Immune Defic Syndr., 45:102–
107. 
Cummings KM, Hyland A, Saunders-Martin T, Perla J, Coppola PR, and Pechacek TF, 1998. 
Evaluation of an enforcement program to reduce tobacco sales to minors. Am J Public Health, 
88, 932–935. 
Curtale F, Siwakoti B, Lagrosa C, Laraja M, and Guerra R, 1995. Improving skills and 
utilisation of community health volunteersin Nepal. Social Science Medicine, 40 (8), 1117-1125. 
Datiko DG, and Lindtjørn B, 2009. Health Extension Workers Improve Tuberculosis Case 
Detection and Treatment Success in Southern Ethiopia: a community randomized trial. PLoS 
ONE, 4(5), e5443. doi:10.1371/journal.pone.0005443. 
Davies R, Hedberg GA, and Fischer M, 1948. A complete community survey for tuberculosis: 
a second report on effectiveness of the procedure as a method of tuberculosis control. Am Rev 
Tuberc., 58(1), 77-84. 
Dean CB, Ugarte MD, and Militino AF, 2004. Penalized quasi-likelihood with spatially 
correlated data. Computation Statistics and Data Analysis, , 45, 235-248.  
Declaration of Alma-Ata, International Conference on Primary Health Care, Alma-Ata, USSR, 
6-12 September 1978. 
De Allegri M, Pokhrel S, Becher H, Dong H, Mansmann U, Kouyaté B, Kynast-Wolf G, Gbagou 
A, Sanon M, Bridges J, and Sauerborn R, 2008. Step-wedge cluster-randomised community-
based trial: an application of the study of the impact of community health insurance. Health 
Research Policy and Systems, 6, 10-17. 
241 
De Cock KM, and Chaisson RE, 1999. Will DOTS do it? A reappraisal of tuberculosis control 
in countries with high rates of HIV infection. Int J Tuberc Lung Dis., 3(6), 457- 465. 
Deddens JA, and Petersen MR, 2004. Estimating the relative risk in cohort studies and clinical 
trials of common outcomes. Am. J. Epidemiol., 159, 213–214. 
Deddens JA, and Petersen MR, 2008. Approaches for estimating prevalence ratios. Occup. 
Environ. Med. 65, 501-506. 
Deddens JA, Petersen MR, and Lei X, 2003. Estimation of prevalence ratios when PROC 
GENMOD does not converge. In: Proceedings of the 28th Annual SAS Users Group 
International Conference, March 30–April 2, 2003. Paper 270-28. Cary, NC: SAS Institute Inc. 
Available at http://www2.sas.com/proceedings/sugi28/270-28. pdf.  
Diciccio TJ, Kass RE, Raftery A, and Wasserman L, 1997. Computing Bayes factors by 
combining simulations and asymptotic approximation. Journal of the Statistical Association, 
92(439), 903 - 915.  
Diehr P, Martin DC, Koepsell T, and Cheadle A, 1995. Breaking the matches in a paired t-test 
for community interventions when the number of pairs is small.Statist. Med., 14(13), 1491-
1504. 
Donner A, 1999. Some aspects of the design and analysis of cluster randomization trials. 
Applied Statistics, 47, 95–113. 
Donner A, Brown KS, and Brahser P, 1990. A methodological review of non-therapeutic 
intervention trials employing cluster randomisation, 1979-1989. International Journal of 
Epidemiology, 19, 795-800. 
Donner A, Eliasziw M, and Klar N, 1994. A comparison of methods for testing homogeneity 
of proportions in teratological studies. Statist. Med., 13, 1253-1264. 
Donner  A , and Klar  N, 2000. Design and Analysis of Cluster Randomization Trials in Health 
Research .Oxford Press, New York. 
Donner A, Klar N, 1996. Statistical considerations in the design and analysis of community 
intervention trials. J Clin Epidemiol, 49, 435–439. 
 
Donner A, Taljaard M, and Klar N, 2007. The merits of breaking the matches: a cautionary 
tale. Statist. Med., 26, 2036-2051. 
Dunson D, 2001. Commentary: Practical advantages of Bayesian analysis in epidemiologic 
data. American Journal of Epidemiology, 153, 1222–1226. 
Dye C, 2006. Global epidemiology of tuberculosis. Lancet, 367, 938-940. 
Eaves L, and Erkanli A, 2003. Markov chain Monte Carlo approaches for the analysis of genetic 
and environmental components of human developmental change and G X E interaction. 
Behavior Genetics,33, 279-299. 
242 
Eubank RL, Huang C, Maldonado YM, Wang N, Wang S, and Buchanan RJ, 2004. Smoothing 
spline estimation in varying-coefficient models. Journal of the Royal Statistical Society B, 66, 653–
667. 
Evans M, and Swartz T, 1995. Methods for Approximating Integrals in Statistics with Special 
Emphasis on Bayesian Integration Problems. Statistical Science, 10 (3), 254-272.  
Fabio LC, Paula GA, and de Castro M, 2012. A Poisson mixed model with non-normal random 
effect distribution. Computational Statistics and Data Analysis, 56, 1499–1510. 
Faridi Z, Grunbaum JA, Gray BS, Franks A, and Simoes E, 2007. Community-based 
participatory research: necessary next steps. Prev. Chronic Dis., 4, 1–5. 
Feldman HA, and McKinlay SM, 1994. Cohort versus cross-sectional design in large field 
trials-precision, sample-size, and a unifying model. Stat. Med. 13, 61–78. 
Feldman HA, McKinlay SM, and Niknian N, 1996. Batch sampling to improve power in a 
community trial: experience from the Pawtucket Heart Health Program. Evaluation Review, 20 
(3), 244-274. 
Feng Z, Diehr P, Peterson A, and McLerran D, 2001. Selected statistical issues in group 
randomized trials. Annual Review of Public Health, 22, 167–187. 
Gambia Hepatitis Study Group. The Gambia Hepatitis intervention study. Cancer Research,  
47, 5782-5787. 
Gamerman D, 1998. Markov chain Monte Carlo for dynamic generalised linear models. 
Biometrika, 85, 215–227. 
Gebrekristos HT, Lurie MN, Mthethwa  N, and Karim QA, 2009. Disclosure of HIV status: 
experiences of patients enrolled in an integrated TB and HAART pilot programme in South 
Africa. African Journal of AIDS Research, 8(1), 1–6. 
Gelberg L, Andersen RM, and Leake BD, 2000. Healthcare access and utilization, the 
Behavioral Model for vulnerable populations: application to medical care use and outcomes 
for homeless people. Health Services Research, 34(6), 1273-1302.  
Gelfand AE, and Smith AFM, 1990. Sampling-based approaches to calculating marginal 
densities. J Amer Statistic Assoc., 85, 398–409. 
Gelman A, 2006. Prior distributions for variance parameters in hierarchical models. Bayesian 
Analysis, 1(3), 515-533.  
Gelman A, and Hill J, 2007. Data analysis using regression and multilevel/hierarchical models-
Analytical methods for social research.1st ed. New York: Cambridge University Press.  
Geman S, and Geman D, 1984. Stochastic relaxation, Gibbs distributions, and the Bayesian 
restoration of images. IEEE Transactions On Pattern Analysis And Machine Intelligence, 6(6), 721-
741. 
243 
Gibbons RD, Segawa E, Karabatsos G, Amatya AK, Bhaumik DK, Brown CH, Kapur K, 
Marcus SM, Hur K, and Mann JJ, 2008. Mixed-effects Poisson regression analysis of adverse 
event reports: the relationship between antidepressants and suicide. Statist  Med., 27(11), 1814-
1833. 
Gilks WR, Thomas A, and Spiegelhalter DJ, 1994. A language and program for complex 
Bayesian modelling. Statistician, 43, 169 –177. 
Gilks WR, and Wild P, 1992. Adaptive Rejection Sampling for Gibbs sampling. Applied 
Statistics, 41, 337-348. 
Girardi E, Antonucci G, Vanacore P, Libanore M, Errante I, Matteelli A, and Ippolito G, 2000. 
Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with 
HIV infection. AIDS, 14, 1985-1991. 
Giuliano M, and Vella S, 2007. Inequalities in health: access to treatment for HIV/AIDS, 43(4), 
313-316. 
Glickman ME, and Dyk DA, 2007. Basic Bayesian Methods.  In Methods in Molecular Biology, 
vol. 404: Topics in Biostatistics, W. T. Ambrosius (eds). Humana Press Inc., Totowa, NJ.  
Glynn JR, Crampin AC, Ngwira BMM, et al, 2004. Trends in tuberculosis and the influence of 
HIV infection in northern Malawi, 1988-2001. AIDS, 18 (10), 1459-1463. 
Glynn JR, Warndorff DK, Fine PE, Munthali MM, Sichone W, and Pönnighaus JM, 1998. 
Measurement and determinants of tuberculosis outcome in Karonga District, Malawi. Bull 
World Health Organ., 76(3), 295–305.  
Goldstein H, and Rasbash J, 1996. Improved approximations for multilevel models with 
binary responses. Journal of the Royal Statistical Society A, 159, 505-513. 
Golub JE, Mohan C, Comstock GW, and Chaisson RE, 2005. Active case finding of 
tuberculosis: historical perspective and future prospects. Int J Tuberc Lung Dis., 9, 1183–1203. 
Gopi PG, Subramani R, and Narayanan PR, 2006. Trend in the prevalence of TB infection and 
ARTI after implementation of DOTS programme in south India. International Journal of 
Tuberculosis and Lung Disease, 10, 346-348. 
Graham SM, Holte SE, Peshu NM, et al, 2007. Initiation of antiretroviral therapy leads to a 
rapid decline in cervical and vaginal HIV-1 shedding. AIDS, 21, 501-507. 
Greenland S, 2004. Model-based estimation of relative risks and other epidemiologic measures 
in studies of common outcomes and in case-control studies. Am J Epidemiol, 160, 301–305. 
Grosskurth H, Mosha F, Todd J, et al, 1995. Impact of improved treatment of sexually 
transmitted diseases on hiv infection in rural tanzania: randomised controlled trial. Lancet, 
346, 530–536. 
244 
Gueorguieva R, and Krystal JH, 2004. Move Over ANOVA: progress in analyzing repeated-
measures data and its reflection in papers published in the Archives of General Psychiatry. 
Archives of General Psychiatry, 61, 310-317. 
Gulliford MC, Ukoumunne OC, and Chinn S, 1999. Components of variance and intraclass 
correlations for the design of community-based surveys and intervention studies. American 
Journal of Epidemiology, 149 (9), 876-83. 
Guo G, and Zhao H, 2000. Multilevel modelling for binary data. Annual Review of Sociology,  
26, 441-462. 
Hallet TB, Aberle-Grasse J, Bello G, et al, 2006. Declines in HIV prevalence can be associated 
with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti. Sex 
Transm Infect, 82 (Suppl I):i1-i8.    
Hannan PJ, Murray DM, Jacobs DR, and McGovern PG, 1994. Parameters to aid in the design 
and analysis of community trials: intraclass correlations from the Minnesota Heart Health 
Program. Epidemiology, 5(1), 88-95. 
Harries AD, Hargreaves NJ, Chimzizi R, and Salaniponi FM, 2002. Highly active antiretroviral 
therapy and tuberculosis control in Africa: synergies and potential. Bulletin of the World Health 
Organization, 80, 464-469. 
Harries AD, Maher D, and Nunn P, 1998. An approach to the problems of diagnosing and 
treating adult smear-negative pulmonary tuberculosis in high-HIV-prevalence settings in 
sub-Saharan Africa. Bulletin of the World Health Organization, 76, 651-662. 
Hartzel J, Agresti A, and Caffo B, 2001. Multinomial logit random effects models [online]. 
Statistical Modelling, 1, 81: Sage. Available at http://smj.sagepub.com/content/1/2/81 
Hastie T, and Tibshirani R, 1993. Varying-coefficient models. Journal of the Royal statistical 
Society Series B, 55, 757-796. 
Hastings WK, 1970. Monte Carlo sampling methods using Markov chains and their 
applications. Biometrika, 57, 97-109. 
Hausman J, Hall BH, and Griliches Z, 1984. Econometric models for count data with 
application to the patents -R & D relationship. Econometrica, 52 (4), 909-938. 
Hayes RJ, Alexander NDE, Bennett S, and Cousens SN, 2000. Design and analysis issues in 
cluster randomised trials of interventions against infectious diseases. Statistical Methods in 
Medical Research, 9, 95-116. 
Hayes R.J and Moulton L.H, 2009. Cluster randomised trials. 1st ed. Florida: Chapman & Hall. 
Hedeker D, and Gibbons RD, 2006. Longitudinal data analysis. 1st ed. New York: Wiley. 
Heo M, and Leon AC, 2005. Performance of a mixed effects logistic regression model for 
binary outcomes with Unequal cluster size. journal of Biopharmaceutical Statistics, 15, 513–526.  
245 
 
Heo M, and Leon AC, 2009. Sample size requirements to detect an intervention by time 
interaction in longitudinal cluster randomized clinical trials. Stat Med., 28(6), 1017–1027. 
Heo M, Xue X,  and Kim MY, 2013. Sample size requirements to detect an intervention by time 
interaction in longitudinal cluster randomized clinical trials with random slopes. 
Computational Statistics and Data Analysis, 60, 169–178. 
Hermans SM, Castelnuovo B, Katabira C, Mbidde P, Lange JMA, Hoepelman AIM, Coutinho 
A, and Manabe YC, 2012. Integration of HIV and TB services results in improved TB treatment 
outcomes and earlier prioritized art initiation in a large urban HIV clinic in Uganda. Journal of 
Acquired Immune Deficiency Syndromes, 60 (2), e29-e35.     
Hoa NB, Sy DN, Nhung NV, Tiemersma EW, Borgdorff MW, Cobelens FGJ, 2010. National 
survey of tuberculosis prevalence in Viet Nam. Bulletin of the World Health Organization, 88, 
273–280. 
Hodgson T and Burke M, 2000. On simulation and the teaching of statistics. Teaching statistics, 
22, 91-96. 
Hoeting JA, Davis RA, Merton AA, and Thompson SE, 2006. Model Selection for Geostatistical 
Models. Ecological Applications, 16(1), 87-98.  
Hoeting JA, Madigan D, Raftery AE, and Volinsky CT, 1999. Bayesian Model Averaging: a 
tutorial. Statistical Science, 14(4), 382–417. 
Hoeting JA, Raftery AE, and Madigan D, 2002. Bayesian Variable and Transformation 
Selection in Linear Regression. Journal of Computational and Graphical Statistics , 11 (3), 485-507.  
Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS, 1998. 
Improved survival among HIV infected individuals following initiation of antiretrovirals. 
JAMA, 279, 450–454. 
Hoover DR, Rice JA, Wu CO, and Yang LP, 1998. Nonparametric smoothing estimates of time-
varying coefficient models with longitudinal data. Biometrika, 85, 809–822. 
Howard AA, and El-Sadr WM, 2010. Integration of Tuberculosis and HIV Services in Sub-
Saharan Africa: Lessons Learned. Clin Infect Dis., 50 (Supplement 3): S238-S244. 
Hox JJ, 2002. Multilevel analysis: techniques and applications. Mahwah, N.J., Lawrence Erlbaum 
Publishers.  
Hu FB, Goldberg J, Hedeker D, Flay BR, Pentz MA, 1998. Comparison of population-averaged 
and subject specific approaches for analyzing repeated binary outcomes. American Journal of 
Epidemiology 147, 694-703. 
Huber PJ, 1967. The behavior of maximum likelihood estimates under non-standard 
conditions. In: Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and 
Probability. Vol 1. Berkeley, CA: University of California Press, pp. 221–233. 
246 
Hussey MA, and Hughes JP, 2007. Design and analysis of stepped wedge cluster randomized 
trials. Contemporary Clinical Trials, 28, 182–191. 
Isaakidis P, And Ioannidis PA, 2003. Evaluation of cluster randomised controlled trials in Sub-
Saharan African. Am J Epidemiol., 158, 921-926. 
Janega JB, Murray DM, Varnell SP, Blitstein JL, and Birnbaum AS, 2004. Assessing 
intervention effects in a school based nutrition intervention trial: which analytic model is most 
powerful. Health Education and Behavior, 31(6), 756-774. 
Kass RE, and Raftery AE, 1995. Bayes factors, Journal of the American Statistical Association, 
90(430), 773-795. 
Kemp J, Mann G, Nhlema Simwaka B, Salaniponi FML, and  Squire S.B, 2007. Can the poor 
afford free TB treatment? Patient and household costs associated with a TB diagnosis in 
Lilongwe. Bulletin of the World Health Organisation, 85(8), 580–585. 
Kenny DA, Mannetti L, Pierro A, Livi S, and Kashy DA, 2002. The statistical analysis of data 
from small groups. Journal of Personality and Social Psychology, 83, 126–137. 
Kerry SM, Bland JM, 1998. The intracluster correlation coefficient in cluster randomisation. 
BMJ, 316, 1455. 
Kerschberger B, Hilderbrand K, Boulle AM, Coetzee D, Goemaere E, De Azevedo V, and Van 
Cutsem G, 2012. The effect of complete integration of HIV and TB services on time to initiation 
of antiretroviral therapy: a before-after study. PLoS ONE, 7(10), e46988. 
doi:10.1371/journal.pone.0046988. 
Kim H-Y, Preisser JS, Rozier RG, and Valiyaparambil JV, 2006. Multilevel analysis of group-
randomized trials with binary outcomes. Community Dent Oral Epidemiology; 34, 241–51. 
 
Kim JY, and Ammann A, 2004.  Is the “3 by 5” initiative the best approach to tackling the HIV 
pandemic? PLoS Med 1: e37. 
Kirk O, Gatell JM, Mocroft A, Pedersen C, Proenca R, Brettle RP, Barton SE, Sudre P, and 
Phillips AN, 2000. Infections with Mycobacterium tuberculosis and Mycobacterium avium 
among HIV-infected patients after the introduction of highly active antiretroviral therapy. 
EuroSIDA Study Group. American Journal of Respiratory and Critical Care Medicine, 162, 865-872. 
Kish L, 1965. Survey Sampling. New York : John Wiley & Sons.  
Klar N and Donner A, 1997. The merits of matching in community intervention trials: a 
cautionary tale. Statist. Med., 16, 1753-1764. 
Kochi A, 1997. Tuberculosis control— is DOTS the health breakthrough of the 1990s? World 
Health Forum, 18, 225-232. 
Koepsell TD, Wagner EH, Cheadle AC, Patrick DL, Martin DC, Diehr PH, Perrin EB, Kristaz 
AR, Allan-Andrilla CH, and Dey LJ, 1992. Selected methodological issues in evaluating 
247 
community-based health promotion and disease prevention programs. Annu. Rev. Public 
Health, 13, 31–57. 
Kramer MS, Martin RM, Sterne JAC, Shapiro S, Dahhou M, and Platt RW, 2009. The double 
jeopardy of clustered measurement and cluster randomisation. BMJ, 339,b2900, doi: 
10.1136/bmj.b2900. 
Kreft IGG, and Leeuw J, 1998. Introducing multilevel modelling. Thousand Oaks, CA: Sage. 
Kuhn L, Davidson LL, and Durkin MS, 1994. Use of Poisson Regression and Time Series 
Analysis for Detecting Changes over Time in Rates of Child Injury following a Prevention 
Program. Am J Epidemiol, 140, 943-955. 
Larsen K, Petersen JH, Budtz-Jorgensen, and Endahl L, 2000. Interpreting parameters in the 
logistic regression model with random effects. Biometrics, 56, 909-914. 
Lawn SD, Afful B, and Acheampong JW, 1998. Pulmonary tuberculosis: diagnostic delay in 
Ghanaian adults. Int J Tuberc Lung Dis, 2(8), 635-640. 
Lawn SD, Harries AD, Anglaret X, Myer L, and Wood R, 2008. Early mortality among adults 
accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS,  22(15), 1897-
1908. 
Legido-Quigley H, Montgomery CM, Khan P, Atun R, Fakoya A, Getahun H, and Grant AD, 
2013. Integrating tuberculosis and HIV services in low- and middle- income countries: a 
systematic review.  Tropical Medicine and International Health,  18(2), 199 - 211. 
Lee J, and Chia KS, 1993. Estimation of prevalence rate ratios for cross sectional data: an 
example in occupational epidemiology. Br J Ind Med, 50, 861- 864. 
Lee D, and Shaddick G, 2005. Modelling the effects of air pollution on health using Bayesian 
Dynamic Generalised Linear Models, Technical report, University of Bath. 
Lee D, and Shaddick G, 2007. Time-Varying Coefficient Models for the Analysis of Air 
Pollution and Health Outcome Data. Biometrics, 63, 1253–1261.  
Lewin S, Dick J, Pond P, Zwarenstein M, Aja G, van Wyk B, Bosch-Capblanch X, and Patrick 
M, 2005.  Lay health workers in primary and community health care.Cochrane Database of 
Systematic Reviews,  CD004015. 
Liang KY, and Zeger SL, 1986. Longitudinal data analysis using generalised linear models. 
Biometrika, 73, 13-22. 
Lin DY, and Wei LJ, 1989. The robust inference for the Cox proportional hazards model.Journal 
of the American Statistical Association, 84, 1074-1078. 
Lobue PA, Perry S, and Catanzaro A, 2000. Diagnosis of tuberculosis. In: Reichman LB, 
Hershfield ES, editors. Tuberculosis— a comprehensive international approach. New York: 
Marcel Dekker. pp. 341-75. 
248 
Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, and  RaviglioneMC, 
2010. Tuberculosis control and elimination 2010–50: cure, care, and social development. 
Lancet, 375, 1814–1829. 
Lönnroth K, Jaramillo E, Williams BG, Dye C, and Raviglione M, 2009. Drivers of tuberculosis 
epidemics: the role of risk factors and social determinants. Social Science and Medicine, 68(12), 
2240-2246.  
Lu Y and Zhang R, 2009. Smoothing spline estimation of generalised varying –coefficient 
mixed model. Journal of Nonparametric Statistics, 21 (7), 815-825. 
Lumley T, Kronmal R, and Ma S, 2006. Relative risk regression in medical research: models, 
contrasts, estimators, and algorithms. UW Biostatistics Working Paper Series, paper 293. 
Lunn DJ, Thomas A, Best N, and Spiegelhalter D, 2000. WinBUGS - a Bayesian modelling 
framework: concepts, structure, and extensibility. Statistics and Computing, 10, 325--337. 
Maas CJM, and Hox JJ, 2005. Sufficient sample sizes for multilevel modelling. Methodology,  
1(3), 86-92. 
Macinko J, Guanais F, de Fatima M, and de Souza M, 2006. Evaluation of the impact of the 
Family Health Programme in infant mortality in Brazil, 1990 – 2002. J Epidemiol Community 
Health, 60(1), 13-19. 
MacPherson P, Corbett EL, Makombe SD, van Oosterhout JJ, Manda E, Choko AT, Thindwa 
D, Squire SB, Mann GH, Lalloo DG,2012. Determinants and consequences of failure of linkage 
to antiretroviral therapy at primary care level in Blantyre, Malawi: a prospective cohort 
study.PLoS One. 7(9):e44794. doi: 10.1371/journal.pone.0044794. Epub 2012 Sep 11. 
 
Madigan D, York J, and Allard D, 1995. Bayesian graphical models for discrete data. 
International Statistical Review, 63 (2), 215-232. 
Maher D, 2010. Re-thinking global health sector efforts for HIV and tuberculosis epidemic 
control: promoting integration of programme activities within a strengthened health system. 
BMC Public Health, 10, 394. doi:10.1186/1471-2458-10-394. 
Mannheim L, 1999. Health services research clinical trials: issues in the evaluation of economic 
cost and benefits. Controlled Clinical Trials, 19, 149–158. 
Mantel N, and Haenszel W, 1959. Statistical aspects of the analysis of data from retrospective 
studies of disease. JNCI, 22, 719-748. 
Marsh VM, Mutemi WM, Muturi J, Haaland A, Watkins WM, Otieno G, and Marsh K, 1999. 
Changing home treatment of childhood fevers by training shop keepers in rural Kenya. Trop 
Med Int Health, 4(5), 383-389. 
249 
Marsh VM, Mutemi WM, Willetts A, Bayah K, Were S, Ross A, and Marsh K, 2004.  Improving 
malaria home treatment by training drug retailers in rural Kenya. Trop Med Int Health, 9(4), 
451-60. 
Martin DC, Diehr P, Perrin EB, and Koepsell TD, 1993. The effect of matching on the power of 
randomised community intervention studies. Statistics in Medicine, 12, 329-38. 
Matebesi Z, and Booysen F, 2004. Treatment adherence among tuberculosis patients. Acta 
Academica, 36(3), 140–171. 
McClatchey MW, Cohen SJ, and Reed FM, 1992. The usefulness of matched pair 
randomization for medical practice-based research. Family Practice Research Journal, 12, 235-
243. 
 
McCullagh P, and Nelder JA, 1989. Generalised Linear Models. Second edition. London: 
Chapman and Hall. 
McNutt LA, Wu C, Xue X, and Hafner JP, 2003. Estimating the relative risk in cohort studies 
and clinical trials of common outcomes. Am J Epidemiol, 157, 940–943. 
Meade TW, Roderick PJ, Brennan PJ, Wilkes HC, Kelleher CC, 1992. Extracranial bleeding and 
other symptoms due to low dose aspirin and low intensity oral anticoagulation. Thromb 
Haemostasis, 68, 1-6. 
Metropolis N, Rosenbluth AW, Rosenbluth MN, and Teller AH, 1953. Equation of state 
calculations by fast computing machines. The Journal of Chemical Physics, 21(6), 1087-1092 
Mickey RM, Goodwin GD, and Costanza MC, 1991. Estimation of the design effect in 
community intervention studies. Statistics in Medicine,10, 53–64. 
Mock J, McPhee SJ, Nguyen T, Wong C, Doan H, Lai KQ, Nguyen KH, Nguyen TT, and Bui-
Tong N, 2007. Effective lay health worker outreach and media-based education for promoting 
cervical cancer screening among Vietnamese American women. Am J Public Health, 97, 1693–
1700. 
Moineddin R, Matheson FI, and Glazier RH, 2007. A simulation study of sample size for 
multilevel logistic regression models. BMC Medical Research Methodology, 7:34 
doi:10.1186/1471-2288-7-34. 
Møller V, and Erstad I, 2007. Stigma associated with tuberculosis in a time of HIV/AIDS: 
narratives from the Eastern Cape, South Africa. South African Review of Sociology, 38(2), 103–
119. 
Møller V, Erstad I, Cramm JM, Nieboer AP, Finkenflügel H, Radloff S, Ndoro T and Kwizera 
SA, 2011. Delays in presenting for tuberculosis treatment associated with fear of learning one 
is HIV-positive. African Journal of AIDS Research, 10(1), 25–36. 
250 
Moore DF and Tsiatis A, 1991. Robust estimation of the variance in moment methods for extra-
binomial and extra-Poison variation. Biometrics, 47, 383-401. 
Mukadi YD, Maher D, and Harries A, 2001. Tuberculosis case fatality rates in high HIV 
prevalence populations in sub-Saharan Africa. AIDS, 15, 143–152. 
Mupere E,  Schiltz NK, Mulogo E, Katamba A, Nabbuye-Sekandi J, and Singer ME, 
2013.Effectiveness of active case-finding strategies in tuberculosis control in Kampala, 
Uganda. The International Journal of Tuberculosis and Lung Disease, 17(2), 207-213. 
Murphy SA and Johnson LC, 2006. Methodological Issues Associated With Group 
Intervention Research. Archives of Psychiatric Nursing, 20 (6), 276–281. 
Murray DM, 1998. Design and Analysis of Group-Randomized Trials. New York : Oxford 
University Press. 
Murray DM, Hannan PJ, and Baker WL, 1996. A Monte Carlo study of alternative responses 
to intraclass correlation in community trials: is it ever possible to avoid Cornfield’s penalties? 
Evaluation Review, 20(3), 313-337. 
Murray DM, Hannan PJ, Wolfinger RD, Baker WL, and Dwyer JH, 1998. Analysis of data from 
group-randomised trials with repeat observations on the same group. Statistics in Medicine, 
17, 1581-1600. 
Murray DM, Pals SL, Blitstein JL, Alfano CM, and Lehman L, 2008. Design and analysis of 
group-randomized trials in cancer: a review of current practices. J Natl Cancer Inst, 100, 483 – 
491. 
Murray DM , Varnell SP, and Blitstein JL, 2004. Design and analysis of group randomized 
trials: a review of recent methodological developments .Am J.Public Health, 94 (3), 423 – 432. 
Malawi National AIDS Commission, 2007. Sentinel Surveillance Report, National AIDS 
Commission, Lilongwe, Malawi. 
Malawi National AIDS Commission, 2010. Sentinel Surveillance Report, National AIDS 
Commission, Lilongwe, Malawi. 
Naidoo S, Taylor M, and Jinabhai C, 2007. Critical risk factors driving the tuberculosis 
epidemic in KwaZulu-Natal, South Africa. The Southern African Journal of Epidemiology and 
Infection, 22, 45–49. 
Nakagawa S and Schielzeth H, 2010. Repeatability for gaussian and non-Gaussian data:  a 
practical guide for biologists. Biol. Rev, 85,935-956. 
National Population Commission (NPC) and ICF Macro. 2009. Nigeria Demographic and Health 
Survey 2008: Key Findings. Calverton, Maryland, USA: NPC and ICF Macro. 
National Statistical Office (NSO), 2010. The Population and Housing census, 2008. Zomba, 
Malawi. 
251 
National Statistical Office (NSO) and ICF Macro. 2011. Malawi Demographic and Health Survey 
2010. Zomba, Malawi, and Calverton, Maryland, USA: NSO and ICF Macro. 
Neal, RM, 2003. Slice sampling. Ann. Statist., 31(3), 705 - 767. 
Needham DM, Foster SD, Tomlinson G, and Godfrey-Faussett P, 2001. Socioeconomic, gender 
and health services factors affecting diagnostic delay for tuberculosis patients in urban 
Zambia. Trop Med Int Health, 6(4), 256-259. 
Nelder JA, and Wedderburn RWM, 1972. Generalised linear Models. Journal of the Royal 
Statistical Society, Series A, 135,  370-384.  
Nijem K, Kristensen P, Al-Khatib A, and Bjertness E, 2005. Application of different statistical 
methods to estimate relative risk for self-reported health complaints among shoe factory 
workers exposed to organic solvents and plastic compounds. Norsk Epidemiologi, 15, 111-116 
Norris SL, Chowdhury FM, Van Le K, Horsley T, Brownstein JN, Zhang X, Jack L Jr, and 
Satterfield DW, 2006. Effectiveness of community health workers in the care of persons with 
diabetes. Diabet Med.,23(5), 544–556. 
Ntzoufras I, 2008. Bayesian Modeling Using WinBUGS. 2nd ed. John Wiley & Sons, Inc.  
Nyirenda T, 2006. Epidemiology of Tuberculosis in Malawi. Malawi Medical journal, 18(3), 147-
159. 
Oakeshott P, Kerry SM, and Williams JE, 1994. Randomised controlled trial of the effect of the 
Royal College of Radiologists' guidelines on general practitioners' referral for radiographic 
examination. Br J Gen Pract, 44,197-200. 
O'Campo P, 2003. Invited commentary: Advancing theory and methods for multilevel models 
of residential neighbourhoods and health. Am J Epidemiology, 157, 9-13. 
O’Donnell MR, Chamblee S, von Reyn CF, Marsh BJ, Moreland JD, Narita M, Johnson LS, and 
Horsburgh Jr CR, 2012. Sustained reduction in tuberculosis incidence following a community-
based participatory intervention. Public Health Action, 2(1): 23–26. 
Omar RZ, and Thompson SG, 2000. Analysis of a cluster randomized trial with binary 
outcome data using a multi-level model .Statist. Med., 19, 2675-2688. 
Osborn J and Cattaruzza MS, 1995. Odds ratio and relative risk for cross-sectional 
data.International Journal of Epidemiology, 24, 464-465. 
Ouedraogo M, Kouanda S, Boncoungou K, Dembele M, Zoubga ZA, Ouedraogo SM, and 
Coulibaly G, 2006. Treatment seeking behaviour of smear-positive tuberculosis patients 
diagnosed in Burkina Faso. Int J Tuberc Lung Dis, 10(2), 184-187. 
Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman D.J, and 
Holmberg SD, 1998. Declining morbidity and mortality among patients with advanced human 
immunodeficiency virus infection. N Engl J Med, 338, 853–860. 
252 
Palmer RH, Louis TA, Hsu LN, Peterson HF, Rothrock JK, Strain R, Thompson MS, and 
Wright EA, 1985.A randomized controlled trial of quality assurance in sixteen ambulatory 
care practices. Med Care, 23, 751–770. 
Pals Sl, Wiegand RE, and Murray DM, 2011. Ignoring the group in group-level HIV/AIDS 
intervention trials: a review of reported design and analytic methods. AIDS, 25, 989-996. 
Parker DR, Evangelou TE, and Eaton CB, 2005. Intraclass correlation coefficients for cluster 
randomized trials in primary care: the cholesterol education and research trial. Contemporary 
Clinical Trials, 26, 260–267. 
Petersen MR, and Deddens JA, 2006. Easy SAS calculations for risk or prevalence ratios and 
differences. Am J Epidemiol, 163, 1157-1163. 
Petersen MR and Deddens JA, 2008. A comparison of two methods estimating prevalence 
ratios. BMC Med Res Methodol. 2008; 8: 9. doi:  10.1186/1471-2288-8-9. 
Phillips K A, Morrison KR, Andersen R, and Aday LA, 1998. Understanding the context of 
health care utilization: assessing environmental and provider-related variables in the 
Behavioral Model of Utilization. Health Services Research, 33, 571–596. 
Pocock SJ, 1997. Clinical trials: a practical approach. New York. John Wiley & Sons Ltd. 
Porter K, Babiker A, and Bhaskaran, 2003. Determinants of survival following HIV-1 
seroconversion after the introduction of HAART. Lancet, 362, 1267-1274. 
Preidis GA, McCollum ED, Kamiyango W, Garbino A, Hosseinipour MC, Kazembe PN, 
Schutze GE, and Kline MW, 2013. Routine inpatient provider-initiated HIV testing in Malawi, 
compared with client-initiated community-based testing, identifies younger children at 
higher risk of early mortality. J Acquir Immune Defic Syndr., 63(1):e16-22. 
Preisser JS, Reboussin BA, Song E, and Wolfson M, 2007. The importance and role of 
intracluster correlations in planning cluster trials. Epidemiology, 18 (5), 552-560. 
Rabe-Hesketh S, and Skrondal A, 2008. Multilevel and longitudinal modelling using Stata. 2nd 
ed. Texas: Stata Press Publication.  
Rabe-Hesketh S, and Skrondal A, 2012. Multilevel and longitudinal modelling using Stata. 3rd ed. 
Texas: Stata Press Publication.  
Rabe-Hesketh S, Skrondal A, and Pickles A, 2002. Reliable estimation of generalized linear 
mixed models using adaptive quadrature. The Stata Journal 2 (1), 1-21. 
Rabe-Hesketh S, Skrondal A, Pickles A, 2005.  Maximum likelihood estimation of limited and 
discrete dependant variable models with nested random effects. Journal of Econometrics, 128, 
301-323. 
Raftery AE, 1996. Approximate Bayes factors and accounting for model uncertainty in 
generalised linear models. Biometrika, 83, 251-266. 
253 
Rajeswari R, Chandrasekaran V, Suhadev M, Sivasubramaniam S, Sudha G,  and Renu G, 
2002. Factors associated with patient and health system delays in the diagnosis of tuberculosis 
in South India. The International Journal of Tuberculosis and Lung Disease, 6 (9),  789-795. 
Rao VG, Bhat J, Yadav R, Gopalan GP, Nagamiah S, et al., 2012. Prevalence of Pulmonary 
Tuberculosis - A baseline survey in Central India. PLoS ONE 7(8), e43225. 
doi:10.1371/journal.pone.0043225.  
Raudenbush SW, and Bryk AS, 2002. Hierarchical Linear Models in Social and Behavioral Research: 
Applications and Data-Analysis Methods, 2nd Edition, Sage Publications, Thousand Oaks. 
Raudenbush SW, and Liu X, 2000. Statistical power and optimal design for multisite 
randomized trials. Psychological Methods,5, 199-213. 
Raudenbush SW, and Xiao-Feng L, 2001. Effects of study duration, frequency of observation, 
and sample size on power in studies of group differences in polynomial change. Psychological 
Methods, 6(4), 387-401. 
Ray M, Logan R, Sterne JA, et al, 2010. The effect of combined antiretroviral therapy on the 
overall mortality of HIV-infected individuals. AIDS, 24, 123-137. 
Rodriguez G, and Goldman N, 1995. An assessment of estimation procedures for multilevel 
models with binary responses. J R Stat Soc A, 158, 73–90. 
Rodriguez G and Goldman N, 2001. Improved estimation procedures for multilevel models 
with binary response: a case study. Journal of the Royal Statistical society, 158, 73-89. 
Rosenstock IM, Strecher VJ, and Becker MH, 1988. Social Learning Theory and the Health 
Belief model. Health Educ. Behav., 15(2), 175 - 183.  
Rotheram-Borus MJ, Lee MB, Gwadz M, and Draimin B, 2001. An intervention for parents 
with AIDS and their adolescent children. Am J Public Health, 91, 1294–1302. 
Russell S, 2004. The economic burden of illness for households in development countries: a 
review of the studies focusing on malaria, tuberculosis and HIV/AIDS. Am J Trop Med Hyg., 
71(Suppl 2), 147–155. 
Salaniponi FM, Harries AD, Banda HT, Kang'ombe C, Mphasa N, Mwale A, Upindi B, 
Nyirenda TE, Banerjee A, and Boeree MJ, 2000. Care seeking behaviour and diagnostic 
processes in patients with smear-positive pulmonary tuberculosis in Malawi. Int J Tuberc Lung 
Dis, 4(4), 327-332. 
Savu A, Liu Q and Yasu Y, 2010. Estimation of relative risk and prevalence ratio. Stat Med., 
29(22), 2269-2281. 
Scheines R, Hoijtink H, and Boomsma A, 1999. Bayesian estimation and testing of structural 
equation models. Psychometrika, 64, 37–52. 
254 
Schouten EG, Dekker JM, and Kok FJ, 1993. Risk ratio and rate ratio estimation in case-cohort 
designs: hypertension and cardiovascular mortality. Stat Med., 12, 1733-1745. 
Schwarz G, 1978. Estimating the dimension of a model. Ann. Statis., 6(2), 461-464. 
Sekandi JN, Neuhauser D, Smyth K, and Whalen CC, 2009. Active case finding of undetected 
tuberculosis among chronic coughers in a slum setting in Kampala, Uganda. Int J Tuberc Lung 
Dis., 13,508–513. 
Seltzer MH, Wong, WH, and Bryk AS, 1996. Bayesian analysis in applications of hierarchical 
models: issues and methods. Journal of Educational and Behavioral Statistics,21, 131–167. 
Simpson JM, Klar N, and Donner A, 1995. Accounting for cluster randomization: a review of 
primary prevention trials, 1990 through 1993 .Am J Public Health, 85(10), 1378 – 1383. 
Simwaka BN, Theobald S, Willets A, Salaniponi FML, Nkhonjera P, Bello G, and Squire SB, 
2012. Acceptability and Effectiveness of the Storekeeper-Based TB Referral System for TB 
Suspects in Sub-Districts of Lilongwe in Malawi. PLoS ONE,  7(9), e39746. 
doi:10.1371/journal.pone.0039746. 
Sjögren T, Nissinen KJ, Järvenpää SK, Ojanen MT, Vanharanta H, and Mälkiä EA, 2005. Effects 
of a workplace physical exercise intervention on the intensity of headache and neck and 
shoulder symptoms and upper extremity muscular strength of office workers: a cluster  
randomized controlled crossover trial. J Int Assoc Stud Pain, 116, 119–128. 
Skordis-Worrall J, Hanson K, and Mills A, 2010. Confusion, caring and tuberculosis diagnostic 
delay in Cape Town, South Africa. International Journal of Tuberculosis and Lung Disease,  14(2), 
171–180. 
Skov T, Deddens JA, Petersen MR, and Endahl L, 1998. Prevalence proportion ratios: 
estimation and hypothesis testing. International Journal of Epidemiology, 27,91-95. 
Smeeth L and Siu-Woon Ng E, 2002. Intraclass correlation coefficients for cluster randomized 
trials in primary care: data from the MRC Trial of the Assessment and 
Management of Older People in the Community. Controlled Clinical Trials, 23, 409–421. 
Snijders TAB, 1996. Analysis of longitudinal data using the hierarchical linear model. Quality 
and Quantity, 30, 405-426. 
Snijders T, and Bosker R, 1999. Multilevel Analysis: an Introduction to basic and advanced 
multilevel modelling, Sage Publications, Thousand Oaks. 
Snijders TAB, and Bosker RJ, 2012. Multilevel analysis: an introduction to basic and advanced 
multilevel modelling. Thousand Oaks, CA:Sage. 
Spiegelhalter DJ, 2001. Bayesian methods for cluster randomized trials with continuous 
responses. Statistics in Medicine, 20, 435–452. 
255 
Spiegelhalter DJ, Best NG, Carlin BP, and van der Linde A, 2002. Bayesian measures of model 
complexity and fit (with discussion). J Roy Statist Soc B, 64, 583-639. 
Spiegelhalter D, Thomas A, Best N, and Lunn D, 2003. WinBUGS user manual. Cambridge: 
MRC Biostatistics Unit. 
Spiegelman D, and Hertzmark E, 2005. Easy SAS calculations for risk or prevalence ratios and 
differences. Am J Epidemiol, 162, 199–200. 
Squire S B, Belaye A K, Kashoti  A, Salaniponi F M L, Mundy CJF, Theobald S, Kemp J, 2005.  
“Lost” smear positive pulmonary tuberculosis cases; where are they and why did we lose 
them? Int J Tuberc Dis., 9, 25-31. 
Stiratelli R, Laird NM, and Ware JH, 1984. Random effects models for serial observations with 
binary response. Biometrics, 40, 961-971. 
Storla DG, Yimer S, and Bjune GA, 2008. A systematic review of delay in the diagnosis and 
treatment of tuberculosis. BMC Public Health, 14, 8:15. 
Stromberg U, 1994. Prevalence Odds Ratios v.s. Prevalence Ratio. Occupational Environmental 
Medicine, 51, 143-144. 
Stryn H, Sanchez J, Morley P, Booker C, and Dohoo IR, 2006. Interpretation of variance 
parameters in multilevel Poisson regression models. Proceedings of the 11th International 
Symposium on Veterinary Epidemiology and Economics. Available at www.sciquest.org.nz  
Styblo K, and Bumgarner JR, 1991. Tuberculosis can be controlled with existing technologies: 
evidence. The Hague: Tuberculosis Surveillance Research Unit; 1991. Progress Report 1991. 
pp. 60-72. 
Subramani R, Radhakrishna S, Frieden TR, Kolappan C, Gopi PG, Santha T, Wares F, 
Selvakumar N, and Narayanan PR, 2008. Rapid decline in prevalence of pulmonary 
tuberculosis after DOTS implementation in a rural area of South, India.  Int J Tuberc Lung Dis, 
12 (8), 916–920.  
Thall PF, and Vail SC, 1990. Some covariance models for longitudinal count data with 
overdispersion. Biometrics, 46, 657-671. 
Thompson B, Coronado G, Snipes SA, and Puschel K, 2003. Methodologic advances and 
ongoing challenges in designing community-based health promotion programs.Annu. Rev. 
Public Health, 24, 315–340. 
Thompson ML, Myers JE, Kriebel D, 1998. Prevalence odds ratio or prevalence ratio in the 
analysis of cross sectional data: what is to be done? Occup Environ Med., 55, 272–277. 
Thompson SG, Warn DE and Turner RM, 2004. Bayesian methods for analysis of binary 
outcome data in cluster randomized trials on the absolute risk scale. Statist. Med., 23, 389–410.  
256 
Torgerson DJ, 2001. Contamination in trials: is cluster randomisation the answer? BMJ, 322, 
355–357. 
Turner RM, Omar RZ, and Thompson SG, 2001. Bayesian methods of analysis for cluster 
randomized trials with binary outcome data. Statistics in Medicine,20, 453–472. 
Tutz G, and Kauermann G, 2003. Generalised linear random effects models with varying 
coefficients. Computational Statistics and Data Analysis,43, 13-28. 
Uplekar M, and Raviglione MC, 2007. The "vertical-horizontal" debates: time for the 
pendulum to rest (in peace)? Bull World Health Organ, 85, 413-414. 
Uwimana J, Zarowsky C, Hausler H and Jackson D, 2012. Training community care workers 
to provide comprehensive TB⁄HIV⁄PMTCT integrated care in KwaZulu-Natal: lessons learnt. 
Tropical Medicine and International Health, 17 (4), 488–496. 
Uyei J, Coetzee D, Macinko J, and  Guttmacher S, 2011. Integrated delivery of HIV and 
tuberculosis services in sub-Saharan Africa: a systematic review. The LancetInfectious Diseases, 
11, 855-867. 
Varnell SP, Murray DM , and Baker WL, 2001. An evaluation of analysis options for the one 
group per condition design: can any of the alternatives overcome the problems inherent in 
this design? Eval Rev., 25(4), 440 – 453. 
Varnell SP, Murray DM, Janega JB, and Blitstein JL, 2004. Design and analysis of group-
randomized trials: a review of recent practices .Am J Public Health, 94 (3), 393 – 399. 
Vernazza PL, Troiani L, Flepp MJ, et al, 2000. Potent antiretroviral treatment of HIV infection 
results in suppression of the seminal shedding of HIV. AIDS, 14, 117-121. 
Verver S, Bwire R, and Borgdorff MW, 2001. Screening for pulmonary tuberculosis among 
immigrants: estimated effect on severity of disease and duration of infectiousness. 
International Journal of Tuberculosis and Lung Disease, 5, 419-425. 
Verver S, Warren RM, Munch Z, Richardson M, van der Spuy GD, Borgdorff MW, Behr MA, 
Beyers N, and van Helden PD, 2004. Proportion of tuberculosis transmission that takes place 
in households in a high-incidence area. Lancet, 363, 212–14. 
Wacholder S, 1986. Binomial regression in GLIM, estimating risk ratios and risk differences. 
Am J Epidemiol, 123, 174–184. 
Wandwalo ER, and Morkve O, 2000. Delay in tuberculosis case-finding and treatment in 
Mwanza, Tanzania. Int J Tuberc Lung Dis, 4(2), 133-138. 
Wasserman L, 2000. Bayesian Model selection and model averaging. Journal of Mathematical 
Psychology, 44, 92-107.  
Wedderburn RWM, 1974. Quasi-likelihood functions, generalised linear models and the 
Gauss-Newton method.  Biometrika, 61, 439-447. 
257 
Weiner B, 1986. An attributional theory of motivation and emotion. New York: Springer-Verlag. 
World Health Organization, 1989. Strengthening the performance of community health workers in 
primary health care. Report of a WHO Study Group. Geneva, World Health Organization (WHO 
Technical Report Series, No. 780). 
World Health Organization, 2004. Interim policy on collaborative TB/HIV activities. Geneva: 
World Health Organization. 
World Health Organization, 2006. The Stop TB Strategy: building on and enhancing DOTS to meet 
the TB-related Millennium Development Goals. Geneva, World Health Organization, 
(WHO/HTM/TB/2006.368). 
World Health Organization, 2007. Global Tuberculosis Control: Surveillane, Planning, 
Financing. Geneva, World Health Organisation Report 2007. 
World Health Organization, 2009. Global tuberculosis control: Epidemiology, Strategy, Financing. 
World Health Organization, Geneva, World Health report, 2009.    
World Health Organization, 2010. Global Tuberculosis Control: Surveillance, Planning, Financing: 
World Health Organisation report, 2010. 
World Health Organization, 2011.  Early detection of Tuberculosis: an overview of 
approaches, guidelines and tools. WHO/HTM/STB/PSI/2011.21.  
WHO/UNAIDS/UNICEF, 2007. Towards universal access. scaling-up priorities HIV/AIDS 
interventions in the health sector. Progress report, April 2007. 
Wood R, Middelkoop K, Myer L, Grant AD, Whitelaw A, Lawn SD, Kaplan G, Huebner R, 
McIntyre J, and Bekker LG, 2007.Undiagnosed tuberculosis in a community with high HIV 
prevalence: implications for tuberculosis control. Am J Respir Crit Care Med., 175,87–93. 
Xiong CF, Fang Y, Zhou LP, Zhang XF, Ye JJ, Li GM, Liu X, Wang XJ, and Yang CF, 2007. 
Increasing TB case detection through intensive referral of TB suspects by village doctors to 
county TB dispensaries. Int J Tuberc Lung Dis, 11(9), 1004–1007. 
XU B, Diwan VK, and Bogg L, 2007. Access to tuberculosis care: What did chronic cough 
patients experience in the way of healthcare-seeking? Scandinavian Journal of Public Health, 35, 
396–402. 
Yee JL, and Niemeier D, 1996. Advantages and disadvantages: longitudinal vs. repeated cross-
section surveys [online]. FHWA, HPM-40. Accessed 23rd April 2013 at 
http://ntl.bts.gov/data/letter_am/bat.pdf.    
Yimer S, Bjune G, and Alene G, 2005. Diagnostic and treatment delay among pulmonary 
tuberculosis patients in Ethiopia: a cross sectional study. BMC Infect Dis, 5, 112. 
doi:  10.1186/1471-2334-5-112. 
258 
You Z, Williams OD, Aban I, Kabagambe EK, Tiwari HK, and Cutter G, 2011. Relative 
efficiency and sample size for cluster randomized trials with variable cluster sizes. Clinical 
Trials 2011; 8: 27–36. 
 
Yu B, and Wang Z, 2008. Estimating relative risks for common outcome using PROC NLP. 
Computer Methods and Programs in Biomedicine, 90, 179–186. 
Zhao Y,  Staudenmayer J, Coull B A,  and Wand MP, 2006. General design Bayesian 
generalized linear mixed models. Statistical Science,  21(1), 35–51. 
Zhang  J, and Yu K, 1998. What’s the relative risk? A method of correcting the odds ratio in 
cohort studies of common outcomes. JAMA, 280, 1690–1691. 
Zhang Z, Hamagami F, Wang L, Grimm KJ, and Nesselroade JR, 2007. Bayesian analysis of 
longitudinal data using growth curve models. International Journal of Behavioural Development, 
31(4), 374-383. 
Zou G, 2004. A modified Poisson regression approach to prospective studies with binary data. 
Am J Epidemiol, 159, 702–706. 
Zocchetti C, Consonni D and Bertazzi PA, 1995. Estimation of prevalence rate ratios from 
cross-sectional data [letter; comment]. International Journal of Epidemiology, 24, 1064-1065. 
Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, and 
Moher D, 2008. CONSORT and Pragmatic Trials in Healthcare (Practihc) group. Improving 
the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ , 337, a2390 
doi: 10.1136/bmj.a2390. 
